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ABSTRACT 
The pathological mechanisms of variant Creutzfeldt-Jakob disease (vCJD) in the 
human brain remain poorly understood. Gene expression data may provide insight 
into the molecular mechanisms involved. This requires analysis of human post-
mortem brain tissue however; the variability in RNA preparations from human brain 
material is a concern. A method for the isolation of RNA from vCJD brains which 
minimized infectivity and reduced Proteinase K resistant prion protein levels to 
undetectable by biochemical assay was developed. RNA preparations were made 
from sample of the frontal parasagital cortex, sub-frontal cortex and cerebellum of 78 
human autopsy cases; 21 vCJD, 26 other neurological disease (OND) and 31 non-
neurological disease (NND). 
Suitable RNA metrics for these human brain RNA preparations were evaluated and 
the intra- and inter-case variability of RNA preparations was determined. There was 
marked intra- and inter-case variability in RNA integrity number (RIN), A260:280 
absorbance ratio and RNA yield. In particular, RIN and A260:280 showed little 
variation intra-patient, although RNA yield was more variable. The effects of post-
mortem interval, tissue pH, age at death, gender, freeze-thaw cycles (including 
storage method and temperature) and agonal state were investigated; none of these 
parameters correlated with the marked variability observed. 
Parameters for matching vCJD and OND/NND cases were considered and RNA 
from three age and gender matched comparison groups, each containing one OND, 
one NND and one vCJD case, were used for gene expression analysis. Data was 
generated using Superarray GEArray® Focused DNA Microarray and analysed using 
the GEArray Expression Analysis Suite and Significance Analysis of Microarray 
software. A comparison between matched vCJD and NND control cases identified 26 
up-regulated and 16 down-regulated genes, showing >1.5-fold change with a false 
discovery rate of 9%. The modulated genes were involved in cell signaling, cell 
death, cholesterol and lipid metabolism. Involvement of these pathways is consistent 
with findings in other transmissible spongiform encephalopathy studies.  
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 2
1 INTRODUCTION 
1.1 TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES 
 
Transmissible Spongiform Encephalopathies (TSE) or prion diseases are a 
biologically unique group of rare and fatal neurodegenerative diseases which include 
Creutzfeldt-Jakob disease and kuru in humans, bovine spongiform encephalopathies 
in cattle, scrapie in sheep and goats and chronic wasting disease in elk and deer. 
TSEs have previously been described as subacute spongiform encephalopathies, slow 
virus diseases and transmissible dementias. Animal TSEs have been recognized for 
well over 200 years (McGowan, 1922). The prototypic disease is scrapie, a naturally 
occurring disease affecting sheep and goats which is endemic in most of Europe and 
North America.  Since scrapie was first described, various forms of human prion 
diseases have been reported, including kuru, Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Sträussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI). 
More recently new forms of animal prion disease have emerged, such as bovine 
spongiform encephalopathy (BSE) in cattle, transmissible mink encephalopathy 
(TME) in mink, chronic wasting disease (CWD) in deer and elk, feline spongiform 
encephalopathy (FSE) in cats and exotic ungulate encephalopathy (EUE) in several 
antelope species including nyala and kudu. 
 
Prion diseases in humans can be sporadic, familial or acquired in origin (Ironside, 
1996; Prusiner, 1998). Currently, there is no epidemiological evidence for the causes 
of sporadic prion diseases, and no association established between disease and 
mutant PrP alleles (Will, 1993; Harries-Jones et al., 1988). Alternative hypotheses 
have suggested exposure to an unidentified virus, spontaneous generation of a non-
viral agent through somatic cell mutations and stochastic initiation of spontaneous 
PrPres formation without PrP mutation as possible causes. Inherited forms account for 
10-15% of all human prion diseases and are associated with an autosomal dominant 
change (mutation or insertion) in the prion protein gene that predisposes to abnormal 
folding of the protein, resulting in disease. Transmission of human TSEs from 
infected individuals is relatively rare, accounting for less than 1% of total CJD cases 
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worldwide. TSEs are not naturally transmissible via airborne droplets, skin contact or 
most other forms of casual contact although experimentally, intra-nasal transmission 
has been proven (Hamir et al., 2008). However, transmission is possible through 
contact with infected tissue, body fluids, or contaminated medical instruments. 
Normal sterilization procedures such as steam sterilization or irradiation do not fully 
inactivate the infectivity, and difficulties in detecting and inactivating infectivity has 
led to iatrogenic transmission of CJD (Powell-Jackson et al., 1985; Heckmann et al., 
1997). More recently and worryingly, there have been three confirmed transmissions 
of vCJD through blood transfusions. With the lack of a non-invasive pre-clinical 
diagnostic assay, there opens up the real possibility of a world-wide public health 
issue regarding iatrogenic spread of vCJD (Llewelyn et al., 2004; Peden et al., 2004). 
 
In recent years, public interest and media attention has brought TSEs to centre stage. 
In 1987, the Central Veterinary Laboratory in England reported the first formal 
diagnosis of a novel prion disease in cattle, known as bovine spongiform 
encephalopathy (BSE) (Wells et al., 1987). With the discovery of yet another novel 
spongiform encephalopathy in 1996 (vCJD), this time in humans, epidemiological 
studies indicated a potential for interspecies transmission of BSE to humans. The 
suspected exposure was believed to be food chain contamination with infected meat 
and other bovine-derived products (Will et al., 1996). This discovery had significant 
implications for human health, as well as other animals, including felines (Wyatt et 
al., 1991) and zoo animals (Sigurdson & Miller, 2003). Molecular strain-typing 
studies and experimental transmission studies into transgenic and conventional mice 
with BSE and vCJD have established that the two diseases are caused by the same 
agent, with biological properties distinct from those in scrapie and sCJD (Collinge et 
al., 1996; Bruce et al., 1997). Since the emergence of vCJD in 1995, a total of 166 
cases have been reported in the UK and 41 further cases worldwide, in countries 
including Japan, France and USA (www.cjd.ed.ac.uk, 2008). 
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1.1.1 Creutzfeldt-Jakob Disease 
Clinical and pathological descriptions of what is now referred to as CJD first 
appeared in the 1920’s. Hans Gerhard Creutzfeldt first described ‘ a new and unusual 
type of neurological disease’ of a progressive mental and neurological disturbance in 
a 22-year-old woman (Creutzfeldt, 1920). Although Creutzfeldt is credited with the 
first description of the disorder, it has since been suggested that his patient did not 
suffer from a TSE and the case would not now meet the diagnostic criteria for CJD. 
One year later, a German neurologist, Alfons Maria Jakob, described four further 
cases of defects in the motor systems, of which at least two had clinical features 
suggestive of the entity now recognised as CJD. Over the decades, considerable 
debate over the nature, identity and clinico-pathological features of these disorders 
have persisted. It was not until the direct experimental transmission of CJD from a 
human to a chimpanzee (Gibbs et al., 1968), that a unique disease entity was 
assigned to this neurodegenerative disorder. 
 
In 1996, neuropathologists and neurologists at the National CJD Surveillance Unit 
(NCJDSU) in the United Kingdom identified a new variant form of CJD, which has 
since been found in several other European countries as well as Japan and the United 
States (www.cjd.ed.ac.uk, 2008). The presenting symptoms of the variant form were 
distinct from those of classic CJD, striking features being the younger age of the 
patients compared to classical forms of the disease. Research suggests that this new 
variant form of the disease may have resulted from human consumption of beef from 
cattle with a TSE disease, as opposed to sheep with scrapie, since scrapie has been 
endemic in the UK for over 400 years and epidemiological studies show no 
association between sheep scrapie and the occurrence of CJD in humans (Brown et 
al., 1987). The emergence of BSE in UK cattle in 1984 however, has been widely 
attributed to scrapie transmission to cattle via contaminated feed prepared from 
rendered sheep carcasses, a practice introduced in the 1950’s (Wilesmith, 1988). An 
alternative hypothesis suggests the 1986 BSE epidemic was a result of recycling 
cattle carcasses of rare sporadic BSE cases for meat and bone meal (MBM) cattle 
feed. Whether or not BSE originated from sheep scrapie or by other means, it 
became clear by 1990, with the occurrence of novel spongiform encephalopathies 
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among domestic cats and eventually humans, that its host range was drastically 
different from that of scrapie.  
 
1.2 NATURE OF THE INFECTIOUS AGENT 
 
The cellular prion protein (PrP), isolated from normal individuals is protease-
sensitive, and is traditionally termed PrPc (for cellular) or PrPsen (for sensitive to 
protease digestion). Modifications of PrP can result in a protease-resistant isoform, 
termed PrPres, or a disease-associated PrP, termed PrPSc or PrPd. As protease 
resistance does not specify that the isoform is capable of transmitting disease, PrPSc 
is used to denote the pathogenic, infectious isoforms and PrPres the proteinase 
resistance isoforms. 
 
The hypothesis first put forward by Alper to define the increasingly confusing 
etiology of ‘slow-virus’ diseases described the unit of TSE pathogenesis and 
transmissibility as a specific aberrantly folded host protein (Alper et al., 1966). By 
the late 1970’s, Prusiner had formulated the protein-only hypothesis, or ‘prion’, 
denoting ‘proteinaceous infectious particle’, postulating that the aberrant protein- 
PrPSc- is the sole infectious component of the agent and is sufficient to be responsible 
for prion propagation. In this hypothesis, normally folded PrPc is induced to a 
misfolded conformation by exposure to aberrant PrP, precipitating an autocatalytic 
conversion cascade. Indeed, evidence of highly purified PrPSc producing disease 
when inoculated into wild-type mice and the observation that PrP knockout mice are 
resistant to infection support the prion hypothesis (Prusiner, 1982; Bueler et al., 
1993). Further research however, raised a number of issues regarding the prion 
hypothesis. For example, recombinant mammalian prions harbouring mutations 
found in familial TSE-affected patients, although exhibiting similar properties to 
PrPSc, were not infectious when inoculated into wild-type hosts (Lehmann & Harris, 
1996; Chiesa et al., 1998). Recently, a recombinant PrP fragment lacking the N-
terminal one-third of the polypeptide was assembled in vitro into amyloid  
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fibrils and found to induce TSE-like disease in transgenic mice over-expressing the 
same truncated portion of PrP (Legname et al., 2004), although this is not conclusive 
evidence that PrP amyloid alone transmits the disease since transgenic animals 
overexpressing PrP can spontaneously develop prion-like diseases (Chiesa et al., 
1998; Westaway et al., 1994). 
 
Nonetheless, it is generally considered that pure in vitro generation of infectivity by 
misfolding of (recombinant) prion protein would provide definitive proof of the prion 
hypothesis (Chesebro, 1998; Soto & Castilla, 2004). A new technique may provide 
this. Protein misfolding cyclic amplification (PMCA) is analogous to polymerase 
chain reaction (PCR) and involves cell free conversion of PrPsen to PrPres using only 
purified constituents (Saborio et al., 2001). Data obtained using this method have 
been challenged because large amounts of same species infectious PrPres are required 
as the seeding substrate, thereby precluding demonstrating the infectiousness of any 
resulting aberrant PrP produced (Hill et al., 1999). Advances in the method have 
resulted in critical studies showing in vitro generation of PrPSc capable of infection 
and de novo formation and propagation of  infectious PrPSc (Castilla et al., 2005; 
Deleault et al., 2007). 
 
Even though the body of evidence in favour of the prion hypothesis is compelling, 
there is still ongoing controversy. Studies of animal brain tissues containing high 
titres of TSE infectivity but undetectable levels of PrPres   (Barron et al., 2007; 
Lasmezas et al., 1997) and the presence of high levels of accumulated PrPres  without 
infectivity (Piccardo et al., 2007) throw doubt on the protein-only theory. Alternative 
models based on viruses, virinos and other infectious agents containing small RNAs 
have been proposed (Narang, 2002; Rohwer, 1984a; Bellinger-Kawahara et al., 
1988; Manuelidis et al., 1988; Bellinger-Kawahara et al., 1988; Rohwer, 1991). 
Evidence that retroviral RNA co-precipitates with PrPSc  and that short (>4 kb) RNA 
fragments are released after nuclease digestion from purified infectious fractions 
lends weight to these models (Murdoch et al., 1990; Akowitz et al., 1990; Akowitz et 
al., 1994). Moreover the addition of polyanions such as RNA promotes PMCA 
(Deleault et al., 2007). 
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1.3 THE PRION PROTEIN GENE (PRNP) 
 
The prion protein gene (PRNP) is a single-copy gene, located on the short arm of 
chromosome 20 in man, spans 16 Kb and contains two exons, encoding 253 amino 
acid residues (Kretzchmar et al., 1986). The translation product of PRNP is 
processed by the removal of an amino terminal signal peptide of 22 amino acids and 
a carboxy terminal hydrophobic peptide of 23 amino acids. A C-terminal 
glycosylphosphatidylinositol (GPI)-anchor is added post-translationally and permits 
attachment to the surface of neurones and other cell types (Prusiner, 1991; Stahl et 
al., 1987). In addition, asparagine residues 181 and 197 also contain highly branched 
glycosyl groups, resulting in PrP being found as a mixture of three forms – 
unglycosylated, with one glycosyl-, and with two glycosyl-groups. Glycoform 
analysis of PrPres as determined by Western blot constitutes the current method of 
classification of CJD subtypes, although glycoform ratios can vary and should be 
interpreted with caution (Telling et al., 1996). The biochemical properties of the 
cellular prion protein differ radically from the properties of the disease-associated 
isoform, even though to date, no identifiable primary structure or covalent 
modification differences have been described for the two isoforms. The difference in 
tertiary structure though, is striking. PrPc is a monomeric protein with a globular C-
terminal domain rich in α-helical structure, whereas PrPSc is rich in β-sheet, highly 
aggregated and contains a C-terminal core with considerable resistance to proteolytic 
degradation in non-denaturing conditions (Pan et al., 1993). Because the amino acid 
sequences of PrPc and PrPSc are identical (apart from the genetic forms), the 
contrasting properties of the two molecules, and to an extent the strain phenomenon 
of TSEs, is generally believed to be due to conformation difference (Bessen & 
Marsh, 1994). Figure 1.1 shows the genetic features of the cellular prion protein.  
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Figure 1.1. Structural features of the cellular prion polypeptide. The primary structure of the 
cellular prion protein including post-translational modifications. A secretory signal peptide resides at 
the extreme N-terminus. The numbers describe the position of the respective amino acids. CC 
(orange) defines the charged cluster. OR, octapeptide repeats. HC (red) defines the ‘hydrophobic 
core’. S-S indicates the single disulphide bridge. The proteinase K (PK) resistant core of PrPSc is 
depicted in gold and the approximate cutting site of PK within PrP is indicated by the lightening 
signal. MA denotes the hydrophobic peptide cleaved when the GPI anchor is attached. Modified from 
(Aguzzi & Heikenwalder, 2006). 
 
 
1.3.1 Cellular Prion Protein 
The cellular prion protein is highly conserved among mammals and is expressed in 
most tissues, although the highest level of PrPc expression is found in the CNS, 
where it is localized to synaptic membranes of neurons and astrocytes (Manson et al., 
1992; Moser et al., 1995). The physiological function of the cellular form is still 
undetermined, although current hypotheses include; copper-related oxidative stress 
resistance (Brown et al., 2001), circadian rhythms (Tobler et al., 1996), copper 
metabolism (Brown et al., 1997a), cell signaling (Mouillet-Richard et al., 2000), 
synaptic function (Maglio et al., 2004) and alterations in superoxide dimutase 
activity (Brown et al., 1997b; Klamt et al., 2001). However, PrPc has yet to be 
proven to be essential for normal neurological development and function. PrP null 
mouse lines were observed to develop normally and PrP knockout mice survive with 
no apparent phenotypic abnormalities. These results suggest that PrP is not essential 
for development, as loss of PrP is physiologically tolerated and the pathophysiology 
seen in prion diseases is not due to loss of normal PrP function (Bueler et al., 1993; 
Mallucci et al., 2002; Manson et al., 1994). Figure 1.2 illustrates the structural 
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Figure 1.2. Tertiary structure of the cellular prion protein. The prion protein is inserted into a 
lipid bilayer, as deduced from NMR spectroscopy, including the ‘unstructured’ N-terminal tail (grey) 
and the glycosylphosphatidylinositol (GPI) anchor. The ribbon schematic represents the α-helices in 
red, the β-strands as blue arrows and the loop regions connecting the second β-sheet and the third α-
helix is indicated by the black arrow. Taken from (Aguzzi & Heikenwalder, 2006).  
 
 
1.3.2 Disease-Associated Prion Protein 
While PrPc is a soluble, protease-sensitive protein, pathological isoforms are 
insoluble in non-ionic detergents and partially resistant to protease treatment, leaving 
an indigestible  carboxyterminal fragment which tends to aggregate, termed PrPres or 
PrP27-30 (Chesebro, 1998). However, these hallmark properties of PrPSc, i.e. 
resistance to proteases and insolubility in non-ionic detergents, which have been 
traditionally linked to the presence of prion infectivity are not absolute (Bolton et al., 
1984). In some experimental systems, protease-resistance and detergent-insolubility 
are not associated with prion infectivity (Shaked et al., 1999) and protease-resistant 
PrP cannot be found in samples containing prion infectivity (Lasmezas et al., 1997; 
Barron et al., 2007).  
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 1   Introduction 
 10
1.3.3 Conversion of PrPc to PrPSc 
The key difference between TSEs and other amyloidoses is the ability of aggregated 
PrP to promote the rearrangement of unmutated protein thereby allowing 
transmission of disease. Two models have been proposed to explain PrPSc-induced 
conversion of PrPc to PrPSc; the template-directed refolding model (Gajdusek, 1988; 
Prusiner & DeArmond, 1990) and the noncatalytic nucleated polymerization model 
(Come et al., 1993). The first mechanism hypothesises that a PrPSc monomer acts as 
a template, promoting the conversion of PrPc to PrPSc or a partially destabilized 
intermediate (PrP*) and involves only a conformational change. In this model PrPSc 
is inherently more stable but kinetically inaccessible. Refolding of PrPc would have 
to overcome a high activation energy barrier, preventing spontaneous conversion. 
Heterodimeric complexes would lower the activation energy barrier or might require 
a chaperone and/or an energy source. α-lytic proteases have been observed to behave 
in this manner. Interconversion of a globule-like intermediate, I, to the more stable 
native form, N, is extremely slow, representing an energy barrier of ~25 kcal/mol. 
However, conversion is greatly accelerated by the addition of a naturally-occurring 
propeptide region, which reduces energy requirement to 14 kcal/mol (Baker & 
Agard, 1994). An alternative modified model supposes the existence of an ancillary 
factor, protein X. PrPc is in equilibrium with PrP* which binds to the putative protein 
X. PrPSc interacts with the PrP*-protein X complex and induces the conversion of 
PrP* to PrPSc (Telling et al., 1995).  
 
The model most widely accepted has been referred to as the ‘seeded polymerization’ 
or noncatalytic nucleated polymerization of PrPc by aggregated PrPSc in a two-step 
process (binding and conversion). In this model, PrPSc is less stable than PrPc but is 
stabilized upon binding to the PrPSc aggregate (Jarrett & Lansbury, 1993; Gajdusek, 
1988), consistent with observations of cell-free conversion studies that indicate PrPSc 
aggregates are able to convert PrPc into a protease-resistant PrP isoform (Caughey et 
al., 1997; Kocisko et al., 1994). Here the energy barrier exists at the initial nucleation 
step, where formation of small aggregates is unfavourable because the free energy 
gained from intermolecular interactions does not overcome the entropic cost of 
binding until the energy threshold determined by a minimum size nucleus is attained. 
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Introduction of a seed, i.e. infection with PrPSc, would circumvent the slow step of 
nucleation. There are biological precedents of such models. Flagellin is a monomeric 
unit and is incorporated into the growing end of a flagellum. Monomers in solution 
are conformationally unfavorable to spontaneous nucleation but if a seed of 
fragmented flagellum is added, then polymerization rapidly ensues. Interestingly, the 
polymerizing monomers can assume the conformation of even heterologous seed 
material, reflecting the template ‘behaviour’ (Asakura et al., 1964; Asakura et al., 
1966). 
 
How this process might result in neurodegeneration is currently unknown but it is 
possible that the PrPc has an antioxidant effect which is lost, accompanied by the 
addition of a gain of cytotoxicity (Giese & Kretzchmar, 2001). A recent structural 
study compared the Doppel protein (a PrP paralog which is topologically identical to 
PrP but does not undergo structural rearrangements) with disease-associated PrP. The 
results indicated that the prion protein contains at least two sequence fragments with 
highly unusual intrinsic properties, PrP (114–125) and helix B. Also, it was possible 
to determine that most PrP mutations associated with neurodegenerative disorders 
had increased local hydrophobicity. It was therefore suggested that the observed 
increase in hydrophobicity may facilitate PrP-to-PrP and/or PrP-to-cofactor 
interactions, and thus promote structural conversion (Kuznetsov & Rackovsky, 
2004). In reality, it is highly possible that the models may not be mutually exclusive, 
biological precedent indicating overlapping aspects of both. Figure 1.3 is a schematic 
of possible mechanisms and sites of PrPc synthesis and PrPc-PrPSc conversion. 
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Figure 1.3. Normal PrPc synthesis and cell turnover with possible sites of conversion to PrPSc.  
Although mechanisms of toxicity and neurotoxicity remain unresolved, it is known that PrP 
accumulating in the cytosol forms aggregates, and once present, continue to persist. PrPSc synthesis 
followed by degradation and clearance of misfolded proteins from the ER must be kept in complete 
control and is a finely balanced function. Compromise of quality control in endoplasmic reticulum 
protein synthesis mean that this harmful soluble conformer are allowed to accumulate. DRM, 




1.4 PATHOLOGICAL MECHANISMS 
1.4.1 Clinical Features of vCJD 
Particular combinations of clinical features distinguish the different forms of CJD. 
The most common form is classical (sporadic) CJD, which exhibits diverse clinical 
features according to the particular physical and chemical properties of PrPSc and the 
codon 129 genotype of the patient. In contrast, vCJD displays a relatively consistent 
clinical phenotype distinct from all other human prion diseases. sCJD onset generally 
occurs at a mean age of 66 years (range 20-95), whereas cases of vCJD show a 
downward shift in average age, with a relatively young age of onset for 
neurodegenerative diseases (mean 29 years, range 14-74). sCJD symptoms progress 
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extremely rapidly, over days or weeks. vCJD has a significantly longer pre-clinical 
phase and relatively slow progression. Initial symptoms are usually psychiatric; 
patients present with depression, delusions, anxiety and withdrawal. Within a median 
of 6 months, multiple clear neurological features develop, including cognitive 
impairment, progressive cerebellar syndrome with gait and limb ataxia and 
myoclonic jerks, always eventually leading to dementia and death occurring a 
median 14 months from onset (range 6-39mnths) (Will et al., 2000). 
 
1.4.2 Histopathology of vCJD 
The pathological features of TSE diseases have long been characterized and 
neuropathological assessment has remained the definitive tool to providing a 
diagnosis. For surveillance purposes, confirmation of diagnosis is done by 
neuropathological examination, and in research, it has allowed the discovery of new 
disease subtypes. A range of investigative techniques, including PrP gene analysis, 
PrP immunocytochemistry and detection by Western blot, histoblot and immunoblot 
techniques, prion rod/SAF detection by electronmicroscopy and transmissibility to 
both wild-type and transgenic laboratory animals are all used as diagnostic 
applications. However, the underlying mechanisms leading to this pathology are not 
understood.  
 
CNS neuropathology of human prion diseases are characterised by five features; 
spongiform change in the CNS, neuronal loss, astrocytosis, microglial proliferation 
(gliosis) and amyloid plaque formation. Histological analysis can be complicated by 
age-associated histological abnormalities and must be distinguished from any 
coexisting CNS disorder. Table 1.1 lists the neuropathological features generally 
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CONSISTENTLY OBSERVED IN 
TSE’s 
Abnormal PrP deposition* 
PrP amyloid plaques * 
Status spongiosus 
Neuronal swelling 
Abnormal neuritic dendrites 




Beta amyloid protein deposition 
Table 1.1. Histopathological changes in human prion diseases. *Indicates histopathological feature 
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Figure1.4. Characteristic neuropathological changes observed in vCJD. (a) A distinctive 
diagnostic neuropathological abnormality observed in vCJD cases is the florid plaque. These comprise 
an eosinophilic core and a pale radial periphery and are most frequently observed in the occipital , 
cerebral and cerebellar cortexes. This section of the frontal cortex from a case of vCJD shows several 
florid plaques and patchy spongiform change (Haematoxlin and eosin, x 200 (b) The spongiform 
change occurs in many forms of human TSE and in vCJD is usually most severe within the basal 
ganglia, thalamus and cerebellar cortex. Vacuoles may also coalesce resulting in complete collapse of 
the cytoarchitecture. Confluent spongiform change from a case of vCJD is evident in the basal ganglia 
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(Haematoxlin and eosin, x100) (c).Marked neuronal loss can be extensive in vCJD and occurs in all 
layers of the cerebellar and cerebral cortex but is most severe in the anterior and medail thalamus. 
This section of the dorsomedial nucleus of the thalamus in vCJD shows almost total neuronal loss and 
marked astrocytosis (Haematoxlin and eosin, x200) (d). Immunohistochemical staining using an 
antibody to GFAP as a marker for active astrocytes shows widespread gliosis in this section of the 
dorsomedial nucleus of the thalamus in vCJD (GFAP, x200) (e). Immunohistochemistry for prion 
protein in vCJD shows intense labelling of the florid plaques and smaller cluster plaques, with 
widespread pericellular positivity within the frontal cortex (KG9 anti-PrP antibody with Haematoxylin 
counterstain, x 200). (f).Immunohistochemical staining using an anti-CD68 antibody demonstrates 
activated microglia from a section of the occipital cortex. Some of the fine cellular processes are 
located towards the periphery of the florid plaques (PGM1(anti-CD68 antibody) with haematoxylin 
counterstain, x100).  
 
Spongiform change, as distinct from non-specific vacuolation which occurs in a 
multitude of disorders as a consequence of neuronal loss, was first characterised as 
being a CJD specific neuropathy by Masters (Masters & Rishardson, 1978). In vCJD, 
spongiform change is most prominent within the cerebral cortex, occipital and 
inferior frontal cortex. Confluent spongiform change is rare in these regions but more 
common in the caudate nucleus and putamen, often without numerous amyloid 
plaques. Florid plaques, defined as diffuse or focally clustered (morula-type) small 
discrete round or oval vaculoles in the neuropil of the whole depth or deep layers of 
the cerebral cortex, cerebellar cortex (predominantly molecular and granular layer) 
and subcortical grey matter (Budka et al., 1995), were seen previously only in 
scrapie and are a particularly unusual but highly consistent feature. Florid plaques are 
readily identifiable on haematoxylin and eosin staining as lesions comprising of an 
eosinophilic central core with radiating fibrils in the periphery of the plaque, which 
are surrounded by a rim of spongiform change in an otherwise intact neuropil 
(Figures 1.4a). PrP deposition patterns in vCJD are quite unique to the disease. 
Amorphous PrP deposition is mainly observed in a pericellular (neuronal and 
astrocytic) pattern in all areas of the cerebral and cerebellar cortex and around 
capillary walls, with additional synaptic accumulation evident in the thalamus 
(Figure 1.4e). PrP accumulation is less evident in other cortical regions. Astrocytosis 
is widespread and does not correlate with the presence of amyloid plaques but rather 
with neuronal loss. Posterior thalamic gliosis is particularly marked in vCJD. 
Neuronal loss is most evident in the occipital cortex and the cerebellum, with severe 
loss in the posterior thalamic nuclei and the dorsomedial nucleus, accompanied by 
severe astrocytosis. As described, these pathological features do not occur uniformly 
throughout the brain, but are consistently focused at certain neuronal regions, a 
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phenomenon called neuropathological targeting (Bell & Ironside, 1993). Western 
blot analysis of PrPres from vCJD brain shows a highly consistent pattern, termed 
type 2B, and is characterized by a 19kDa non-glycosylated fragment with a 
predominance of the diglycosylated form (Collinge et al., 1996; Parchi et al., 1997). 
 
1.4.3 Pathological Mechanisms 
Many of the key issues of how PrPSc or PrPc carrying mutations might cause 
neurodegeneration are still unclear. Numerous studies show that abnormal forms of 
the prion protein play a predominant role in both the etiology and the pathogenesis of 
all forms of prion disorders. Neuronal loss caused by the accumulation and/or 
conversion of PrP is the pivotal event of neurodegeneration, but how the process of 
conversion and aggregation causes neurodegeneration is unknown. Proposed 
mechanisms of neurodegeneration include; loss of cytoprotective properties 
associated with PrPc , acquisition of cytotoxicity properties of PrPSc (Giese & 
Kretzchmar, 2001), increased oxidative stress (Gotz et al., 1994; Beal, 1995), 
dysfunction of iron (Gerlach et al., 1994), copper (Jobling et al., 2001; Quaglio et al., 
2001) and calcium metabolism (Thellung et al., 2000; Florio et al., 1996). 
GAIN OF FUNCTION 
Many of the pathogenic properties of PrPSc, such as neurotoxicity, proteinase-
resistance and induction of hypertrophy and proliferation of astrocytes, have been 
attributed to the peptide fragment corresponding to residues 106–126 (PrP[106–126]) 
(Forloni et al., 1993). Neurotoxicity studies use either this fragment or purified PrPSc, 
although it must be noted that PrP [106-126] may not fully encapsulate normal PrP 
physiological or structural properties. Neuronal expression of PrPc is essential for 
cellular neurotoxic damage; neurons not expressing PrPc are resistant to in vitro 
PrP[106-126 ] toxicity (Brown et al., 1994) and in vivo neurodegeneration (Bueler et 
al., 1993). Additionally, overexpression of PrPc increases cellular toxic sensitivity to 
the fragment (Brown, 1998). Investigations have also revealed that in culture, 
microglia mediate neurotoxic cell damage; neurons are resistant to fragment 
mediated cell-death after depletion of contaminating microglia (Brown et al., 1996). 
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However, this has only been observed in vitro and needs to be reproduced in vivo to 
validate its biological relevance.  
 
Toxic gain of function properties possessed by PrPSc unrelated to the normal 
physiological function of PrPc may be causative of neuronal death. Indeed co-
localisation of accumulated PrPSc and neuropathy indicates a toxic effect is exerted 
by PrPSc. It has been suggested that the toxic effects arise from blocked axonal 
transport, interference with synaptic function or activation of apoptotic pathways. 
Mice expressing a PrP mutation without the N-terminal ER-targeting signal sequence 
spontaneously developed neurodegeneration when the mutant protein was 
synthesised in the cytosolic compartment (cytoPrP) (Ma et al., 2002). cytoPrP 
neurotoxicity is dependent on association with intracellular membranes and Bcl-2 (an 
antiapoptotic protein present at the cytosolic side of ER and mitochondrial 
membranes) (Wang et al., 2006; Rambold et al., 2006). It has also been shown that 
PrPSc inhibits the 26S proteosome and causes dysfunction of the ubiquitin-
proteosome system (UPS) in prion infected mice (Kristiansen et al., 2007) and 
compromised proteosome activity increases PrP accumulation in the cytosol, via 
retrograde transportation out of the ER, and generates amorphous partially PK 
resistant PrP aggregates (Ma & Lindquist, 2001). Interestingly, inherited human 
pathogenic PrP mutants are partially mis-targeted to the cytosol (Zanusso et al., 
2000). However, the recent demonstration of PK-resistant PrP core fragments in non-
CJD brains argues against PrPSc neurotoxicity; small quantities of abnormal prion 
may not be pathogenic and these might be lying dormant in many human brains 
(Yuan et al., 2006). 
 
LOSS OF FUNCTION 
Prenatal ablation of PrP confers resistance to prion infection (Bueler et al., 1993) 
whereas postnatal depletion of neuronal PrP can prevent neuronal loss and reverse 
early spongiform change with no progression to clinical disease (Mallucci et al., 
2003). These observations argue against a loss of function being causative for 
pathology. However it is possible PrPc may possess a biological activity that is lost 
upon conversion into PrPSc, or the loss of function exacerbates pathology caused by 
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toxic gain or other functional mechanism, leading to neurodegeneration. Evidence 
for this was first observed in cell culture experiments with primary neurons. Prnp-/- 
cells underwent apoptosis within 4 days when serum was removed from cell cultures, 
but showed greater survival after transfecting with PrPc expression vectors 
(Kuwahara et al., 1999). In vivo experiments demonstrated larger infarct volumes 
after ischaemic brain injury in PrPc-knockout mice  (McLennan et al., 2004).  Anti-
apoptotic function of PrPc has also been proven in in vivo and in vitro modeling 
systems ( Roucou & LeBlanc, 2005). Figure 1.5 is a schematic representation of 
















Figure 1.5. Possible implication of neuronal death in prion diseases. Schema representing the 
processes underlying prion pathology. Three types of cells that are known to be involved in the 
pathophysiology of prion diseases, but the exact involvement and method of cell death have yet to be 
determined. ECM, extracellular matrix. Modified from (Rezaie & Lantos, 2001). 
 
 
OXIDATIVE STRESS AND ANTIOXIDANT STRESS DEFENCE 
Oxidative stress induced by reactive oxygen species (ROS) or free radicals has been 
suggested as a causal factor in the pathogenesis of Alzheimer’s as well as prion 
diseases (Guentchev et al., 2000). The CNS is particularly vulnerable to oxidative 
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large amounts of lipids and metals capable of free-radical formation, all increase 
susceptibility to damage (Halliwell et al., 1992). Dysfunction of any of several 
interconnected cellular pathways is sufficient to cause oxidative stress in the brain, 
including impaired mitochondrial function, increased oxidative damage, defects in 
the ubiquitin-proteosome system, presence of aggregated proteins, excitotoxicity and 
inflammation. Neurodegenerative disorder brain tissues have been observed to have 
higher levels of oxidant by-products (Gotz et al., 1994; Beal, 1995). The potential 
link between oxidative stress and prion diseases is marked by two pathophysiological 
events; 1) enhanced production of ROS and reactive nitrogen species (RNS), 2) 
impairment of the cellular oxidative stress defense. 
 
Primary neuronal cultures were only affected by PrP [106-126] toxicity when 
activated microglia were present to respond by production of oxygen radicals (Brown 
et al., 1996). In scrapie-infected mice, increased free radical generation, including 
superoxide anion (O2-), was coupled with an increase in oxidative stress markers, 
malondialdehyde (MDA) and heme oxygenase-1 (HO-1). Conversely, an antioxidant 
enzyme (Cu/ZN-superoxide dimutase (SOD)) remained unaffected, while a 
mitochondrial enzyme (Mn-SOD) involved in scavenging O2- was markedly 
decreased (Choi et al., 1998; Choi et al., 2000; Lee et al., 1999). Although the latter 
observation has not been reproduced (Waggoner et al., 2000; Hutter et al., 2003). 
The accumulation of iron has also been linked to brain pathology, as iron potentiates 
oxygen toxicity via a reaction termed the iron-catalyzed Harber-Weiss reaction. For 
example, in the presence of iron, superoxide anion and hydrogen reoxide can easily 
be converted into more dangerous species, such as highly reactive hydroxyl (˙OH) 
radicals (Halliwell et al., 1992). Evidence for this was observed in scrapie mice 
models, where levels of total iron and ferric iron (Fe3+) were significantly increased 
(Kim et al., 2000).  The presence of high levels of ferric iron may exacerbate 
oxidative damage as it induces hydroxyl radical formation and lipid peroxidation 
(Ben-Shachar et al., 1991). Elevated ROS generation, changes in iron levels and in 
iron redox states, in conjunction with lowered scavenging activity in mitochondria 
might lead to free radical damage to neuronal cells in neurodegenerative disorders. 
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PrPc has been shown to have direct antioxidative protective effects as seen by 
comparison of wild type and PrP null mouse lines. Cell cultures derived from PrP0/0 
mice have increased susceptibility to agents that induce oxidative stress and brain 
tissue from PrP0/0 mice also exhibits biochemical changes indicative of oxidative 
stress (Brown et al., 1997b; Brown et al., 2002; Wong et al., 2001). PrPc itself has 
been reported as having intrinsic SOD-line activity, which can be inhibited by the 
addition of PrP [106-126], although this observation may not be biologically 
relevant, as supra-physiological concentrations of copper were required for 
enzymatic activation (Brown et al., 2001). PrPc may also act indirectly to protect 
cells from oxidative stress by up-regulating the activities of ROS detoxifying 
proteins, such as Cu-Zn or Cu-dependent SOD. PrP0/0 mice have 10-50% less Cu-Zn 
SOD activity (Brown et al., 1997b; Klamt et al., 2001), although these observations 
have failed to be reproduced by others (Waggoner et al., 2000; Hutter et al., 2003). 
PrPc contains a unique octapeptide-repeat sequence at its N-terminal region (51-90). 
ROS provoke cleavage of the cellular prion at the octagon repeat, which is also the 
region at which copper-binding occurs (McMahon et al., 2001). Defects in copper 
metabolism may affect copper-dependent SOD, diminishing its enzymatic ability to 
detoxify ROS (Brown et al., 2001; Brown et al., 1999) although again, these findings 
have not been replicated (Jones et al., 2005). Figure 1.6 illustrates potential roles of 











Figure 1.6. Possible role of oxidative stress in neurodegeneration in prion diseases. 
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(Kim et al., 2001).  
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ENDOPLASMIC RETICULUM STRESS 
The endoplasmic reticulum (ER) carries out numerous fundamentally important 
functions including; post-translation modification, folding and assembly of newly 
synthesized proteins, biosynthesis of proteins, steroids, cholesterol and other lipids 
and calcium storage and calcium signaling. Critically, it also discriminates between 
normal (native) and abnormal proteins, initiating retro-translocation of misfolded 
proteins for degradation. Therefore, the ER is extremely sensitive to changes that 
may affect its structure, integrity and function. Dysfunction or loss of integrity of the 
ER leading to stress can be caused, for example, by accumulation of unfolded 
proteins and by changes in calcium homeostasis within the ER. Such stress elicits 
cellular responses which confer protective effects against the toxic buildup of 
misfolded protein. If accumulation is excessive or if ER dysfunction is severe or 
prolonged, a signaling cascade termed the unfolded protein response (UPR) becomes 
activated, increasing expression of chaperones and folding enzymes that decrease 
unspecific aggregation or targets misfolded proteins to proteasome-mediated 
degradation (Sitia & Braakman, 2003). If the UPR is unable to rectify ER folding 
capacity, death pathways mediators are induced, ultimately leading to organelle 
dysfunction and cell death (Breckenridge et al., 2003). Cell culture studies have 
suggested that PrPc-PrPSc conversion occurs post-translationally on the cell surface or 
in the endocytic pathway, although the precise subcellular compartments, the 
molecular mechanisms of this process and the pathways that links ER stress to 
programmed cell death remain poorly understood (Borchelt et al., 1992; Caughey & 
Raymond, 1991). 
 
Wild-type PrP staining patterns suggests localization to an intracellular compartment, 
most likely the perinuclear Golgi. In contrast, mutant PrP localized in a more 
widespread pattern, largely with the ER marker protein disulphide isomerase, where 
delayed biosynthesis and export out of the ER resulted in increased protein 
concentrations within the ER (Ivanova et al., 2001; Piccardo et al., 1990). It is 
possible that the delayed transportation of mutant PrP within the ER is due to post-
translational modifications conferring proteinase K (PK) resistance and detergent 
insolubility properties to PrPSc (Caughey et al., 1991). In addition, retrotransport of 
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PrPc from trans- Golgi compartments toward the ER occurs in scrapie -infected 
neuroblastoma cells (Taraboulos et al., 1992). However brefeldin A, an ER-Golgi 
trafficking inhibitor, results in decreased levels of PrPSc, suggesting that the ER alone 
is insufficient for PrPc-PrPSc conversion and requires transition via the endocytic 
pathway to the Golgi (Taraboulos et al., 1992; Hetz et al., 2007).  
 
Several ER-related chaperones are up-regulated and the ER-related intrinsic 
apoptotic pathway mediator caspase-12 is activated in vitro in human and 
experimental prion diseases. PKR-like endoplasmic reticulum kinase (PERK) and its 
downstream effector, eukaryotic translation initiation factor 2α (eIF2α), are both 
activated in AD pathology but have normal expression levels in prion pathology 
(Unterberger et al., 2006). Glucose-regulated proteins (GRPs) are Ca2+-binding 
chaperones with ER protective properties. In scrapie murine models, accumulation of 
PrPSc was closely followed by induction of the ER chaperone Grp58, but not Grp78 
or GADD153/CHOP, indicating that Grp58 induction is a specific response to prion 
replication (Rao & Bredesen, 2004). Figure 1.7 illustrates the ER stress pathways 
which may be modulated during prion infection. 
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Figure 1.7. Signal transduction events associated with ER stress.  Accumulation of misfolded 
proteins in the ER can disrupt ER function resulting in ‘ER stress’. The ER responds by triggering 
specific signaling pathways including the unfolded protein response (UPR). The UPR is co-ordinately 
regulated by the three proximal sensors, IRE1, PERK and ATF6. The activation of all three proximal 
sensors results in reduction in the amount of new protein translocated into the ER lumen, increased 
degradation of ER-localized proteins and increased protein folding capacity of the ER. ATF6DC 
represents the 50 kDa cytosolic bZIP-containing fragment that translocates to the nucleus to activate 




PrPc attaches to the lipid bilayer membrane via a GPI-anchor and resides in lipid raft 
domains which serve as molecular scaffolds for signal transduction (Mouillet-
Richard et al., 2000). Since the PrPc polypeptide chain is entirely extracellular, 
transmission of signals into the cytoplasm would require interaction with 
transmembrane adaptor proteins. This has raised interest in identifying PrP cell-
surface signaling or cell adhesion functions, and whether loss, gain or subversion of 
these functions accounts for the pathological outcome. PrPc may mediate signal 
transduction pathways directly, although to date it has not been possible to elucidate 
how this may occur, or indirectly by activating transmembrane signaling pathways, 
either constitutively or by interaction with specific ligands. One example of this is 
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activation of a tyrosine kinase (Fyn) by PrPc. Serotoninergic or noradrenergic 
neurons exhibit Fyn activity under the mediation of caveolin-1 and possibly clathrin 
(Williams et al., 1994). Activated glial cells are a prominent feature of prion 
diseases; these are generally confined to regions of vacuolation and PrP deposition 
(Brown et al., 1996). This is consistent with the observation that PrP neurotoxicity 
requires microglial cells (Diedrich et al., 1991a). Time course experiments have 
established that microglial activation precedes neuronal death and prion protein is 
known to accumulate in astrocytes prior to neuropathological changes in scrapie 
(Williams et al., 1997; Giese et al., 1998). Therefore glial activation is not just a 
sequelae of cell destruction (Peyrin et al., 1999). Induction of proinflammatory 
microglial cytokines have been shown (IL1β, IL6 and TNFα ) and actrocytes up-
regulate glial fibrillary acidic proteins (GFAP) (Kim et al., 1999; Campbell et al., 
1994; Williams et al., 1994), however results show that the aging brain displays a 
pro-inflammatory gene expression profile similar to prion-infected brain, therefore 
the role of glial cells and the interactions of PrP with signal transduction pathways in 
TSE disease remain unclear. 
 
Reactive oxygen species (ROS) have been suggested as intracellular effectors in gene 
regulation and may be involved in signal transduction pathways. Among the most 
important pathways affected by oxidants are the NF-κB signalling pathways (Kim et 
al., 1999). The NF-κB/Rel family of transcription factors is important in the 
regulation of numerous genes involved in mediating inflammatory and immune 
responses to stress (Vassallo et al., 2005; Weise et al., 2006). Immunostaining for 
activated NF-кB localizes with reactive astrocyte and PrP-amyloid plaques (Ju et al., 
1998). Representative target genes for NF-кB pathway activation also show 
significant increases in scrapie models (Baeuerle & Henkel, 1994). PrPc may also 
activate the PI3/Akt pathway to modulate neuroprotective effects during stress.  
Prnp-/- mouse brain tissue shows reduced Akt pathway activity relative to Prnp+/+ 
brain tissue when subjected to ischemic brain injury. Moreover, pharmacological 
inhibition of Akt reduced the ability of PrPc to protect cells against oxidative insult 
(Mironov et al., 2003). 
 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 1   Introduction 
 26
PrP TRAFFICKING AND CHOLESTEROL 
When PrP accumulates in the cytosol, neurotoxicity and neurodegeneration are 
observed (Magalhaes et al., 2002; Ma et al., 2002). The exact mechanism of how this 
occurs has not been elucidated, but provides a possible explanation as to how 
heritable and transmissible forms of the same disease can share certain characteristic 
pathological changes. Access of PrP to the cytoplasm of neurons and the endocytic 
processes involved would be a commonality between all forms of the disease. 
Internalisation of PrPc co-localises with endosomal markers and FM4-64 (Borchelt et 
al., 1992). Involvement of the endocytic recycling pathway adds evidence to findings 
that the initial steps in conversion may take place on the plasma membrane or 
immediately following internalisation of PrPc (Shyng et al., 1994; Shyng et al., 1995; 
Madore et al., 1999).  
 
Surprisingly, clathrin coated pits and vesicles are primarily responsible for the 
endocytic uptake of PrPc. GPI-anchored proteins lack cytoplasmic domains and are 
unable to directly interact with adapter proteins and clathrin. Nonetheless, uptake of 
PrPc is mediated by recognition of the N-terminal sequence; deletions in this region 
diminish internalisation efficacy (Gauczynski et al., 2001; Horonchik et al., 2005; 
Hijazi et al., 2005; Zanata et al., 2002).  It is highly likely that there is a putative PrPc 
receptor containing a transmembrane domain, a localisation signal within its 
cytoplasmic domain and a extracellular domain binding the N-terminal of PrPc. 
Currently this putative ligand has not been identified, although candidates have been 
suggested including laminins and glycoaminoglycans (Madore et al., 1999; Parkyn et 
al., 2008). 
 
PrPc, like other GPI-anchored proteins, resides in raft-like microdomains of the 
plasma membrane believed to be foci for signal transduction events (Hugel et al., 
2004; Tarraboulos et al., 1995). Indeed, raft location of PrPc is a prerequisite for its 
involvement in signal transduction (Vey et al., 1996). In addition, there is growing 
evidence to suggest an integral role of lipid rafts with PrPSc conversion; first, both 
PrPc and PrPSc co-localise to rafts (Taraboulos et al., 1995b; Bate et al., 2004); 
second, cholesterol depletion and thus lipid raft dissociation redistributes PrPc 
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outside rafts, decreases formation of PrPSc and reduces PrPc degradation in prion 
infected cell lines (Kaneko et al., 1997); and thirdly, recombinant transmembrane 
forms of PrPc which do not localised to rafts are not substrates for the formation of 
PrPSc (Kazlauskaite & Pinheiro, 2005; Taylor & Hooper, 2006).  
 
Previous links between cholesterol levels and/or metabolism and AD development 
indicated the possibility of a similar link in prion disease pathogenesis. Low-density 
lipoprotein (LDL) receptor-related protein (LRP) is involved in the clearance of 
amyloid deposits (Kazlauskaite et al., 2003). Studies have shown that modifying 
cholesterol levels disrupts lipid raft formation and thereby prion conversion. 
Furthermore, binding of PrP to lipid membrane causes structural changes to PrP 
depending on the environmental conditions. Membrane-induced alteration in 
conformation can lead to amporphous protein aggregation or formation of amyloid 
fibrils and can cause integrity destabilization of the lipid bilayer (Chandler, 1961; 
Chandler & Turfrey, 1972).  
 
 
1.5 MODEL SYSTEMS 
 
Transgenic models have been fundamental in understanding the normal and 
abnormal function of the PrP protein. TSE transmission experiments to mice were 
first introduced in the 1960’s and to hamsters in the 1970’s (Nonno et al., 2006). 
Experimental scrapie models have typically been used as representative of TSE 
diseases, although experimental CJD models have also been developed. More 
recently, bank voles have been described as being susceptible to CJD (Bruce et al., 
1991; Bruce, 2003). Availability of inbred mouse strain has enabled standardisation 
of brain lesion profiling and characterisation of TSE strain types (Bueler et al., 1993; 
Bruce et al., 1991; Moore et al., 1995; Manson et al., 1994; Sakaguchi et al., 1996). 
Two approaches to generating transgenic mice have been described; 1) by 
homologous recombination of defined genetic alterations or gene of interest 
introduced at the defined site of integration in the mouse genome of transfected 
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murine stem cells or 2) by direct microinjection of a transgenic DNA sequence 
encoding the gene of interest into the pronucleus of a mouse oocyte which leads to 
insertion of the transgene randomly into the mouse genome. Transgenic mice 
harbouring modifications of the endogenous murine PrP gene (produced by gene 
targeting) permits modifications to be introduced in situ. Therefore, the gene can be 
altered within its natural context, being in the correct genomic location and under the 
control of the normally regulated expression components. This is particularly useful 
as any alteration in the disease must therefore be attributed to the modification and 
this is essential for the direct comparison of different transgenic lines. 
 
A number of PrP knockout mouse lines have been produced using gene targeting to 
investigate the role of PrPc in normal and diseased tissues. Phenotypically, PrP0/0 are 
overtly normal at the macroscopic, microscopic and behavioural levels, with subtle 
differences which may be attributed to other genes compensating for lack of PrP 
rather than the absence of the endogenous/original PrP. All four extant lines of null 
mice are resistant to scrapie (Fischer et al., 1996). Furthermore, when a murine PrPc 
transgene is reintroduced into these mice, they become susceptible to infection 
(Westaway et al., 1991; Scott et al., 1989). Mutant PrP expression models which 
over- or under-express either the endogenous or heterologous species of prion have 
demonstrated a link between expression levels of PrP and disease progression. Over-
expression of the PrP gene leads to shorter incubation times, provided the inoculating 
strain is compatible with the origin of the transgene. The efficiency of transmission is 
affected by the donor PrP versus recipient PrP compatibility but may also be 
influenced by strain specific effects. This observation has prompted development of 
a wide range of transgenic mouse lines expressing human, mink, bovine, ovine, 
caprine, cervid and mouse PrPc (Hsiao et al., 1990; Westaway et al., 1994). Over-
expression can also result in spontaneous disease, which can be transmissible 
(Manson, 1996; Bueler et al., 1993). The effects of under-expression of PrP have 
emerged from observation of heterozygous offspring from the production of PrP0/0 
mice. Such offspring contain only one functional copy of murine Prnp gene, and 
when inoculated with various TSE strains, have exhibited relatively longer 
incubation times than wild-type controls (Xiang et al., 2004; Skinner et al., 2006; 
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Baker & Manuelidis, 2003; Brown et al., 2004; Brown et al., 2005a; Sorensen et al., 
2008; Dandoy-Dron et al., 2000; Booth et al., 2004; Riemer et al., 2004). 
 
Recent transcription-profiling studies have found distinct gene-expression patterns in 
diseased tissue of a number of model systems, shedding light on the principal 
mechanisms involved in TSE disease (Vuong et al., 2000; Brown et al., 2004; Brown 
et al., 2005a; Huber, 2003; Fountolakis, 2004). Comprehensive genome-wide studies 
screen for molecular changes associated with TSEs and identify host genes which 
exhibit modified expression patterns. The expression pattern of a gene or gene 
product during disease may provide insight into cellular processes which are a cause 
or a consequence of disease. The human genome encodes >30,000 genes and it is the 
selective expression of a specific subset of these genes under defined conditions 
which gives the cell or tissue type its phenotype. Dynamic gene expression can be 
studied using two approaches. Quantification of mRNA levels, or transcriptome 
analysis, identifies the particular response of the cells to an insult (i.e. TSE infection) 
by modification of the transcriptional program. However, the expression of many 
genes is regulated after transcription, so an increase in mRNA concentration need not 
always increase expression. In addition, analysis of relative mRNA expression levels 
can be complicated by the fact that relatively small changes in mRNA expression can 
produce large changes in the total amount of the corresponding protein present as 
there is no strict linearity between gene expression and steady-state protein level. 
Alternatively, proteomic analysis measures the entire complement of proteins 
expressed at a given time point under defined conditions. It is estimated that the 
average protein undergoes between 2 and 20 post-translational modifications such as 
amino- and carboxyl-terminal cleavage, phosphorylattion, glycosylation and 
myristoylation, greatly increasing the protein isoforms present in cells and 
complicating proteome studies (Gorg et al., 2004; Santoni et al., 2000). Proteomics is 
a relatively new field and has certain disadvantages; technologically, it is not suited 
to high-throughput methodologies, is much harder to standardise and requires large 
amounts of protein. Proteins, and particularly their modifications, are less stable than 
RNA and are susceptible to degradation. Detection methods are not as sensitive as 
RNA methods and, confounded by the unavailability of amplification method like 
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PCR, are unable to detect certain classes of proteins i.e. hydrophobic membrane 
bound and low or high molecular weight . Nonetheless, transcriptomics and 
proteomics are complementary technologies, combining genotype and phenotype 
data to further the understanding of the neurobiology of disease. 
 
Previously published mouse and human brain gene expression studies have identified 
commonly altered pathways during TSE infection. Oxidative and ER stress, activated 
ER and mitochondrial apoptosis pathways and activated cholesterol biosynthesis 
were identified in  ME7/CV mouse scrapie models (Brown et al., 2005a). Increased 
mRNA levels for inflammatory response, proteolysis and signal transduction genes 
were also observed (Riemer et al., 2004; Xiang et al., 2004). In sCJD human brain, 
similar genes involved in stress-response factors and elements involved in cell death 
and down-regulation of genes encoding synaptic proteins have been identified 
(Xiang et al., 2005). The large data volumes generated from gene expression studies 
can be confusing; however fundamental changes which are causative in TSE 
pathology should be common to all types of TSE. The finding that scrapie responsive 
genes are comparably altered in BSE-infected mouse brain suggests common 
pathogenic events occur in different TSEs (Dandoy-Dron et al., 2000). Comparative 
transcriptome analysis of brains from experimental mouse TSE, BSE, sheep scrapie 
and human TSEs are therefore warranted and needed. A number of gene expression 
studies on TSE infected mouse brain exist as does a study of sCJD brain (Brown et 
al., 2004; Brown et al., 2005a; Riemer et al., 2004; Xiang et al., 2004; Xiang et al., 
2005). Studies on the BSE infected cow brain and the scrapie infected sheep brain 
are in progress.  This project investigates the feasibility of studying the transcriptome 
of the human vCJD brain. 
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AIM: 
Extract and characterize RNA from human autopsy vCJD and control brains, 
determine pre- and post-mortem factors affecting quality and quantity of this 
RNA and carry out preliminary studies to determine its suitability for gene 
expression studies. 
OBJECTIVES 
• Establish safe protocols for the extraction of RNA from human post-mortem 
vCJD and control brain material; 
• Determine whether it is possible to remove infectivity, as defined by PK 
resistant PrP detection, from RNA preparations derived from TSE infected 
human brain material; 
• Determine suitable assays for assessment of yield and quality of this RNA; 
• Assess the quality and quantity of RNA isolated from human autopsy brain 
material. 
• Assess whether pre- and post-mortem parameters affect RNA yield and 
quality; 
• Identify RNA preparations (case control and RNA quality) suitable for 
comparative transcriptome analysis; 




This study addresses two hypotheses: 
1.  That the quality and yield of RNA preparations from human post-mortem brain 
material are related to pre- and post-mortem factors. 
2.  That RNA preparations isolated from human autopsy material is suitable for 
microarray comparison of gene expression in vCJD and control brain. 
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2 MATERIALS AND METHODS 
 
2.1 RNA EXTRACTION PROTOCOL 
2.1.1 RNA Extractions 
All procedures were conducted entirely in the Class 1 microbiological safety cabinet 
in the Category 3* high risk lab wearing standard gown and disposable high-risk 
over-gown, protective footwear, protective eyewear and double gloves.  
 
Tissues were removed from RNAlater (Ambion Biosystems, Warrington, UK) and 
80 – 100 mg dissected for homogenisation. A freezer cooled, RNase-free plastic 
micro-pestle (Eppendorf, Cambridge, UK) was used to homogenise the sample. RNA 
was extracted using the Rneasy lipid tissue mini kit (Qiagen, Crawley, UK), with an 
extra phenol:chloroform extraction as described by Maniatis et al (Maniatis et al., 
1982). RNA was stored at –80ºC in RNase/ DNase-free TE-buffer pH 8.0 (Sigma-
Aldrich, Dorset, UK).  
 
Qiagen RNeasy Lipid tissue RNA Extraction  
Total cellular RNA was isolated from the samples using the RNeasy Lipid Tissue 
mini kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. Briefly, 
1000 µl of Qiazol was added to a 100 mg sample, and the mixture was homogenised 
using a pre-chilled RNase-free plastic micro-pestle (Eppendorf, Cambridge, UK) for 
cell lysis.  After homogenation, 200 µl chloroform (Sigma-Aldrich, Dorset,UK) was 
added and the mixture was vortexed. The subsequent aqueous and organic layers 
were separated by centrifugation (FastPrep-120; Q BIOgene) at 12,000 x g for 15 
minutes at 4°C. The upper aqueous phase containing the RNA was removed and 200 
µl of 70% ethanol (Sigma-Aldrich, Dorset, UK) was added to adjust binding 
conditions. The mixture was applied to the silica-gel matrix and centrifuged through 
at 8,000 x g for 15 seconds to allow RNA to adsorp to the membrane (Qiagen, 
Crawley, UK). Contaminants were washed through by wash spins (8,000 x g for 15 
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seconds) using wash buffers supplied with the kit (RW1 and RPE).  RNA is then 
eluted in > 30 µl RNase-free H2O (supplied in kit). 
 
Phenol:chloroform RNA extraction 
Total RNA samples were then re-extracted using phenol:chloroform extraction 
protocol as described by Maniatis et al (Maniatis et al., 1982). Briefly, RNA sample 
were made up to 300 µl using RNase-free TE-buffer (Sigma-Aldrich, Dorset, UK) 
and carrier transfer RNA (tRNA) (final concentration 0.1mg/ml) (Sigma-Aldrich, 
Dorset, UK). 300 µl phenol:chloroform:isoamyl alcohol was added and vortexed. 
The subsequent aqueous and organic phases were separated by centrifugation at 
12,000 x g for 15 seconds at room temperature. The upper aqueous phase containing 
the RNA was removed and reserved. The organic phase was back-extracted by 
adding an equal volume of TE-buffer (pH 8.0) (Sigma-Aldrich, Dorset, UK) and 
vortexing. The aqueous and organic phases were separated by centrifugation at 
12,000 x g for 15 seconds and the upper aqueous phases was removed and combined 
with the first. An equal volume of chloroform (Sigma-Aldrich, Dorset, UK) was 
added to the aqueous phase and vortexed. The phases were again separated by 
centrifugation at 12,000 x g for 15 seconds. The upper aqueous phase was removed 
and ammonium acetate solution was added to a final concentration of 2M. In order to 
recover the RNA, 2.5-3 volumes of cold (-20°C) 100% ethanol was added and the 
RNA prepitated overnight at -20°C. The precipitate was spun at 12,000 x g for 15 
minutes, all excess ethanol was removed and the pellet was allowed to air-dry in a 
microbiological safety cabinet for <2 hours to ensure no carry over of contaminating 
organic solvents. The pellet was then resuspended in 100 µl TE-buffer (pH 8.0) 
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2.1.2 Nucleic Acid Quantification and Quality Assessment 
RNA quantification and quality assessments were carried out at the Centre of 
Infectious Diseases, Summerhall. 
The RNA samples quality were analysed on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Edinburgh, UK). In this system, micro-channels on an Agilent chip are 
filled with a gel matrix, which acts as a sieving polymer. Sample components are 
electrophoretically separated and detected by their fluorescence and visualised on a 
gel-like image and an electropherogram (Figure 2.1). This determines the quantity 
and quality of the RNA extracted from the sample and the ratio of 28S rRNA to 18S 
rRNA. The Bioanalyzer also produces a RNA Integrity Number (RIN), a software 
algorithm developed by Agilent Technologies in order to standardise the assessment 
of RNA quality. The RIN scales between N/A or 0.0 (completely degraded, 
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Figure 2.1. Electropherogram and gel-like image from Agilent 2100 Bioanalyzer output. 
 
 
RNA peak area = 57.1 RNA conc. = 108 ng/µl
rRNA ratio = 1.0 RIN value =  8.0
RNA peak area = 104.1 RNA conc. = 104 ng/µl
rRNA ratio = 0.6 RIN value =  6.3
RNA peak area = 999.2 RNA conc. = 473 ng/µl







Figure 2.1. Electropherogram 
and gel-like image from Agilent 
2100 Bioanalyzer output. A. 
Agilent gel-like image shows the 
two major bands corresponding to 
28S and 18S rRNA bands (arrows). 
Each sample can be visualised as an 
electropherogram.  B. This sample 
is an excellent example of RNA 
which is not degraded. The 5S peak 
(30 sec) is just visible along with 
the 18S and 28S rRNA peaks. 
There is no evidence of degraded 
RNA because the base line is flat. 
In some tissues the 28S peak has 
twice the RNA content of the 18S 
peak. The 28S species is highly 
susceptible to degradation- hence 
any degradation can be seen as a 
reduction in the 18S:28S ratio. C. 
This electropherogram highlights a 
partially degraded sample. Notice 
the 28S peak is reduced and 
degraded RNA is visible as peaks 
in the base line emerging at time 
frames 30-40 sec. D. This 
electropherogram shows a degraded 
RNA sample. Notice the peaks at 
25-30 sec, indicative of small RNA 
fragments. 
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The RNA sample quantities were analysed on a Nanodrop ND-1000 
Spectrophotometer (Nanodrop Technologies, Washington, USA). In this system, 1 µl 
of sample is pipetted directly on to the end of a fibre optic cable (receiving fibre). A 
second fibre optic cable (source fibre) is brought into contact with the liquid sample 
and a liquid column is formed, bridging the gap between the two fibres. A pulsed 
xeon flash lamp provides the light source and a spectrometer utilizing a linear CCD 
array is used to analyse the light after it has passed through the sample.  
 
All DNA samples were quantified on the Nanodrop ND-1000 spectrophotometer 




2.2 Assessing RNA preparation 
2.2.1 Sample Preparation for Western Blot Analysis 
Standardised brain reference sample preparations were carried out as described 
below. Wet tissue weighing of ~80-100 mg was taken from frozen samples. A 
freezer cooled, RNase-free plastic micro-pestle (Eppendorf, Cambridge, UK) was 
used to homogenise this in 4ºC extraction buffer, to obtain a 10 % (w/v) brain 
homogenate. A non-ionic detergent insoluble pellet (nucleocytoskeletal fraction) was 
collected by centrifugation at 2,000 x g for 5 minutes at 4ºC (Eppendorf 5417R). 200 
μl of the detergent soluble (cytoplasmic and membrane fraction) supernatant was 
digested using proteinase K (VWR International, Leicestershire, UK) at a final 
concentration of 50 μg/ml at 37ºC for 1 hour. Protease digestion was terminated by 
the addition of Pefabloc (Roche, Hertfordshire, UK) to a final concentration of 1 mM 
and the sample was stored at –20ºC or used immediately for analysis. 
 
RNA sample preparations were carried out as described below. 10 μl of the RNA 
extract or human recombinant PrP was digested using proteinase K (VWR 
International, Leicestershire, UK) at a final concentration of 50 μg/µl at 37ºC for 1 
hour. Protease digestion was terminated by the addition of Pefabloc (Roche, 
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Hertfordshire, UK) to a final concentration of 1 mM and the sample was stored at –
20ºC or used immediately for analysis. 
 
An equal volume of 2X sample buffer (Invitrogen, Paisley, UK) was added to an 
aliquot of sample and heated to 100ºC for 10 minutes. Samples were collected at the 
bottom of the tube by a brief spin. The samples were run at 200 V constant current 
for 50 minutes, using 10% Bis-Tris pre-set gel cassettes (Invitrogen) and NuPAGE 
MES-SDS 1X running buffer (Invitrogen). A pre-stained benchmarker (Invitrogen) 
was run in conjunction with the samples.  
 
The gel was blotted onto a polyvinylidene difluoride (PVDF) membrane (Hybond-P, 
Amersham, UK). The membrane was first wet in MeOH, incubated in dH2O for 10 
minutes and equilibrated for 20 minutes in transfer buffer (Invitrogen). 4-6 pieces of 
blotting paper were wet in transfer buffer for 20 minutes. The transfer cell was 
assembled; 2-3 pieces of pre-soaked padding, followed by 1 piece 3MM blotting 
paper (Hybond), the gel (dye side up), pre-soaked PVDF membrane, 1 piece 3MM 
blotting paper and finally 2-3 pieces of pre-soaked padding. The cell was assembled 
and covered in transfer buffer, and the outer tank was filled with water. The transfer 
was run at 30V constant current for 1 hour.  
 
For detection, the PDVF membrane was washed twice in 40 ml TBS-T (Sigma-
Aldrich, Dorset UK) for 3 minutes. The membrane was then blocked by incubation 
in 50 ml 5 % non-fat powdered milk (Safeway, Bradford, UK) in TBS-T (Tris-
buffered saline; 10 mM Tris, pH 7.4, 150 mM NaCl containing 0.1 % Tween 20) for 
45 minutes. The membrane was then washed three times for 3 minutes each, in 40 ml 
TBS-T and incubated with a  mouse monoclonal antibody 6H4 (epitope hPrP144-
152) (100 µg, Prionics, Schileren, Switzerland) at 1:20,000 (2 μl) in 40 ml of TBS-T 
for 45 minutes. Another three washes were carried out using 40 ml TBS-T for 3 
minute incubations. A secondary antibody incubation of horseradish peroxidase-
HRP-conjugated anti-mouse (from sheep, GE Lifesciences, Buckinghamshire,UK) at 
1:40,000 (1 μl) in 40 ml TBS-T for 45 minutes was followed by a final three washes 
of 3 minute incubations in 40 ml TBS-T. Chemiluminescent substrate was prepared 
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by combining 4 ml ECL PLUS reagent A with 100 μl reagent B (Lumigen, 
Amersham, Buckinghamshire, UK), dispensed onto drained membrane and incubated 
for 5 minutes. Transfers were visualised using Hyperfilm ECL film (GE 
Lifesciences) and developed using the Hyperprocessor (GE Lifesciences), with 
exposure times of 30 seconds, 3 minutes and 30 minutes. All reagent recipes are 




2.3 Oligo GEarray Protocol 
2.3.1 cRNA Preparations and Labelling 
TrueLabeling-AMP 2.0 kits (SuperArray Bioscience, Maryland, USA) were used to 
amplify and label antisense RNA (aRNA) for hybridisation to the Oligo GEArray 
from SuperArray Bioscience.  Briefly, annealing mixtures were prepared for each 
RNA sample by combining the following in a sterile, RNase-free PCR tube: 0.1 – 3.0 
µg total RNA, 1.0 µl component G1 and RNase-free H2O to a final volume of 10 µl. 
The annealing mixture was then incubated at 70°C for 10 minutes and then placed on 
ice.  
 
cDNA synthesis master mixes were prepared by mixing the following in a sterile, 
RNase-free PCR tube for each reaction: 4 µl RNase-free H2O, 4 µl 5X cDNA 
synthesis buffer (G3), 1 µl RNase inhibitor (RI), 1 µl cDNA synthesis enzyme mix 
(G2). 10 µl cDNA synthesis master mix was added to each tube containing 10 µl 
annealing mixture and mixed well. The reaction was incubated at 42°C for 50 
minutes followed by 72°C for 5 minutes then cooled to 37°C.  Amplification master 
mixes were prepared by mixing the following in a sterile, RNase-free PCR tube for 
each reaction: 16 µl 2.5X RNA polymerase buffer (G24), 2 µl biotinylated-UTP 
(10Mm) (Sigma Aldrich, Dorset, UK), 2 µl RNA polymerase enzyme (G25). 20 µl of 
amplification master mix was added to 20 µl cDNA synthesis mix, mixed well and 
incubated for at least 1 hour and up to overnight at 37°C. 
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cRNA PURIFICATION 
60 µL RNase-free H2O was added to each cRNA synthesis reaction to a final volume 
of 100 µl and transferred to a 1.5 ml RNase-free microcentrifuge tube. 350 µl lysis 
and binding buffer (G6) was added to each reaction mixture and mixed well. 350 µl 
room temperature ACS-grade 100% ethanol (Sigma Aldrich) was added to the 
reaction tubes and mixed well. Each sample was pipetted directly onto the centre of a 
spin column and centrifuged at 8000 x g for 30 seconds. The flow through was 
discarded and 600 µl washing buffer (G17 with ethanol) was pipetted directly onto 
the spin column filter. The sample was centrifuged at 8000 x g for 30 seconds and 
the flow through was discarded. Another 200 µl of washing buffer was pipetted 
directly onto the spin column filter and centrifuged at 11000 x g for 60 seconds, 
followed by 11000 x g for 2 minutes, ensuring all wash buffer was spun through.  
The spin columns were transferred to a new sterile, RNase-free microcentrifuge tube 
and 50µl of room temperature RNase-free 10 mM Tris buffer pH 8.0 (G26) was 
pipetted directly onto the spin column filter and left to incubate at room temperature 
for 2 minutes. The sample was then centrifuged at 8,000 x g for 60 seconds and 
collected. The purified cRNA was stored at -20°C. 
 
2.3.2 cRNA Quantification and Quality Assessment 
Quantification was done by two methods: Agilent 2100 Bioanalyzer (Agilent 
Technologies, Edinburgh, UK) and NanoDrop ND-1000 spectrophotometer 
(Nanodrop Technologies, Washington, USA).  Both methods are described in 
Chapter 5. 
 
2.3.3 RNeasy Mini Protocol for RNA Cleanup 
For cRNA samples that did not fall within set criteria (concentration A260  ≥ 11 ng/µl; 
A260:280 ≥2.0; A260:230 ≥ 1.7 and clear 18S and 28S rRNA peaks as analysed by 
Agilent 2100 Bioanalyzer (Figure 2.1)), the RNeasy mini RNA cleanup protocol 
(Qiagen, Crawley, UK) was followed. Briefly, β-mercaptoethanol (β-ME) was added 
to buffer RLT and ethanol was added to buffer RPE before use, as per kit 
instructions. Sample volumes were adjusted to 100 µl with RNase-free water. 350 µl 
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buffer RLT was added and mixed. 250 µl ethanol (96-100%) was added to RNA 
sample and mixed thoroughly. Immediately, 700 µl of the sample was applied to the 
RNeasy mini column in a 2 ml collection tube, and centrifuged for 15 seconds at 
8,000 x g. The flow-through was discarded and the rest of the sample was spun 
through in the same manner, until completed. The column was transferred to a new 2 
ml collection tube, 500 µl buffer RPE was applied to the column and centrifuged for 
15 seconds at 8,000 x g. The flow-through was discarded, another 500 µl buffer RPE 
was applied to the column and centrifuged for 2 minutes at 8,000 x g, to dry the silica 
membrane. The RNeasy column was placed in a new 2 ml collection tube and 
centrifuged for 1 minute at full speed. The RNA was eluted by transferring the 
column to a new 1.5 ml collection tube, and 30-50 µl RNase-free water was applied 




2.3.4 Hybridisation Protocol 
 
PRE-HYBRIDISATION 
To pre-wet array membranes, 5 ml of deionised water was added to the hybridization 
tubes, inverted and incubated for 5 minutes. The GEAhyb hybridization solution was 
warmed to 60ºC. 2 ml of hybridization solution was added to the hybridization tubes 
and vortexed briefly. At least 2 µg of biotin-labelled cRNA was added to 0.75 ml of 
pre-warmed hybridization solution, and kept at 60ºC. The pre-hybridization solution 
was discarded and the target hybridization solution containing the labelled cRNA 
target was added to the tube. Hybridization was carried out overnight, with 
continuous but slow agitation at 5 to 10 rpm. 
 
WASHING 
5 ml of wash solution 1 and 5 ml of wash solution 2 were prepared for each array 
(Appendix 9.1) and pre-warmed to 60°C. 5 ml of wash solution 1 was added to the 
hybridization tube, vortexed and placed in to the incubator at 60°C with 20 to 30 rpm 
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agitation for 15 minutes. Wash solution 1 was then discarded and 5 ml of wash 
solution 2 was added to the hybridization tube, vortexed briefly and placed back in 
the incubation oven for exactly 15 minutes at 60°C with 20 to 30 rpm agitation. 
Wash solution 2 was immediately discarded and the tubes were resealed to prevent 




2 ml GEAblocking solution Q was added to the hybridisation tube, vortexed briefly 
and incubated for 40 minutes with continuous agitation at 20 to 30 rpm. 16 ml 1X 
buffer F was prepared for each array membrane, and 16 ml 1X buffer F was prepared 
to dilute alkaline phosphatase-conjugated streptavidin (AP-SA) buffer. After 
appropriate incubation, buffer Q was discarded and 2 ml dilute AP-SA buffer was 
added, vortexed and incubated for exactly 10 minutes with continuous 5 to 10 rpm 
agitation. The membranes were then washed four times, each time using 4 ml 1X 
buffer F for 5 minutes with gentle agitation. After the final wash, the membranes 
were rinsed twice, using 3 ml buffer G. 1 ml CDP-Star chemiluminescent substrate 
was added to the hybridisation tube and placed in room temperature rotating oven for 
5 minutes. After incubation, the arrays were removed, dried of excess CDP-Star 
solution without drying out membrane and placed in a plastic sheet protector, array 
face up, for image acquisition. 
 
2.3.5 Microarray Analysis 
Image acquisition was carried out using an Epson Perfection 1640SU (Epson, Herts, 
UK) flatbed scanner. Images were uploaded onto SuperArray proprietary web-based 
analysis software (SuperArray GEArray Expression Analysis Suite.  
http://geasuite.superarray.com/ ). Probe signal and background signal were 
determined using the GEArray Expression Analysis Suite (Superarray, Washington, 
USA). To normalise signal intensity across the array slide, arrays were intra-
normalised using the GEArray Expression Analysis Suite (Superarray, Washington, 
USA) in the following manner; background correction was based on the lowest 
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average density spot on the array. Summation correction was based on the total 
density divided by the number of pixels. Arrays were then inter-normalised by 
comparing the interquartile values (between 25 -75%) of all probe signals. The 
values were converted to log base 10. Detailed information about this 
oligonucleotide array including description of gene probes, experimental protocol, 





2.4 POLYMERASE CHAIN REACTIONS (PCR)  
 
2.4.1 Primer Design 
A set of 5 primers was designed for use in the quantitative PCR machine ( Rotogene 
3000, Corbett Research, Australia) (Table 2.1). All primers were designed using 
Primer3 software (available online @: http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and verified for low spontaneity to form duplexes 
and hairpin loops using Netprimer software (available online @: 
http://www.premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html).  
Primer specifications: 
• Primer length between 18 – 22 base pairs (optimum 20 base pairs) 
• GC content of between 45 – 55% (optimum 50%) 
• Maximum self complementarity predictions less than 3 were favoured, where 
software could predict suitable primer oligo, otherwise higher 
complementarity was allowed. 
• Maximum 3’ self complementarity predictions less than 2 were favoured, 
where software could predict suitable primer oligos otherwise higher 
complementarity was allowed. 
• (ΔG) values similar for both sense and antisense primers were favoured. 
• Melting temperature of primer oligos between 58 – 62°C (optimum 62°C) 
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• BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/) carried out for each 
primer set to ensure specificity to gene of interest within E value >1.0. 
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Table 2.1. Forward and reverse primer sequences and product size of primers used for PCR and QRT-PCR analysis. a is accession number.  
 
Gene name UniGene Symbol Forward primer Reverse primer Annealing 
temp 
(C°) 






Hs.544577 GAPDH TCATCATCTCTGCCCCCTCT CCATCACGCCACAGTTTCC 60 458 698 241 
Beta-actin 
 
Hs.520640 ACTB ATTCCTATGTGGGCGACGAG GCTGGGGTGTTGAAGGTCTC 60 225 465 241 
Cyclophilin A 
 
Hs.356331 PPIA GGCAAGACCAGCAAGAAGA GGGAGGGAACAAGGAAAAC 58 520 718 179 
Ubiquitin C 
 
Hs.520348 UBC TGGGTCGCAGTTCTTGTTTG GGGTGGACTCTTTCTGGATGTT 58 403 647 245 
18S rRNA X03205a 18S 
rRNA 
TCAAGAACGAAAGTCGGAGG GGACATCTAAGGGCATCACA 60 1025 1513 468 
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2.4.2 Reverse Transcription of RNA for cDNA Synthesis  
In 0.2 ml thin-walled PCR tubes (Axygen Scientific Inc, California, USA), the 
following were added: 1 μl random pentadecamer primer (MWG Biotech, Ebersberg, 
Germany), 5 μl total RNA, 1 μl 10 mM dNTPs (Promega, Mannheim, Germany) and 
DNase/RNase- free, DEPC-treated water to make a final volume of 12 μl. An 
Express Thermohybaid cycler (Thermo Fischer Scientific, Epsom, UK) was used to 
heat samples for 5 minutes at 65ºC, before chilling tubes on ice for at least 1 minute. 
The following were added to the tubes: 4 μl 5X first strand buffer (Invitrogen, 
Paisley, UK), 2 μl 0.1 M DTT (Invitrogen), 1 μl RNAsin Recombinant Ribonuclease 
Inhibitor (Promega) and tubes were incubated at 25ºC for 2 minutes. After 
incubation, 1 μl of Superscript III Rnase H- reverse transcriptase enzyme (Invitrogen) 
was added and tubes incubated at 50 minutes at 50ºC. Samples were inactivated by 
heating at 70ºC for 15 minutes before storage at –20ºC. 
 
2.4.3 PCR Amplification 
Amplification of the cDNA was carried out in 0.2 ml thin-walled PCR tubes 
(Axygen). To these tubes, reaction mixtures of 50 µl containing the following were 
added: 5 μl 10X PCR reaction buffer, 1 μl dNTPs, 7 μl MgCl2 (25 mM), 0.25 μl 
Upstream primer (50 pM), 0.25 μl Downstream primer (50 pM), 1 μl sample cDNA, 
0.25 µl Taq DNA polymerase and Dnase/Rnase-free, DPEC-treated water to make a 
final volume of 50 μl. Rnase/Dnase-free water was substituted for sample cDNA and 
used as negative controls. An Express Thermohybaid cycler (Thermo Fischer 
Scientific) was used to heat samples at 95ºC for 2 minutes. The samples were then 
denatured during cycling at 95ºC for 30 seconds, followed by primer annealing at 
60ºC for 35 seconds. A primer extension cycle was run at 72ºC for 1 minute, and for 
30 cycles. The final extension stage was at 72ºC for 15 minutes. Non-template (H2O) 
controls were run in parallel with every PCR to test for reagent contamination.  
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2.4.4 Agarose Gel Electrophoresis for PCR Products 
DNA and RNA were analysed by agarose gel electrophoresis. Briefly, 0.7 - 2 % gels 
were prepared using 0.5 M Tris acetate EDTA (TAE) buffer with 0.5 µg/ml ethidium 
bromide for visualisation under UV. Samples were mixed with 6 X loading buffer 
and loaded into wells. Depending on the size and agarose percentage of the gel, an 
electrical current of between 100-130 volts was applied, for approximately 1 hour. 
This allowed separation of nucleic acid fragments. A 100 bp ladder (New England 
Biolabs) or 1 kb ladder (Invirtrogen) was run in parallel as a size reference marker. 
The gel was then viewed under the UV transilluminator (UltraViolet Products, UK).  
PCR products were stored at -20°C for further analysis.  
 
2.4.5 PCR Product Purification from Agarose Gel 
High pure PCR purification kits (Roche Applied Science, Mannheim, Germany) 
were used to isolate PCR products from amplification reactions. The process’ 
principle is based on PCR amplified DNA binding selectively to special glass fibres 
pre-packed in the High Pure Filter Tube when in the presence of the chaotrophic salt 
guanidine thiocyanate. The glass fibres only bind to DNA fragments with a minimum 
length of 100 bp, thus oligonucelotides and dimerized primers from PCR reactions 
are selectively removed. Bound DNA is purified in a series of rapid wash-and-spin 
steps to remove contaminating primers, nucleotides, and salts, and then eluted using 
a low salt solution. The simple method eliminated the need for organic solvent 
extractions and DNA precipitation. Two PCR product purification methods are 
possible; from solution after amplification or alternatively purification of DNA 
fragments from agarose gel.  
 
For purification of DNA fragments from agarose gel, the desired DNA band was cut 
from the gel using a sterile scalpel and placed into a 1.5 ml DNase-free 
microcentrifuge tube. 300 µl binding buffer was added for every 100 mg agarose gel 
slice. The gel and buffer was incubated at 56°C for 10 minutes or until the gel was 
completely dissolved. 150 µl isopropanol was added for every 100 mg agarose gel 
slice in the tube and vortexed thoroughly. The solution was pipetted directly onto a 
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High Pure Filter and centrifuged at 13,000 x g at room temperature, for 60 seconds. 
The flow-through was discarded and 500 µl Wash buffer was pipetted directly onto 
the filter and centrifuged as above. This was repeated with 200 µl Wash buffer, 
twice. The flow-through was discarded each time and the spin column was placed in 
a clean 1.5 ml DNase-free microcentrifuge tube. 50 µl Elution buffer was pipetted 
directly onto the filter and centrifuged at 13000 rpm at room temperature for 60 
seconds, and the purified DNA was collected and stored at -20°C.  
 
For purification of PCR products in solution after amplification, the PCR reaction 
volume was adjusted to 100 µl using DNase-free H2O. 500 µl Binding Buffer was 
added and mixed well. The sample was applied to the filter column and centrifuged 
at 13,000 x g for 1 minute. The flow through was discarded, 500 µl Wash Buffer was 
applied directly to the filter membrane and centrifuged again at 13,000 x g for 1 
minute. An additional 200 µl Wash Buffer was added and centrifuged at 13,000 x g 
for 1 minute to ensure complete removal of Wash Buffer from the membrane. The 
spin column was placed in a clean 1.5 ml DNase-free microcentrifuge tube. To elute 
the DNA, 50 µl Elution Buffer was applied directly to the filter membrane and 




2.4.6 Molecular Cloning 
 
pGEM-T Easy Cloning 
 
PCR fragments were cloned into the pGEM®-T Easy vector according to the 
manufacturer’s instructions. Briefly, 5 µl of 2X Rapid Ligation buffer, 1 µl (50 ng) 
pGEM-T-Easy vector, 1 – 3 µl PCR product (calculated from the measured DNA 
concentration), 3 Weiss units of T4 DNA ligase (1 µl) and molecular grade H2O to a 
final volume of 10 µl were mixed together. The reaction was incubated for 
approximately 16 hours at 4°C for maximum transformations. Following incubation, 
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3 µl of the ligation reaction were used to transform subcloning efficiency DH5α and 




All bacterial protocols were performed under aseptic conditions. 
 
Bacterial Culture 
Various laboratory strains of E.Coli were grown in Luria-Bertani (LB) medium or on 
LB agar plates (1.5% agar). Media was sterilized and agar melted by autoclaving. 
Media was supplemented with appropriate antibiotics (100 µl/ml ampicillin) prior to 
use. LB agar was poured into 10 cm diameter Petri dishes. Bacteria were plated on 
the surface of LB agar by spreading with a glass spreader, inverted and incubated at 
37°C for approximately 16 hours. Single colonies from agar plates were used to 
inoculate liquid medium. Liquid cultures were incubated for approximately 16 hours 
with constant shaking at 225 rpm in an orbital shaker at 37°C.  
 
 
Transformation of One Shot® DH5αTM Chemically Competent cells 
 
One Shot DH5α – T1 chemically competent cells were transformed with the products 
of the pGEM-T-Easy cloning reaction. Briefly, a 50 µl aliquot of competent cells 
were thawed on ice for approximately 10 minutes. 2 µl of the cloning reaction was 
added to the cells, mixed gently and incubated on ice for 30 minutes. The cells were 
then heat-shocked for 20 seconds at 37°C. 950 µl pre-warmed SOC medium was 
added to the cells and incubated for 1 hour at 37°C with constant shaking at 225 rpm 
in an orbital shaker. 50 µl or 150 µl of the transformation reaction was then plated on 
LB agar plates supplemented with 100 µg/ml ampicillin and incubated, inverted, at 
37°C for approximately 16 hours. 
pGEM-T-Easy vectors allow blue/white colony screening for selection of colonies 
containing recombinant plasmids. Briefly, pGEM-T-Easy vectors contain the β-
galactosidase gene. Insertion of the PCR fragment into the plasmid disrupts the 
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coding sequence of β-galactosidase. Colonies containing recombinant plasmids 
therefore appear white on indicator plates. Indicator plates were made by spreading 
100 µl of 100 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) and 20 µl of 50 
mg/ml 5-bromo-4-chloro-3-inodlyl-β-D-galactopyranoside (X-Gal) on the surface of 
LB agar plates supplemented with 100 µg/ml ampicillin. Plates were allowed to 
absorb IPTG/X-Gal for 30 minutes at 37°C. To allow development of colour, these 
plates were incubated, inverted, for approximately 17 hours at 37°C. 
 
 
Transformation of JM109TM Chemically Competent cells 
 
JM109TM chemically competent cells were transformed with the products of the 
pGEM-T-Easy cloning reaction. Briefly, a 50 µl aliquot of competent cells were 
thawed on ice for approximately 10 minutes. 2 µl of the cloning reaction was added 
to the cells, mixed gently and incubated on ice for 30 minutes. The cells were then 
heat-shocked for 35 seconds at 42°C. 950 µl pre-warmed SOC medium was added to 
the cells and incubated for 1 hour at 37°C with constant shaking at 225 rpm in an 
orbital shaker. 50 µl or 150 µl of the transformation reaction was then plated on LB 
agar plates supplemented with 100 µg/ml ampicillin and incubated, inverted, at 37°C 
for approximately 16 hours. 
 
 
Plasmid DNA Extraction (Miniprep) 
 
QIAprep Spin Miniprep kits were used according to the manufacturer’s instructions, 
for isolation of small amounts of plasmid DNA. Briefly, a single colony was isolated 
from an LB agar plate and used to inoculate 5 ml of LB medium supplemented with 
100 µl/ml ampicillin in universal tubes. Inoculations were then incubated for 
approximately 16 hours at 37°C, shaking at 225 rpm in an orbital shaker. Cultures 
were then centrifuged at 1500 x g for 6 minutes. Pelleted bacterial cells were 
resuspended in 250 µl Buffer P1 and transferred into a sterile microcentrifuge tube. 
250 µl of Lysis buffer P2 was added and mixed gently by repeated inversions. Lysis 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 2  Materials and Methods 
 51
was allowed to proceed for 5 minutes and 350 µl Buffer N3 added and again gently 
mixed by repeated inversions. The mixture was centrifuged at 17,900 x g for 10 
minutes and the supernantant transferred to a QIAprep Spin column. The spin 
column was centrifuged for 1 minute at 17,900 x g to bind the DNA to the silica-gel 
membrane. The membrane was then washed using 500 µl Buffer PB and centrifuged 
at 17,900 x g for 1 minute. An additional wash step using 750 µl Buffer PE was 
carried out, followed by centrifugation at 17,900 x g for 1 minute. The column was 
then centrifuged for an additional minute to remove any residual wash buffer. To 
elute DNA, 50 µl DNase-free H2O was added directly to the silica-gel membrane and 
was allowed to incubate for 1 minute at room temperature. The column was 
centrifuged at 17,900 x g for 1 minute to elute the DNA. DNA samples were 
quantified and checked for quality as described in section 1.1.2 and stored at -80°C. 
 
 
Large Scale Plasmid DNA Extraction (Maxiprep) 
 
Qiagen EndoFreePlasmid Maxi Kits were used according to the manufacturer’s 
instructions, for isolation of large amounts of high quality plasmid DNA. Briefly, a 
single colony was isolated from an LB agar plate and used to inoculate 5 ml of LB 
broth supplemented with 100 µl/ml ampicillin in universal tubes. The starter culture 
was incubated for 6 – 8 hours at 37°C, shaking at 225 rpm in an orbital shaker. 500 
µl of the starter culture was used to inoculate 250 µl LB medium supplemented with 
100 µl/ml ampicillin. The culture was grown for 14 – 16 hours at 37°C, shaking at 
225 rpm in an orbital shaker. Bacterial cells were harvested by centrifugation at 
6,000 x g for 15 minutes at 4°C. The bacterial pellet was resuspended in 10 ml of 
Buffer P1 and 10 ml of Buffer P2 was added. The mixture was mixed gently by 
repeated inversions and lysis was allowed to proceed for no more than 5 minutes. 10 
ml of chilled Buffer P3 was added to the lysate and poured into the barrel of the 
QIAfilter Cartridge and incubated for 10 minutes at room temperature. Cell lysate 
was filtered into a 50 ml tube and 2.5 ml Buffer ER was added. The tube was 
inverted 10 times to mix and incubated on ice for 30 minutes. A QIAGEN-tip 500 
was equilibrated by applying 10 ml Buffer QBT; Buffer was allowed to flow through 
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by gravity flow. The filtered lysate was added to the equilibrated QIAGEN-tip and 
allowed to enter the resin. The QIAGEN-tip was washed twice using 30 ml Buffer 
QC. 15 ml Buffer QN was used to elute the DNA. DNA was precipitate by the 
addition of 0.7 volumes of isopropanol and centrifuged at 15,000 x g for 30 minutes 
at 4°C. The pellet was washed with 5 ml of 70% ethanol and centrifuged at 15,000 x 
g for 10 minutes. The supernatant was removed and the pellet was allowed to air-dry. 
Once dry, the pellet was resuspended in 300 µl DNase-free H2O and stored at -80°C. 
 
 
Preparation of frozen stocks of transformed bacteria 
 
A single colony from an LB agar plate was used to inoculate 5 ml of LB medium 
containing 100 µl/ml ampicillin. The culture was grown for approximately 16 hours 
at 37°C at 225 rpm in an orbital shaker. Cells were pelleted by centrifugation at 1500 
x g for 6 minutes and the pellet resuspended in 1 ml 50% glycerol in H2O. The 
sample was transferred to a sterile eppendorf tube and snap frozen on dry ice. 
Samples were stored at -80°C. 
 
 
Plasmid DNA Restriction Digestion 
 
Restriction endonucleases were used to digest plasmid DNA. A number of different 
restriction endonucleases were used for this project. Generally restriction digestion 
reactions contained: 2 µl digestion buffer, 2 µl 10X BSA, 1 µl restriction 
endonucleases, plasmid DNA (volumes adjusted depending on the required amount 
needed in subsequent reactions) and DNase-free H2O to a final volume of 20 µl. The 
reactions were incubated for 2 – 4 hours at the optimum temperature for the 
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Purification of Restriction Digestion Products 
 
QIAquick PCR purification Kits were used to purify DNA fragments from restriction 
digestion reactions, according to the manufacturer’s instructions. Briefly, 5 volumes 
of Buffer PB was added to 1 volume of digestion reaction and missed by pippeting. 
The DNA sample was applied directly to the QIAquick spin column and centrifuged 
for 1 minute at 17,900 x g. All flow-through was discarded and 750 µl Buffer PE was 
added. The column was spun at 17,900 x g for 1 minute and again any flow-through 
was discarded. An additional centrifugation at 17,900 x g for 1 minute was carried 
out to remove any residual buffer. 30 µl DNase-free H2O was applied directly to the 
silica-gel membrane and DNA was eluted by centrifugation at 17,900 x g for 1 
minute. DNA samples were stored at -20°C. 
 
 
Sequencing of Plasmid DNA and Sequence analysis 
 
To verify that the gene of interest was amplified and cloned successfully into the 
pGEM-T-Easy vector, approximately 300 ng in 15 µl DNase-free H2O was sent to 
for sequencing at The Sequencing Service (School of Life Sciences, University of 
Dundee, Scotland, www.dnaseq.co.uk) using the M13 forward and reverse primers. 
 
DNA sequencing was performed by The Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer. Sequences were analysed using BLAST 
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2.5 QUANTITATIVE POLYMERASE CHAIN REACTION (Q-
PCR) 
 
2.5.1 Reverse Transcription of RNA for QRT-PCR 
cDNA was synthesised from total RNA by reverse transcription using the method 
previously described in section 1.4.2. 
 
2.5.2 Quantitative PCR assay 
cDNA was amplified using a Rotor-Gene Version 5 (Corbett Research, Australia) 
QRT-PCR machine. In 0.1 ml PCR tubes, the following was added: 0.4 μl of 
Upstream primer (50 pM), 0.4 μl of Downstream primer (50 pM), 0.4 μl dNTPs, 2.8 
μl MgCl2 (25 mM), 2 μl 10X PCR reaction buffer, 11.15 μl Dnase/Rnase-free, 
DPEC-treated water, 0.7 μl of 1:100 diluted SYBR green (Biogene, USA), 0.15 μl 
Taq Faststart (Roche, Switzerland) and 2 μl sample cDNA. Rnase/Dnase-free water 
was substituted for sample cDNA and used as negative controls. An initial 
denaturation step of 95ºC for 10 minutes was followed by 40 cycles of: 30 seconds at 
95ºC, 20 seconds at 62ºC and 20 seconds at 72ºC. Fluorescence was measure at the 
end of each 72°C stage.  
At the end of the PCR cycle, a melt curve analysis was performed according to the 
manufacturer’s instructions: measuring fluorescence during the incremental increase 
in temperature from 65°C to 94°C. A standard curve was generated from a series of 
10-fold dilutions of its corresponding gene-inserted plasmid of known concentration. 
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2.6 STATISTICAL ANALYSIS 
 
All statistical analysis was carried out using Microsoft excel (with SAM add-on 




2.7 MOUSE TISSUE SAMPLING 
 
Mouse tissue was obtained from the Animal Unit, Centre for Infectious Diseases, 
University of Edinburgh. All mice were 10 week old males, of mixed genotype. The 
mice were carbon monoxide gas chamber euthanized and tissues were harvested 
immediately.  
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3 ASSESSMENT OF RISK AND DECONTAMINATION 
 
3.1 STABILITY OF TSE AGENTS TO INACTIVATION 
PROCEDURES 
 
TSE agents exhibit exceptional stability and resistance to conventional chemical and 
physical decontamination methods. In addition, decontamination issues are 
complicated by the fact that the material or surface to be treated, the type of 
contaminating organism present and the circumstance of use (for example, allowing 
contamination to dry or treatment with formalin) affect the efficacy of 
decontamination. This project requires evidence-based guidelines for 
decontaminating CJD infectivity and in particular RNA preparations derived from 
CJD material (Asher et al., 1986; Asher et al., 1987; Taylor & McBride, 1987; 
Taylor & McConnell, 1988).  
 
It is well documented that different strains of TSE vary in their resistance to 
inactivation, but there is limited information on the properties of human disease 
agents. As the longest recognised and most intensively studied of the TSEs, scrapie is 
the acknowledged model for the majority of decontamination studies. The two strains 
most commonly used for comparative studies are; 263K hamster-passaged scrapie, a 
strain which contains the highest infectivity levels in the brain and 22A, mouse-
passaged scrapie which is considered one of the most thermal stable of the TSE 
agents. It is generally assumed that decontamination studies with these scrapie 
isolates are applicable to human TSE infected material. However, there remains the 
possibility that human TSE agents are more or less resistant; the former has 
particular implications for risk assessments.  
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3.1.1 Factors Affecting Efficacy of Decontamination 
Although the precise molecular nature of TSE agents is unknown, there have been a 
significant number of important studies relating to their inactivation. The uncertainty 
surrounding the exact nature of TSE infectivity has however complicated data 
interpretation and comparisons. Host species, strain of agent, origin of agent, prion 
concentration in test material, sample preparation (e.g. macerate, homogenate and 
partially purified preparations), test animals, duration of follow-up of inoculation test 
animals and route of infection are all issues that affect how an agent will react to 
decontamination and quantification of agent inactivation. 
 
To date, highly purified native infectious agent has not been achieved to a standard 
that eliminates the possibility of co-purification (Hunter & Millson, 1967; Caughey 
& Baron, 2006; Silveira et al., 2005). Without a suitable technique to purify native 
infectious agent, decontamination studies rely on the use of high-titre infected tissues 
(usually brain). The interpretation of TSE agent infectivity titres is a significant 
aspect of decontamination studies. Western blot analysis of immunoreactive PrPSc, as 
assessed by staining with antibodies, is commonly used in diagnostics and has been 
used to evaluate the removal of PrPSc in decontamination studies (McLeod et al., 
2004). The sensitivity of western blots is however a potential problem. Currently the 
gold standard for measuring prion infectivity is animal bioassay based on 
intracerebral inoculation of mice, which is slow (~140 days). The dose of infectious 
agent administered and the resulting incubation period in rodents follows a precise 
relationship, therefore allowing titres of infectivity to be measured from a standard 
dose-response curve (DRC) for any particular strain of agent within a specific host 
genotype (Dickinson et al., 1968; Kimberlin & Walker, 1977; Kimberlin & Walker, 
1986).  
 
Incubation period assays (IPA) can be used to titre the concentration of infectious 
agent extrapolation from a DRC. However, IPAs cannot be relied upon to measure 
infectivity which survives chemical or physical treatments. Some treatments 
(including heat, sodium dodecyl sulphate and sodium deoxycholate) can modify the 
pathogenesis independently of titre, altering the relationship between infectivity dose 
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and incubation period. This can modify the DRC, causing delays when compared 
with equivalent titres of untreated infectivity, and lead to under estimation of titre. 
Full titration assays involving a range of dilutions are considered more accurate and 
would be most suitable for decontamination studies (Dickinson & Fraser, 1969; 
Kimberlin, 1977; Somerville & Carp, 1983; Kimberlin & Walker, 1977; Lax et al., 
1983; Taylor & Fernie, 1996). 
 
The successful transmission of CJD from human to rodents has provided a suitably 
cheap and reproducible bioassay for accurate titrations of infectivity (Tateishi et al., 
1981; Bruce et al., 1997; Manuelidis, 1975; Manuelidis et al., 1977). Even with the 
development of suitable rodent assays, a number of factors make direct comparisons 
of inactivation data difficult. The chosen route of infection may affect the pathogenic 
pattern and incubation period. If using IPAs, only a limited number of dilutions are 
assayed. Therefore, it requires a prediction of the amount of inactivation which might 
be achieved and a suitable dilution selected. This can be problematic if an unsuitable 
dilution is assayed and used to extrapolate results from a DRC.  With regards to 
titrations of infectivity, extending the observation times of test animals to at least 200 
days beyond that of the usual dose-response end-point, so as not to miss late 
developing cases, would diminish overestimations of titre loss. Titrations are most 
often carried out by the inter-cranial (i.c.) route, the most efficient for detecting small 
amounts of infectivity. However, the loss of titre on treatment may in part be due to 
an impaired ability of residual agent to infect by the i.c. route but not by other routes 
(Dickinson & Fraser, 1969; Bruce et al., 1997). Therefore titre changes may not 
reflect exactly the physicochemical destruction of the agent. Organ specific 
modifications of pathogenic characteristics have also been demonstrated, 
highlighting the level of complexity of the disease agent and the importance of 
experimental rationale of strain choice and titre quantification (Robinson et al., 
1990).  
 
Tissue types vary in their infectivity levels. Peripheral tissues have lower titres of 
infectivity per gram of wet tissue than brain tissue (WHO guidelines; 2006). 
Infectivity levels also vary according to the host species. Although Brown et al 
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demonstrated that infectivity levels in two CJD models (guinea-pig and mouse) were 
comparable to human tissue infectivity levels and inferred that the levels observed 
were substantially lower than in mouse or hamster scrapie, inactivation of guinea-pig 
and mouse passaged CJD agent were not studied (Brown et al., 1982).  It would be 
reasonable to assume that agents adapted to a different species might possess 
different characteristics from the human CJD agent. Most inactivation studies are 
therefore based on the well known thermostable 301V or the high titre 263K strains, 
so as to be more likely to overestimate than to underestimate inactivation 
requirements. 
 
Different strains of agent vary in their resistance to inactivation methods (Kimberlin 
et al., 1983; Taylor et al., 2002; Dickinson & Taylor, 1978). It is well established 
that PrPSc is an excellent surrogate marker of prion infectivity but in certain 
circumstances, infectivity and PrPSc have different characteristics. A number of TSE 
strains, on application of heat, have a significant reduction in infectious titre with 
little or no reduction in the level of PrPSc, as quantifiable by western blot (Somerville 
et al., 2002). To conclusively prove complete inactivation, the decontamination 
protocol must demonstrate activity against PrPSc and also requires verification by 
bioassay for infectivity. 
 
Decontamination becomes progressively more difficult as infectivity titre and 
concentration of tissue debris increases (Rohwer, 1984b). As TSE agents cannot be 
purified to homogeneity, and as the relevant risk material is frequently tissue 
samples, decontamination studies are generally done using crude tissue homogenates. 
This adds further problems. The exact concentration of brain tissue inoculum is 
difficult to quantify and can vary between inoculations and studies. Additionally, 
most inactivation studies use brain homogenate or brain macerate, a tissue that 
contains very high levels of lipid membrane. It is possible that the TSE agent is 
protected from assaults of chemical or thermal inactivation by binding to lipid 
membranes. This may explain how resistant sub populations of agent exist and 
display persistent infectivity in bioassays. The propensity of PrPSc to aggregate may 
also have a protective effect. These factors may allow the prion protein to survive 
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harsh conditions (Rohwer, 1984a; Rohwer, 1984b) and may also account for reports 
of reversible inactivation (Prusiner et al., 1981; Shaked et al., 2001). Regardless of 
the assumed protection from decontamination, there is no doubt that the agent’s 
relative resistance to chemical and physical inactivation is several orders greater than 
that for conventional micro-organisms.  
 
3.1.2 Current Recommendations for Decontamination 
The safest method of dealing with the issue of spread of TSE infectivity by 
instruments and devices is to make them single-use and dispose of them by 
incineration. This option is not always possible; therefore methods of disinfection are 
needed. It is difficult to gain a consensus opinion on what constitutes optimal and 
practical conditions for inactivation of TSE infectivity on medical instruments and 
devices. Different protocols are employed by different agencies. Table 3.1 
consolidates the recommended methods from the Advisory Committee on Dangerous 
Pathogens (ACDP), the Spongiform Encephalopathy Advisory Committee (SEAC) 
and the World Health Organisation (WHO) into ineffective and recommended 
methods of decontamination of TSE agents, specifically CJD.  
 
To distinguish the terminology used for this project, they are defined as: 
Disinfection, for general cleaning of the work area and as good laboratory practise 
(GLP). The use of Virkon (a widely used anti-viral detergent) for disinfection is not 
suitable for decontamination of TSE agents; Decontamination, specific for TSE work 
and must follow the decontamination protocol as set out in Appendix 9.6. 
Sterilisation, involves the removal of microbiological infectious agent from devices 
or surfaces; and Inactivation, the process of inactivating the infectious agents so that 
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Sodium dichloroisocyanurate (‘presept’) 
Sodium dodecyl sulphate (SDS) (5%) 






Dry heat (<300˚C) 




Autoclaving at 121°C for 
15 minutes and pourous 
load autoclaving for 
extended cycles and times 
‘Prion Cycle’ on some 
bench top autoclaves 
 








Urea (6 M) 
 
 VARIABLY OR 
PARTIALLY 
EFFECTIVE 




20,000 ppm available chlorine or 
sodium hypochloride for 1 hour 
2M sodium hydroxide for 1 hour 
 RECOMMENDED 
 
**WHO states as effective, while UK advisory committee states as ineffective 
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Table 3.1. Ineffective and recommended effective methods of decontamination of TSE agents. 
Modified from (1996; Advisory Committee on Dangerous Pathogens & Spongiform Encephalopathy 
Advisory Committee, 2003).  
 
 
3.2 CONCLUSIONS FOR DECONTAMINATION PROCEDURES 
 
The results of numerous studies designed to define conditions for inactivation of TSE 
infectivity have concluded that protein denaturants are effective at reducing 
infectivity but that complete inactivation requires extremely harsh conditions. The 
majority of published recommendations suggest a combination of soaking in NaOH 
or NaOCl, followed by autoclaving at either 121°C or 134°C. It is important to note 
that these conditions, on which some current guidelines are based, were determined 
for rodent strains, before it was known that prion strains may exhibit different 
stabilities to denaturation by heat, as well as chaotropes (Taylor et al., 2002; Peretz et 
al., 2001).  
 
In 2000, the WHO published updated recommendations on how to deal with surgical 
equipment used on people with confirmed or suspected CJD. The guidelines offered 
a number of different options, identifying incineration of suspect instruments as 
being the safest method. The WHO also listed six rigorous decontamination 
methods; three of the chemical and autoclave sterilization methods outlined in Annex 
3 of the WHO infection control guidelines are given in Appendix 9.7. The WHO also 
suggests a list of general considerations when considering an effective policy for 
TSE agent decontamination. Firstly, that decontamination is context-dependent and 
may not be completely effective under all circumstances. Secondly, that the chosen 
method of cleaning facilitates decontamination by reducing infectivity and organic 
load. The policy must use the best-validated methods available and it is advisable to 
use an orthogonal strategy––two different methods––whenever possible (WHO 
guidelines, 1996). 
 
The UK ACDP and SEAC guidelines suggest using ambient temperature and 2 M 
NaOH for 1 hour, or 20,000 ppm available chlorine of NaOCl for 1 hour, as the most 
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effective chemical methods. Unfortunately, this concentration of chlorine is 
impractical for most uses, requiring respirator protection or evacuation of the 
immediate area. In addition, chemical breakdown of stock solutions and difficulties 
in establishing actual free chlorine levels make this approach difficult to implement. 
The use of 10,000 ppm hypochlorite is stated as being ineffectual against TSE agents 
and is not recommended. There are no current recommendations with regards to 
autoclaving (Advisory Committee on Dangerous Pathogens & Spongiform 
Encephalopathy Advisory Committee, 2003). 
 
The NCJDSU laboratory decontamination and risk management protocols (Table 
3.2) are in accordance with UK ACDP and SEAC guideline recommendations.  The 
principle of all work is containment followed by decontamination. Training for this 
project was carried out by the NCJDSU Chief Biomedical Scientist and Health and 
Safety Advisor (Linda McCardle). All personnel underwent a probationary period 
which was signed off by the supervisor, before being permitted to work within 
Category laboratory (CL) 3* laboratory. 
 
ITEM CONCENTRATION CONTACT TIME 
Disposable PPE, paper 
tissues, etc 
Double bag, I.D. tag and 
incinerate2.  
Disposable sharps and 
instruments 
Decontaminate with 2M 
NaOH. Collect in 
sharpsafe or similar 
container with safety signs 
and incinerate. 
Minimum 60 minutes 
Non-disposable metal 
instruments 
Steam autoclave at 134°C 
– 136°C (GD or PL). 
GD – 60 minute cycle 
PL – 18 minute cycle 
Work surfaces Flood with 2 M NaOH. Rinse before next usage*. Minimum 60 minutes 
Class 1 cabinets1 
Wipe with excess 2 M 
NaOH. Fumigation with 
formalin prior to contract 
servicing. Dispose of high 
efficiency particulate 
Minimum 60 minutes 
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absorption (HEPA) and 
dust filters by double 
bagging and incineration. 
Contaminated fluids 
Decontaminate in a 
container of 1 litre of 2 M 
NaOH (at final 
concentration). When 1/3 
full, absorb in sawdust, 
double bag and incinerate. 
Minimum 60 minutes 
Contaminated organic 
solvents 
Absorb small amounts in 
sawdust in a falcon tube 
with lid, double bag and 
incineration. 
Minimum 60 minutes 
* 2 M NaOH will damage aluminum or zinc surfaces. 
Table 3.2. Decontamination procedures to be used in this project. This protocol is in accordance 
with UK ACDP and SEAC guideline recommendations. 1. Decontamination of class 1 
microbiological safety cabinets. From evidence provided by decontamination studies, it has been 
established that conventional methods of safety cabinet fumigation using formalin or vaporised 
formaldehyde are not effective against TSE agents. Nonetheless, fumigation is still necessary as a 
precaution against other infectious agents that may be present within the cabinet or on the surface of 
the HEPA filter. Also, fumigation is a requirement of contracted service engineers, even though 
contract companies are fully aware of it being ineffectual on TSE agent. Service personnel will be 
informed of TSE work with the cabinet in advance of visits. Full fumigation protocol is supplied in 
Appendix 9.8. 2. Disposal of waste. Disposal of all waste is in accordance with the statutory 
requirements under the Controlled Waste Regulations 1992. Incineration is completed by a verified, 




3.3 ASSESSMENT OF RISK FOR THIS PROJECT 
 
Due to their unique biological and biochemical properties and their human disease 
potential, safety considerations are particularly important in working with the TSE 
agents derived from humans, or which are known to be capable of infecting and 
causing disease in humans. The nature of this project means that RNA preparation 
protocols need to take into account the necessity for removal of the infectious agent, 
as molecular studies are to be carried out in a CL2 laboratory. Transfer of the work 
was necessary since specialist equipment required was only available at the CL2 
laboratory. How to work with infectious tissues, how to remove infectious material 
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from tissues while leaving RNA intact and how to decontaminate equipment and 
utensils that have come into contact with infectious material are the main 
considerations. 
 
The NCJDSU receives fixed and frozen tissue samples from autopsies of 
neurological patients suspected of CJD. Due to the TSE agent’s resistance to most 
normal processes of inactivation, tissue received is considered highly infectious. Risk 
assessments and safe working procedures were already in place at the NCJDSU, but 
as this project introduced a number of new techniques, updated and revised proposals 
were needed.  
 
3.3.1 Hazards and Risks Associated with Workplace Exposure to 
TSE Agents. 
The factors to be considered when working with TSEs are set out by the Advisory 
Committee on Dangerous Pathogens (ACDP) and the Spongiform Encephalopathy 
Advisory Committee (SEAC) and include or comprise the following: 
i. Is intention to work with the agent deliberate 
ii. Hazard categorisation of the agent 
iii. Origin of the agent 
iv. Type of tissue handled 
v. Knowledge of expression of the agent in any experimental model and whether 
the work is likely to result in a high titre of infectivity 
vi. Assessment of the type of task (e.g. concentration/purification) 
vii. Frequency of contact with the agent or materials likely to contain them 
viii. Potential for inoculation injury and other possible routes of exposure. 
(Advisory Committee on Dangerous Pathogens & Spongiform Encephalopathy 
Advisory Committee, 2003) 
 
At the NCJDSU, multiple organ samples are handled and stored. Within the scope of 
this project, only frozen human brain tissue will be accessed. Infectivity of the TSE 
agent varies according to the agent strain, host and tissue type (Table 3.3). Based on 
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accumulated data, the WHO issued updated guidelines on tissue infectivity in 
naturally occurring disease or in primary experimental infections by the oral route. 
Tissues, regardless of the stage of disease, are categorised as having high, low or 
undetectable levels of infectivity (WHO guidelines,2006).  
 
Table 3.3. High infectivity tissues. Generally, CNS tissues and certain tissues anatomically 
associated with the CNS, attain a high titre of infectivity in the later stages of TSE. Modified from 
WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies and 
guidelines from Advisory Committee on dangerous pathogens and the Spongiform Encephalopathy 
Advisory Committee. The detection of misfolded host prion protein (PrPTSE) has proven to be a 
reliable indicator of infectivity and has been presented in parallel with bioassay data. Data entries are 
shown as follows: + Presence of infectivity or PrPTSE; - Absence of detectable infectivity or PrPTSE; 
NT Not tested. P Infectivity has been proven in experimental transmission studies. 
1. Infectivity bioassays of human tissues have been conducted in either primates or mice (or both). 2. 
In experimental models of TSE, the optic nerve has been shown to be a route of neuroinvasion and 
contains high titres of infectivity. 3. No experimental data about infectivity in human pituitary gland or 
dura mater have been reported, but cadaveric dura mater allograft patches, and growth hormone 
derived from cadaveric pituitaries have transmitted disease and are therefore included in the category 
of high-risk tissues.  Modified from (WHO guidelines, 2006). 
 
HUMAN TSEs 
vCJD Other TSEs 
 
Tissue 
Infectivity1 PrPTSE Infectivity PrPTSE 
Brain + P + + + 
Spinal cord + P + + + 
Spinal ganglia + + + + 
Dura mater3 NT - + - 
Cranial nerves + + + + 
Cranial ganglia + + + + 
Retina NT + + + 
Optic nerve2 NT + NT + 
Spinal ganglia + + NT + 
Trigeminal ganglia + + NT + 
Pituitary gland3 NT + + + 
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Human CNS tissues are considered to contain the highest titres of infectivity and 
require stringent precautionary handling protocols. Based on accumulated evidence, 
as a frame of reference, brain typically contains about 106 LD50 /g, spleen up to 100 
LD50 /g and blood generally < 100 LD50 /ml (Brown & Abee, 2005; WHO 
guidelines,2006). For the purpose of this project, it is assumed that human brain 
tissue contains high levels of infectivity. It is important to point out that categories of 
infectivity are distinct from categories of risk. The latter requires consideration not 
only of the level of infectivity but also of the amount of material to which a person is 
exposed, and the potential route(s) of transmission.   
 
Extraction of RNA from tissues is generally based on phenol-chloroform extraction 
(Maniatis et al., 1982). The RNA extraction protocol will include the use of 
guanidinium thiocyanate (GTC, a strong protein denaturant and a known inactivator 
of TSE agents) and phenol. The lysis reagent contains GTC concentrations of ~ 4 M 
and phenol concentrations of ~ 2M. Based on evidence discussed in section 1.1.3, > 
2.5 M GTC should be effective at reducing even high titres of CJD in brain tissue 
and although phenolics are considered ineffective at inactivating PrPSc, the 
monophasic purification steps should retain PrPSc within the organic phases. Thus, 
the agent should be inactivated by two separate mechanisms; 4 M GTC should 
denature the proteinaceous material and inactivate PrPSc; the additional phenol 
extraction should retain all remaining PrP/PrPSc. RNA should fractionate into the 
aqueous phases and the proteinaceous fractions will be retained in the phenol and 
discarded. Since TSE infectivity co-purifies with the proteinaceous fraction of brain 
material (Bolton et al., 1982), this should therefore remove the majority, if not all, of 
the infectious material. After this stage, the infectivity risk should be considerably 
reduced. 
 
Having considered the criteria set out by ACDP and SEAC, the main risk in this 
project lies prior to phenol-chloroform extraction of the brain homogenate. The 
majority of the brain sampling will be carried out by trained experienced staff, which 
will further minimise sharp and inoculation risks and sample preparation work will 
be carried out in a microbiological class 1 hood within the high risk CL3* laboratory, 
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to protect against aerosol and volatile chemical inhalation. Subsequent work with the 
extracted RNA samples represents minimal risk and can be carried out in a CL2 
laboratory.  
 
3.3.2 Transport of RNA Preparations 
All RNA extractions were required to be carried out in the NCJDSU CL3* high-risk 
laboratory. After RNA extraction (as described in Chapter 2), RNA samples were 
deemed safe for transportation to the CL2 laboratories at Summerhall.  
For transportation, government regulation standards set by the Department of Health 
in conjunction with the ACDP and SEAC were followed.  
 
CLASSIFICATION AND PACKAGING 
Clinical samples known or suspected to contain disease-form prions (e.g. CJD, vCJD 
etc) are a Category B infectious substance under the transport regulations. Based on 
the nature of the materials and purpose for which they are being transported, they are 
assigned to UN3373 with the proper shipping name Biological Substances Category 
B. This UN number and proper shipping name identifies and classifies the substances 
under the international system. 
 
All materials transported to and from the NCJDSU were packaged using a triple 
layer packaging system. This comprises a leak proof primary receptacle, a leak proof 
secondary packaging and an outer packaging. Absorbent material, in sufficient 
quantity to absorb the entire contents of any leakage from the primary, was placed 
between the primary and the secondary layers. The primary receptacle was placed in 
the secondary in such a way that under normal conditions it cannot be punctured or 
leak. The secondary was secured or supported in the outer with suitable cushioning 
material. This system was in line with the packaging instructions published by the 
Department of Transport, Carriage of Dangerous Goods ADR 650. A sticker stating 
UN 3373 was displayed on the outer box and a warning sticker stating ‘DO NOT 
OPEN EXCEPT IN LABORATORY CONDITIONS’ was displayed on the surface 
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of the receptacles. An emergency procedures protocol and a packaging procedure 
information sheet were packaged with the samples. 
 
3.4 ETHICAL STATEMENT FOR ANIMAL WORK 
 
All mice were derived from stock bred in the Animal Unit, Centre for Infectious 
Diseases, University of Edinburgh and were used at less than 10 weeks of age. Mice 
were healthy, and were used for control brain tissue for assay optimisation. All 
procedures involving animal work complied with the Animals (Scientific 





3.5 ETHICAL STATEMENT FOR HUMAN WORK 
 
With regard to the removal of tissues, the main ethical principles from the donor’s 
point of view are: 
• respect for the human body, even after the person’s death 
• respect for the autonomy of the donor; thus, tissue may not be removed 
whenever the person refuses. For deceased persons, this implies that tissues 
may not be removed if the person refused consent during her/his lifetime 
• protection of vulnerable people, namely people unable to give consent 
• respect for private life and medical confidentiality, which is a fundamental 
right 
• the right to prior information on the conditions of removal and the expected 
use of the tissues 
• the right not to be subjected to unfair discrimination, which could result from 
the revelation of data collected from the donor, or the family, to third parties 
(e.g. employers and insurance companies). 
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All procedures involving the use of human tissues comply with the Human Tissue 







An extensive number of decontamination studies and reviews have been undertaken 
in response to concerns about CJD transmission associated with blood transfusion, 
dura mater and cadaver derived growth hormone contamination (Llewelyn et al., 
2004; Esmonde et al., 1993; Powell-Jackson et al., 1985). Even so, it has still not 
been possible to reach a consensus as to which method of decontamination is most 
suitable, within clinical, pharmaceutical or research settings. There is ongoing 
dispute as to whether the prion protein is the only infectious component of the TSE 
agent (Manuelidis et al., 1987). It seems unlikely that current decontamination issues 
will be resolved in the near future. 
 
The different experimental systems and methodologies employed to compare 
decontamination and differences between TSE agents, make direct comparison of 
decontamination results difficult. Direct comparison of TSE agents in different hosts 
would make it easier to evaluate which model is the best predictor of CJD in humans. 
The biological relevance of scrapie for CJD, given that strains exhibit such variation 
in thermostability for example, is an issue that also requires attention.  
 
Decontamination studies which use high titre strains of TSE have been criticised for 
being prone to recommending extreme inactivation protocols. While some may 
consider the use of high titre agents (1010-11 infectious units per gram of brain tissue 
for many scrapie strains) to infer appropriate decontamination procedures for lower 
titre agents, such as BSE and/or vCJD or sCJD agents (infectivity titres of 
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approximately 108-9 infectious units per gram of brain tissue) as excessive, it is 
probably preferable to overestimate the resistance of TSE agent, especially with 
relevance to human strains, for fear of increased iatrogenic spread. The direct use of 
low titre agents as a study model may be problematic as large log reductions in 
infectivity cannot be demonstrated and arguably may not provide sufficient evidence 
of decontamination. Consequently, while some researchers may consider scrapie 
models unsuitable for testing decontamination methods for CJD, testing on CJD 
material is not plausible unless more sensitive infectivity detection methods are 
developed (Peretz et al., 2006).  
 
There has been controversy as to whether the protease-resistant and detergent- 
insoluble characteristic of prion proteins is necessarily associated with prion 
infectivity (Shaked et al., 1999). If this is indeed the case then protease sensitive 
and/or detergent soluble agent could remain infective. This holds significant 
consequences for decontamination studies that have assumed that the absence of 
residual PrPres or detergent-insoluble PrP has proven successful inactivation. This is 
another reason why it is very important to carry out full end point titration bioassays 
as they are currently the most sensitive method of detecting infectivity (Shaked et al., 
1999).  
 
Inactivation methodologies involving the use of heat would seem to be highly 
specific for a particular agent, having clear evidence of thermostable variation and 
the ability to acquire resistance (Taylor et al., 1998). While this may pose 
complications for inactivation and kinetic studies, fortunately as yet there have been 
no reported differences in the chemical susceptibility between TSE agents; leading to 
the conclusion that chemical inactivation of infectious agents may be more practical. 
For this project, Qiagen RNA extraction kits containing a lysis buffer with ~4 M 
GTC and ~2 M phenol at a pH of 5.0 were used. These concentrations have been 
observed to reduce CJD titre by > 99.7% and increased acidity increases inactivation 
of the scrapie agent when using GTC as a denaturant (Manuelidis, 1997; Caughey et 
al., 1997).  Inactivation studies often state incomplete tissue penetration as a reason 
for incomplete inactivation. Strong chaotropic ions such as GTC are extremely 
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disruptive and should significantly enhance tissue penetration, an issue of more 
importance when working with high lipid tissues such as brain.  
 
Although phenolics have been specified as being ineffective for complete 
inactivation of TSE agents, retention of the proteinaceous infectious material within 
the phenol phase and the denaturing action of the GTC should be sufficient to 
remove infectivity from the RNA preparations. Nonetheless, the absolute inactivation 
of CJD agent from human brain cannot yet be guaranteed, and although these 
evidence-based guidelines provide a good basis to assume CJD inactivation >99.7% 
was achieved, it was necessary to treat RNA preparations as low risk samples. RNA 
preparations were tested for the presence of PrPSc, to determine the RNA extraction 
protocol (refer to Chapter 2) efficacy of protein removal and the results are discussed 
in detail in Chapter 5. 
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• Evaluate suitable case selection criteria and select suitable cases. 
 
4.2 CONCEPT  
 
Tissues were supplied for this project from two brain banks; the National Creutzfeldt-
Jakob Disease Surveillance Unit (NCJDSU) and the Medical Research Council 
(MRC) Sudden Death Brain and Tissue bank. The purpose was to acquire brain 
material from cases of variant Creutzfeldt-Jakob disease (vCJD), non-neurological 
disease (NND) and other neurological disease (OND), to prepare TSE agent 
decontaminated RNA preparations from human autopsy brain material, to evaluate 
human RNA quality and quantity and to determine sample suitability for a 
comparative study of gene expression. vCJD and OND cases were obtained from the 
NCJDSU Brain Bank and NND cases were obtained from the MRC Sudden Death 
Brain Bank. vCJD diagnosis was confirmed by histopathology. OND cases in the 
NCJDSU constitute suspected CJD cases, which were subsequently shown by 
histopathology not to be prion disease. NND control case diagnosis is based on the 
tissue analysis report completed by a consultant neuropathologist.  
Material was obtained from cases in which consent for research had been obtained 
from relatives. The NCJDSU Brain Bank and MRC Sudden Death Brain Bank have 
ethical approval to store and use autopsy brain tissues for research (NCJDSU LREC: 
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4.3 NATIONAL CREUTZFELDT-JAKOB DISEASE BRAIN 
BANK 
 
The NCJDSU was set up in response to recommendations from the Report of the 
Working Party (The Southwood Committee) on Bovine Spongiform Encephalopathy 
(BSE), following the discovery that UK cattle were infected with this transmissible 
spongiform encephalopathy.  The NCJDSU is directly funded by the Department of 
Health and the Scottish Executive Health Department and is a member of the 
BrainNet Europe consortium (Bell et al., 2008). The primary aim of the NCJDSU is 
to identify and monitor all suspected cases of CJD within the UK, and identify 
patterns of disease epidemiology and risk factors that may be linked to the emergence 
of vCJD. Each suspected CJD case is investigated thoroughly by clinical examination, 
clinical investigations, neuropathological examinations, genetic analysis, molecular 
biological investigations, and the acquisition of basic epidemiological data.  Current 
surveillance involves three types of referrals; clinical, death certificate and other 
sources. At the point of referral, cases are classified according to established criteria 
(Appendix 9.2). Whenever possible, all referrals to the NCJDSU categorised as 
‘definite CJD’, ‘probable CJD’, ‘possible CJD’ and ‘ diagnosis unclear’ are visited in 
life by a NCJDSU neurologist, at which point physical examination, a blood specimen 
and clinical information are collected and the classification is re-assessed.  If the case 
classification requires it, a final review form is opened for each suspect case and is 
held as an ‘opened’ case file at the NCJDSU. All incoming clinical and laboratory 
data is recorded and stored on file until the patient’s death, at which point a post-
mortem may be performed if consent is granted.  If this is the case, all investigational 
data, reports and pathological materials are also logged and stored in the case file. 
Referrals for probable or definite genetic CJD or iatrogenic CJD are not followed up 
by the NCJDSU, unless the diagnosis is unclear or a specific request is made by the 
local clinician for a visit by a neurologist from the NCJDSU. Professor Michael 
Preece, Institute of Child Health, London, follows up cases of growth hormone related 
iatrogenic CJD and the investigation of cases of familial CD is undertaken by staff at 
the National Prion Clinic, London.  
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Following appropriate consent, post-mortems are performed by a neuropathologist. 
For diagnostic purposes, the brain is examined macroscopically by a neuropathologist 
and the whole organ or regionally defined specimens of it are retained in fixative. The 
samples are decontaminated in formic acid, processed to paraffin blocks, cut and 
stained immunohistochemically, primarily for prion protein. The neuropathologist 
then examines the slides for microscopic changes and either confirms or makes an 
alternative final diagnosis. If consent has been obtained and frozen brain tissue is 
available, a western blot is carried out to detect abnormal prion protein and to 
determine prion protein isotype. This is based on the Parchi classification system 
(Parchi et al., 1999). If specific consent for genetic analysis is obtained from the 
family, prion protein gene codon 129 determination and in some cases full sequencing 
of the gene is also carried out, usually on a blood specimen taken in life, but this can 
also be performed from frozen tissue obtained at autopsy. Cases stored at the Brain 
Bank include; sporadic, familial and variant CJD, as well as suspected cases of CJD, 
which diagnostic tests have shown not to be CJD. The latter form the majority of the 
OND controls in this study.  
 
4.3.1 Autopsy Protocol (NCJDSU) 
A full, informed, written consent post-mortem is requested for each patient, and use of 
tissues for research purposes requires specific permission from the family of the 
deceased. Post-mortems must be carried out in a mortuary with high-risk facilities. In 
Edinburgh, the registered neuropathology centre with a high-risk mortuary is sited at 
the New Royal Infirmary (NRIE), Little France. Patients suspected of having CJD 
within the north of England and the East of Scotland are normally referred to NRIE. 
Post-mortems can be organized for these patients at the NRIE, to be performed by 
consultant neuropathologists (Prof. J. Ironside, Prof. J. Bell, and Dr. C. Smith). In 
these cases, it is possible to collect and store tissues of specific interest at the brain 
bank, once full consent has been obtained.  
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4.3.2 Arrangements for Post-Mortems (NCJDSU) 
There are two types of post-mortem: Hospital post-mortems and Coroner post-
mortems. Coroners can request a post-mortem examination and do not need relative’s 
authorization. Hospital post-mortems can only be carried out with fully informed 
consent from the relatives. In order for full informed consent, relatives only complete 
the authorization form having been made aware of the meaning of its various sections 
particularly with regards to the retention of tissue and individual organs for diagnosis 
and/or teaching and research. All requests for hospital post-mortem include a 
correctly completed request form. This form includes space for full patient 
identification and brief clinical summary. This is a legal requirement and must be 
completed before the post-mortem can commence.  
 
4.3.3 Tissue Storage (NCJDSU) 
The NCJDSU has been involved in the surveillance of CJD cases, in particular (new) 
variant CJD cases within the UK from its establishment in 1990. This involves the 
collection and storage of tissues in a purpose-built brain bank and laboratory, as well 
as the accumulation of clinical, pathological and epidemiological data on each case. 
Tissue samples can come from local autopsies or from autopsies carried out 
elsewhere. In-house autopsies have a PM protocol (Appendix 9.3), which standardizes 
the types of samples collected. Autopsies carried out at one of the other 27 registered 
neuropathology centres in the UK means samples can vary in tissue type, sample size 
and post-mortem interval and are therefore less predictable and uniform. At all local 
autopsies, samples are collected by identical methods and stored using one of three 
techniques. Whole half-brains and 29 specified regional brain samples are frozen by 
immediately placing them in a -80°C freezer. Prior to changes in the health and safety 
regulations of the NCJDSU, small samples were snap frozen by immersion in liquid 
nitrogen. This is no-longer the procedure as it was deemed to involve unnecessary 
risk. Since 2000, specimen requests at post-mortem have included nine specified brain 
areas collected and fixed in paraformaldehyde-lysine-periodate (PLP) for histological 
analysis. Samples of other organs, blood and cerebral spinal fluid are also collected 
and frozen at -80°C. For the purpose of this study, the specimen request was extended 
to include an additional 12 specified samples from the frontal cortex and cerebellum. 
These 12 samples were taken adjacent to the samples already routinely taken for 
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histology, to allow comparative histological and molecular studies. Six of these were 
placed immediately into RNAlater, and six were frozen at -80°C (Appendix 9.4).  
 
4.3.4 Histology (NCJDSU) 
Sections processed from all specimens taken for histological analysis undergo 
hematoxylin and eosion (H & E) staining. A select few tissue samples also have PrP 
immunohistochemisty tests (IHC), using a variety of PrP antibodies. Selected tissues 
that are H & E stained and IHC stained and used to identify any morphological and 
pathological changes, are referred to as the ‘immuno-set’. These are used at the 
NCJDSU for diagnostic purposes. 
 
 
4.4 MEDICAL RESEARCH COUNCIL SUDDEN DEATH BRAIN 
BANK 
 
Non-neurological control cases were provided for this study by the MRC Sudden 
Death Brain and Tissue bank, also a member of BrainNet Europe (Bell et al., 2008). 
The purpose of the MRC Brain Bank is to retain, store and make available for 
research use, post-mortem tissue samples from victims of sudden death. All samples 
are authorised and ethically approved for research (ethical code LREC: 2003\8\37). 
Tissue samples date back to the start of the bank’s inception in 1990. Tissue that is 
authorised for retention from hospital and medicolegal post-mortem examinations are 
collected, with the majority of post-mortem tissues having been obtained 8-27 hrs 
after death. Brain pH measurements are made on coronally cut whole brains and a 
hand held digital pH meter with glass electrode is inserted into the lateral ventricle. 
Tissue is retained from all regions of the brain and spinal cord, peripheral nervous 
system and many non-CNS organs and tissues and is stored both in formalin fixed, 
paraffin embedded blocks and in snap frozen samples. For snap- frozen samples, 
tissues are sampled at post-mortem, frozen in liquid nitrogen and stored at -80°C. 
Non-neurological disease (NND) control case diagnosis is based on the tissue analysis 
report completed by a consultant neuropathologist.  
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4.5 TISSUE SAMPLING PLAN 
 
A prospective and retrospective tissue sampling system was defined. At the NCJDSU 
for autopsies carried out after the start of this project, 12 specified samples from the 
frontal cortex (sub frontal cortex) and cerebellum, adjacent to the samples already 
routinely taken for histology were requested. Tissue supplied by the MRC Brain Bank 
(autopsy samples and stored tissues) was sampled from the frontal cortex (frontal 
parasaggital, 2nd gyrus from midline). Retrospective tissue sampling from frozen 
whole half brains stored at the NCJDSU corresponded to the areas sampled at autopsy 
from the NCJDSU and supplied by the MRC bank. Neuroregional matching was 
carried out to limit the effect of regional variation. Figure 4.1 illustrates the areas 
sampled for this project. 
 
Figure 4.1. Sagittal view of human brain indicating area of sampling as determined by post-
mortem protocol. The decision to study mainly areas in the frontal region of the brain is based on 
evidence that significant pathological change is seen in this particular region of the human brain in 
vCJD patients.  In order to reduce regional disparity of gene expression, attempts were made to ensure 
that tissue samples were taken from corresponding regions. 1. Cerebral hemisphere; 2. corpus 
callosum; 3. cerebellum; 4. superior frontal gyrus; 5. sub frontal cortex; 6. occipital lobe; 7. temporal 
pole. Red box represent anatomical region taken by NCJDSU neuropathologist at autopsy and either 
snap frozen or stored in RNAlater (sub frontal cortex, dentate nucleus of cerebellum). Blue boxes 
represent the anatomical regions sampled from frozen half brains for regional study (sub frontal cortex 
and frontal parasaggital, 2nd gyrus left of frontal gyrus midline).  The star represents the anatomical 
region provided by the MRC Brain Bank for this study (frontal parasaggital, 2nd gyrus left of frontal 
gyrus midline).  
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4.6 CLINICAL HISTORY AND CONSENT 
 
Medical records and information for individual cases was accessed at the NCJDSU, 
Western General Hospital, Edinburgh. Due to the importance of patient 
confidentiality, all research carried out respected patient anonymity by using coded 
samples for this study, and protected the rights of the patient and their families. All 
clinical data was obtained with permission from the NCJDSU Director. 
Tissues stored at the brain bank may or may not have consent for use for research 
purposes, and only those cases with full consent for research use were available for 
this study. 
The procurement of human tissues requires the prior, informed and free consent of the 
person concerned or their proxy. The information provided to the donor should 
concern: 
• The procurement arrangements, in particular concerning the free nature of the 
donation, and the extent of its anonymity. 
• Possible tissue storage time and conditions, and conditions of registration of 
data in databases, in conformity with requirements of private life protection 
and medical confidentiality. 
• Foreseeable use of the tissues (diagnostic, allograft or autograft, 
pharmaceutical products, research, production of cellular lines etc.).  
• The donor may at any time withdraw her/his consent. 
 
4.6.1 Index of Agonal State Scoring System 
Agonal factors (AF) are defined as the condition of the patient and the circumstances 
immediately preceding the time of death. The agonal state is determined by the length 
of time AFs have been present. Certain AFs are suggested to significantly impact on 
RNA quality, including hypoxia, dehydration and seizures. It was necessary to 
establish a system which could evaluate the agonal state of a patient, to allow 
comparisons between samples to be carried out. For the purpose of this study, the 
Index of Agonal State (IAS) was developed as a graduated scoring system from 0-20. 
This system incorporates more detail than the Agonal Factor System (AFS) developed 
by Tomita et al (Tomita et al., 2004), because the cause as well as the duration of the 
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conditions leading to death is accounted for. Clinical case histories, histology reports, 
autopsy reports and histopathological slides were examined for all NCJDSU cases and 
a list of 10 factors was scored in the following manner; 
• Duration (1 score per 9 mnth duration) 
• Mode of death (0 - 4, as described by (Hardy et al., 1985) (see Table 4.5) 
• Seizures (0 for absent, 1 for present) 
• Coma (0 for absent, 1 for present) 
• Hypoxic and/or ischaemic change (0 for none, 1 for evidence of, 2 for severe) 
(see Figure 4.2) 
• Pyrexia (0 for absent, 1 for present) 
• Dehydration (0 for none, 1 for evidence of, 2 for severe) 
• Hypoglycemia (0 for none, 1 for evidence of, 2 for severe)  
• Multiple Organ Failure (0 for absent, 1 for present) 
• Neurotoxic substances (0 for absent, 1 for present) 
 
The sum of each factor gives the IAS for each case. Where possible, assessment of all 
case information was done with discussion with the registrar and nurse practitioner 
involved in the case and the neuropathologist involved in the autopsy and histology 




Figure 4.2. Microscopic photographs of a representative example of severe (grading 2) ischemic changes observed in brain tissue. 
Figure 4.2. Microscopic 
photographs of a representative 
example of severe (grading 2) 
ischemic changes observed in brain 
tissue. Eosinophilic shrunken 
neurones in the hippocampus from a 
case of global cerebral hypoxia in a 
56 year old male. The affected cells 
also show nuclear shrinkage, but not 
fragmentation. Images courtesy of 
Prof. J. Ironside 
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4.7 ASSESSMENT OF CASE SELECTION REQUIREMENTS 
 
4.7.1 Difficulties in Studying Gene Expression in Human Brain 
Tissue 
Identification of differentially expressed genes in CJD versus control brains could be 
affected by a huge range of pre- or post-mortem factors that can affect the outcome of 
the measurements. This is a major disadvantage to studying human tissues instead of 
experimental animal tissue. For experimental animals, rigid controls are in place, both 
during the animal’s lifetime and at death. Human studies have uncontrollable 
variables during life, illness and death, which increase the potential of change in gene 
expression levels unrelated to the disease pathology. 
 
A DNA-RNA hybridization study in rodents indicates that gene expression in the 
brain may exhibit a greater level of variation than any other region of the body (Hahn 
& Laird, 1971). It seems reasonable to extrapolate this to humans. Furthermore, the 
heterogeneity of cell sub-types and their function, for example, in areas of cognition, 
is so diverse that controlling for brain region in gene expression studies is only 
practical to a limited extent. Gene expression levels are dynamically regulated by 
developmental times, spatial positioning (e.g. cell-type specific manner), 
environmental factors (e.g. activity-dependent gene expression) and disease states 
(Sporns et al., 2000; Tononi et al., 1994).  
 
While it is entirely possible that disease relevant genes are expressed differentially 
throughout the brain, it is equally possible that disease related genes are only 
expressed differentially in a specific brain region. As it is impractical to study the 
human brain as a single entity, to choose areas to study one can make the assumption 
that the most disease affected area of the brain, according to neuropathological and 
biochemical criteria, are the areas most likely to show pathology related changes in 
gene expression. Although this approach is practical, the selected brain region chosen 
on the basis of neuropathology, neuroimaging or biochemical studies, may not 
coincide with the brain region(s) having the greatest changes in gene expression 
relevant to the pathophysiology of CJD. Disease specific gene expression may only 
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occur within certain timeframes in disease progression and may not be observed in 
areas of greatest pathology at post-mortem. If this is the case, then gene expression 
studies may not identify causative genes, but secondary and subsequent changes in 
gene expression. However, these secondary changes may still be crucial for 
understanding the effects of the disease on the brain, as well as potential marker for 
diagnostics and development of pharmacological therapies.  
 
Concerns about brain region sampling were raised when significant genetic variation 
was observed between different samples within the BSE-infected bovine caudal 
medulla (Brown, 2005). Recently, region specific patterns of gene expression in the 
human brain were demonstrated using microarrays (Ernst et al., 2007; Roth et al., 
2006). Studies based on regional patterns of gene expression in human and 
chimpanzee brains give insight into the gene expression differences between brain 
regions. Observed transcriptome variation was greater between individuals than 
within individuals and notably, the sets of genes selectively expressed in the 
cerebellum were particularly large and diverse (Khaitovich et al., 2004; Enard et al., 
2002). To appreciate the vast heterogeneous nature of the brain, studies generating 
RNA profiles extracted from single cell nuclei were able to show comparable degrees 
of variation. Expression patterns, while consistent for a single type of brain nuclei, 
showed significant differences between different nuclei (Bonaventure et al., 2002; 
Kacharmina et al., 1999; Kacharmina et al., 1999). This has implications for gene 
expression studies based on tissue samples containing an array of cell types; 
endogenous variation between cell types may confound any gene expression 
alterations identified. Such heterogeneity would therefore make accurate analysis of 
the brain region necessary (Colantuoni et al., 2000; Watakabe et al., 2001). 
 
The NCJDSU has three neuropathologists that routinely carry out autopsies on 
referred cases.  Although specimens will be from as close to the same region as is 
possible, slight discrepancies in the exact region that is dissected may affect gene 
expression levels and lead to identification of differences that are caused by regional 
variation rather than between individuals. The distinctive pattern of expression in each 
region of the brain requires precise dissection of the tissue at post-mortem, in order to 
limit significant intra-regional gene differences. Morphological variation between 
individual human brains and irregularities of anatomy might cause problems in 
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identifying correct spatial positioning for sampling. When tissue is dissected from 
larger pieces or from the whole organ, for example, it is possible a sample may 
contain a cross section of cortical ribbon and white matter, while another sample may 
contain no white matter. If these two samples were to be compared, differences that 
would be observed would not be due to the disease, but in fact to the differences of 
the material included in the dissection.  
 
Post-mortem gene expression in the brain of each individual is likely to be affected by 
a unique combination of variables, including immediate cause of death, temperature 
and interval between death and refrigeration of the body (refrigeration interval, RI), or 
removal of the brain tissue and freezing or fixing it (post-mortem interval, PMI) and 
the interval of storage before the tissue is used for research purposes, freezer interval 
(FI). While it is possible to control post-mortem factors to some extent, inevitably 
variations in tissue handling happen. It is not feasible to control for these pre-mortem 
variables, although the consensus opinion within the literature is that these factors are 
likely to have the greatest impact on RNA populations in brain tissue. Pre-mortem 
variables considered to have an effect on mRNA stability and integrity include; age, 
gender, ethnicity, medication, agonal state, disease severity and laterality of the brain, 
and are discussed below. 
 
Addressing the issue of high mRNA variance observed in human post-mortem brain, 
Preece et al evaluated whether mRNA transcripts within a single brain were degraded 
in an ordered system, either by confounding factors or as a function of time. If 
degradation of transcriptomes occurred in a highly randomized manner, the post-
mortem mRNA representation would bear no resemblance to the in vivo situation and  
inferred differences in mRNA levels due to pathology would not be distinguishable 
from post-mortem changes and would render expression data worthless (Preece et al., 
2003). While absolute levels of mRNA showed high variance between individuals 
(>1000-fold), relative mRNA (3 positive and 3 reference genes) levels had 
insignificant (<0.001) mean change. Evidence of such an ordered degradation of 
transcriptome allows for the removal of inter-individual variation from the statistical 
model and infers a more authoritative gene expression profile. 
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It is possible to limit the amount of background genetic variation by using a 
genetically homogenous population of subjects. While theoretically possible, say, if 
studying familial forms of E200K CJD in Jews of Libyan descent (Sachs & Bat-
Miriam, 1957; Kahana et al., 1974), this would drastically limit the sample size (for 
example, at the NCJDSU, sample size would be limited to less than 8 cases) and 
therefore the statistical strength of the study. Thus it was not possible for this study to 
match for genetics in the most general sense. However for certain disease specific 
genes implicated in CJD, this is possible. All frozen tissue from the NCJDSU has a 
record of the codon 129 genotype of the prion protein gene, although the gene may 
not be completely sequenced, if consent was not obtained. All 21 vCJD cases 
included in this study were MM at codon 129 and of these, 18 cases were tested for, 
and did not contain, any other disease-related polymorphisms within the prnp gene.   
But this criterion is not considered of high relevance when selecting cases, since there 
is limited evidence that differences in the genotype would have an effect on the 
disease pathogenesis gene expression profile. 
 
4.7.2 Analysis of Available Samples  
The NCJDSU has the largest collection of CJD and non-CJD infected tissue in 
Britain, dating from the Oxford study by Professor Robert Will and Professor Bryan 
Matthews in 1980’s. Tissues are stored frozen (-80°C), snap frozen (historical; liquid 
nitrogen, recent; -80°C) and PLP fixed. The types and amounts of tissues stored vary, 
as the brain bank receives samples collected from autopsies all over Britain. Therefore 
it may not be possible to use cases from other neuropathology centers if frontal cortex 
and cerebellum have not been supplied, or if only small amounts of tissue were 
provided. Non-neurological control cases provided by the MRC Sudden Death Brain 
Bank are requested based on the availability of suitable cases within the NCJDSU. 
Since a peak in the number of vCJD cases in 2000, there has been a decrease in the 
number of cases referred to the NCJDSU. This may in part be due to better diagnosis 
and more family members unwilling to consent to tissue use for research, making it 
difficult to find suitable cases for this study. The scarcity of donor tissue and the 
restrictions on sample size places limits on the power and resolution of any statistical 
analysis. If the sample size is too limited, any inferences that are drawn from the data 
may not be representative of the population. Therefore, it is important to consider the 
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number of samples available and not to limit the sample size by insisting on matching 
cases based on too many restrictive and unnecessary criteria. 
 
4.7.3 Stability of Archived Material 
Liquid nitrogen snap frozen tissue, -80°C freezer stored tissue and RNAlater treated 
tissues were compared in order to identify the most suitable method of storing tissue 
while retaining RNA quality and quantity, in an unbiased manner. Retrospective and 
prospective comparisons were also carried out to determine the utility of archived 
material. Tissue samples from the 1970’s exist at the brain bank at the NCJDSU. It is 
not known whether the RNA in these tissues is still suitable for RNA profiling. Once 
removed or collected, tissues are subject to a series of operations: 
• processing 
• preserving and storage 
• registration (to collect the data which will enable in particular the source of the 
tissues to be traced) 
• distribution and delivery. 
Older samples may have been removed from the freezer a number of times and 
potentially have been subjected to numerous freeze-thaw cycles. The effects on 
mRNA stability of long-term storage of tissue in the frozen state and therefore the 
subsequent damage to the integrity of the RNA will be an important aspect to the case 
selection criteria. 
 
4.7.4 Inclusion and Exclusion Criteria 
For a genetic comparison to be successful, case matching must be done to a high 
standard. Therefore, an assessment of relevant inclusion and exclusion criteria was 
undertaken. As human tissue is scarce, it was imperative to make informed decisions 
and not waste material. Pre-mortem and post-mortem factors that can affect RNA 
integrity may have implications for downstream analysis. Every individual is a 
composite of many different factors; variations in brain RNA levels are necessarily 
going to be the net result of an exceedingly complex set of underlying conditions. 
Ultimately gene expression analysis will be carried out, using two types of control 
cases. The purpose of two control groups is to establish TSE-specific modulated 
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genes from non-specific alterations. NND cases were used as normal control cases, 
allowing identification of any neurological disease modulation, whereas OND cases, 
being a pooled collection of various non amyloidgenic diseases, would allow a 
comparative list to be compiled and help identify TSE-specific gene changes. 
Clinical backgrounds of all patients are accessible from patient records. Based on the 
classical clinical features of vCJD, case matching for two control types (NND and 
OND) becomes a complicated matter. vCJD clinical features include; long disease 
duration ( ~ 12 months), young age of onset ( ~ 27 years), and neurological 
presentation. Typically OND cases have an older age of onset, variable lengths of 
disease duration and may or may not have neurological presentation depending on the 
individual case selected. NND cases have no known disease and therefore, at a 
minimum, would be matched by age and sex. In the MRC Sudden Death Brain Bank, 
a significant percentage of the cases are of a younger age group, overlapping with the 
young onset age of the vCJD group.  
 
CONFOUNDING FACTORS 
Factors such as age at death and pH of the brain are confounding variables (or 
covariates). These factors correlate with both the dependent variable (i.e. altered gene 
expression) and the independent variable (i.e. disease).  Factors such as species are 
fixed factors. For accurate data analysis, confounding variables must be removed so 
that observed effects are not attributed to a confounder rather than the independent 
variable (i.e. vCJD). There are two methods of removing confounding variables in a 
study; matching for them or measuring them and using stratification or multivariate 
analysis (or both). Matched or case-controlled studies are slightly better than 
controlling by multivariate analysis because while multivariate analysis can 
accommodate some of the differences in confounding variable (i.e. age and sex), so 
many other variables depend on age and sex, it is simpler if the groups have similar 
profiles.  
 
A large proportion of CJD patients normally succumb to a respiratory infection of the 
bronchi, or starvation and thirst. Dehydration and hypoglycaemic effects on RNA 
would therefore be relevant when studying vCJD patients. Co-infected individuals 
could exhibit different gene expression profiles, if this “secondary” infection affects 
mRNA expression in the brain. This may vary according to the infection and the 
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immune response at the time of death. For example, infections such as 
broncopneumonia would alter peripheral cytokine levels which could also affect gene 
expression in the brain. Cytokines such as interleukin (IL)-10, -1 and -6 have been 
shown to regulate microglia maturation and activation. Extraneural complement 
activation in response to infection may also affect RNA expression within the brain 
(Mabbott, 2004; Kovacs et al., 2004; John et al., 2003; Gasque et al., 2000; Singhrao 
et al., 2000). Viruses can  target the CNS  and routine post-mortem human specimens 
are frequently infected by a range of viruses, including; hepatitis, herpes and  JC 
viruses (Sanders et al., 1996; Shapshak et al., 1986; White et al., 1992). Viruses are 
able to induce apoptosis and other host responses and also infect and affect regions of 
the brain differently, potentially complicating vCJD gene expression studies (Kumar 
et al., 2007; Allsopp & Fazakerley, 2000; Kristensson, 1992). Patients with 
simultaneous infections of the brain are useful control cases. Neuropathological gene 
expression changes may be confounded by other factors, for example age of patient.  
 
PRE-MORTEM FACTORS 
Although pre-mortem factors have been evaluated for their effect on RNA integrity, 
the published data are contradictory. Brain pH and agonal state are thought to exert 
the most damage to RNA and are interdependent factors. Prolonged agonal state 
causes an increase of lactic acid in the brain, thereby reducing the pH. Studies on pH 
from the frontal cortex indicate a long terminal phase of disease results in a lower pH 
than rapid death. The low pH (6.0-6.5) observed corresponded to lactic acid 
concentrations (20-25 mM) known to be neurotoxic (Kingsbury et al., 1995). This 
effect has been observed to alter RNA yield, mRNA integrity and enzymatic activity 
(Harrison et al., 1995; Johnston et al., 1997; Barton et al., 1993; Harrison et al., 1991; 
Hardy et al., 1985; Taylor et al., 1986; Yates et al., 1990; Perry et al., 1982). 
Individuals who suffer prolonged agonal states, such as respiratory arrest, multi-organ 
failure or coma, or who have an increased age at death, tend to have lower brain pH, 
whereas those who experienced quick death, accidents, cardiac events or asphyxia, 
generally have normal pH. Lower pH brain samples generally contain degraded 
mRNA while brain samples from higher pH tissue contain more intact mRNA; 
pathological brain samples are comparable to control material of similar pH (Hardy et 
al., 1985; Harrison et al., 1991; Morrison & Griffin, 1981; Harrison et al., 1995; 
Kingsbury et al., 1995). Tissue pH is therefore likely to be a good indicator of mRNA 
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preservation. Hypoxia often leads to metabolic acidosis and lactic acid accumulation 
but brain tissue pH does not always correlate with the histological presence of 
hypoxic change (Harrison et al., 1995). The cerebellar cortex and the hippocampus 
are particularly vulnerable to hypoxic damage (Graham & Lantos, 1997). Therefore it 
was decided that for this study the dentate nucleus within the cerebellum would be 
sampled, as this region would be less likely to be affected by hypoxic changes. 
Irrespective of agonal state, brain tissue pH stabilises post-mortem. Animal studies 
have shown that although there may be a rapid drop in pH in the initial 10 mins after 
death, brain tissue pH then remains stable for 24-36 hrs (Johnston et al., 1997; 
Kingsbury et al., 1995; Ravid et al., 1992; Trotter et al., 2002; Hardy et al., 1985). In 
addition, brain tissue pH has been shown to be unaffected during freezer storage and 
is remarkably consistent across different brain regions (Johnston et al., 1997). Table 
4.1 lists previously published pre- and post-mortem parameters which may affect 










Brain pH lower in AD 
brains than controls 
 
GENDER  No pH difference 
AGE AT DEATH  No correlation in brain pH 
AGONAL STATE  Poor predictor of brain pH 
POSTMORTEM 
INTERVAL 
AD correlation with pH 
Controls not correlated to 
brain pH 
mRNA 
Brain pH correlation with 
mRNA amount 
Not applicable 
TOTAL RNA YIELD  
No difference in pathology 
or gender 
RNA YIELD AND pH  
No correlation of total 
RNA to pH 
Table 4.1. Factors contributing to variation in human brain tissue pH. Modified from (Preece & 
Cairns, 2003).  
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Treatment plans are prescribed based on the nature of the illness. The types of 
palliative medication prescribed to vCJD patients and OND patients will differ and 
older patients are often prescribed many different medications, which may further 
confound analysis. The drug history of the patient and preceding medical history are 
both relevant for gene expression studies. The use of opiates or other pain-relief 
medicines, prior blood transfusions, neurosurgery, viral encephalitis and previous 
childbirth are all factors which warrant consideration when selecting cases. It is 
highly unlikely that all these criteria will be matched for each case. It is unclear which 
medications might be most likely to affect CNS transcriptome profiles. Figure 4.3 





Figure 4.3. Handling of bodies and tissues used in study. RoD: rapidity of death. RI: refrigeration 




Post-mortem factors have an adverse effect on the integrity of mRNA, although they 
are considered less important  than pre-mortem factors (Tomita et al., 2004; Barton et 
al., 1993; Hynd et al., 2003; Burke et al., 1991). While a number of studies have 
indicated that agonal factors significantly affect the integrity of RNA and that post-
mortem factors have only a relatively small effect, this is not always the case (Bahn et 
al., 2001; Barton et al., 1993; Harrison et al., 1995; Kingsbury et al., 1995; Perrett et 
al., 1988). Studies have shown a relationship between PMI and RNA quality (Lipska 
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et al., 2006). However, other studies have concluded that there is at best a modest 
relationship (Barton et al., 1993; Lukiw et al., 1990; Harrison et al., 1995) or no 
relationship (Cummings et al., 2001; Kobayashi et al., 1990; Johnson et al., 1986; 
Morrison & Griffin, 1981; Heinrich et al., 2007; Miller et al., 2006; Schramm et al., 
1999; Watakabe et al., 2001), with the Heinrich et al studies testing PMI up to 118 
hrs, and the Schramm et al studies testing PMI up to 4 days. Given the contradictory 
reports, it cannot be concluded that RNA quality and yield are impervious to PMI. 
Just because overall RNA or mRNA content may not be affected markedly by PMI, it 
cannot be assumed that individual transcripts are all unaltered. If RNAs are 
selectively degraded post-mortem, then the pool of RNA can only be representative of 
a disordered system and would not resemble the in vivo situation. If RNAs are 
degraded in a random manner as a function of time, the pool of RNA remains in 
quantitative order and it is still possible to determine biologically relevant changes in 
post-mortem brain tissue. It has been shown that the pool of post-mortem human 
mRNA is essentially an ordered system. Such quantitative order of variation means 
that mRNAs are retained in the relative representative states that existed before death 
(Preece et al., 2003). For practical and ethical reasons, a PMI of at least 1 hour and 
usually considerably longer is inevitable. 
 
Storage method and freeze-thaw cycles may have more influence on mRNA 
preservation than agonal state or PMI. Although mRNA remains stable for extended 
periods of time within the body (<48 hrs), this greatly depends on the temperature of 
storage (Barton et al., 1993; Leonard et al., 1993; Schramm et al., 1999). Once tissue 
has been harvested from the human body, it comes under a barrage of assaults and 
RNA can easily become degraded. Preservation techniques used in the NCJDSU have 
previously included liquid nitrogen freezing, but this is no longer permitted for health 
and safety reasons. Currently, tissue is stored frozen at –80˚C, either as small 
specimens or as whole half brains. Small tissue pieces freeze relatively quickly, 
whereas large organs take longer. Tissue storage time must also be considered. There 
is evidence that storage of human brain material at –70˚C for up to 15 years results in 
little or no degradation of RNA until it is thawed (Yasojima et al., 2001). In contrast, 
in another study, RNA degradation was observed in human post-mortem brain stored 
at -70°C for more than 5 yrs (Leonard et al., 1993). While the total amount of RNA 
that can be isolated from freezer-stored tissues may not vary significantly, the quality 
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of the RNA may deteriorate over time, affecting biological activity but not 
quantification of mRNA. Full length RNA is more vulnerable to degradation and 
fragmentation with extended PMI. Modern PCR techniques are able to tolerate partial 
RNA degradation. If enough full-length and partial transcripts (which are observed to 
Be more stable) remain for amplification, it is possible to use post-mortem tissue 
isolated RNA to study RNA transcript levels (Johnson et al., 1986; Schramm et al., 
1999). Gene transcript levels from tissue stored by overnight refrigeration or 4 hrs at 
room temperature and then overnight refrigeration were similar to levels in tissue 
processed immediately (Trotter et al., 2002). A decrease in transcipts was observed 
only after 8-24 hrs at room temperature and overnight refrigeration, but even then 90-
95% of detected transcripts were within 40% of baseline levels.   
Preservation of the messenger fraction of RNA is of particular importance. Directly 
after tissue harvesting, changes in gene expression may occur due to specific and 
nonspecific RNA degradation as well as due to transcriptional induction. Such 
changes need to be avoided for all reliable quantitative gene expression analyses. 
Long term storage of tissues for gene expression studies can only be done by freezing. 
The freezing procedures may affect the RNA that can subsequently be isolated. This 
may be due to autolysis of tissue, ice crystal formation and cellular dehydration. 
Whole organ freezing results in non-uniform freezing condition throughout the tissue. 
Cryopreservation using liquid nitrogen vapor results in less macroscopic artifact of 
anatomical structure and less friable frozen tissues, whereas liquid nitrogen or liquid 
nitrogen cooled isopentane is more prone to cracks or disintegration. With regards to 
gene expression investigations, tissue stored using any method of liquid nitrogen 
freezing shows minimal effects on DNA and RNA (Vonsattel et al., 1995).  Sample 
preparation requires thawing tissues from -80°C to at least 0°C. The number of 
freeze-thaw cycles can have serious adverse affects on the resulting isolated RNA, 
disrupting the cellular membrane and allows mixing of cellular enzymes and 
substrates which are normally segregated. The addition of chemical additives may 
help to minimize cellular stresses during freezing. Although the exact mechanism is 
unknown, the agents may protect the cell against harmful electrolyte concentrations 
which arise when water molecule crystallize (Hardy & Dodd, 1983; Leal-Klevezas et 
al., 2000; Bischof, 2000; Karlsson & Toner, 1996). The RNA stabilization reagent 
‘RNALater’ (Ambion, Warrington,UK) is designed for stabilization and protection of 
cellular RNA in animal tissues.  
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Table 4.2 summarizes the criteria to be considered when selecting cases for this study. 
It will not be possible to match all these criteria and not all information is available 
for all cases. Having considered all the literature, the table indicates the importance of 
each factor and ranks them in descending order of importance. The foremost factor for 
selecting tissue for inclusion in this study is neuropathological verification of the 
clinical diagnosis (if possible). This is especially critical for disorders such as CJD, 





CRITERIA IMPORTANCE POSSIBILITY 




2 REGION OF BRAIN 
ANALYSED (frontal 
cortex and cerebellum) 
5 HIGH 
3 TISSUE STORAGE 
METHOD 
3 HIGH 
4 POST MORTEM 
INTERVAL (PMI) 
2 LOW 
5 AGE 4 MEDIUM/HIGH
6 AGONAL STATE 3 HIGH 
7 pH OF BRAIN 2 LOW 
8 SEX 5 HIGH 
9 DURATION OF 
ILLNESS 
2 MEDIUM 
10 MEDICAL HISTORY; 
i.e. drugs prescribed, 
clinical trials, final 
diagnosis 
2 MEDIUM 
11 BACKGROUND; i.e 
vegetarian, ethnic 
origin, familial medical 
history 
1 LOW 
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12 LENGTH OF TIME OF 
TISSUE STORAGE 
2 HIGH 
13 CODON 129 
GENOTYPE  
1 HIGH 
Table 4.2. Case selection criteria. IMPORTANCE- indicates how suitable it will be to case match for 
this criteria (1-5, 1= unsuitable to attempt to match this criteria, 5= suitable to match for this criteria). 
POSSIBILITY- indicated how possible it would be to obtain the necessary information in order to 
match the samples (HIGH- MEDIUM- LOW). 
 
The exclusion of certain cases will be necessary to ensure that selections for case 
matches are as appropriate as possible. Table 4.3 lists the exclusion factors in order of 




CRITERIA DESIRABILITY OF 
EXCLUSION 
1 OLDER SAMPLES that have 
been free-thawed  
MEDIUM 
2 CLINICAL TRIAL CASES HIGH 
3 NEUROSURGERY PATIENTS HIGH 
4 ALZHEIMER DISEASE 
PATHOLOGY/ DIAGNOSIS 
HIGH 
5 VIRAL INFECTIONS especially 
encephalopathies 
MEDIUM 
6 STATE OF DIAGNOSIS; must 
be definite diagnosis, i.e. 







Table 4.3. Exclusion criteria for case selection. 
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4.8  DEMOGRAPHICS OF SELECTED CASES  
 
Based on the inclusion and exclusion criteria, brain samples from a total of 78 cases 
were requested from the NCJDSU and MRC Brain Banks. The selected cases were 
then matched for as many parameters as possible.  
 
4.8.1 Demographics of the Patients Studied  
The demographic details of the cases selected for inclusion in this project are 
summarized in Table 4.4 and Table 4.5. There are two control groups; other 
neurological disease (OND) and non-neurological disease (NND). The NND control 
cases had no history of neurological disorders, the recorded cause of death was 
unrelated to neurological disorders and no neuropathological changes were observed 
by a consultant neuropathologist. OND control cases obtained at the NCJDSU are 
patients with neurological disorders, usually suspected CJD. The final diagnosis 
however was not CJD or other human prion disease, as established by a consultant 
neuropathologist. For experimental purposes, Alzheimer disease cases were excluded 
due to pathological and biochemical similarities to vCJD. vCJD cases were confirmed 
diagnostically by western blot and immunohistochemical staining and reported as 
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Table 4.4 shows the age range of cases, the ratios of male to female cases and the 
range of PMI from each cohort group. Brain pH was only recorded from the MRC 
post-mortems and is therefore only available for NND cases. 
 






Age at death (yrs) 40.3 ± 1.7 (16-82) 65.5 ± 1.4 (25-86) 30.8 ± 1.0 (17-53) 
Onset of symptoms 
(months) 
- - 12.8 ± 1.3(7-33) 
Sex (M:F) 21:10 17:9 12:9 
PMI ( hrs) 64.1 ± 2.6 (37-115) 68.6 ± 4.5 (6-288) 50.4 ± 2.5 (24-120) 
Brain pH 6.56 ±0.05 
(5.55-7.50) 
- - 
Table 4.4. Demographic details of NND, OND and vCJD groups. Values are mean ± SEM, with 
range in parentheses.  Age; p-value >0.0001. PMI: p-value = 0.277.  
 
 
One way ANOVA analysis for the three groups reveals a significant difference in the 
median age, with the 95 % CI for the means being most different for the OND group. 
vCJD and NND CI overlap demonstrating greater age similarity between these two 
groups than with the OND group. This result is expected because the majority of 
NND are sudden death cases, where healthy young adults die unexpectedly and vCJD 
typically affects young adults. The median age of onset in vCJD is 28 years with 
median illness duration of ~ 14 months. Table 4.4 shows the age of the patients at 
time of death, not time of onset. If the median age of onset (28 years) and duration of 
illness (~ 1 year) are extrapolated to time of death, a median time of death of ~ 29 
years would be expected. This is essentially similar to the 30.8 ± 1.0 years (Table 
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The spread of age at death (yrs) for male and female patients is shown in Figure 4.4.  
 
 
Figure 4.4. Combined scatter and box and whisker plots showing age range and gender 
proportion for each group. Compares the sample distribution of (■) non-neurological disease patients 
(NND), ( ) other neurological disease patients (OND) and (●) vCJD disease patients. Blue symbols are 
male and pink symbols are female. The boxes represent the 25th – 75th quartiles, divided horizontally 
by the median. The whiskers represent the range and the adjacent scatter plots represent the individual 
values from which the box and whiskers are derived. Outliers are denoted by (*). Male to female ratio 
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Modes of death were classified into four groups by examination of clinical notes and 
autopsy reports. Using a modification of the method described by Hardy et al (Hardy 
et al., 1985). Table 4.5 details the cause of death, mode of death and drug regime for 
each case. Mode of death was classified as follows;  
1. Violent fast death. Death was due to shooting (accidental, homicidal or 
suicidal) or blunt force trauma. Typical cases are trauma sustained in road 
traffic accidents.  
2. Fast death of natural cause. Death was sudden, unexpected deaths of otherwise 
healthy individuals. Typical cases are suspension by ligature. 
3. Intermediate death. Death of patients suffering from illness but whose death 
was unexpected. These cases could neither be classified as sudden deaths 
(above) nor as slow deaths (below). Most of these cases died in hospital. 
Typical cases include myocardial infarctions. 
4. Slow deaths. Death of patients suffering from a long period of illness with a 
prolonged terminal phase.
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD) 
Notes/ Mode of death (MOD) 
M 28 Suspension by ligature 39 7.5 1 - 2 
M 53 Suspension by ligature 37 6.4 1 - 2 
M 54 
Ischaemic heart disease. Severe coronary artery 
atheroma. COPD. 70 6.34 1 - 3 
F 53 Suspension by a ligature 87 6.14 1 - 2 
F 58 
Haemopericardium. Left ventricle rupture. Acute 
myocardial infarct. Coronary artery thrombosis. 47 6.25 1 - 3 
M 50 GI haemorrhage & liver failure 61 7.2 1 - 3 
M 24 Fatal poisoning with alcohol 51 6.3 1 - 2 
F 52 Acute myocardial infarct  64 6.4 1 - 3 
M 40 Acute myocardial infarct 48 6.2 1 - 3 
M 41 Dilated cardiomyopathy 48 6.4 1 - 3 
M 37 Acute myocardial infarction 92 ? 1 - 3 
M 25 Internal bleeding. Rupture of thoracic aorta. 92 6.6 2 - 3 
M 58 
Internal bleeding. Rupture of an abdominal aorta 
aneurysm. 67 6.4 2 - 3 
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD) 
Notes/ Mode of death 
M 20 Hyperglycaemic coma 37 5.55 2 - 4 
F 20 Combined drug poisoning 95 6.39 2 - 3 
M 53 Acute myocardial infarct 51 6.3 2 - 3 
M 25 Acute hydrocarbons poisoning 55 6.63 2 - 2 
F 59 Subarachnoid haemorrhage 48 ? 1 - 3 
M 16 Suspension by a ligature 48 6.3 1 - 2 
M 17 Severe head and neck trauma 55 6.63 2 - 1 
M 43 Ischaemic heart disease 76 7.3 1 - 3 
F 51 Hypertensive heart disease & cirrhosis 115 6.4 1 - 3 
M 53 
Combined effects of ischaemic heart disease and 
hypertensive heart disease 44 6.4 2 
- 3 
F 48 Pulmonary thromboembolism 50 6.5 1 - 3 
M 42 Pulmonary thromboembolism 98 7.1 1 - 3 
F 49 
Congestive cardiac failure and acute intoxication with 
alcohol 111 ? 1 
- 3 
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD) 
Notes/ Mode of death 
F 30 Positional asphyxia 71 6.4 1 - 2 
M 22 Suspension by a ligature 101 6.56 1 - 2 
M 28 Multiple injuries 48 7.3 1 - 1 
M 19 Fatal amitriptyline poisoning 51 6.26 1 - 2 
F 82 Bronchopneumonia 44 ? 1 - 4 
F 28 Bilateral bronchopneumonia 72 - 13 5 4 
M 26 Bronchopneumonia 48 - 17 7 4 
F 30 Bilateral bronchopneumonia 24 - 14 6 4 
M 27 
Acute bronchopneumonia and pulmonary 
congestion 48 - 18 9 4 
F 17 Bronchopneumonia 24 -  7 4 
M 27 Bronchopneumonia 24 - 3 7 4 
M 17 Bronchopneumonia 120 - 3 8 4 
F 53 
Acute bronchopneumonia with severe oedema 
and congestion 48 - 12 6 4 
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD) 
Notes/ Mode of death 
F 30 Bronchopneumonia 48 - 11 8 4 
F 35 Bronchopneumonia 72 - 3 8 4 
M 31  Bronchopneumonia ? - 23 7 4 
M 25 ? 24 - 7 8 4 
M 36 Bronchopneumonia 24 - 7 7 4 
M 20 Bilateral bronchopneumonia and immobility 72 - 13 9 4 
M 36 Acute bronchopneumonia 96 - 23 8 4 
M 39 Bronchopneumonia 24 - 4 9 4 
F 17  Bronchopneumonia 24 - 6 10 4 
M 33  Bronchopneumonia 48 - 8 7 4 
F 51 Bronchopneumonia and pulmonary odema 48 - 7 11 4 
M 39 
Bronchopneumonia and immobility and testicular 
tumour (pending histology investigation) 24 - 16 8 4 
F 29 Bronchopneumonia and cerebral palsy 96 - 15 8 4 
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD) 
Notes/ Mode of death 
M 71 
Bronchopneumonia and liver cirrhosis with periportal 
fibrosis, artheriosclerosis with severe ischaemic 
damage to basal ganglia.  
120 - 2 - 4 
M 68 
Bronchopneumonia with infective necrotising 
meningoencephalitis. 48 - 2 5 4 
F 25 
Bilateral thromboemboli, deep vein thrombosis, 
Guillan-Barre syndrome, possible Degos' disease 120 - 3 5 4 
M 67 
Bronchopneumonia and mild cerebral atrophy, 
generalised muscle wasting, healed tracheostomy. 48 - 6 11 4 
M 40 Familial Alzheimer’s disease (?) 6 - 5 7 3 
M 86 
Bronchopneumonia and arteriosclerosis and lacunar 
infarction. 96 - 4 5 4 
F 70 
Widespread small vessel cerebrovascular disease, 
bilateral bronchopneumonia 24 - 2 6 4 
F 85 B-cell lymphoma 96 - 2 8 4 
F 66 Vascular dementia. Bronchopneumonia to immobility 72 - 3 8 4 
M 76 
Road accident- was ix factor defective hemophiliac, 
therefore at high risk from use of blood product.   - 2 - 1 
M 43 Bronchopneumonia and Lewy Body dementia 6 - 1 7 4 
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD 
Notes/ Mode of death 
F 74 
Diffuse Lewy Body disease and congophilic 
angiopathy 24 - 2 6 4 
M ? 
Bronchopneumonia, myocardial hypertrophy and 
fibrosis 288 - 2 - 4 
M 69 Malignant angioendotheliosis 





Multifocal calcifying leucoencephalopathy and 
artheriosclerosis 96 - 2 10 4 
F 44 No significant abnormalities 24 - 2 - 2 
F 68 
No evidence of primary neurodegenerative disorder. 
Oedema and gliosis, artheriosclerosis. Speticemia and 
cerebral hypoxia. 
96 - 5 11 4 
F 47 
Multifocal hypoxic/ischaemic brian damage and 
cerebrovascular dementia 72 - 1 6 4 
M 72 
Bronchopneumonia, severe emphysemia. Chronic 
obstructive airways disease. 48 - 2 11 4 
F 77 Bronchopneumonia and Lewy Body dementia 48 - 1 7 4 
M 67 
Bilateral severe bronchopneumonia with abscess 
formation. Metastatic carcinoid tumour. 48 - 7 6 4 
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Sex Age Cause of death/associated diseases PMI 
(hrs) 
pH FTC IAS (including 
MOD 
Notes/ Mode of death 
M 79 Severe artheriosclerosis 96 - 5 10 4 
M 78 Multifocal calcifying leucoencephalopathy 72 - 8 - 4 
M 78 Bronchopneumonia and Lewy Body dementia 24 - 3 7 4 
M 79 Bronchopneumonia and pulmonary oedema 48 - 3 - 4 
M 55 Bronchopneumonia and Lewy Body dementia 72 - 12 6 4 
 
Table 4.5. Detailed individual case information for all NND, vCJD and OND cases included in this study. Normal = non neurological cases. Bold = variant CJD cases. 
Italics = other neurological disease cases. 
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4.8.2 Case matched comparison groups for gene expression 
Table 4.6 summarises the matched comparison groups, suitable for gene expression 
analysis, which were possible based on the inclusion and exclusion criteria for case 
selection and matching for sex and age (within 10 years). 
 












1 NND 18 M 1 vCJD 17 M 1 OND 19 M 
2 NND 54 M1 2 vCJD 39 M 2 OND 41 M 
3 NND 18 M 3 vCJD 27 M 3 OND 28 M 
4 NND 18 M 4 vCJD 27 M 4 OND 25 M 
5 NND 25 F 5 vCJD 30 F 5 OND 31 F 
6 NND 43 M 6 vCJD 30 M 6 OND 25 M 
7 NND 43 M 7 vCJD 33 M 7 OND 37 M 
Table 4.6. Summary of comparison groups, matched by age and sex. All ages are ± 10years with 
the exception of 1. 
 
 
7 matched comparison groups possible from tissues stored at the NCJDSU (vCJD and 
OND) and the MRC brain bank (NND). These cases are suitable for gene expression 
analysis, as they fulfilled the RNA quality criteria set by this project. Briefly the 
criteria were; RIN value ≥ 5.0, A260:280 nm absorbance ≥ 2.0 and A260:230 nm 
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4.9  DISCUSSION 
 
Brain bank organizations are established to provide clinically and neuropathologically 
well-documented specimens for research purposes. Although there is no consensus on 
how to prepare, categorise and store the specimen, appropriate strategies for tissue 
preservation and data collection are important for successful and reproducible 
application of quantitative competitive RT-PCR, western blotting, microarray and 
proteomic assays of unfixed tissues. It can also help link the clinical, pathological and 
scientific aspects of research. Prospective harvesting and storing of tissues gives 
researchers access to an invaluable resource. A worrying continuous decline in 
autopsy rates worldwide is serious cause for concern (Anderson & Hill, 1989), further 
limiting this precious and scarce source of tissue. Therefore it is imperative that 
maximum use is made of the tissue, by retaining samples with biochemical, molecular 
and structural integrity. Furthermore, the use of standardized tissue methods promotes 
multicentre collaborations. As new genetic techniques have emerged, there is an 
increased demand for post-mortem tissue. Brain banking will need to accommodate 
the requirements of these techniques.  
 
In order for studies to be meaningful, optimized tissue collection and storage methods 
should limit post-mortem variability, and in depth pre-mortem data collection will 
help identify and adjust for pre-mortem confounding factors. While the list of pre- and 
post-mortem factors discussed earlier in this chapter is by no mean exhaustive, a 
balance must be struck between matching for the various factors and building a 
sufficiently large sample population. Interpretation of the results of post-mortem 
studies requires fastidious consideration of these factors in order to separate changes 
due to disease from epiphenomena. Without pre-mortem data, it would be difficult to 
separate disease-related changes from changes unrelated to disease and/or artefact. 
Post-mortem measurements therefore need to be complemented by pre-mortem data.  
 
An important consideration is to separate disease-specific changes from the non-
specific effects of factors, such as PMI and AS that may contribute to RNA quality 
and quantity and which may affect gene expression analysis. Pre-mortem variation is 
inevitable, not only age and gender but every individual is subjected to many different 
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factors. By matching cases based on pre-mortem factors, confounding effects are 
minimized. The question is which pre-mortem factors have the greatest effect and are 
most important to match? Pre-mortem factors which correlate with RNA quality 
and/or quantity would be important as would pre-mortem factors which affect CNS 
gene expression. Post-mortem variation can be more easily controlled. For example, 
regional differences in human brain can be minimized by careful selection of suitable 
regions. The choice of frontal cortex and cerebellum for this study is based on data 
indicating that CJD generally affects these areas of the brain. It is however, possible 
that these regions do not have gene expression changes related to disease pathology, 
or there is considerable variation in gene expression, even in control brains, within 
these regions. One approach to address this is to study as many samples as possible 
within a region; another is to use pooled samples. Using pooled samples also reduces 
the problem of case matching. The advantages of this method would be to eliminate a 
source of inter-patient variation. The disadvantage is that it may reduce the magnitude 
of observed changes in gene expression. Further complications are introduced by the 
common practise of using one hemisphere for biochemical analysis and the other for 
pathological examination.  
 
Based only on age (± 10 yrs) and gender, from a total of 78 cases, it was possible to 
match cases across the 3 cohort groups, and to generate 7 comparison groups, each 
containing one vCJD, one NND and one OND case. This is a promising sign that 
future studies will not be constrained by limited samples, and that close adherence to 
case selection criteria is possible without restricting the strength of any potential 
findings. 
 
While it has been found in this project that it is possible to study RNA from a large 
number of post-mortem brains, it has not been possible to account for the variability 
between samples. Chapter 5 covers this is more detail. By using multivariate analysis 
methods, it may be possible to identify a variety of potentially important covariates on 
RNA transcript levels that can help researchers devise appropriate tissue collection 
methods and analysis plans.
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 5  Isolation of RNA from human brains 
 110
 
5 PREPARATION AND ASSESSMENT OF RNA FROM HUMAN BRAINS111 
5.1 OBJECTIVES ................................................................................................111 
5.2 RNA EXTRACTION AND ANALYSIS ......................................................111 
5.3 ASSESSING THE QUALITY AND QUANTITY OF RNA 
PREPARATIONS......................................................................................................117 
5.3.1 Pilot Study on Mouse Brains .................................................................117 
5.3.2 Comparison of Extraction From Human and Mouse Brains .................118 
5.3.3 Reproducibility ......................................................................................122 
5.4 SAFETY ANALYSIS OF PROCEDURES DEVELOPED ..........................124 
5.4.1 Presence of Detectable Protein ..............................................................124 
5.4.2 Presence of Detectable PrP Protein After Protocol................................125 
5.4.3 Presence of PrP Protein in Control Cases ..............................................126 
5.5 ISOLATION OF RNA FROM HUMAN BRAIN MATERIAL ...................127 
5.5.1 Variation in RNA Quantification Assay Method...................................128 
5.5.2 Correlation Between Individual Abs or rRNA Ratios and RIN Values 130 
5.5.3 RNA Preparation Characteristics ...........................................................131 
5.5.4 Cases Suitable For Downstream Processing..........................................135 
5.6 INTRA-PATIENT VARIATION ..................................................................136 
5.7 INTER-PATIENT VARIATION...................................................................140 
5.7.1 Effects of Tissue Storage Methods on RNA..........................................140 
5.7.2 Freezer Interval Correlations With RNA Integrity ................................145 
5.7.3 Storage at -20°C or -80°C Freezer .........................................................147 
5.7.4 Affect of Age at Death, Tissue pH, PMI and FT Cycles on RIN ..........150 
5.7.5 Affect of Age at Death, Tissue pH, PMI and FT Cycles on Yield ........152 
5.7.6 Affect of Age at Death, Tissue pH, PMI and FT Cycles on A260:280......154 
5.7.7 Index of Agonal State Correlations with RNA Metrics.........................155 
5.7.8 Overall Cases .........................................................................................158 
5.8 SUMMARY OF FINDINGS .........................................................................160 
5.9 DISCUSSION ................................................................................................161 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 5  Isolation of RNA from human brains 
 111





• Assess the quality and quantity of RNA extracted from human brain autopsy 
material. 
• Identify the level of intra- and inter-case variability of RNA quality and yield. 
• Evaluate retrospective and prospective tissue storage methods. 
• Identify post-mortem variables which impact on RNA quality. 
• Identify metrics which could be used to prospectively screen samples prior to 
their use for gene expression analysis. 
 
5.2 RNA EXTRACTION AND ANALYSIS 
 
RNA is traditionally isolated from tissues by homogenisation in guanidinium 
thiocyanate (GTC), phenol extraction and ethanol precipitation. Different organic 
solvents, alcohols and salts have been used. The selection of these is determined by 
the future work required. For example, a common method of removing proteinaceous 
material from nucleic acid solutions is to extract first with phenol-chloroform 
followed by chloroform. The use of both organic solvents is more effective than use 
of phenol alone because; 1) deproteinization is more efficient when two organic 
solvents are used, 2) although phenol denatures proteins efficiently, it does not 
completely inhibit RNase activity and it is a solvent for RNA molecules that contain 
long tracts of poly(A) (Brawerman et al., 1972) and 3) subsequent extraction with 
chloroform removes residual traces of phenol from the nucleic acid preparation.  
A mixture of phenol:chloroform:isoamyl alcohol (25:24:1) is the most commonly 
used solvent. Following extraction, nucleic acids are then generally precipitated in 
the presence of monovalent cations, recovered by centrifugation and redissolved in 
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an appropriate buffer. Ammonium acetate was selected for use in this project because 
other commonly used salts can inhibit downstream processes. For example, sodium 
or lithium chlorides are unsuitable as chloride ions suppress the activity of RNA-
dependent DNA polymerase. Carrier RNA, for example yeast tRNA, is frequently 
added before precipitation to improve the recovery of small amounts of RNA.  
 
When working with RNA, care must be taken to avoid degradation by RNases, 
which are extremely stable and active. Intracellular RNases are released during the 
lysis step of the RNA isolation procedure and must be rapidly and thoroughly 
inactivated to obtain high quality RNA. Proteins dissolve readily in solutions 
containing potent denaturing agents such as GTC. Cellular structures disintegrate and 
nucleoproteins dissociate from nucleic acids as protein secondary structure is lost  
(Cox, 1968; Sela et al., 1957).  Phenol also has denaturing properties, but is less 
effective at inactivating RNases than GTC. Nevertheless, phenol phase extraction is 
efficient at de-polarising proteins and partitioning the phenol-soluble proteins within 
the phenol phase (Kickhoefen & Buerger, 1962). GTC and phenol in combination are 
therefore generally the method of choice to separate nucleic acids from proteins and 
inhibit RNase activity (Chirgwin et al., 1979). 
 
In recent years these empirical methods have been replaced by kits based on a single-
step RNA isolation method using acid GTC as first described by Chomczynski and 
Sacchi (Chomczynski & Sacchi, 1987). One such commercially available kit is the 
Qiagen RNeasy lipid tissue extraction kit, designed for high lipid tissues such as 
brain. A specialized buffer included with the Qiagen RNA isolation kit contains ~ 4 
M GTC, to inactivate RNases. The Qiagen kit extraction method includes the use of 
a silica-gel based membrane spin column, which selectively binds RNA >200 bp 
length.  This process partially enriches for mRNA since the majority of small RNA 
such as 5.8S rRNA, 5S rRNA and tRNAs, which together comprise 15-20% of total 
RNA, do not bind to the membrane. A specialised high-salt buffer system allows up 
to 100 µg of RNA >200 bases to bind to the RNeasy silica-gel membrane. Proteins, 
lipids, DNA and small RNA molecules do not bind to the membrane and are spun 
out of the columns, see www.qiagen.co.uk for more details.  
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One aim of this project is to investigate gene expression in vCJD brains. Analysis of 
gene expression is dependent upon the quality of the RNA that can be isolated. 
Minimally degraded RNA yields reliable microarray data, although this depends on 
the method of evaluating degrees of degradation (Schoor et al., 2003). 
 
To obtain RNA samples suitable for gene expression analysis it is necessary to 
consider RNA quantity, quality and purity. RNA quantity is generally assessed by 
UV spectrophotometric analysis, although it is susceptible to interference from 
contaminants (Sambrook & Russel, 2001). Nanodrop ND-1000 Spectrophotometer 
(Nanodrop Technologies, Washington, USA) measures the optical density of a 
sample over a continuous spectrum of wavelengths from 200 – 750 nm. In this 
system, 1 µl of sample is directly scanned without the use of cuvettes or capillaries. 
Nucleotides, RNA and ss/dsDNA will absorb at 260 nm and contribute to the total 
absorbance. A280 readings estimate the degree of protein material. A260 readings and 
the ratios of absorbance at 260 nm and 280 nm are usually used to asses the purity of 
RNA. Although it is possible to have A260:280 ratios of ~1.8, the purity can vary 
greatly, especially when using organic solvents during extraction. A peak at 230 nm 
may be evidence of contamination with organics, thiocyanates, phenolate ions, 
ethanol or isopropanol. A260:230 ratios are much more variable but generally, ratios ~ 
1.7 indicate good purity and no contamination. 
 
Quality assessment of total RNA is traditionally determined by reference to the size 
of 28S and/or 18S rRNA bands on ethidium bromide gels. Good quality RNA is 
based on subjective interpretation of > 2:1 ratio of 28S rRNA to 18S rRNA. The 
28S:18S rRNA ratio is however inconsistent and unlikely to be > 2.0 for RNA 
isolated from dense connective tissue (Reno et al., 1997), RNase-rich tissue 
(Monstein et al., 1995) or tumour tissue (Skrypina et al., 2003).  
 
There is currently no gold standard to define the RNA quality prior to gene 
expression analysis. Using a single simple feature to judge RNA integrity has been 
shown to be insufficient (Miller et al., 2006). No single method fully reflects all the 
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properties of the degradation process. Using several features which complement each 
other, an enhanced profile of the degradation ‘fingerprint’ of RNA preparation can be 
achieved, reducing the error to a minimum value which is in the order of the natural 
noise of the target data.  
 
Recently two computer methods; the degradometer software (Auer et al., 2003) and 
the Agilent RNA integrity number (RIN) algorithm (Schroeder et al., 2006) have 
been described. Agilent Bioanalyzers generate electropherograms which visualise 
many more components of total RNA than was previously possible on standard gel 
electrophoresis.  
 
The Agilent 2100 Bioanalyzer is a platform designed for electrophoretic analysis of 
RNA samples. The molecular weights of RNA species are determined by their 
migration distance, as on a gel, and the Bioanalyzer plots an electropherogram of 
each sample (Figure 5.1). The quantity and quality of RNA are determined in three 
ways; RNA integrity number (RIN), the ratio of 28S to 18S rRNA and the 











Figure 5.1. Electropherogram detailing the regions indicative of RNA quality. The area preceding 
the lower marker is the pre-region. The lower marker peak is an internal standard used to align the 
ladder data with the data from the sample wells. The marker region coincides with the area occupied 
by the marker peak. These two regions are not accounted for in the RIN algorithm.  The 5S-region 
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The most distinct features on the electropherogram are the 18S and 28S ribosomal 
RNA peaks. Intact mRNA migrates between these two ribosomal peaks and for good 
quality RNA the trace here is smooth and lacks distinct peaks. For good quality 
RNA, the baseline between ~25 seconds and the 18S rRNA is relatively flat and free 
of peaks (corresponding to smaller RNA molecules). Qiagen RNA extraction kits 
remove smaller RNA molecules and should leave the mRNA and two large rRNA 
peaks. The RIN value is described in detail by Schroeder et al (Schroeder et al., 
2006). Briefly, the algorithm primarily utilizes the area of the 28S peak, the area of 
the 18S peak (the percent of total electropherogram area represented by both is 
proportional to RIN) and the area of the fast region (which is inversely proportional 
to RIN). The RIN values range from N/A or 0.0, completely degraded, undetectable 
RNA to 10.0, completely intact RNA.  
 
Figure 5.2 details a standard operating procedure (SOP) for RNA quality assessment 
for this study. It has been suggested that this working procedure be integrated into 
the NCJDSU Brain Bank SOP. An RNA integrity database would provide valuable 
information for future molecular studies and facilitate case selection. A similar 
system is under review at the MRC Sudden Death Tissue Bank. 
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Figure 5.2. Work flow of operational procedure for RNA quality assessment. Integrity of the 
RNA, once extracted and purified from tissue samples, is controlled from the bioanalyzer 
electrophoretic traces. As standard, the Agilent software RIN metric is calculated, scoring each RNA 
sample into 10 numerically predefined categories of integrity (RIN, from 1 to 10; n is the users 
predefined threshold value). As an independent control, UV absorbance readings will also be 
recorded. Such double classification will improve documentation of RNA integrity and degradation, 
and data can be stored alongside clinical, genetic and histological information at the NCJDSU. This 
will aid in future projects for case selection, as cases of comparable RNA integrity would be recorded, 
thereby limiting unnecessary tissue usage. A standard operating procedure would be beneficial and 
feedback information would help users to define threshold integrity metrics based on the results of any 
RNA-based analyses (modified from (Imbeaud et al., 2005). 
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For this study it was decided to use the Qiagen RNeasy lipid tissue extraction kit for 
the isolation of brain RNA. This method contains ~ 4 M GTC and ~ 2 M phenol, 
which should be sufficient to inactivate TSE agents (see Chapter 3); however for 
safety, it was decided to carry out a further double phenol-chloroform extraction to 
remove any remaining protein (infectious material). RNA quantity, quality and purity 
will be assessed by measuring the 28S:18S rRNA ratio, A260:280 ratio and the RIN. 
 
5.3 ASSESSING THE QUALITY AND QUANTITY OF RNA 
PREPARATIONS 
 
5.3.1 Pilot Study on Mouse Brains 
To test the RNA isolation protocol, RNA was extracted from 8 mouse brain samples 
using the Qiagen RNeasy lipid tissue kit. The RIN, 28S:18S rRNA ratio and total 
RNA yield were determined. Samples were then processed through a double phenol-
chloroform extraction and the RIN, 28S:18S rRNA ratio and RNA yield again 
measured. The results for RIN and RNA yield after Qiagen kit processing and after 
double phenol-chloroform processing are shown in Table 5.1.  
 










8.8 ± 0.49 
 (8.2-9.9) 
1.3 ± 0.08 
(1.2-1.4)  
96.8 ± 37.7  
(51.0-186.6) 
8.9 ± 0.32 
 (8.4-9.6) 
1.1 ± 0.16 
 (0.9-1.3) 
46.7 ± 17.8  
(21.3-82.5) 
Table 5.1. RNA Integrity Number (RIN), 28S:18S rRNA ratio as determined by Agilent 2100 
Bioanalyzer.  Concentration readings (ng/µl) were also determined and used to calculate RNA yield 
(µg) per 100 mg starting brain material.   Aliquots of RNA from after Qiagen extraction and after a 
second phenol-chloroform extraction were tested for RNA integrity and concentration. Values are 
mean ± SD with range in parentheses. Average difference: RIN= 0.1, 28S:18S ratio= 0.2, Yield (ng) = 
50.0. P-values, RIN= 0.321, 28S:18S ratio= 0.003, RNA yield< 0.0001. n=12. (Significance level= 
0.05). 
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Paired dependent t-test analysis showed no significant difference between the RIN 
value of samples after Qiagen extraction or after the additional phenol-chloroform 
step. However, there was a significant difference between the 28S:18S ratio and the 
RNA yields. Approximately 50% RNA was lost in the phenol-chloroform extraction. 
The reduction in yield of RNA was considered acceptable in the interest of the 
additional safety. 
 
5.3.2 Comparison of Extraction From Human and Mouse Brains 
To determine the quantity, quality and reproducibility of the RNA isolation protocol 
for mouse and human brain material, RNA preparations were compared from mouse 
and human brains. Samples were coded to anonymize them and eliminate bias and all 
extractions were carried out in parallel. Figure 5.3 shows the Agilent Bioanalyzer 











Figure 5.3. Agilent Bioanalyzer gel image using the RNA LabChip (1 µl RNA extract). Lane L. 
150 ng RNA ladder.  Lanes 1-6, RNA from the brains of 10 week old mice. Lane 7-12, RNA 
preparations from human brains. Most samples have two clearly resolved bands which correspond to 
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Figure 5.4 represents the electropherogram and gel-like image of RNA isolated and 



















Figure 5.4. Examples of Agilent Bioanalyzer profiles. RNase degradation of total RNA samples 
produces a shift in the RNA size distribution towards smaller fragments and a decrease in 
fluorescence signal. Profile A; typical electrophoretic trace and gel-like image of total RNA extracted 
from mouse brain, a. RIN value of 7.5. Profile B; typical electrophoretic trace and gel-like image of 
total RNA extracted from human brain material, a RIN value of 5.3 is typical. 18S rRNA baselines 
corresponding to florescent peaks are labeled with a pink line. The 28S rRNA baselines corresponding 
to the florescent peaks are labeled with a green line. Blue arrows indicate regions where smaller 
fragments of RNA appear, indicative of degradation of mRNA. 
 
 
The RNA isolated from mouse brains contained fewer small RNA fragments (< 
35secs) than RNA isolated from human brains. This is evident from the reduced 
number of bands eluting during the fast region and a clear separation in 28S and 18S 
rRNA bands. In human RNA samples, the banding pattern was less well resolved and 
a higher level of small RNA fragments was detected. These smaller fragments are 
indicative of RNA degradation and show that all the RNA preparations from human 
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Panel A is an example of a mouse RNA sample with little evidence of degradation. 
The flat baseline and lack of peaks eluting at the < 40 sec timeframe indicates there 
are few small RNA fragments in the sample. Panel B is an example of a human RNA 
sample with degradation. Although two main RNA bands or peaks corresponding to 
the 28S and 18S rRNA species are still visible, degradation products are observed as 
ragged peaks eluted during the fast and mid-regions. 
 
As RNA degrades; 
• The peaks begin to shift towards the left of the electropherogram 
• The baseline between and to the left of the ribosomal bands becomes jagged 
and more defined looking peaks appear. 
• The intensities of the ribosomal peaks decrease relative to the peaks resulting 
from their degradation. 
• The intensity of smaller degraded RNA increases. The most highly degraded 
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All RNA preparations were also tested by UV spectrometry using the Nanodrop ND-
1000 Spectrophotometer. Optical density (OD) measurements were taken over a full 




Figure 5.5. Nanodrop spectrophotometeric full wavelength profile scan. Comparison of high 
purity RNA preparation and low purity RNA preparation. Black profile corresponds to RNA sample 
with A260:280 of 1.8 and A260:230 of 2.0, indicative of high purity RNA, free from organic solvent, 
protein or genomic DNA contamination. Red profile corresponds to RNA sample with A260:280 of 
0.3 and A260:230 of 3.4, indicative of significant organic solvent contamination and would be 
evaluated as a low purity sample and excluded from further analysis. 
 
 
For this project, GTC and phenol-chloroform were used for RNA extractions. UV 
measurements are greatly affected by phenol contamination, even at low 
concentrations. 0.5% w/v results in a 300% error in concentration measurements 
(Lightfoot, 2002). Residual GTC and phenol absorb at ~230 nm, consequently 
altering the 260:230 ratio. Therefore, this method is highly sensitive to phenol or 
GTC contamination of the samples. Contaminated preparations are unsuitable for RT 
or PCR amplification reactions, since carryover reduces the efficacy of or inhibits 
enzymatic activity. 
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5.3.3 Reproducibility  
To determine the reproducibility of the extraction method and the Agilent 
Bioanalyzer, a single tissue sample was split into two and both samples were 
extracted and measured on the Agilent Bioanalyzer (Figure 5.6A). A single sample 
















Figure 5.6. Reproducibility of the RNA extraction procedure and of Agilent Bioanalyzer measurements. 
 
As expected, the level of variation when comparing two separate extractions is 
marginally greater than when comparing the same sample twice. However, it should 
be noted that when comparing the same sample although the RIN value didn’t 
change there was a considerable difference in the 28S:18S ration and the 
concentration, showing that differences in the latter values must be interpreted with 
caution. A more detailed analysis of yield measurements is presented in section 5.5.  
 
The extraction reproducibility was also tested on the Nanodrop. A single tissue 
sample was split into two and both samples were processed through the extraction 
protocol and measured on the Nanodrop (Figure 5.7A). In addition, the Nanodrop 
A 
B 
Figure 5.6. Reproducibility of 
the RNA extraction procedure 
and of Agilent Bioanalyzer 
measurements. A.  A single 
brain sample was separated into 
two and RNA extracted. Each of 
the extractions was assayed by 
the Agilent Bioanalyser once. 
Red profile; RIN =4.7, 28s:18S 
ratio = 1.7, total RNA 
concentration (ng/μl) =272.  Blue 
profile; RIN =5.1, 28S:18S ratio= 
1.4, total RNA concentration 
(ng/μl) = 447. B. Single brain 
RNA preparation assayed on the 
Agilent Bioanalyzer twice. Red 
profile; RIN =5.5, 28s:18S ratio 
= 0.4, total RNA concentration 
(ng/μl) =266.  Blue profile; RIN 
=5.5, 28S:18S ratio= 0.7, total 
RNA concentration (ng/μl) = 
383. 
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Figure 5.7. Nanodrop spectrophotometeric full wavelength profile scan. 
Figure 5.7A superimposes the full wavelength profiles from the Nanodrop 2100 
spectrophotometer of repeated preparations. Figure 5.7A shows the variation within 
the extraction protocol as well as variation within the Nanodrop. Figure 5.7B 
indicates the level of variability within the Nanodrop measurement only. Figure 5.7B 
demonstrates the high level of reproducibility of the Nanodrop measurements. This 
indicates that the variation identified in Figure 5.7A, while limited, is mostly due to 
processing variation and/or human error. When compared to the Agilent Bioanalyzer 




Figure 5.7. Nanodrop 
spectrophotometeric 
full wavelength profile 
scan. Panel A. 
Superimposed profiles 
of adjacent tissue 
samples, RNA isolated 
individually and 
measured. Red profile. 
A260:280 = 2.11. 
A260:230 = 2.17. Black 
profile. A260:280 = 
2.07. A260:230 = 2.16.  
Panel B. Superimposed 
profiles of a single 
RNA preparation 
measured on the 
Nanodrop twice. Red 
profile.A260:280 = 
2.12. A260:230 = 2.13. 
Black profile. A260:280 
= 2.12. A260:230 = 
2.13. 
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5.4 SAFETY ANALYSIS OF PROCEDURES DEVELOPED 
 
After assessment of risk, an evidence based protocol for RNA preparations was 
developed (see Chapter 3). This was deemed suitable for inactivating and removing 
PrP and infectivity from human brain material. RNA preparations were only handled 
by expert personnel (Karen Sherwood) and transported as if low risk infectious 
specimens. In order to assess whether the RNA extraction protocol efficiently 
removed PrP , PrPres levels were investigated by western blot. 
 
5.4.1  Presence of Detectable Protein  
To determine the sensitivity of the western blot, dilutions of brain homogenates from 
a vCJD brain were investigated (Figure 5.8, 5.9). PrP protein was assessed by 
immunoblotting using 6H4 antibodies (50 ng /ml) on a half log serial dilution of 10 
% (w/v) human brain homogenate. 6H4 antibody was used because it recognises an 
epitope within helix 1 of the prion protein, considered to be a prerequisite for 
infectivity (Heller et al., 1996). The sequence DYEDRYYRE is present on both 
human PrPc and PrPSc (144-152) and is highly conserved in mammalian PrP proteins.  
 
 
Figure 5.8. Western blot dilution end point assay of half log serial dilution of 10 % (w/v) frontal 
cortex sample from vCJD patient brain tissue, with proteinase K treatment.  The supernatant of 10% 
centrifuged homogenate from frontal cortex of human autopsy brain material was incubated with 6H4 
antibodies. Precipitate was analysed on a western blot for the presence of PrP using a HRP-conjugated 
sheep anti-mouse IgG. For each lane, corresponding amounts of brain material are: lane 1, 500 µg; 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 5  Isolation of RNA from human brains 
 125
lane 2, 158 µg; lane 3, 50 µg; lane 4, 15 µg; lane 5, 5 µg; lane 6, 1.5 µg; lane 7, 0.5 µg, lane 8, 0.15 
µg. Red arrow indicates the limit of detection. Numbers of the left correspond to molecular weight 
markers in kilodaltons (kDa). 
 
 
From this assay, it was possible to detect PrPres in > 0.5 µg vCJD brain equivalent.  
 
5.4.2 Presence of Detectable PrP Protein After Protocol 
Human brain RNA preparations were assessed for levels of PrPres by western blot 
(Figure 5.9). 
 
Figure 5.9. PrP western blot analysis of RNA preparations from human, with (+) or without (-) 
proteinase K treatment. Lane 1 and 2, type 2B vCJD (0.5 mg brain equivalent); lane 3 and 4, type 
2B vCJD RNA extracts (10 mg brain equivalent); lane 5 and 6, NND RNA extracts (10 mg brain 
equivalent); lane 7 and 8, human recombinant PrP (0.1 µl). Immunoblot profiles in lanes 1 and 2 are 
characteristic of type 2B CJD. Red arrow indicates band of molecular weight of 23 kilodaltons, which 
is the expected molecular size of human recombinant PrP-PURE (Alicon). PrP-PURE is completely 
digested by proteinase K. Numbers on the left correspond to molecular weight markers in kilodaltons. 
 
 
Lanes 3 and 4 were loaded with 20-fold more brain equivalent of the RNA extract 
than un-extracted brain loaded in lanes 1 and 2. Since the detection limit of western 
blot is ~ 1 µg brain equivalent, and 10 mg of brain homogenate equivalent from 
RNA extracts were loaded, the negative result would indicate the level of PrPres is at 
least 10,000-fold less than in the starting brain homogenate. From this data, it is 
possible to conclude that the following RNA extraction protocol, when assessed by 
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western blot, the levels of PK resistant PrPSc have been reduced by at least 104 fold. 
Assuming that the infectious agent is indeed the proteinase-K resistant PrP isoform, 
the RNA extraction protocol was able to remove sufficient PrPSc from infectious 
brain material as to be immeasurable and was therefore considered a suitable method 
of sample preparation. 
 
5.4.3 Presence of PrP Protein in Control Cases 
To establish that NND control brain did not contain detectable amounts of PK-
resistant PrP, brain homogenate and RNA extracts were tested for PrPres by western 
blot (Figure 5.10). 
 
Figure 5.10. Western blot analysis of NND human frontal cortex samples from 10 % (w/v) human 
brain homogenate (lanes 1-3, 5, 7) or RNA extract (lanes 4 and 6 ), with (+) or without (-) PK 
treatment. Lane 1, type 1 CJD; lane 2, NND; lane 3, type 2B CJD; lane 4, NND (RNA extract); lane 5, 
type 1 CJD; lane 6, NND (RNA extract); lane 7, type 2B CJD. Red arrow indicates the lower band of 
molecular weight ~21 kDa, characteristic of type 1 CJD PrP immunoblot profiles. Black arrow 
indicated the lower band of molecular weight ~19 kDa, characteristic of type 2B CJD PrP immunoblot 
profiles. Numbers on the left correspond to molecular weight markers in kilodaltons. 
 
 
In conclusion, NND brain homogenate contains significant amounts of PrPc, but 
undetectable amounts (> 0.5 µg brain equivalent) of PK resistant PrPSc. Also, from 
the two NND cases tested, RNA extract preparations contain undetectable amounts 
of PK resistant PrPSc. 
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5.5 ISOLATION OF RNA FROM HUMAN BRAIN MATERIAL 
 
Following the pilot comparison of RNA quantity and quality from human and mouse 
brain and the analysis of PrP in the human preparations from vCJD brains, it was 
decided to prepare RNA from a large number of human brains in order to compare 
the quality and yield and determine parameters that affect these values. It was 
necessary to carry out these preparations on different days and as positive controls, 
samples of mouse brain tissue were included in each batch of RNA prepared. RNA 
was prepared from 78 cases, selected from the NCJDSU and MRC brain banks based 
on criteria set out in Chapter 4. RNA preparations were measured for quality and 
quantity using a variety of techniques; RIN value, concentration and 28S:18S rRNA 
ratio as measured by the Agilent 2100 Bioanalyzer and full UV spectrum absorbance, 
specifically the A260:280 and A260:230 ratios and concentrations as measured by the 
Nanodrop ND-1000 spectrophotometer. The most reliable parameters for assessing 
RNA quality and quantity were determined by comparing all methods and evaluating 
suitability. 78 cases were included in this evaluation (unless otherwise stated). From 
the 78 cases, selected cases were used to determine the intra-patient variation 
between neurological distinct regions and adjacent samples and are detailed in 
section 5.6. Inter-patient variation due to a number of pre- and post-mortem 
parameters were also evaluated and are detailed in section 5.7. Analysis of all inter-
patient variation was based on the Agilent and Nanodrop measurements taken from 
all 78 cases (unless otherwise stated). Clinical and histological notes used for IAS 
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5.5.1 Variation in RNA Quantification Assay Method  
Bland-Altman plots are generally used to describe the agreement between two 
quantitative measurements. Figure5.11 shows a Bland-Altman plot between two 
methods of measuring total RNA concentration; Agilent 2100 Bioanalyzer and 
Nanodrop ND-1000 spectrophotometer.  
 
 
Figure 5.11. Bland-Altman plot to determine agreement between two quantitative measurements; 
instrument A (Agilent) and instrument B (Nanodrop), when measuring the quantity of total RNA 
(ng/µl). Bias = -50.67. SD of bias = 69.32. 95% confidence = -186.53, + 85.19.  
 
 
The difference of the paired measurements is plotted against the mean of the two 
measurements. A good concordance in the measurements is present when 95% of the 
data points lie within ± 2SD of the mean difference. The data points should cluster 
around the ‘difference = 0’ line. Any large variations were checked, as anomalies 
could have been due to wrong data-entry. From the plot, it is observed that 18/361 
(4.9%) of the points are beyond the ± 2SD lines which gives 95.1% corroboration 
between the two assays measurements, within 2SD agreement tolerance. As observed 
by the greater number of points below the ‘difference = 0’ line, instrument A 
(Agilent) is measuring lower than instrument B (Nanodrop) the majority of the time. 
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UV spectrophotometeric quantitation of RNA has generally been the standard 
method of RNA quantitation. The use of intercalating fluorescent dyes to detect RNA 
is more specific and sensitive, but much less reproducible due to additional mixing 
and incubation steps. UV spectrophotometeric analysis is much more reproducible, 
largely due to the simplicity of the method. Although Agilent quantitation accuracy 
is ± in the range of 35% of UV measured values, it was decided to base all further 
quantitation of RNA samples on Nanodrop measurements. In addition, UV 
spectrophotometric analysis allows for sample retrieval, whereas Agilent analysis 
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5.5.2 Correlation Between Individual Abs or rRNA Ratios and RIN 
Values 
Potential correlation between individual measurements made with the Nanodrop 
Spectrophotometer (A260:280, A260:230) and the Agilent Bioanalyzer (RIN, 28S:18S 
ratio) were examined (Figure 5.12). 431 samples were analysed on the Bioanalyzer 
and 316 samples were analysed on the spectrophotometer (72% human, 28% mice).  
 
Figure 5.12. Correlation between individual absorbance A260:280 nm ratios, A260:230 nm 
ratios, 28S:18S rRNA ratios and RIN. Spearman rank correlation analysis; A: r2 = 0.69, p-value 
<0.0001. n = 431. B: r2 = 0.12, p-value = 0.022.  n = 316. C: r2 = -0.11, p-value = 0.047.  n = 316.  
(Significance level = 0.05).  
 
 
Spearman rank correlation analysis shows a highly significant, positive correlation 
between 28S:18S ratios and RIN values, as would be expected. Both A260:280 and 
A260:230 show no correlation with RIN values. Clustering of data around the ~2.0 
point in figures B and C is expected if the majority of samples constitute 
uncontaminated, high purity RNA. In addition, low A 260:280 correlated with low 
A260:230 (data not shown). 
A 
C B 
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5.5.3 RNA Preparation Characteristics 
Figure 5.13 graphically represents the distribution of 368 human and 102 mouse 
brain RNA preparations. 
 
Figure 5.13. Characterisation of  RNA preparations and their distributions. A. 441 RIN values 
were returned by the Agilent Bioanalyzer. B. 28S:18S rRNA ratios were automatically assigned by the 
Agilent software for 458 samples. C and D. A260:280 and A260:230 ratios for 365 samples were calculated 
automatically by the Nanodrop Spectrophotometer software, from a full UV spectrum profile reading. 
The distribution of all samples was plotted. Black human. Grey mouse. The lines are the mean 
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Overall, RIN analysis was successful on 441 samples. Data from 19 samples was not 
obtained due to software default anomaly parameters. In each case, the reading was 
flagged as error corresponding to critical anomalies including unexpected data in 
sample type, (or) ribosomal ratio, (or) baseline and signal in 5S region. The average 
RIN value was 4.46 (Confidence Intervals (IC) 4.25-4.67). 28S:18S readings were 
automatically calculated for 458 samples, with a mean value of 0.56 (IC 0.51-0.60). 
Although due to software programming, 28S:18S ratio readings were not considered 
to be accurate. Software recognition of the 28S and 18S rRNA peaks was inflexible 
and limited. Agilent software recognises peaks with the 35-40 second time frame as 
18S rRNA and peaks within the 45-50 second time frame as 28S rRNA. If peaks are 
out-with these time frames, the software will assign the sample a 28S:18S value of 
0.0. Atypical migration of peaks generally occurs with degraded samples, which 
results in 28S:18S values of 0.0. This low 28S:18S ratio assessment done by the 
Agilent has been recorded in other published literature, where < 44% of samples 
were within expected range (Imbeaud et al., 2005). In addition, 28S:18S reading can 
be highly variable (see Figure 5.13) and it is suggested that 28S:18S ratio of 2.0 is an 
unsuitable and outdated calibrator of RNA (see discussion).  
 
Nanodrop readings were carried out on 365 samples in total, with 100% success rate.  
The expected range for A260:280 ratios is 1.8-2.1 and an average A260:280 ratio of 2.06 
was observed (IC 2.05-2.09) with 94% of the values falling within the expected 
range. The expected range for A260:230 ratios is 1.7-2.2 and an average A260:230 ratio of 
2.16 was observed (IC 2.09-2.24) with ~80% of the values falling within the 
expected range. This result is similar to published data on RNA quality 
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Table 5.2 shows the percentage of RNA preparations that would fit the various 
definitions of good quality RNA suitable for subsequent analysis. 
 







20 0.9 97 95 
% MOUSE 
SAMPLES 
93 0 92 97 
Table 5.2. Percentage of samples which fulfil either the Agilent assessment of RNA quality or 
the UV spectrophotometer assessment of RNA quality. Human samples; Agilent criteria* n=342, 
Nanodrop criteria n= 297. Mice samples; Agilent criteria* n= 97, Nanodrop criteria n= 66.  
 
 
Depending on which method is used, different numbers of cases would be considered 
suitable for genetic analysis. Generally A260:280 ratios > 1.8 and A260:230 ratios > 1.7 
should provide sufficient evidence of high purity RNA samples uncontaminated with 
organic solvents or proteinaceous material. Pure RNA should have equivalent A260:280 
and A260:230 ratios which are ≥ 1.8 (Manchester, 1996; Manchester, 1995; Glasel, 
1995).  
 
The majority of samples have ≥ 1.7 A260:230 ratios suggesting that very few samples 
were contaminated by GTC or phenol-chloroform. From this data, there is sufficient 
evidence to indicate that 28S:18S ratio determination of RNA quality is unsuitable 
for total RNA isolated from brain tissue. The use of 28S:18S rRNA ratio would have 
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Mouse tissues were processed in parallel with human tissues. The quality of the RNA 
preparations from each was compared (Table 5.3).  
 
 RIN 28S:18S 
rRNA ratio 
A260:280 ratio Yield (µg) 
MOUSE 7.57 ± 1.47 0.93 ± 0.32 2.05 ± 0.18 129 ± 105 
HUMAN 3.59 ± 1.45 0.46 ±0.48 2.06 ±0.08 52 ± 29.8 
P-value <0.0001 <0.0001 0.325 <0.0001 
Table 5.3.  Comparison of human and mouse brain RNA preparations. Values are mean ± SD. 
 
 
With the exception of the A260:280 ratio, there is a highly significant difference 
between the two groups. There is more degradation in the human than the mouse 
RNA preparations as determined by RIN and the median 28S:18S rRNA ratio which 
is higher for the mouse brain RNA preparations. Interestingly, even for mouse brains, 
where tissue has been handled in near optimal conditions, the 28S:18S ratio is rarely 
near 2.0, confirming the suggestion that 28S:18S ratios are unsuitable for assessing 
RNA isolated from brain tissue. RNA yields achievable from mouse brain material 
are approximately 30-48 % greater that RNA yields achievable from human brain 
material. Similar differences in the range of yields for mice and human tissues are 
observed in the literature (Johnson et al., 1986). Mouse and human samples were 
extracted in parallel, but only human cases had low values, therefore either the RNA 
extraction process only adversely affects human brain RNA samples or there are 
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5.5.4 Cases Suitable For Downstream Processing 
For this project, human RNA samples with a RIN ≥ 4.5 were considered suitable for 
microarray and qRT-PCR (Table 5.4). Previous studies have recommended a RIN ≥ 
5.0 as being good total RNA quality and ≥ 8.0 as perfect RNA for downstream 
applications (Fleige et al., 2006; Fleige & Pfaffl, 2006). If these criteria were used 
within the scope of this project, the sample size would be too small to provide any 
reasonable statistical strength. 
 
 NND OND vCJD MICE 
Cases tested [samples]  31 [83] 26 [160] 21 [110] [101] 
RIN ≤ 4.4  18 [48]  20 [104] 16 [98] [6] 
RIN ≥ 4.5 and A260:280 ≥ 1.8  13 [31]  6 [53]  5 [9] [90] 












Suitable for downstream 
processing  
(e.g. microarray or qRT-PCR) 
50% 23% 24% 91% 
Table 5.4. Summary of cases from which RNA was extracted. Yield values are mean ± SEM, with 
range in parentheses.  
 
 
NND cases have a greater number of samples (42%) which fulfil the RIN and UV 
absorbance criteria than diseased cases (OND or vCJD) (23%). Samples were 
selected for transcriptional analysis if the following criteria were fulfilled; 
• RIN value ≥ 5.0 
• A260:280 nm absorbance ≥ 1.8 
• A260:230 nm absorbance ≥ 1.7 
Samples with 4.5 < RIN ≤4.9 were reserved for contingency. 
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5.6 INTRA-PATIENT VARIATION 
 
To investigate intra-patient variation of RNA a whole half human brain was sampled 
from three anatomically distant regions and RNA extracted and tested for quality and 
quantity (Table 5.5).  
 
REGION 






CB (n=2) 6.40 (0.283) 4.32 (1.98) 1.000 (0.141) - 
FPS (n=6) 4.03 (1.145) 76.86 (38.26) 0.567 (0.308) 2.082 (0.012) 
SFC (n=11) 5.09 (1.503) 58.53 (50.01) 0.72 (0.316) 2.080 (0.020)a 
P-VALUE 0.049 0.056 0.126 1.000 
Table 5.5. Intra-patient variation. Results of Kruskal- Wallis analysis for RNA variable and brain 
region within a single organ. Means are shown with SD in brackets. 
 
 
The results indicate that there is no evidence for a difference between the means of 
each region, regardless of RNA parameter. The p-values for RIN and yield are 
approaching significance, but given the power of the small sample size, the results 
are difficult to draw conclusions from. However, it is suggested here that there is no 




For each NCJDSU case sampled, a minimum of three contiguous tissue samples 
were taken at a single sampling. For MRC cases, a minimum of two contiguous 
tissue samples were supplied. All RNA preparations were measured on the Agilent to 
obtain a RIN value and on the Nanodrop for quantitation. To determine the inter- and 
intra-patient variation in RNA quality (based on RIN values only) and quantity 
(based on Nanodrop values), samples were categorised by status (vCJD, NND and 
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OND) and replicate (1, 2 or 3 contiguous tissues samples) and data analysed by one-
way ANOVA (Table 5.6). 67 brains (284 samples) were included in this analysis (21 
from MRC, 46 from NCJDSU).  
 
 
















0.7 19.5 0.4 24.8 0.7 15.2 0.7 19.3 
Table 5.6. Variation of RIN value and total RNA yield (µg) due to inter-brain effect or intra-
brain effect. Values are the estimated standard deviation in the RIN values or the total RNA yield 
(µg). All n = 184.  vCJD n = 56. NND n = 83. OND n = 45.  
 
Approximately 65% of the variability of RIN values is due to inter-patient 
differences. The vCJD cases show the least amount of RNA quality variation intra-
patient, while the OND cases showed the greatest variation. This may be due to the 
agonal state of the patient and the pathogenesis occurring within the brain. All vCJD 
patients generally have a very similar agonal state (see Chapter 4, Table 4.5), 
respiratory infection being the most common cause of death. The cause of death of 
OND patients is not as uniform, with vastly differing mode of deaths. Although NND 
cases also have very different modes of death, the duration of death is rapid (see 
Chapter 4, Table 4.5) and there may be insufficient time for any affects to manifest in 
the brain. The pathogenic mechanisms occurring within the brains of vCJD patients 
are less variable than it is within the OND group. For example, the pathological 
mechanisms involved in Lewy Body dementia and B-cell lymphoma are extremely 
different.  In contrast, >50% of the yield variation is due to the intra-brain effect. The 
reasons for this difference are unclear as all samples were prepared in the same way. 
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To determine the amount of variation in RNA quality and yield within a single brain 
(intra-brain), nine contiguous samples were taken from single frozen OND and vCJD 
brains and RNA extracted. RNA preparations were measured for quality and 
quantity. Sample variation was calculated and tabulated (Table 5.7).
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OND 1 2 3 4 5 6 7 8 9 Mean ± SD 
RIN values 2.60 2.60 2.70 2.80 2.80 2.90 2.50 2.70 2.60 2.69 ± 0.13  
28S:18S rRNA ratio 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.06 ± 0.11 
A260:280 ratio 2.12 2.10 2.06 2.07 2.07 2.08 2.09 2.08 2.07 2.08 ± 0.02 
YIELD (µg) 26.43 38.79 35.99 28.37 36.26 27.96 27.48 43.15 21.36 31.75 ± 7.05  
 
vCJD 1 2 3 4 5 6 7 8 9 Mean ± SD 
RIN values 2.6 2.6 2.6 2.3 2.8 2.4 3.2 2.3 2.4 2.58 ± 0.29 
28S:18S rRNA ratio 0.0 0.0 0.0 0.3 0.1 0.2 0.0 0.0 0.0 0.07 ± 0.11 
A260:280 ratio 2.07 1.67 1.87 2.09 2.11 2.08 2.02 1.98 2.08 2.00 ± 0.14 
YIELD (µg) 45.12 10.72 28.51 95.91 94.93 104.48 45.39 54.97 49.47 58.5 ± 32.5 
Table 5.7. Quality metrics from 9 RNA preparations, sampled contiguously from single brains. Each preparation was measured using the Bioanalyzer 
and the Nanodrop. A. Samples from other neurological diseased brain. B. Samples from a vCJD diseased brain.
A 
B 
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Standard deviation of RIN and A260:280 ratios show very little variation (< 10%) 
across each of the two sets of 9 contiguous samples. 28S:18S ratios and total RNA 
yields (µg) were more variable, although this was expected. Limited intra-patient 
variation in two main RNA metrics is promising, as this indicates that RNA quality is 
fairly consistent within a single case. Regional variation of RNA quality can 
therefore be excluded as a source of variation in subsequent analysis.  
 
If the variation intra-patient is compared to the variation observed inter-patient (see 
Table 5.6), it shows there is less variation of RNA metrics within a single organ than 
across many. RIN values for contiguous samples have an average standard deviation 
of 0.21, whereas the standard deviation for non contiguous samples is much greater 
(1.45). Total RNA yields vary most, both intra- and inter-patient. Even so, the 
average standard deviation intra-patient is much less than that observed inter-patient 
(29.8 and 19.8 respectively). This result would suggest that variation of RNA quality 




5.7 INTER-PATIENT VARIATION 
One aim of this project is to identify whether any pre- or post-mortem factors are 
predictive of RNA quality and yield. Initially, factors which were controllable, such 
as tissue storage method and storage temperature were evaluated. Freezer Interval 
(FI) was also assessed. Pre- and post-mortem factors out-with the control of the 
investigator, for example, PMI and age at death, were also assessed. 
 
5.7.1 Effects of Tissue Storage Methods on RNA 
Tissues collected at autopsy are stored snap frozen, frozen or fixed. For the RNA 
profile study, all tissues used were either snap frozen or frozen. In addition to this, it 
was possible to arrange for additional samples to be collected at autopsy, which were 
stored in RNAlater then frozen. Quality and quantity of total RNA extracted from 
100 mg brain tissue were measured using the Agilent 2100 Bioanalyzer and the 
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Nanodrop ND-1000 spectrophotometer. Two sample t-test analysis was carried out to 
determine if storage method affected RNA quality or quantity. RNA that had been 
isolated from autopsy material has been shown to be of sufficient integrity for RT-
PCR analysis. RNA from post-mortem tissue is known to be relatively stable and 
suitable for RNA research, as long as pre- and post-mortem factors are accounted for 
(Barton et al., 1993; Brown, 2005; Schramm et al., 1999; Perrett et al., 1988). If 
RNA quality is poor, measurements of cDNA after reverse transcription cannot be 




To investigate variability in a relatively homogenous population of RNA 
preparations, the inter-case variability of all the mouse brain RNA preparations, 
which were routinely done with the human brain RNA preparations, was determined. 
A total of 65 samples stored using two different methods (-80ºC freezer and 
RNAlater) were tested. Mouse RNA preparations were not subjected to much pre- or 
post-mortem variation. All mice were sacrificed at 10 weeks of age, PMI was 
approximately 15 mins, brain tissue was not subjected to freeze-thaw cycles and 
none of the mice were infected with pathogens or had any clinically apparent disease. 
Figure 5.14 shows the variability of the three RNA metrics in relation to the tissue 
storage method used. 
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Figure 5.14. Box and whisker 
plot comparison of storage 
method of mouse brain tissue 
and quality and quantity 
metrics of RNA extracted 
from brain tissue. The boxes 
represent the 25th – 75th 
quartiles, divided horizontally 
by the median. The whiskers 
represent the range. The circles 
represent the mean. Outliers 
are denoted by (*). Panel A. 
RIN values. RNAlater; n = 54, 
mean =7.83, SD =1.73, SEM 
=0.24. Snap frozen; n =42, 
mean =7.23, SD =1.04, SEM 
=0.16, p value =0.051. Panel 
B. A260:280 absorbance 
ratios.  RNAlater; n = 33, 
mean =2.02, SD =0.21, SEM 
=0.037. Snap frozen; n =32, 
mean =2.08, SD =0.12, SEM 
=0.02, p value =0.138 
(significance level =0.05). 
Panel C. Total RNA yield from 
100 mg starting brain material. 
RNAlater; n = 55, mean =113, 
SD =95.4, SEM =13. Snap 
frozen; n =43, mean =148 SD 
=114, SEM =17, p value 
=0.098. 
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Based on two-sample t-test analysis, mouse brain tissue which has been stored in 
RNAlater or frozen at -80°C showed no significant difference in the median RIN 
value, A260:280 ratio or the total RNA yield (µg). During mouse tissue harvesting, 
other factors which may have had an affect on RIN, UV absorption and yield are 
controlled for, i.e. age, agonal state (and therefore pH) and sex. It is reasonable to 
assume from these results that, if confounding factors are removed, tissue storage 




For human brain, RNA preparations derived from (i) liquid nitrogen (N2) stored 
(referred to as snap frozen), (ii) whole half brains frozen at -80ºC or (iii) from 
RNAlater stored dissected autopsy brain samples were compared for the quality and 
yield of the RNA (Figure 5.15). 
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Figure 5.15. Box and whisker plot comparison of storage method of human brain tissue and quality and quantity metrics 




Figure 5.15. Box and whisker 
plot comparison of storage 
method of human brain tissue 
and quality and quantity 
metrics of RNA extracted from 
brain tissue. The boxes 
represent the 25th – 75th 
quartiles, divided horizontally by 
the median. The whiskers 
represent the range. The circles 
represent the mean. Outliers are 
denoted by (*).  Panel A. RIN 
values. RNAlater; n = 16 , mean 
= 5.06, SD = 1.61. Snap frozen; n 
= 8, mean = 3.05, SD = 0.59. 
Half brain; n = 37, mean = 3.69, 
SD = 1.34. p value = 0.001. 
Panel B. A260:280 absorbance 
ratios. RNAlater; n = 14 , mean = 
2.10, SD = 0.05. Snap frozen; n = 
8, mean = 2.10, SD = 0.02. Half 
brain; n = 37, mean = 2.10, SD = 
0.04. p value = 0.341. Panel C. 
Total RNA yield isolated form 
100 mg starting brain material. 
RNAlater; n = 16 , mean = 42.06, 
SD = 17.35. Snap frozen; n = 8, 
mean = 65.97, SD = 17.07. Half 
brain; n = 41, mean = 59.54, SD 
= 32.89. p value = 0.072. 
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One-way ANOVA analysis reveals a significant difference between the RIN values 
of (i) RNA isolated from dissected samples stored in RNAlater and (ii) liquid 
nitrogen snap frozen or -80°C half brain stored tissues. 95% CI show similarities 
between the RIN values of tissues stored in liquid N2 or as whole half brains. It is 
preferable to store tissue in RNAlater. There are no significant differences between 
A260:280 readings or total RNA yield (µg) relative to storage method. UV absorbance 
readings were expected to be unaffected by storage method as A260:280 readings are 






5.7.2 Freezer Interval Correlations With RNA Integrity 
To determine the effect of F.I. on RNA quality, a large sample of mouse and human 
brain tissue was taken from a number of different cases. A small sample (~100mg) 
was used to prepare RNA (t = 0) and the remaining tissue stored at -80ºC. At defined 
time points, the tissue was again sampled and RNA prepared and measured on the 
Agilent Bioanalyser and Nanodrop. Figure 5.16 graphically represents the F.I. 
against the RNA metrics. 
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Figure 5.16. Freezer 
interval (F.I.) and RNA 
metrics. RNA was extracted 
from brain tissue and the 
remaining tissue was frozen 
at -80ºC (t = 0).  At defined 
time points, tissues were 
removed from storage and 
RNA was extracted from a 
sample and measured. A. 
Change in RIN value with 
time. B. Change in 28S:18S 
ratio with time. C. Change 
of RNA yield (µg/100mg) 
with time. Regression 
coefficient (r2) and p-values 
are displayed in the figure. 
n= 20. 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 5  Isolation of RNA from human brains 
 147
Despite trends in the data, multiple regression analysis indicates the variation 
observed in the RIN value, A260:280 and RNA yield cannot be accounted for by the 
F.I. Although the time range tested is not extensive (17 months), these results are in 
accordance with the literature, including a 15 year study on AD brain tissue stored at 
-70ºC (Yasojima et al., 2001; Leonard et al., 1993; Johnson et al., 1986; Schramm et 
al., 1999). Two-sample t-test analysis between sample metrics before freezing and 
after a defined period of storage also shows no significant difference (p> 0.05). The 
data shows a lot of variation between different RNA preparations, irrespective of the 
F.I. This data is in agreement with the data shown in Table 5.3 and Figure 5.13. This 




5.7.3 Storage at -20°C or -80°C Freezer 
To investigate whether storage temperature of the RNA preparation has an effect on 
RNA preparations, aliquots of 7 human RNA preparations were stored at either. -
20°C for 12 months or at -80°C for 12 months. After this time, quality and quantity 
were measured. The results are shown in Table 5.8.
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 



























82.3 ± 30 
(24.6-252.2) 
77.8 ± 30 
(19.9-194.5) 
60.3 ± 19 
(24.3-162.0) 
51.5 ± 10 
(31.6-90.8) 
p-value 0.907a  0.545b  0.438c  
Table 5.8. RIN values and concentration (ng/µl) measurements of tissues stored at -20°C and -80°C.  
 1 = Agilent 2100 Bioanalyzer readings. 2 = Nanodrop ND-1000 spectophotometer readings. a = RIN value of RNA preparations stored at -20ºC compared to -80ºC. b= 
yield (as measured by Agilent Bioanalyzer) of RNA stored at -20ºC compared to -80ºC. c= yield (as measured by Nanodrop) of RNA stored at -20ºC compared to -
80ºC. Values are mean ± SEM, with range in parentheses.   n=7.  
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Two-sample t-test analysis reveals no significant difference (p > 0.05) between the 
RIN or yield of RNA (as measured by Agilent Bioanalyzer or Nanodrop 
spectrophotometer) stored at -20°C or -80°C freezer, for a period of 12 months. 
Nonetheless all RNA preparations were stored at -80°C, especially if storage time is 




Based on the results from sections 5.7.1-3, it is concluded that tissue storage method 
or storage time has only a limited affect on RNA quality and quantity. Therefore, all 
further analysis has assumed that the variation observed within human cases is most 
likely due to pre- and/or post-mortem factors. 
 
Analysis of two pre-mortem (age and agonal state) and three post-mortem factors 
(post-mortem interval (PMI), pH of brain, freeze-thaw cycle (FTC)) for human cases 
with available data were carried out to elucidate any effects these parameters have on 
the quality or quantity of RNA extracted from human post-mortem brain material. 
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5.7.4 Affect of Age at Death, Tissue pH, PMI and FT Cycles on RIN 
Clinical and autopsy data from all 78 cases were examined and RIN values measured 
using the Agilent 2100 Bioanalyzer. For cases with all relevant data, correlation 
analysis was carried out. Figure 5.17 shows four graphs corresponding to the analysis 
of the four parameters studied; age of patient at time of death (yrs), brain tissue pH at 
post-mortem, PMI (hrs) and freeze-thaw cycles (FTC), in relation to RIN values.  
 
Figure 5.17.  Correlation between RIN values and pre- and post-mortem parameters of human 
cases.  A. Age of patient at time of death (yrs). n♂= 50. n♀= 27. B. pH of brain tissue at post-mortem. 
n♂= 20. n♀= 7. C. Post-mortem interval (hrs). n♂= 49. n♀= 27. D. Freeze-thaw cycles prior to RNA 
extraction. n= 54. Blue ♂ symbols are male cases. Pink ♀ symbols are female cases. Solid regression 
line is regression of male data set. Dashed regression line is regression of female data set.  Vertical 
lines are error bars (± 1SD). P-values and correlation coefficients from two-tailed Pearson linear 
correlation analysis are given.  
 
 
RNA integrity as assessed by RIN showed no significant correlation with; age of 
patient at time of death or PMI for either male and female cases (Figure 5.17A, C). 
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Brain pH at time of autopsy indicated a significant (p<0.05) 16.7% positive 
correlation with RIN in the male data set, and a 73% negative but non-significant 
correlation within the female data set. It should be noted that the female dataset was 
small. There were relatively few samples with freeze-thaw data so these were not 
analysed separately as male and female. There was a highly significant (p<0.0001) 
56% negative correlation between the number of times the brain tissue had been 
thawed and the quality (RIN) of the extracted RNA. Freeze-thaw cycles were 
measured in a discrete manner; only tissue that had been removed from -80°C 
storage for ~60 minutes were considered to have been subjected to 1 cycle. Minor 
thaw events (i.e. transferring tissue between freezers) were not taken into account, as 
this result is based on whole half brains and large organs take time to change 
temperature. A similar study on AD human brains observed minimal degeneration of 
specific mRNA’s with PMI up to 96hrs or when thawed for 1-2 hours (Yasojima et 
al., 2001). 
 
On consideration of data in panel A, it is apparent that certain cases, regardless of 
age, are either variable or not variable. These data points have either very large or 
very small error bars and occur throughout the dataset. Similar data points can be 
seen in panels B and C and suggests that the amount of variation of RNA quality 
(RIN) is intrinsic to the particular sample and does not correlate with age at death, 
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5.7.5 Affect of Age at Death, Tissue pH, PMI and FT Cycles on 
Yield 
Figure 5.18 shows the relationship between yield and; age of patient at time of death 
(yrs), brain tissue pH at post-mortem, PMI (hrs) and freeze-thaw cycles (FTC). 
 
 
Figure 5.18. Correlation between total RNA yields (µg) extracted from 100 mg starting brain 
material and pre- and post-mortem parameters of human cases.  A. Age of patient at time of 
death (yrs). n♂= 50. n♀= 27. B. pH of brain tissue at post-mortem. n♂= 20. n♀= 7. C. Post-mortem 
interval (hrs). n♂= 49. n♀= 27. D. Freeze-thaw cycles at time of RNA extraction. n= 54. Blue ♂ 
symbols are male cases. Pink ♀ symbols are female cases. Solid regression line is regression of male 
data set. Dashed regression line is regression of female data set. Vertical lines are error bars (± 1SD). 
P-values and correlation coefficients from two-tailed Pearson linear correlation analysis are given. 
 
 
Age, brain pH at post-mortem and PMI had limited correlation with yield within the 
male data sets (Figure 5.18B, C). Within the female data sets, PMI showed no 
significant correlation but there was a significant (p = 0.054) negative correlation 
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with pH (although the p-value was close to the tolerance limit of this experiment). 
There was a significant 42% negative correlation within the female data set between 
yield and age. Although figures 5.17D and 5.19D shows a significant negative 
correlation between the number of freeze-thaw cycle and the quality of the RNA, no 
such effect was present with yield. No significant correlation between the yield and 
number of FT cycles may suggest that although the mechanisms of ice crystal 
formation and re-formation may significantly damage the RNA molecules, the 
overall amount of RNA within the tissue is unaffected. This suggests that RNA 
molecules are subjected to mechanical damage due to ice crystal formation and 
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5.7.6 Affect of Age at Death, Tissue pH, PMI and FT Cycles on 
A260:280  




Figure 5.19. Correlation between A260:280 ratios and pre- and post-mortem parameters of 
human cases.  A. Age of patient at time of death (yrs). n♂= 44. n♀= 22. B. pH of brain tissue at post-
mortem. n♂= 17. n♀= 4. C. Post-mortem interval (hrs). n♂= 43. n♀= 21. D. Freeze-thaw cycles at 
time of RNA extraction. n= 48. Blue ♂ symbols are male cases. Pink ♀ symbols are female cases. 
Solid regression line is regression of male data set. Dashed regression line is regression of female data 
set. Vertical lines are error bars (± 1SD). P-values and correlation coefficients from two-tailed Pearson 
linear correlation analysis are given. 
 
 
With relation to the A260:280 ratios; nether age nor PMI showed a correlation within 
male or female data sets. There was a significant positive correlation between pH and 
A260:280 within the female data set. This effect may be due to the small numbers in 
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this data set and seems unlikely to be a true correlation. FT cycles do not have a 
significant effect on the A260:280 ratios. This is expected, as RNA molecules of any 
length will absorb at 260 nm and this agrees with the results seen with FTC and total 
RNA yield. Quantification of RNA by UV spectrophotometric methods can be 




5.7.7 Index of Agonal State Correlations with RNA Metrics 
Clinical notes, autopsy and histological reports from all 47 NCJDSU cases were 
examined and an Index of Agonal State (IAS) assigned for each case. Clinical notes 
were only available for confirmed vCJD cases, autopsy and histological reports were 
available for all 47 cases. Since only vCJD cases had detailed clinical notes 
available, the length of time between first symptoms and death (disease duration) 
was only available for vCJD cases. Therefore analysis was done using two separate 
scores; one including a score for disease onset (total score) and a second not 
including disease onset score (histology score). 
RNA preparations from these cases were quality and quantity tested using the 
Agilent Bioanalyzer for RIN values, A260:280 ratios and total RNA yield measured 
using the Nanodrop ND-1000 spectrophotometer. For cases with all relevant data, 
correlation analysis was carried out. Figure 5.20 shows three graphs corresponding to 
the analysis of the total IAS scores and histology only IAS scores. 
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Figure 5.20. IAS correlations (including (total) or excluding (histology) onset score) with RNA 
metrics as determined by Agilent Bioanalyzer (RIN value) and Nanodrop Spectrophotometer (A260:280 
ratio and total RNA yield (µg)). A. total: r2 = 0.100. histology: r2 = -0.004. B. total: r2 = -0.025 
histology: r2 = -0.006. C.  total: r2 <-0.001. histology: r2 = -0.009. n = 19 for total scores. n = 47 for 
histology scores.  
 
 
Multiple regression analysis revealed no significant correlation between total IAS 
scores or histology only IAS scores and any of the three RNA metrics used to 
measure quality and quantity (Figure 5.20A). The greatest correlation is observed 
with RIN values but only 12% of the RIN variation can be account for by variation in 
total IAS score. IAS scores take into account a range of factors (listed in section 
4.6.1). It is therefore surprising that there is very limited correlation between RNA 
quality and agonal state. This data may be limited by its small sample size. In 
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damage in the brain, are subjective. However, this analysis suggests that AS does not 
affect RNA quality or yield. 
 
 
Inclusion of the disease onset score (Figure 5.20A) had a large effect on the 
correlation with RNA quality.  Therefore further analysis was carried out to 
determine whether the duration of disease, in months, would have an affect on RNA 
quality. Relevant data was available from 27 of the NCJDSU cases (Figure 5.21). 
 
Figure 5.21. Duration of illness (months) correlations with RNA metrics, as determined by 
Agilent Bioanalyzer (RIN value) and Nanodrop Spectrophotometer (A260:280 ratio and total RNA 
yield (µg)). A. r2 = -0.008. B. r2 = 0.003. C. r2 = 0.052. .n = 27. 
 
 
Multiple regression analysis reveals no correlation between the time of disease onset 
and death and RNA quality or quantity. Individuals, who suffered prolonged agonal 
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be expected to have had increased levels of plasma acidosis. Build up of lactic acid 
in the brain can lower the pH environment to neurotoxic levels (pH 6.0-6.5) and 
cause degradation of RNA. These results do not appear to represent this effect and 
are contrary to published data (Kingsbury et al., 1995; Harrison et al., 1995; Hardy et 
al., 1985). Disease onset was not always recorded in clinical notes, in addition, 
neurological signs can often be subtle, and recollection of disease onset may not be 
accurate. 78% of the cases included for analysis were vCJD cases, which may 




5.7.8 Overall Cases 
To determine whether gender had an influence on the results in sections 5.7, an 
overall comparison was carried out between the measured RNA variables and the 
same pre- and post-mortem factors. The results are summarised in Table 5.9. 
 
 RIN YIELD (µg) 260:280 RATIO 
 r2 p-value r2 p-value r2 p-value 
AGE 
(yrs) 
0.073a 0.527 -0.272a 0.017* 0.130c 0.303 
PMI 
(hrs) 
0.007b 0.950 0.008b 0.945 0.133e 0.294 
pH 0.099f 0.623 -0.088g 0.663 -0.016h 0.946 
Table 5.9. Correlation between age, post-mortem interval and pH of brain and RIN, 28S:18S 
ratio, A260:280 ratio and total RNA yield from all cases. n values; a=77. b=76. c=65. d=75. e=64. 
f=27. g=26. h=21. * = significant. 
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Two-tailed Pearson correlation analysis shows that there was only a statistically 
significant correlation between yield and age and this was a slight negative 
correlation. There were no other statistically significant correlations between any of 
the investigated parameters when gender effects are removed. In conclusion, RNA 
levels and quality are relatively consistent under the four investigated conditions. 
This is in agreement with the majority of published literature (see Chapter 4). 
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5.8 SUMMARY OF FINDINGS 
 
• Human brain RNA preparations have lower quality and yield than mouse 
brain preparations. 
• The Nanodrop ND-1000 is more reproducible in determining RNA yield than 
the Agilent Bioanalyzer RNAchip. 
• No PrPres was detectable in RNA preparations (10,000-fold less than in brain 
homogenate). 
• No PrPres was detectable in NND brain homogenates or RNA preparations. 
• 367 human brain and 102 mouse brain RNA preparations were generated. 
20% human RNA preparations and 93% mouse RNA preparations had RIN 
>5.0 and were potential samples for down-stream gene expression analysis. 
• There was considerable variation in quality and quantity of RNA from 
samples generated from within the same brain and from samples between 
brains. The RIN variation was greater inter-case. 
• RIN, A260:280 and yield values showed no correlation with tissue 
preparation/storage method, including F.I. and storage temperature. 
• There was a significant (p < 0.05) negative correlation between RNA of RNA 
preparations and FTC. 
• There was no significant (p > 0.01) correlation between quality and quantity 
of the RNA preparations and age, PMI, pH and IAS. There was however a 
possible correlation between yield and age. 
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The isolation of intact RNA is integral to reliable transciptome analysis and 
constitutes the best representation of the steady-state of transcription. For a disease 
such as CJD, it is essential to investigate gene expression patterns within the post-
mortem human brain. This study first determined which methods were most suitable 
to assess RNA prepared from human brain material. Traditionally, 28S:18S ratio and 
UV spectrophotometric A260:280 ratios have been the accepted techniques for 
assessing the quality of RNA, but these provide limited information about the degree 
of RNA degradation.  
 
RNA subjected to electrophoresis separates according to size. The estimated ratio of 
28S to 18S rRNA should be approximately two to one in total RNA samples for the 
mRNA quality to be acceptable (Sambrook & Russel, 2001). Although this method 
of screening is widely accepted, I have not been able to locate the original data for 
this premise. Considering there are significant structural differences between mRNA 
and rRNA, it is perhaps surprising that rRNA is considered a suitable marker for 
mRNA, as structural difference may elicit differences in stabilities. 18S integrity may 
more closely reflect mRNA integrity, since the average length of 18S is more closely 
aligned to the average mRNA length (review; (Noller, 1984; Maden & Hughes, 
1997). If transcriptional or maturation processes differ for the 18S and 28S subunits 
under different conditions, or if degradation events preferentially target the 28S 
subunit, 28S:18S ratios of ~2.0 could not be an accurate measure for assessing 
mRNA degradation. Increased RNA length leads to a greater statistical chance of 
cleavage and  ‘hidden’ breaks can be introduced into the large ribosomal subunits of 
some eukaryotic organisms in vivo, leading to two molecules of equivalent size that 
cannot be distinguished from the smaller ribosomal subunit (Davis & Mullersman, 
1981; Santiago et al., 1986). Evidence that cellular 28S:18S rRNA is not always 
constant comes from data that shows a decrease in the ribosomal ratio with age in 
both humans and mice (Payao et al., 1998; Mori et al., 1978). Also it has been 
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demonstrated that the level of 28S RNA in mouse cell line infected with murine 
hepatitis virus (MHV) decreases and after 24 hrs practically no intact 28S RNA is 
left, while there is no observed specific damage to the 18S RNA fraction (Banerjee et 
al., 2000).  
 
Low rRNA band intensity ratios may be a consequence of post-mortem degradation 
or to destruction of cellular RNA during purification. There are numerous examples 
demonstrating that post-mortem changes in tissue do not occur rapidly (Mann et al., 
1978; Hardy & Dodd, 1983). RNA damage during purification depends on the nature 
of the tissue; it is difficult to isolate RNA with 2:1 28S:18S ratio from dense 
connective tissue (Reno et al., 1997), RNase-rich tissue (Monstein et al., 1995) and 
some tumours (Skrypina et al., 2003). Certainly RNase activity will eventually lead 
to the loss of both components, although there are circumstances under which in situ 
rRNA will be completely degraded but mRNA remains intact (Mayne et al., 1999; 
Inoue et al., 2002). 
 
Published literature evaluating the fidelity of 28S:18S rRNA ratio to RNA quality is 
highly contradictory. Weis attempted to identify predictive factors for sample 
selection of human post-mortem tissues. The quality thresholds for RIN metrics were 
highly correlated to good quality RNA, whereas 28S:18S was found to be 
unacceptably variable, although it was still possible to use the 28S:18S ratio as a 
predictive model for microarray analysis (Weis et al., 2007) The latter outcome is in 
stark contrast to data published by Miller where no correlation between 28S:18S and 
the RNA status for RT-PCR was observed (Miller et al., 2006). The reason for this 
may be due to the specific priming technique requirement for RT-PCR (random-
hexamer) and Affymetrix platforms (oligo-dT), the latter being much less forgiving 
of decrements in the poly-A tail of the mRNA. Furthermore, low 28S:18S rRNA 
(~0.4) ratio does not preclude correct measuring of individual RNA levels provided 
that random primer directed cDNA synthesis is used for RT-PCR and that the 
amplified product does not exceed 700 nucleotides Also the shorter the desired 
amplicon length, the lower the threshold of 28S:18S ratio can be (Skrypina et al., 
2003). 
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The use of 28S:18S rRNA ratio would have incorrectly excluded a large proportion 
of the sample set. This finding is particularly important to studies of post-mortem 
human tissue, which is valuable, difficult to acquire, and necessitates large sample 
sets to achieve significant results.  
 
Agilent Bioanalyzer RIN calculations are heavily biased towards the electorphoretic 
profile produced from an RNA sample. Although multiple studies have shown the 
RIN calculations to be reliable and stable (Copois et al., 2007; Imbeaud et al., 2005; 
Weis et al., 2007; Atz et al., 2007), certain treatments can significantly change the 
electoropherogram characteristics and thus the RIN calculation. Concentrating RNA 
in a SpeedVac has been shown to have a positive impact on the RNA quality 
measurements derived from the Agilent Bioanalyzer. Weis suggested it was not the 
extraction process but rather some mechanism which occurred during the 
concentration process which is likely to alter the RNA structure, facilitating its 
migration through the capillary chip. As it is highly unlikely that such a structural 
alteration would result in restoration of degraded mRNA to a nondegraded form, this 
factor is another variable which must be controlled for when testing RNA quality 
(Weis et al., 2007).  
 
Spectrophotometric analysis of nucleic acids is highly susceptible to sample 
contamination. While this is beneficial for excluding substantially contaminated 
samples, such sensitivity may interfere with obtaining reliable results and lead to 
high false exclusion rates. A260 readings are normally compromised by the presence 
of genomic DNA, A230 readings indicate the level of residual organic contamination 
whereas A280 readings inform of the level of proteinaceous contamination of the 
sample. A260:280 ratios are taken to determine the quality and purity of RNA and 
A260:230 ratios are used as an additional criterion of purity. Individual wavelength 
readings can easily be misinterpreted and it is more common for ratios to be 
measured. A260:280 and A260:230 being roughly equivalent is accepted for pure RNA 
preparations (Sambrook & Russel, 2001; Manchester, 1995; Manchester, 1996). As 
discussed in Chapter 4, the RNA extraction protocol used in this project utilises GTC 
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and phenol-chloroform. These chemicals can contaminate preparations and even 
minimal residual amounts can give erroneous measurements. The additional 
chloroform extraction at the end of the procedure should have removed any residual 
phenol which would alter OD ratios. Tissue-specific variation of UV measurement 
has not been observed and is invariate relative to purification method and tissue of 
origin (Imbeaud et al., 2005). 
 
Degradation issues fall under two broad questions; 1) is it possible to determine 
whether RNA decay has occurred via in vivo cellular regulatory mechanisms or 
processing of extraction? 2) If the later is true, how much RNA destruction due to 
handling can be tolerated while still retaining the appropriate information concerning 
the level of expression of the gene of interest? 
 
RNA of any gene, including rRNA, can be specifically degraded due to some 
specific regulatory process or as a result of response to some external factors within 
the living cell (Pardue et al., 1994; Taylor et al., 1986; Banerjee et al., 2000; Payao 
et al., 1998; Mori et al., 1978). If degradation has occurred in an unspecific pattern, 
where unspecific damage has occurred to many different RNAs in a similar way and 
to a similar degree, it may be as a result of mishandling, post-mortem degradation, 
massive cell death or massive infection. One way to overcome this problem is to 
define a set of well characterised marker RNAs and a methodology to conclude 
whether most of them are degraded similarly or differently. If damage is randomised 
along RNA and a number of different RNAs are damaged to approximately the same 
degree, unspecific degradation can be presumed. The correct data on relative 
concentration of the RNA of interest will be obtained if the probability of having a 
cut site within the amplified fragment is low and random primer not oligo-dT is used 
for RT-PCR. There is published evidence that this is indeed the case (Preece et al., 
2003).  
 
The mechanisms of RNA degradation in the ex vivo context are not well understood, 
although mechanical alterations in cell structure following death render organelles 
physiologically ineffective long before any significant changes in certain constituent 
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biochemical are detected. Degradation mechanisms are likely to involve different 
rates and mechanisms for different RNA species (Jacobson & Peltz, 1996; Ross, 
1996; Shapiro et al., 1987; Noguchi et al., 1991). It has been reported that an 
immediate and rapid loss of low molecular weigh RNA species, usually tRNA and 
mRNA, occurs at death, although there is little alteration in rRNA levels (Mann et 
al., 1978). Furthermore, Inoue illustrated that total RNA and mRNA isolated from 
dead rat bodies degrades in the same manner. Degradation rates of three house-
keeping genes in the brains of dead rats were identical, suggesting that the mRNA of 
constitutively expressed genes are degraded via a similar mechanism  (Inoue et al., 
2002). These finding and the findings from (Castensson et al., 2000) suggest that it is 
possible to isolated total RNA from autopsy brain tissue that is suitable for mRNA 
analysis. mRNA of inducible genes is less stable than that of constitutively expressed 
genes in vivo. However, stability of mRNA in inducible gene ex vivo is still to be 
studied.  
 
Gene expression regulation is intrinsically related to mRNA stability. The stability of 
individual mRNA transcripts are in turn regulated by specific interactions between 
structural elements (cis-elements) and trans-acting factors. These interactions are 
regulated by environmental stimuli such as nutrient levels, cytokines and hormones, 
as well as environmental stresses like hypoxia and tissue injury, factors which are of 
particular relevance when studying neurodegenerative disorders (Liebhaber, 1997; 
Mitchell & Tollervey, 2000; Guhaniyogi & Brewer, 2001; Hollams et al., 2002). The 
most important structure which determines the stability of the mRNA structure is a 
destabilizing sequence found in the 3’ untranslated region. The general motif is a 
series of AUUUA pentamers. The greater the number of A + U rich elements 
(AREs), the greater the vulnerability to decay. In yeast cells, decapping of the 5’ 
structure follows poly(A) shortening to promote nucleolytic decay (Shaw & Kamen, 
1986). Highly labile mRNA species such as c-fos also contain decay elements within 
their coding regions. Degradation initiation begins by the progressive deadenylation 
of the poly(A) tail, thereby reducing the efficacy with which poly(A) binding protein 
can attach to the mRNA molecule. This therefore permits attack by endonucleases 
and exonucleases. Direct endonucleolytic decay can also occur (Sachs, 1993).  If the 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 5  Isolation of RNA from human brains 
 166
degradation mechanism model proposed by Sachs (Sachs, 1993) is correct, it may be 
possible to predict genes which are more susceptible to decay by searching for the 3’ 
untranslated region reported in Genbank. 
 
Despite the relative stability of RNA in postmortem tissue studies, human post-
mortem brain tissue often yields RNA levels that vary widely among samples. The 
abundance and integrity of RNA and constituent mRNAs varies markedly between 
one human brain and another. The average amount of RNA isolated per gram from 
human post-mortem tissue was ~ 260 µg/g, and was significantly less than the 
amount routinely isolated from rodent brains, either immediately or after freezing 
and storing for a length of time (~ 960 µg/g). This is confirmed by other observations 
(Johnson et al., 1986; Perrett et al., 1988; Sajdel-Sulkowska et al., 1983). The 
manipulation of brains at time of autopsy (examination for gross anatomy, weighing, 
slicing and dissection) may contribute to this effect; smaller rodent brains require 
less handling. Such additional manipulations (especially cutting tissue and disrupting 
cells) may increase the risk of releasing alkaline ribonucleases as well as the normal 
lysosomal, acidic ribonucleases. However, one report of RNA yields from a human 
brain sample taken at biopsy was in the range of 600 µg/g of tissue (Johnson et al., 
1986), suggesting that rather than loss due to manipulation, the total amount of RNA 
in human brains may be less per gram of tissue than in rodents. Variations in brain 
RNA levels could be the net result of an exceedingly complex set of underlying 
circumstances. 
 
Screening RNA to exclude samples prior to cDNA synthesis or probe generation 
saves time and effort on wasted experiments. Gene expression analysis invariably 
involves cDNA synthesis by RNA reverse transcription and subsequent quantitative 
evaluation of the DNA product by PCR (Wang et al., 1989) or hybridization (Taylor 
et al., 1986). Although shorter fragment length or lack of poly(A) tail may reduce 
efficiency of cDNA synthesis or probe hybridization, a moderate degree of 
degradation does not exclude the viability of microarray analysis (Schoor et al., 
2003). Overall, although an accurate, in vivo representation of the transcriptome may 
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seem difficult to achieve, it is still possible to study mRNA, as these factors are most 
likely to affect detection of full length mRNA of labile species. 
Building a RNA profile for each sample utilising three historically relevant methods 
of RNA assessment and one recently described computer algorithm ensures a 
stringent assessment evaluation of all RNA preparations. This is one method of 
normalization which will improve the quality of the resulting microarray data. 
Categorisation of borderline samples can still be tricky and can be heavily affected 
by investigator bias. While an in-depth interpretation of RNA quality is valuable and 
necessary, it is important that the investigator select what is acceptable in terms of 
false inclusion and false exclusion. To this end, the experiments were optimized 
towards correctly identifying good quality sample, at the risk of including some poor 
quality samples, because the value of post-mortem human brain tissue is so high. 
Other normalisation strategies applied in the project were; similar sample size/ tissue 
volume and the use of total RNA instead of alternative RNA species or specific 
mRNA or rRNA house-keeping genes. Normalisation of tissue volume is a simple 
first step process which will reduce experimental error, but may be difficult to 
estimate and/or may not be biologically representative. Total RNA will provide a full 
picture about the sample integrity, although this greatly depends on the technique 
used. This method of normalization however, does not control for error introduced at 
the reverse transcription or PCR stages. It also makes the assumption that there is no 
variation in the rRNA:mRNA ratio, an assumption known to be incorrect.  
 
While many RNA extraction protocols and recommendations for TSE agent 
decontamination have been described, there are limited guidelines on how to extract 
RNA from tissues while simultaneously decontaminating or removing the TSE agent. 
The majority of decontamination procedures are extremely harsh and are likely to 
have a detrimental affect on RNA populations. This project has described an RNA 
extraction protocol for use with TSE infected high-lipid tissues, but it was necessary 
to determine the level of TSE decontamination or removal achieved.  Having 
established a method for detecting proteinase-K resistant PrP and determining the 
limit of detection, a random selection of RNA extracts were tested. The RNA 
extraction protocol was developed specifically for removal of proteins while 
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conserving the RNA population. Based on the results of the risk assessment, it was 
considered that the RNA extracts did not contain detectable amounts of infectious 
PrPSc. Studies investigating the efficacy of organic solvent extraction protocol for 
purification of phospholipids from brain tissue concluded that scrapie-like agents can 
be decontaminated from brain samples, provided only the organic phases are used. In 
vitro results were similar to those seen for this project and the results from the study 
were confirmed by in vivo endpoint titrations (Di Martino et al., 1994). Single 
exposures to organic solvents are evidently insufficient to inactivate TSE agents, but 
it is likely that continuous and prolonged exposure may affect infectivity titres 
(Millson et al., 1976). In this case, extraction by organic solvents using the organic 
phase only for product purification would be considered a useful procedure for 
reduction and/or removal of infectivity, especially since scrapie agent is not soluble 
in many organic solvents. The cessation of solvent extraction for the production of 
animal feed has been indicated as one of the major concurrent causes for the sudden 
BSE epidemic (Kimberlin, 1992; Taylor & Woodgate, 1997).  
 
In vitro test methods such as Western blot are only considered useful for studying the 
initial effects of treatments on prion proteins, since it has been proven that such 
methods may not be sufficiently sensitive to detect extremely low levels of PrPres and 
therefore infectivity (Fichet et al., 2004). Conventional in vivo assays are widely 
accepted as being more reliable and able to detect much lower titres of infectivity, 
although factors such as the presence of species barriers will inevitably lead to a loss 
in sensitivity. While it is clear that protein western immunoblotting is suitable and 
reliable for PrPres detection, it remains questionable as to whether this method is 
sensitive enough to detect low, but still infectious, titres of agents (McLeod et al., 
2004). Immunodetection of PrP by western blot has a dynamic range of ~ 100 fold, 
whereas bioassays measure prions over a ~ 109 fold range (Peretz et al., 2006), so 
although it is possible to state the inadequacy of using Western blot for assessment of 
decontamination/inactivation of TSE, bioassays were not a viable choice for this 
project and there are limited alternative methods.  
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It is possible that the phenol treatment will disassociate or denature the PrPSc 
aggregates within a sample, thereby rendering the PrPSc susceptible to proteinase K 
treatment. For this safety assessment, it has been assumed that this effect is minimal 
at best, and these results are consistent with the assumption that PK resistant PrPSc is 
indicative of infectivity. If there was significant effect on PrPSc aggregates, infectious 
PrPSc would have been rendered PK sensitive and would not be detected on the 
western blots. Under these circumstances, if phenol treatment had indeed denatured 
the PrPSc aggregates and assuming the prion hypothesis is true, a bioassay would also 
be unsuitable in detecting PK sensitive PrPSc.  
 
The findings from this chapter agree with the consensus published data. RIN, 
28S:18S rRNA ratio, total RNA yield and A260:280 ratio do not correlate with gender, 
age of patient or post-mortem interval. Based on the IAS, there is also no evidence of 
agonal state impacting on RNA integrity. Findings from the Tomita study showing 
that agonal state had a drastic effect on RNA integrity and decreased brain tissue pH 
were not confirmed in this study (Tomita et al., 2004). It was not possible to study 
IAS against tissue pH in this study as only NND cases had pH information but did 
not have clinical notes. The reasons for the different findings may be due to 
difference in methodology. Tomita used 240 Genechips to test 40 subjects 
(psychiatric and control) and measured global RNA integrity based on indicators on 
Affymetric Genechips. However, when specific mRNA levels were tested against a 
range of agonal variables, no correlation was observed (Burke et al., 1991). Although 
the IAS is more detailed than the AFS, assessment of degradation was more 
comprehensive in the Tomita study. The use of the Agilent RIN is a simple assay 
requiring limited sample, cost and expertise. RNA samples assessed using the RIN 
have been shown to be suitable for gene expression studies. Therefore, for 
transcriptome analysis on human tissue, the effect of agonal state is insufficient to 
affect gene expression results. The pH data does indicate a level of correlation, but 
this effect is debatable and is probably due to the small sample size rather than to a 
true correlation. Although Bahn suggests the use of pH of brain tissue as a suitable 
method for predicting the RNA quality, this has not been confirmed in other studies. 
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As yet, it has been not been possible to identify a predictive model from which to 
select suitable cases for molecular genetic analysis (Bahn et al., 2001).  
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6  GENE EXPRESSION ANALYSIS 
 
6.1 OBJECTIVES  
 
• Select suitable arrays for gene expression analysis. 
• Assess reproducibility and specificity of chosen array technology. 
• Compare OND, NND and vCJD cases matched cases on selected arrays. 
 
6.2 INTRODUCTION  
 
Molecular methods offer insight into the underlying mechanisms of brain function 
and in the case of disease, the underlying pathological mechanisms.  With the 
availability of the nearly complete human and mouse genome sequences, the 
development of genomic tools allows investigators to exploit this valuable 
information. Such ‘gene-centric’ approaches permits broad, system-based 
approaches, while simultaneously obtaining a gene-specific molecular view.  
 
The cellular state is dynamically maintained by a defined set of gene transcripts, or 
transciptome, which becomes altered at times of stress and disease. In addition, 
mRNA expression profiles are anatomically specific and because expression levels 
are influenced by both genetic polymorphisms and environmental input, microarray 
technologies have the potential to elucidate the underlying molecular changes which 
occur during the disease state. In contrast to more traditional ‘one-gene-at-a-time 
approaches’, large scale parallel views of hundreds of genes allows investigators not 
just to explain the behavior of a singe gene, but to develop explanations which are 
consistent and well supported in the context of complementary information on 
thousands of genes. 
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A microarray or gene chip is an ordered arrangement of nucleotide molecules 
representing specific gene coding regions, chemically bonded to a specifically 
designed spotted or arrayed membrane surface. ‘Probes’ are the arrayed membrane-
tethered nucleic acid of known sequence, whereas the ‘target’ is the free nucleic acid 
in the biological sample to be analysed. Microarray analysis of gene expression 
allows the investigator to analyze the expression level of genes in complementary 
DNA (cDNA), which is prepared from purified mRNA. RNA transcribed from this is 
then fluorescently- or radioactively labeled and hybridized to the array. Membranes 
are washed to remove non-hybridized excess sample and imaged, usually by laser 
scanning or autoradiographic imaging. At this stage, the data is uploaded onto a 
database, where the image is recognized and processed, then analyzed by any 
number of statistical packages currently available. 
 
During the mid 1980’s, the first arrays called macroarrays were fabricated by 
spotting DNA probes of ~300 µm diameter, limiting the density to ~ 2,000 probes 
per spot, each spot being a single feature. Microarrays created by pin-based robotic 
systems can dispense an accurate volume of a DNA solution in a spot of about 150 
µm, creating much higher density arrays. Stephen Fodor and colleagues produced the 
world’s first microarray using a microscope glass slide and chemically synthesized 
oligonucleotides (Fodor et al., 1991; Fodor et al., 1993). Since then, variations of this 
original technique have led to vastly improved genetic array platforms, for example, 
the most recent Affymetrix GeneChips contains over 1.3 million features, equivalent 
to over 47,000 RNAs which encompass nearly every known human gene. 
 
The two basic types of microarrays are oligonucleotide and cDNA microarrays. 
Oligonucleotide microarrays are directly synthesized and arrayed in a discrete 
regular manner on the chip surface, whereas cDNA microarrays are previously 
prepared DNA clones (generally a PCR product of longer than 100 nucleotides). The 
primary commercial DNA microarray providers are Affymetrix and Agilent, aimed 
at genome wide panels usually with >3,000 features per chip.  
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Complex diseases often result from both genetic and environmental influences. DNA 
diagnostics provides a static test of the composition of the genome that does not 
illustrate the full cellular picture. RNA diagnostics is a more dynamic test, capable of 
detecting change due to complex environmental factors, in this instance neurological 
disease state. However, due to cost constraints and due to the subsequent 
bioinformatics time required to analyse the data, it is not always feasible to monitor 
all 44,000 different mRNA species transcribed from the human genome for multiple 
samples simultaneously. To circumvent this problem, ‘focused arrays’ containing a 
limited number of mRNAs on a low-density array are also available.  
 
Focused microarrays are smaller versions of whole genome arrays, comprising a 
thoroughly researched set of relevant, pathway- or disease- focused genes. Generally, 
such focused microarrays are used to study gene expression associated with a 
biological pathway or disease state, or to customize the arrays for a selected panel of 
genes tailored to specific research needs. Because of their focused design, it becomes 
possible and affordable to process larger number of samples. Also, data handling is 
easier and more straightforward, allowing research to progress faster.  
 
Commercial availability of focused microarrays is increasing, to accommodate the 
demand of customized arrays applied to specific clinical disease studies. SuperArray 
(Bethesda, MD, USA) is one such company with a comprehensive list of focused 
microarrays. SuperArray OligoArrays have 300–600 bp probes spotted in 
quadruplicate in 1-mm-diameter “tetrads”. These tetrads are arranged in 8 columns 
and 14 rows, and for the human specific Alzheimer Disease (AD) OligoArray (OHS-
057) and Signal Transduction (ST) PathwayFinder OligoArray (OHS-014), there are 
96 experimental features per array. Also included on the array design are internal 
control features consisting of; plasmid (pUC18), blank (no DNA), artificial 
sequences and biotinylated artificial sequences and four potential normalization 
genes (Glyceraldehyge-3-phosphate dehydrogenase [GAPDH], β-2- microglobulin 
[B2M], Heat shock protein 90 [HSP90AB1], and β-actin [ACTB]). 
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The human AD array has been designed to included genes implicated in amyloid β-
peptide (Aβ) generation, clearance and degradation, as well as genes involved in Aβ 
signal transduction leading to neuronal toxicity and inflammation. The ST array 
incorporates markers of 18 signal transduction pathways, including the p53, Jak-Stat 
and calcium and protein kinase C pathways. These arrays were selected as there are 
pathological similarities between AD and vCJD and evidence of altered expression 
of genes involved in a number of apoptotic and metabolic signaling pathways in 
animal models of TSE (Duguid et al., 1989; Diedrich et al., 1991b; Diedrich et al., 
1987).   
 
Microarray data in itself is insufficient evidence for gene expression changes and 
must be independently verified by real-time quantitative polymerase chain reaction 
(qRT-PCR). Chapter 8 outlines the proof of concept for RT-PCR to verify gene 
expression changes observed with the microarray results. 
 
Having established that it is possible to extract RNA from human brains of suitable 
quality for microarray and real time analysis, the next objective was to determine 
whether it was possible to obtain statistically significant gene expression data. The 
experimental design included three comparison groups. Each comparison group 
contained an age and gender matched vCJD, NND and OND case. Each sample was 
hybridised to the focused AD and ST arrays, where possible, in duplicate. The array 
data was analysed for; 
• Variation between replicate arrays and replicate samples. To determine 
variability of the RNA preparations and of the arrays. 
• Variation between cases of the same status, i.e. vCJD vs vCJD. To determine 
if gene expression changes were associated with inter-patient variability. 
• Variation between cases of different status, i.e. vCJD vs NND control cases. 
To determine disease associated changes. 
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Figure 6.1. Flow chart showing case 
selection process used to include and then 




The analysis was also done within the comparison groups, i.e. using age and gender 
matched cases only, and across all the cases, i.e. using all vCJD hybridised arrays 
compared to all NND hybridised arrays (see section 6.4). Figure 6.1 shows the total 
number of cases from which eventually 3 matched cases, one each of 
vCJD/NND/OND, was selected for microarray analysis. Figure 6.2 illustrates the 
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Figure 6.2. Grid model of analysis.  Variation may be introduced by; 1) replicates (black dashed 
lines). 2) intra-status variation (pink box). 3) across comparison groups, i.e. age and/or gender related 
variation (blue box).  These factors must be accounted for before disease associated gene changes can 
be determined. V1.1= vCJD, comparison group 1, replicate 1.  N1.1= NND, comparison group 1, 
replicate 1. O1.1= OND, comparison group 1, replicate 1.  Analysis to determine the degree of 
variation was done; between replicates (black dashed line), intra-status (pink box), inter-status (blue 
box) and overall (outer purple box). 
 
In order to determine disease status related changes, replicate effects, intra-status 
effects and across comparison group effects must be accounted for and/or removed. 
If replicate effect, intra-status effect and age/gender effects are removed or are 
minimal, remaining gene expression changes can be considered to be potential 
disease associated changes. 
 
It must be noted however that the use of focused gene arrays such as the AD 
OligoArray has biased the study towards the genes printed on the array membrane. 
The main aim of this experiment was to determine whether RNA isolated from 
human autopsy brain material from tissues stored at the NCJDSU and the MRC brain 
banks could be hybridized to cDNA microarrays and whether reliable and 
reproducible data to be generated. Ideally future work including whole transcriptome 
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6.3 CASE COMPARISON GROUPS 
From the seven matched comparison groups possible (see Table 4.6), three groups 
were used for gene expression analysis. These were selected to cover a range of ages 
and to include both genders; to isolate age- or gender- related gene expression 
changes. Comparison groups used for gene expression analysis are defined in Table 
6.1.  
 
 vCJD NND OND 
Grp 1 17/M 19/M 18/M 
Grp 2 39/M 41/M 54/M* 
 Grp 5 30/F 31/F 25/F 
Table 6.1. Matched comparison groups containing one vCJD case, one NND control and oneOND 




6.4 ALZHEIMER DISEASE OLIGOARRAY 
 
Expression of 113 genes (Appendix 9.10, Table 9.4) implicated in AD pathogenesis 
were screened on GEarray Q series non-radioactive Alzheimer Disease gene chips 
(Tebu-Bio, Cambs, UK), using total RNA (1 µg) from brain tissue of vCJD (n=3), 
OND (n=3) and NND (n=3). Total RNA was amplified and labelled using the 
Superarray TrueLabeling-Amp 2.0 kit according to the manufacturer’s instructions. 
Membranes were developed using CDP-star as chemiluminescent substrate. 
Membranes were exposed to X-ray films and developed. Images were digitalised on 
an Epson Perfection flatbed scanner. Images were acquired at 200 pixels/in and were 
formatted (squared, cropped, inverted, and saved in TIF format) with Adobe 
Photoshop version 7.0 (Adobe Systems, Uxbridge, UK). Examples are shown in 
Figure 6.3. The web-based GEArray Expression Analysis Suite version 1.2 software 
(Superarray, MD, USA) overlays a grid of spots (10 pixel diameter) on the TIF 
image, which is centered over each feature tetrad. The average pixel intensity (API) 
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within each spot was measured and used to calculate gene spot density levels for 
each feature. The usable range of API values with this instrumentation was 9,000–
65,000, as described by the manufacturer’s manual. The range was established from 
determining that the minimum (background) API value detected on the 
autoradiographs was ~8,000 and the maximum or plateau API was ~65,000. API 
values that fell within these limits were accepted for analysis. Images were verified 
by visual comparison with the autoradiographs. Background-corrected densities of 
each tetra-spot (representing each gene) were averaged across that spot. For 
normalisation, only the genes between the 25th and 75th quartile from the summation 
of all spot densities were considered. Regulated genes were identified by ratio 
changes of ≥ 1.5, unless otherwise stated. All formulae for data analysis can be found 




Figure 6.3. Array images (un-edited) of comparison group 1 (see Table 6.1). Total RNA extracted 
from control cases and vCJD cases was labeled and hybridized to membranes pre-loaded with 96 
cDNA representing disease specific genes of interest. Representative images of three membranes 
hybridized to labeled RNA extracted from vCJD (A), NND control (B) and OND control (C) are 
shown. Gene spots encased in red circles are induced in vCJD compared to normalized NND and 
OND controls. Gene spots encased in green squares are reduced. Filled red circles are induced 
compared to NND controls only. Filled green circles are reduced compared to NND controls only.  
 
A vCJD B NND C OND
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6.4.1 Reproducibility and Variation Between Replicates 
The variability of technical replicates was determined in two ways; (i) Total RNA 
from a single RNA preparation was amplified and hybridised to two arrays, to 
establish the variability of the array analysis. (ii) Two contiguous samples from a 
single human brain was used to prepare RNA, amplified in parallel and hybridised to 
two arrays, to establish the variability of RNA preprations and array analysis. All 
RNA samples were labeled as described in Chapter 2, to generate labelled cRNA 
target. cRNA quantification and quality assessment was measured by UV 
spectrophotometry. Samples ≥ 11 ng/µl total RNA, A260:280 ratio ≥ 2.0 and A260:230 
ratio ≥ 1.7 were considered as suitable for hybridization to microarrays. 2 µg of 
cRNA was hybridised to each of the two separate AD arrays and processed in 
parallel.This was carried out on all cases in comparison groups 1 and 5. Figure 6.4A 
represents one such replicate set using two RNA preparations analysed on two 
separate arrays. It is expected that the combined variability of the RNA preparations 
and array analysis would be greated than the variability of the array analysis only. 
However, Figure 6.4B shows the multiple regression analysis which reveals a 
significant correlation coefficient of 0.97, indicating that replicate arrays assessing 




Figure 6.4. A. Replicate array images of case 124. B. Scatter plot of replicate 1 against replicate 2. 
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Another measure available to compare two samples is the coefficient of variation 
(CV) which shows the degree of deviation from the mean. The diagonal line in 
Figure 6.4B indicated how correlated the data is and the CV indicates how close the 
values are to the line. Replicate AD arrays were hybridized using (i) a single RNA 
preparation on two separate arrays for all three cases in comparison groups 1 and (ii) 
two RNA preparations on two separate arrays for all three cases in comparison group 
5. Figure 6.5 shows scatter plots of replicate cases of comparison group 1. The 
average CV value (based on internal chip control spots) for group 1 was 19% and for 
group 5, 14%. The greater variation observed in comparison group 1 is expected 
since using two RNA preparations would introduce the variation of the sample as 
well as the variation of the array analysis. For comparison group 5, the variability of 
the array analysis is comparable to the Superarray quoted values (CV of 10%) of a 
single sample on replicate arrays (Fox-Brashears et al., 2000).  
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Figure 6.5. Scatter plot of relative spot density of replicate 1 plotted against replicate 2 from 
comparison group 1. Panel A. vCJD. Panel B. NND. Panel C.OND.  All panels show boundaries as 
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6.4.2 Intra-Status Effects 
The next assessment was to determine the degree of variation between cases of the 
same status (i.e vCJD vs vCJD). In this analysis, CV values were calculated but it 
should be noted that these have little power due to the small sample sizes and the 
limitation of not having identical biological replicates.  Figures 6.6, 6.8, 6.10 show 
all possible intra-status combinations. Figures 6.7, 6.9, 6.11 show more detailed 
examples of individual intra-status comparisons. Table 6.2 gives the correlation 




Figure 6.6. Integrated matrix plot of all vCJD cases  plotted against each other. Lines represent 
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Figure 6.7. Scatter plot of vCJD1 against vCJD2. 
OND 
 
Figure 6.8. Integrated matrix plots of all OND cases plotted against each other. Lines represent 




Figure 6.7. Scatter plot of vCJD1 
against vCJD2. Outer diagonal lines 
represent 1.5-fold threshold limits. Axes 





Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 6  Microarray Gene Expression Analysis 
 185
 
Figure 6.9. Scatter plot of OND2 against OND5. 
NND 
 
Figure 6.10. Integrated matrix plots of all NND cases plotted against each other. Lines represent 




Figure 6.9. Scatter plot of OND2 
against OND5. Outer diagonal lines 
represent 1.5-fold threshold limits. 
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Figure 6.11. Scatter plot of NND1 against NND5. 
 Correlation coefficient 
(r2) 
Coefficient of Variation 
(CV) (%) 
vCJD vs vCJD 0.83 23 
OND vs OND 0.86 18 
NND vs NND 0.94 23 




CV and r2 values were consistent across all intra-status comparison, suggesting that 
within all 3 disease statuses, there was similar but limited variation between the 
cases. Single samples run on replicate arrays showed an average CV ~18% and an 
average r2 of 0.97. The intra-status comparisons have an average CV of 21% and an 
average r2 value of 0.88, suggesting the data is slightly more variable intra-status 





Figure 6.11. Scatter plot of NND1 
against NND5. Outer diagonal 
lines represent 1.5-fold threshold 
limits. Axes are log10 spot density 
values. 
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6.4.3 Inter-Status, Matched Cases   
Variation between vCJD, OND and NND was evaluated. Figures 6.12, 6.13 and 6.14 
show vCJD vs NND, OND vs NND and vCJD vs OND for comparison groups 1, 2 
and 5 respectively, set at 1.5- (left) and 3-fold (right) boundary threshold limits. 
Figure 6.15 is a graphical representation of genes observed with ≥ 2- fold changes in 
gene spot density. Differentially expressed genes observed in vCJD vs NND and in 
vCJD vs OND but not observed in OND vs NND were considered to be candidate 
vCJD specific changes.  
 
The average CV across all comparisons in group 1 was 44%. The overall percentage 
of genes flagged as regulated and the degree of variation observed was greater than 
the variation observed in the replicate pairs or the intra-status comparisons. This was 
expected as inter-status comparisons are between different diseased cases and 
controls.  
 
From these results, the average percentage of genes which were flagged as regulated 
in comparison group 2 was ~38% at the 2-fold threshold limit, consistent with the 
result in comparison group 1. An average CV of 40% indicated a greater level of 
variability in the data than for replicates or intra-status comparison.  
 
The average percentage of genes flagged as regulated in comparison group 5 was 
~20% at the 2-fold threshold limit, with an average CV of 37%. The percentage of 
genes flagged as regulated is slightly lower than observed in comparison group 1 and 
2, although the degree of variation is consistent. The reason for this is unclear. In this 
comparison groups cases were female, but is unlikely that gender affected the results, 
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Figure 6.12. Scatter plot of inter-status comparisons of group 1. Panel A. vCJD vs NND. Panel B. 
OND vs NND. Panel C. vCJD vs OND. Left panels. Outer lines represent 1.5-fold threshold boundary 
of gene spot density changes. Right panels. Outer lines represent 2- fold threshold boundary of gene 
spot density changes. Red points represent genes up-regulated; green points represent genes down-
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Figure 6.13. Scatter plot of inter-status comparisons for group 2.  Panel A. vCJD vs NND. Panel 
B. OND vs NND. Panel C. vCJD vs OND. Left panel. Outer lines represent 1.5-fold threshold 
boundary of gene spot density changes. Right panel. Outer lines represent 2-fold threshold boundary 
of gene spot density changes. Red points represent genes up-regulated; green points represent genes 
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Figure 6.14. Scatter plot of inter-status comparisons for group 5. Panel A. vCJD vs NND. Panel 
B. OND vs NND. Panel C. vCJD vs OND. Left panel. Outer lines represent 1.5-fold threshold 
boundary of gene spot density changes. Right panel. Outer lines represent 2-fold threshold boundary 
of gene spot density changes. Red points represent genes up-regulated; green points represent genes 
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Figure 6.15 Bar chart representing genes with greater than 2-fold change in expression levels, as 
determined by normalized densitometric analysis of gene arrays. (see Appendix Table 9.6-8 for 
tabulated gene names). X-axis is the order in which genes showing ≥2-fold change were flagged, 
based on chip position and may not match across charts. 
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Differentially expressed genes which were flagged in vCJD vs NND and vCJD vs 
OND, but not flagged in OND vs NND comparisons were considered to be potential 
vCJD-specific gene changes. Group 1, 2 and 5 comparisons of vCJD vs NND/OND 





Figure 6.16 compares comparison group with one another. If the assumption is made 
that there is no gender/age effects, the datasets represents the disease status effects 
across the comparison groups. 
 
Figure 6.16. Integrated matrix plot of all three comparison groups, separated into status, based on 
AD array results. 
 
Comparison of the data sets across comparison groups shows whether there were any 
disease status effects of the case. Looking at each individual scatter, for example, 
vCJD cases correlate more closely to one another than to OND/NND cases. Due to 
the lack of biological replicates, it was not possible to determine exactly where the 
effect was coming from. Sections 6.4.1 and Section 6.4.2 shows there are limited 
replicate and age/gender effect, so it is reasonable to assume that there are 
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differences between the different disease status cases, regardless of age/gender. This 
suggests it will be possible to identify potential disease-specific changes. OND cases 
in all comparisons were the most scattered indicating the greatest amount of variation 
when compared across comparison groups. This is to be expected, as the disease of 
the OND case in each group were not the same disease. NND cases are very closely 
clustered, suggested very little spread of the data, regardless of comparison group 
effect. Since NND cases were selected on the same criteria, i.e. short agonal state, no 
pre-existing disease etc, this clustering is not surprising. This results is in agreement 




Hierarchical clustering partitions data points into subsets (clusters), such that points 
within each cluster are more closely related to one another than points assigned to 
different clusters. In this case, API was clustered by ratios relative to the central 
(control) case. Each row represents a specific gene and each column a specific 
disease status (Figure 6.17). OND and NND cases are more similar to one another 
than they are to vCJD cases. 
 
 
Figure 6.17. Clustergram analysis of all AD Specific oligoarrays 
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Clustergram analysis of 
all AD Specific 
oligoarrays, carried out 
on GEarray Expression 
Anlaysis Suite web-based 
software. Genes which are 
more similar are joined at 
lower heights in the 
dendrogam and those that 
are less similar are joined 
at higher heights.  
Average linkage methods 
were used. The colour-
coding legend (below) 
displays the maximum 
values as red (furthest 
right) and minimum 
values as green (furthest 
left), as a function of the 
samples (vertical 
direction). The vertical 
dendrogram links the 
comparison groups 
according to similarity. 
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Based on all 16 AD arrays, it was possible to generate volcano-plots for vCJD vs 
NND and OND vs NND. Volcano plots summarize both fold-change and t-test 
criteria. Briefly, a volcano plot is a scatter plot of the negative log10-transformed p-
values from the gene specific t-test plotted against the log2 fold-change. Genes with 
statistically differential expression, according to the gene specific t-test, lie above the 
horizontal threshold line. Genes with large fold-change values lie outside the pair of 
vertical threshold lines (set at 1.5-fold here). The significant genes identified by the 
fold-change and p-value boundaries are located in the upper left (down-regulated) or 
upper right (up-regulated) sectors of the plot. Figure 6.18A highlights the statistically 
significant regulated genes in the vCJD vs NND comparisons. Figure 6.18B 
highlights the statistically significant regulated genes in the OND vs NND 
comparisons. Figure 6.19 is a graphical representation of the genes observed to have 
≥ 2-fold change in expression. Table 6.3, 6.4 and 6.5 list the significantly regulated 
genes and respective fold-changes. 
 
 
Figure 6.18. Volcano plots of relative gene expression, based on all 16 AD arrays. A. all vCJD vs 
NND. B. all OND vs NND. Horizontal lines are set at 0.05 significance threshold limits. Vertical lines 
are set at 1.5-fold change threshold limits. Red points represent genes up-regulated; green points 




At the 1.5-fold change threshold (significance level= 0.05), there were 18 up-
regulated and 10 down-regulated genes from the vCJD vs NND comparison 
A B
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(Figure6.18A, Table 6.3). For the same criteria, 19 genes were up-regulated and 2 
genes were down-regulated from the OND vs NND comparison (Figure 6.18B, Table 
6.4). Only 1 gene was flagged in both comparisons (ERN2). For vCJD vs OND 
comparisons 11 genes were up-regulated and 13 were down-regulated (graph not 
shown, see Table 6.5); 16 of these were identical to those flagged in the vCJD vs 
NND comparison, suggesting these genes are vCJD-specific changes. The GEArray 
Expression Analysis Suite determines significance using a conservative method 
which utilizes a logarithmic transformation of the raw data, de-emphasizes the 
contribution of outliers and noise and facilitates comparisons across experiments. 
Figure 6.19 shows genes which were significantly regulated with a >2.0 fold change. 
 































Figure 6.19. Bar chart representing significantly regulated genes with greater than 2-fold change 
in expression levels, as determined by normalized densitometric analysis of gene arrays. (see 
Appendix Table 9.9 for tabulated gene names). 
 
 
Of the 28 significantly (p<0.05) regulated genes in vCJD vs NND, 10 were down-
regulated and 18 up-regulated. Functional clustering revealed 39% were involved in 
β-amyloid generation, oligomerization, clearance, and degradation,; 32% in cell 
signaling, 25% in synaptic formation and 21% in cholesterol or lipid metabolism. 
There were 21 significantly regulated genes in OND vs NND, of which only 2 were 
down-regulated. 19% were involved in β-amyloid generation, oligomerization, 
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clearance, and degradation, but only APP was common to both comparisons. 23% 
were involved in cell signaling and 9% in lipid metabolism, but these were all unique 
genes to this particular comparison. There were no synaptic formation genes flagged. 
The 24 significantly regulated gene in vCJD vs OND showed 13 down-regulated 
genes (refer to Table 6.4). Of these 24, 15 were also regulated in vCJD vs NND 
comparison but not in the OND vs NND comparison (refer to Table 6.2, 6.3). That 
these 15 genes were flagged in these two comparisons (vCJD vs NND and vCJD vs 
OND) strongly suggests that they are vCJD-specific changes. 33% were involved in 
β-amyloid generation, oligomerization, clearance, and degradation, none of which 
were flagged in the OND vs NND comparison, but 5 were also flagged in the vCJD 
vs NND comparison. 46% of genes were involved in cell signaling, none of which 
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6.4.5 SAM Analysis of AD Arrays 
False discovery rates (FDR) are not calculated by the GEArray software, and CV 
values are not adjusted. To gain an indication of the FDR, Significance Analysis of 
Microarrays (SAM) analysis was also carried out. Significance Analysis of 
Microarrays (SAM) software was used to determine the false discovery rate (FDR) 
and to avoid problems associated with multiple testing. Software downloads and 
details on formula and programming are available at http://www-
stat.stanford.edu/~tibs/SAM/. Briefly, SAM calculates a test statistic for relative 
difference in gene expression data and calculates a FDR. This analysis is based on 
non-parametric statistics which may be more appropriate since gene expression data 
may not follow a normal distribution. By using a calculated constant to modify the 
coefficient of variance, SAM analysis accounts for the range of variation and applies 
a weighting for smaller values. SAM analysis requires a minimum sample size to 
calculate significance and FDR. Therefore analysis had to be done across all 
comparison groups. This requires the assumption that there are no differences 
between cases of the same disease status (i.e.vCJD cases, for example, are the same, 
irrespective of age/gender). SAM software was used to calculate statistically 
significant gene expression changes and the FDR of all the AD arrays, using vCJD, 
OND and NND as three parameters and analyzing in a pair-wise method. Figure 6.20 
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Median number of false positives: 0.46
False Discovery Rate (%): 15.36


























Median number of false positives: 0.92
False Discovery Rate (%): 10.24


























Median number of false positives: 0.96
False Discovery Rate (%): 8.01
Tail strength (%): 32.7
se (%): 27.1
 
Figure 6.20. SAM analysis of all inter-status comparisons. Panel A. vCJD vs NND. FDR = 
15.36%.  Significantly up-regulated genes = 0. Significantly down-regulated genes = 3. Panel B. OND 
vs NND. FDR = 10.24%. Significantly up-regulated genes = 7. Significantly down-regulated genes = 
2. Panel C. vCJD vs OND. FDR = 8.01%. Significantly up-regulated genes = 3. Significantly down-
regulated genes = 9. Outer lines represent 1.5-fold threshold limit. Red plots represent significantly 
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SAM analysis calculated; 0 up- and 3 down-regulated genes in vCJD vs NND, 7 up- 
and 2 down-regulated genes in OND vs NND and 3 up- and 9 down-regulated genes 
in vCJD vs OND comparisons. The small sample size of this analysis means that the 
strength of any findings is limited and the SAM analysis of significance may be too 
stringent in this case. SAM analysis revealed FDR’s of 15%, 8% and 10% for vCJD 
vs NND, OND vs NND and vCJD vs OND, respectively. Generally FDR thresholds 
of 5% or less are accepted, in order to limit false-positive identification, but to avoid 
losing relevant information, FDR thresholds at the 1.5-fold level, were more flexible 
to allow identification of significance. If the FDRs calculated from SAM analysis is 
used with the significance as calculated by GEArray Expression Analysis Suite, of 
the 28 vCJD vs NND significantly modulated genes, potentially 4could be false 
discoveries, of the 21 OND vs NND flagged genes, 2 may be falsely discovered and 
of the 24 vCJD vs OND significant genes, 2 potentially are false discoveries. 
 
The number of significantly regulated genes calculated by the SAM analysis was not 
in good agreement with the numbers calculated by the GEArray Expression Analysis 
Suite. This was due to differences in statistical formulae and the use of the modified 
coefficient of variance formulae used by the SAM software. On such small sample 
sizes, is would be difficult to obtain meaningful significant data. Similar studies on 
sCJD did not use age/gender matched cases (Xiang et al., 2005), so although the data 
yielded more significant results, it is not possible to determine whether age or gender 
affected the expression levels observed. Evidence of gender and age-related changes 
have been published, therefore it is reasonable to assume that there may be age- or 
gender- related effects (Galvin & Ginsburgh, 2005; Vawter et al., 2004; Colantuoni 
et al., 2008). 
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Gene UniGene Description 
Fold-
change p-Value 
ABCA1 Hs.429294 ATP-binding cassette, sub-family A (ABC1), member 1 5.64 0.04 
APBA1 Hs.592974 Amyloid beta (A4) precursor protein-binding, family A, member 1 (X11) 1.67 0.03 
APBA3 Hs.465607 Amyloid beta (A4) precursor protein-binding, family A, member 3 (X11-like 2) 2.57 0.04 
APH1A Hs.108408 Anterior pharynx defective 1 homolog A (C. elegans) 1.73 0.03 
APLP1 Hs.74565 Amyloid beta (A4) precursor-like protein 1 2.07 0.01 
APOA1 Hs.633003 Apolipoprotein A-I 1.84 0.05 
APOE Hs.515465 Apolipoprotein E 2.95 0.03 
BACE2 Hs.529408 Beta-site APP-cleaving enzyme 2 1.89 0.00 
BCHE Hs.420483 Butyrylcholinesterase 1.92 0.00 
BDNF Hs.502182 Brain-derived neurotrophic factor 1.71 0.05 
CHAT Hs.302002 Choline acetyltransferase 1.76 0.02 
CTSD Hs.121575 Cathepsin D 1.77 0.01 
ERN2 Hs.592041 Endoplasmic reticulum to nucleus signalling 2 2.48 0.00 
BPTF Hs.444200 Bromodomain PHD finger transcription factor 1.80 0.01 
GNB4 Hs.270543 Guanine nucleotide binding protein (G protein), beta polypeptide 4 1.93 0.01 
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GNG5 Hs.645427 Guanine nucleotide binding protein (G protein), gamma 5 1.61 0.02 
LPL Hs.180878 Lipoprotein lipase 2.83 0.04 
LRP10 Hs.525232 Low density lipoprotein receptor-related protein 10 1.88 0.01 
APP Hs.434980 Amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) 0.39 0.01 
CDK5 Hs.647078 Cyclin-dependent kinase 5 0.63 0.02 
NPY Hs.1832 Neuropeptide Y 0.07 0.00 
PRKCB1 Hs.460355 Protein kinase C, beta 1 0.26 0.00 
PRKCZ Hs.496255 Protein kinase C, zeta 0.51 0.05 
PSEN1 Hs.592324 Presenilin 1 (Alzheimer disease 3) 0.65 0.01 
SNCA Hs.271771 Synuclein, alpha (non A4 component of amyloid precursor) 0.55 0.04 
SPINT2 Hs.31439 Serine peptidase inhibitor, Kunitz type, 2 0.62 0.03 
SST Hs.12409 Somatostatin 0.36 0.00 
UQCRC2 Hs.592048 Ubiquinol-cytochrome c reductase core protein II 0.51 0.01 
Table 6.3.Differentially expressed genes from vCJD vs NND comparisons revealed by focused AD microarray analysis.  Fold-change threshold limit = 1.5. 
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SYMBOL UniGene Description Fold-change p-Value 
RPS27A Hs.311640 Ribosomal protein S27a 1.74 0.02 
CLU Hs.436657 Clusterin 1.84 0.01 
CTSB Hs.520898 Cathepsin B 1.59 0.03 
ERN2 Hs.592041 Endoplasmic reticulum to nucleus signalling 2 1.79 0.00 
GNB1 Hs.430425 Guanine nucleotide binding protein (G protein), beta polypeptide 1 1.62 0.02 
GSK3A Hs.466828 Glycogen synthase kinase 3 alpha 1.75 0.02 
IL1A Hs.1722 Interleukin 1, alpha 1.76 0.02 
PLAT Hs.491582 Plasminogen activator, tissue 4.06 0.04 
PLAU Hs.77274 Plasminogen activator, urokinase 2.17 0.02 
PRKCI Hs.478199 Protein kinase C, iota 3.96 0.00 
SERPINA13 Hs.527795 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 13 (pseudogene) 1.54 0.02 
SERPINA3 Hs.510334 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 2.06 0.01 
SNCB Hs.90297 Synuclein, beta 1.79 0.01 
UQCRC1 Hs.119251 Ubiquinol-cytochrome c reductase core protein I 1.71 0.00 
VSNL1 Hs.444212 Visinin-like 1 1.57 0.03 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 6   Microarray Gene Expression Analysis 
 204 
HSP90AB1 Hs.509736 Heat shock protein 90kDa alpha (cytosolic), class B member 1 1.80 0.01 
HSP90AB1 Hs.509736 Heat shock protein 90kDa alpha (cytosolic), class B member 1 1.80 0.01 
ACTB Hs.520640 Actin, beta 1.81 0.01 
ACTB Hs.520640 Actin, beta 1.82 0.01 
APP Hs.434980 Amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) 0.48 0.03 
GNB2 Hs.185172 Guanine nucleotide binding protein (G protein), beta polypeptide 2 0.64 0.02 
Table 6.4 Differentially expressed genes from OND vs NND comparisons revealed by focused AD microarray analysis.  Fold-change threshold limit = 1.5. 
Significance level = 0.05. Red = up-regulated genes. Green = down-regulated genes. 
 
 
SYMBOL UniGene Description Fold-change p-Value 
APH1A Hs.108408 Anterior pharynx defective 1 homolog A (C. elegans) 1.63 0.03 
APLP1 Hs.74565 Amyloid beta (A4) precursor-like protein 1 1.99 0.01 
BACE2 Hs.529408 Beta-site APP-cleaving enzyme 2 2.26 0.00 
BCHE Hs.420483 Butyrylcholinesterase 2.11 0.00 
CDKL1 Hs.280881 Cyclin-dependent kinase-like 1 (CDC2-related kinase) 2.06 0.01 
CHAT Hs.302002 Choline acetyltransferase 1.82 0.02 
CTSD Hs.121575 Cathepsin D 1.67 0.05 
ECE2 Hs.146161 Endothelin converting enzyme 2 1.67 0.00 
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EGR3 Hs.534313 Early growth response 3 1.89 0.00 
GNB4 Hs.270543 Guanine nucleotide binding protein (G protein), beta polypeptide 4 1.87 0.02 
GNG5 Hs.645427 Guanine nucleotide binding protein (G protein), gamma 5 1.99 0.01 
NCSTN Hs.517249 Nicastrin 0.40 0.03 
NPY Hs.1832 Neuropeptide Y 0.10 0.04 
PKP4 Hs.407580 Plakophilin 4 0.60 0.03 
PLG Hs.143436 Plasminogen 0.38 0.02 
PRKCA Hs.531704 Protein kinase C, alpha 0.34 0.03 
PRKCB1 Hs.460355 Protein kinase C, beta 1 0.34 0.01 
PRKCQ Hs.498570 Protein kinase C, theta 0.49 0.03 
PSEN1 Hs.592324 Presenilin 1 (Alzheimer disease 3) 0.63 0.01 
SNCA Hs.271771 Synuclein, alpha (non A4 component of amyloid precursor) 0.46 0.01 
SPINT2 Hs.31439 Serine peptidase inhibitor, Kunitz type, 2 0.56 0.02 
SST Hs.12409 Somatostatin 0.33 0.01 
UQCRC2 Hs.592048 Ubiquinol-cytochrome c reductase core protein II 0.49 0.01 
VSNL1 Hs.444212 Visinin-like 1 0.47 0.02 
Table 6.5. Differentially expressed genes from vCJD vs OND comparisons revealed by focused AD microarray analysis.  Fold-change threshold limit = 1.5. 
Significance level = 0.05. Red = up-regulated genes. Green = down-regulated genes. 
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6.5 SIGNAL TRANSDUCTION PATHWAY FINDER GENE 
ARRAYS 
 
Signal transduction pathway finder gene arrays were analysed as described for AD 
arrays. Expression of 113 genes (Appendix 9.10, Table 9.5) representative of 18 
signal transduction pathways were screened by a cDNA-based microarray technique 
using the GEarray Q series nonradioactive Signal Transduction Pathway Finder 
(Tebu-Bio, Cambs, UK), using total RNA (1 µg) from brain tissue of vCJD (n=3) , 




Figure 6.21. Array images (un-edited) of comparison group 2 (see Table 6.1). Total RNA 
extracted from control cases and vCJD cases was labeled and hybridized to membranes pre-loaded 
with 96 cDNA representing disease specific genes of interest. Representative images of three 
membranes hybridized to labeled RNA extracted from vCJD (A), NND control (B) and OND control 
(C) are shown. Gene spots encased in red circles are induced in vCJD compared to normalized NND 
and OND controls. Gene spots encased in green squares are reduced. Filled red circles are induced 
compared to NND controls only. Filled green circles are reduced compared to NND controls only. 
 
 
A vCJD B NND C OND
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6.5.1 Reproducibility and Variation Between Replicates 
The reproducibility of replicate arrays was assessed by amplifying a single RNA 
preparation and hybridizing 2 µg cRNA to two separate ST arrays which were 
processed in parallel. This was carried out on all cases in comparison group 2 only. 
Figure 6.22A represents one such replicate set. Figure 6.22B shows the multiple 
regression analysis of an example replicate set. Figure 6.23 shows scatter plots of 





Figure 6.22. A. Replicate array images of case 129. B. Scatter plot of replicate 1 against replicate 2. 
Axis values are log10 gene spot densities. r2 = 0.963.  
 
Multiple regression analysis reveals a significant correlation coefficient of 0.96, 
suggesting that replicate arrays are highly correlated. The average CV value (based 
on internal chip control spots) was 8%. Therefore, reproducibility of hybridization 
and array processing was considered satisfactory and it was assumed that replicate 
effect on gene variation for subsequent analyses was minimal. In Figure 6.22B, it is 
clear that the scatter plot points are clustered tightly for the majority of the genes, 
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Figure 6.23. Scatter plot of relative spot density of replicate 1 plotted against replicate 2 from 
comparison group 2. Panel A. vCJD. Panel B. NND. Panel C.OND.  All panels show boundaries as 
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6.5.2 Intra-Status Effect 
The next assessment was to determine the degree of variation of gene spot density 
between same status cases (i.e vCJD vs vCJD). Figures 6.24, 6.26, 6.28 show 
integrated matrix plots representing all possible intra-status combinations. Figures 
6.25, 6.27, 6.29 show more detailed examples of individual intra-status comparisons. 





Figure 6.24. Integrated matrix plots of all vCJD cases plotted against each other. Lines represent 
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Figure 6.25.  Scatter plot of vCJD2 against vCJD5. 
OND 
 
Figure 6.26. Integrated matrix plots of all OND cases plotted against each other. Lines represent 





Figure 6.25.  Scatter plot of vCJD2 
against vCJD5. Outer diagonal lines 
represent 1.5-fold threshold limits. Axes 
are log10 spot density values. 
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Figure 6.27.  Scatter plot of OND2 against OND5. 
NND 
 
Figure 6.28. Integrated matrix plots of all NND cases plotted against each other. Lines represent 




Figure 6.27.  Scatter plot of OND2 
against OND5. Outer diagonal lines 
represent 1.5-fold threshold limits. Axes 
are log10 spot density values.  
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Figure 6.29. Scatter plot of NND1 against NND2. 
 Correlation coefficient 
(r2) 
Coefficient of Variation 
(CV) (%) 
vCJD vs vCJD 0.81 9 
OND vs OND 0.84 3 
NND vs NND 0.89 4 
Table 6.6. Correlation coefficient and coefficient of variation values for all intra-status 
comparison. 
 
The average CV values (Table 6.6) indicate that the data are closely clustered around 
the mean and the r2 values show close correlation between cases of the same status. 
CV and r2 values were similar across all intra-status comparisons and are similar to 
the values calculated from the AD arrays. Taken together, this suggests that 
age/gender effects are limited.  
 
 
6.5.3 Inter-Status, Matched Cases 
As for the AD array analysis, the level of variation observed between matched 
disease and control cases was evaluated. This was done by comparing gene spot 
density between disease-specific (vCJD) vs non-diseased controls (NND) and 
disease-unspecific (OND) vs non-diseased controls (NND), within the matched 
comparison groups (see Table 6.1). This method of comparison removes gender-
Figure 6.29. Scatter plot of NND1 
against NND2. Outer diagonal lines 
represent 1.5-fold threshold limits. Axes 
are log10 spot density values. 
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specific and age-related confounding effects; any variation is likely to be due to 
disease regulated gene expression. The analysis is broken into comparison groups 1, 
2 and 5. Figure 6.30, 6.31 and 6.32 show vCJD vs NND, OND vs NND and vCJD vs 
OND comparisons respectively, set at 1.5- (left) and 2-fold (right) boundary 
threshold limits. Figure 6.33 is a graphical representation of genes observed with ≥ 2- 
fold changes in gene spot density. 
 
The average percentage of genes which were flagged as regulated in comparison 
grou p1 was ~34%, at the 2-fold threshold limit. The average CV across all 
comparisons was 49%. This is consistent with the results from comparison group 1 
using the AD arrays. 
 
In comparison group 2, the average percentage of genes which were flagged as 
regulated was ~17% at the 2-fold threshold limit. An average CV of 27% was 
observed. This result is in contrast to the result observed in comparison group 2 from 
the AD array results. Less variation in the data may indicate that the selection of 
genes on the signal transduction array may not be greatly altered during vCJD 
disease. This is not to suggest there is no relevant results observed, simply that the 
genes selected for the AD array were more relevant to the pathogenic mechanism of 
vCJD. 
 
From comparison group 5, the average percentage of genes which were flagged as 
regulated was ~31% at the 2-fold threshold limit, with an average CV of 48%. This is 
consistent with comparison group 1 results and also with the AD comparison results. 
The degree of variability inter-status is greater than is observed intra-status or in 
replicates, therefore these changes suggest the intre-status comparison is useful for 
identifying changes in gene expression in signal transduction pathways. 
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Figure 6.30. Scatter plot of inter-status comparisons of group 1. Panel A. vCJD vs NND. Panel B. 
OND vs NND. Panel C. vCJD vs OND. Left panels. Outer lines represent 1.5-fold threshold boundary 
of gene spot density changes. Right panels. Outer lines represent 2- fold threshold boundary of gene 
spot density changes. Red points represent genes up-regulated; green points represent genes down-
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Figure 6.31. Scatter plot of inter-status comparisons of group 2. Panel A. vCJD vs NND. Panel B. 
OND vs NND. Panel C. vCJD vs OND. Left panels. Outer lines represent 1.5-fold threshold boundary 
of gene spot density changes. Right panels. Outer lines represent 2- fold threshold boundary of gene 
spot density changes. Red points represent genes up-regulated; green points represent genes down-
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Figure 6.32. Scatter plot of inter-status comparisons of group 5. Panel A. vCJD vs NND. Panel B. 
OND vs NND. Panel C. vCJD vs OND. Left panels. Outer lines represent 1.5-fold threshold boundary 
of gene spot density changes. Right panels. Outer lines represent 2- fold threshold boundary of gene 
spot density changes. Red points represent genes up-regulated; green points represent genes down-
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Figure 6.33. Bar chart representing genes with greater than 2-fold change in expression levels 
from comparison group 5, as determined by normalised densitometric analysis of gene arrays. (see 
Appendix Table 9.10-12 for tabulated gene names). X-axis is the order in which genes showing ≥2-
fold change were flagged, based on chip position and may not match across charts. 
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Differentially expression genes which were flagged in vCJD vs NND and vCJD vs 
OND, but not in OND vs NND were considered potential vCJD-specific gene 
changes. From group 1,2 and 5 comparisons of vCJD vs NND/OND, a total of 58, 33 






Figure 6.34 shows all possible comparison group combinations. The variable on the 
Y-axis appears at the horizontal, the variable on the X-axis appears on the vertical for 
each block of plots. This method of analysis assumes equal gender/age effects for all 
cases and represents the disease status effects across the comparison groups. 
 
 
Figure 6.34. Integrated matrix plot of all three comparison groups, separated into status, based on 
ST array results. 
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Comparison of the data sets across comparison groups shows whether there were any 
effects on the disease status of the case. Simultaneous comparisons clearly identifies 
which comparison is most effected by comparison group effects. The plots are much 
more scattered than those in the AD integrated matrix plot (see Figure 6.16), 




Figure 6.35 shows the average density of each individual gene from group 1, 2 and 5, 
aligned according to the relative ratios for that gene.The clustergram classifys the 
data in each subset by expression trait and clustering those with a closer degree of 





Figure 6.35. Clustergram analysis of all Signal Transduction PathwayFinder oligoarrays 
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which are more 
similar are joined at 
lower heights in the 
dendrogam and those 
that are less similar 
are joined at higher 
heights.  Average 
linkage methods were 
used. The colour-
coding legend 
(below) displays the 
maximum values as 
red (furthest right) 
and minimum values 
as green (furthest 
left), as a function of 
the samples (vertical 
direction). The 
vertical dendrogram 
links the comparison 
groups according to 
similarity. 
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6.5.5 Significant Gene Expression Changes 
All 12 arrays used in the ST array analysis, were included for a test of significance. 
This was done using the GEArray Expression Analysis Suite volcano-plots. Figure 
6.36A highlights the statistically significant regulated genes in the vCJD vs NND 
comparisons. Figure 6.36B highlights the statistically significant regulated genes in 
the OND vs NND comparisons. 
 
 
Figure 6.36. Volcano plots of relative gene expression, based on all 12 ST arrays. A. all vCJD vs 
NND comparisons. B. all OND vs NND comparisons. Horizontal lines are set at 0.05 significance 
threshold limits. Vertical lines are set at 1.5-fold change threshold limits. Red points represent genes 
up-regulated in the comparison; green points represent down-regulated genes in the comparison. X-
Axis is negative log10-transformed p-values and Y-axis is log2 fold-change, as determined by the 
GEArray Expression Analysis Suite. 
 
 
At the 1.5-fold change threshold (significance level= 0.05), there were 15 up-
regulated and 9 down-regulated genes from the vCJD vs NND comparison (Figure 
6.36A). For the same criteria, 6 genes were up-regulated and only 1 gene was down-
regulated from the OND vs NND comparison (Figure 6.36B). Six genes were 
flagged in both comparisons (GREB1, HOXB1, IGFBP4, IL1A, IL4, CDKN1B), the 
remaining 18 genes were considered vCJD-specific. For the vCJD vs OND 
comparison, 4 genes were up-regulated only (graph not shown, see Table 6.9), 2 of 
which were also observed in vCJD vs NND comparisons (confirming their status as 
vCJD-specific). One gene was flagged in all three comparisons (IGFBP4). 
A B
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Figure 6.37 represents significantly regulated (>2.0 fold) gene changes. 
 































Figure 6.37.Bar chart representing significantly modulated genes with greater than 2-fold change 
in expression levels, as determined by normalised densitometric analysis of gene arrays. (see 
Appendix Table 9.13 for tabulated gene names). 
 
 
Of the 24 significantly regulated genes in the vCJD vs NND comparison, 15 were 
up-regulated and 9 were down-regulated. Functional clustering revealed 38% of 
regulated genes were involved in oestrogen and androgen, 21% in the NFкB, 13% in 
survival (P13 kinase/AKT and Jak/Src) and 13% in the phospholipase C pathways 
(refer to Table 6.7).  
 
The OND vs NND comparison revealed 7 regulated genes, 6 of which were also 
flagged in the vCJD vs NND comparison. Therefore those 6 were not considered 
vCJD-specific. The OND VS NND unique gene was FOXA2, a gene involved in the 
hedgehog pathway (refer to Table 6.8).  
 
Only 4 genes were significantly regulated in the vCJD vs OND comparison. BCL2 
and BCL2A1 were also flagged in vCJD vs NND comparisons, providing 
confirmation   of them being vCJD-specific regulated genes involved in 
phospholipase C and survival pathways (refer to Table 6.9). 
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6.5.6 SAM Analysis of ST Arrays 
As described in section 6.4.6, GEArray Expression suite software returns significant 
genes based on modified t-testing methods, but does not adjust the CV values or 
estimated the FDR. Therefore SAM analysis was also carried out. Figure 6.38 shows 
the SAM plot output for ST array results of vCJD vs NND and OND vs NND and 
vCJD vs OND comparisons respectively. 
 
 
As mentioned in section 6.4.6, generally FDR thresholds are 5% or less are accepted, 
in order to limit false-positive identification, but to avoid losing relevant information, 
FDR thresholds at the 1.5-fold level, were more flexible to allow identification of 
significance. SAM analysis revealed FDR’s of 6%, 70% and 8% for vCJD vs NND 
(5 significant genes), OND vs NND (47 significant genes) and vCJD vs OND (12 
significant genes) respectively. The FDR for OND vs NND is significantly higher 












Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 

























Median number of false positives: 0.3
False Discovery Rate (%): 5.94























Median number of false positives: 33.19
False Discovery Rate (%): 70.61


























Median number of false positives: 0.96
False Discovery Rate (%): 8.01
Tail strength (%): 32.7
se (%): 27.1
 
Figure 6.38. SAM analysis of all inter-status comparisons. Panel A.  vCJD vs NND. FDR = 5.9%.  
Significantly up-regulated genes = 0. Significantly down-regulated genes = 5. Panel B. OND vs NND. 
FDR = 70.6%. Significantly up-regulated genes = 45. Significantly down-regulated genes = 2.  Panel 
C. vCJD vs OND. FDR = 8.01%. Significantly up-regulated genes = 3. Significantly down-regulated 
genes = 9. Outer lines represent 1.5-fold threshold limit. Red plots represent significantly up-regulated 
genes. Green plots represent significantly down-regulated genes. 
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Symbol UniGene Description Fold-change p-Value 
BCL2 Hs.150749 B-cell CLL/lymphoma 2 2.14 0.03 
BCL2A1 Hs.227817 BCL2-related protein A1 3.51 0.02 
CDK2 Hs.19192 Cyclin-dependent kinase 2 1.57 0.03 
CDKN1A Hs.370771 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 3.05 0.00 
CEBPB Hs.517106 CCAAT/enhancer binding protein (C/EBP), beta 1.82 0.00 
EGFR Hs.488293 Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) 1.55 0.04 
GREB1 Hs.467733 GREB1 protein 1.70 0.04 
HOXB1 Hs.99992 Homeobox B1 2.02 0.04 
HSP90AA2 Hs.523560 Heat shock protein 90kDa alpha (cytosolic), class A member 2 2.12 0.01 
ICAM1 Hs.643447 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 1.55 0.02 
IGFBP4 Hs.462998 Insulin-like growth factor binding protein 4 3.35 0.00 
IL1A Hs.1722 Interleukin 1, alpha 1.68 0.01 
IL2 Hs.89679 Interleukin 2 1.64 0.01 
IL4 Hs.73917 Interleukin 4 2.03 0.00 
IL4R Hs.513457 Interleukin 4 receptor 3.05 0.00 
CDKN1B Hs.238990 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 0.49 0.02 
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CDKN2D Hs.435051 Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 0.42 0.01 
EGR1 Hs.326035 Early growth response 1 0.56 0.01 
PRKCB1 Hs.460355 Protein kinase C, beta 1 0.27 0.00 
RBP1 Hs.529571 Retinol binding protein 1, cellular 0.59 0.02 
TMEPAI Hs.517155 Transmembrane, prostate androgen induced RNA 0.47 0.00 
TNF Hs.241570 Tumor necrosis factor (TNF superfamily, member 2) 0.50 0.03 
TRIM25 Hs.528952 Tripartite motif-containing 25 0.54 0.00 
WNT2 Hs.567356 Wingless-type MMTV integration site family member 2 0.42 0.00 
Table 6.7. Differentially expressed genes from vCJD vs NND comparisons revealed by focused ST microarray analysis.  Fold-change threshold limit = 1.5. 
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Table 6.8. Differentially expressed genes from OND vs NND comparisons revealed by focused ST microarray analysis.  Fold-change threshold limit = 1.5. 
Significance level = 0.05. Red = up-regulated genes. Green = down-regulated genes. 
 
 
Table 6.9. Differentially expressed genes from vCJD vs OND comparisons revealed by focused ST microarray analysis.  Fold-change threshold limit = 1.5. 
Significance level = 0.05. Red = up-regulated genes. Green = down-regulated genes. 
 
Symbol UniGene Description Fold-change p-Value 
FOXA2 Hs.155651 Forkhead box A2 1.56 0.03 
GREB1 Hs.467733 GREB1 protein 1.84 0.02 
HOXB1 Hs.99992 Homeobox B1 1.70 0.02 
IGFBP4 Hs.462998 Insulin-like growth factor binding protein 4 1.86 0.02 
IL1A Hs.1722 Interleukin 1, alpha 1.62 0.04 
IL4 Hs.73917 Interleukin 4 1.89 0.04 
CDKN1B Hs.238990 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 0.51 0.03 
Symbol UniGene Description Fold-change p-Value 
BCL2 Hs.150749 B-cell CLL/lymphoma 2 3.30 0.01 
BCL2A1 Hs.227817 BCL2-related protein A1 3.97 0.03 
BRCA1 Hs.194143 Breast cancer 1, early onset 1.83 0.01 
IGFBP4 Hs.462998 Insulin-like growth factor binding protein 4 1.80 0.03 
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6.6 SUMMARY OF FINDINGS 
• Replicate arrays were comparable to SuperArray quoted variability for 
replicates. 
• Intra-status variability was only slightly more than observed in replicates.  
• Variablity of data inter-status showed a CV of ~38%.  
• The overall statisitcal analysis suggests that replicate (13% CV) and intra-
status (i.e. age/gender) effects (13% CV) were minimal and that remaining 
gene expression changes are potential disease associated changes. 
• SAM analysis of AD arrays showed a FDR of ~ 11%. ST comparison of 
OND vs NND gave an anomylous result of a FDR of 70%, and if removed, 
ST arrays showed a FDR of ~7%.  
• From the overall AD comparisons, 37 genes were identified as significantly 
up-regulated and 17 as significantly down-regulated. Of these, 38 genes were 
potential vCJD-specific changes (see Table 6.10). 
• From the overall ST comparison, 17 genes were identified as significantly up-
regualted and 9 as significantly down-regulated. Of these, 15 genes were 
potential vCJD-specific changes (see Table 6.11). 
• 12 of the potential vCJD associated genes identified in this study were also 
identified in a larger scale gene expression study of sCJD patients (Xiang et 
al., 2005). 
• 25 of the potential vCJD associated genes have previously been described in 
gene expression studies in experimental models of TSEs (Booth et al., 2004; 
Brown et al., 2005a; Skinner et al., 2006; Riemer et al., 2004; Sorensen et al., 
2008; Xiang et al., 2004) 
• 22 genes have not been previously been described in the context of prion 
disease. 
• Functional grouping of modulated genes revealed alterations in a number of 
pathways including; genes involved in β-amyloid generation, 
oligomerization, clearance, and degradation; cell signaling; synaptic 
formation; cholesterol or lipid metabolism; NFкB and survival (P13 
kinase/AKT and Jak/Src) and phospholipase C pathways. 
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In this study, the variability of technical replicates was assessed for, (i) a single RNA 
preparation run on two separate arrays, this reports the variability of the array 
analysis and, (ii) separate RNA preparations from the same case run on separate 
arrays, this reports the variability of the RNA preparation plus the array analysis.  
These technical replicates had CV values of 10% and 19%, respectively.  This first 
value is close to the SuperArray quoted CV value of 10% for replicate arrays with a 
single sample.  The reproducibility of the microarray analysis also showed a highly 
significant correlation based on r2 values. 
 
In the present study, biological (intra-status) replicates are not exactly identical.  For 
example, the vCJD cases are not exact biological replicates, they differ in age and 
gender.  The lack of exact biological replicates has presented challenges for this 
project.  Biological replicates allow increased precision of gene expression 
measurement and identification of outliers. In clinical and pathological studies, exact 
biological replicates are rare and require studies of identical twins.  The use of non-
identical biological replicates, whilst less desirable, is preferable to no replication 
and still lends statistical power that increases the confidence of the conclusions.  
However, issues of how the non-identical parameters confound the data remain and 
need to be taken into account.  Intra-status variation revealed an r2 value >0.8 and a 
CV of ~13%.  This significant correlation and low overall variation is promising.  If 
variation between cases of the same status had been high, it would be more difficult 
to differentiate between this variation and that between diseased and non-diseased 
controls. 
 
Overall, inter-status variation (vCJD vs NND vs OND) had a CV value of 44%.  This 
is greater than the overall intra-status variation (13%) or the technical variation 
(10%) indicating that cases of different status were more different than were cases of 
the same status or technical replicates.  This is as would be expected if the arrays had 
picked up disease specific gene expression changes.  If the arrays had not picked up 
disease specific gene expression changes, the intra-status variation and the inter-
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status variation might have been expected to be similar.  Indeed, given that the inter-
status cases in each comparison group were age and gender matched whereas the 
intra-status cases (across comparison groups) were not, the variation might have been 
expected to be higher intra-status than inter-status.  With the exception of vCJD vs 
OND in the ST arrays, the average FDR (SAM analysis) for the inter-status 
comparisons was ~9%.  This is slightly higher than the generally accepted 5% FDR, 
but it should be recognised that the project’s small sample size places limits on the 
statistics. 
 
As with all transcriptome analysis studies, two important factors must be taken into 
account.  Firstly, that the stability of the mRNA may not correlate with the stability 
of the protein it encodes (Hargrove & Schmidt, 1989). Secondly, that intronic regions 
of genes are also involved in a number of processes related to post-transcriptional 
control of gene expression (Nakaya et al., 2007). Transcriptome analysis should 
therefore be followed by proteomics or other work. 
 
While these results have shown in principle that reliable and reproducible microarray 
data can be collected and processed successfully using RNA preparations isolated 
from human vCJD autopsy brain material, the use of focused arrays has biased the 
results towards the identification of relevant genes, especially with the use of an 
Alzheimer’s disease targeted array. The results shown in Chapter 6 will be discussed 
in the context of the published literature, but as the gene expression data from such 
focused array lists is insufficiently robust, any interpretations should be done with 
caution.  
 
Array analysis was carried out for matched cases (within a comparison group: 1, 2 or 
5) and across all comparison groups (1, 2 and 5).  Criteria A1, A2 and A3 will be 
used to refer to matched case comparison results (within a single comparison group) 
where at least one of the comparisons (eg vCJD vs NND) shows a fold-difference 
greater than 1.5.  A1 will refer to genes with altered expression levels within an 
age/gender matched vCJD vs NND comparison; A2 within a matched OND vs NND 
comparison and A3 within a matched vCJD vs OND comparison.  Criteria B will be 
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used to refer to genes with significantly (p =< 0.05, threshold change of 1.5) altered 
expression as identified by analysis (GE software) of the data from all 3 comparison 
groups (see Tables 6.3-6.5 and 6.7-6.9); again 1, 2 and 3 refer to vCJD vs NND, 
OND vs NND and vCJD vs OND, respectively.  The suffix AD or ST indicates 
which array type was used.  For example, apolipoprotein (APO) (AD:A1) would 
indicate that regulated expression of APO was observed in one of the vCJD vs NND 
comparisons on the AD oligoarray, whereas APO (AD:B2) would indicate that 
significantly regulated expression of APO was observed in OND vs NND when all 3 
comparison groups were considered.  Tables 6.10 and 6.11 lists those genes with 
significant changes in gene expression which can be considered to be vCJD specific 
(vCJD vs NND/OND) or can be considered to be potential vCJD specific changes 
(vCJD vs NND or OND). 
 
vCJD-specific changes 
VCJD VS NND VCJD VS OND  
SYMBOL FOLD-CHANGE P-VALUE FOLD-CHANGE P-VALUE 
APH1A 1.73 0.03 1.63 0.03 
APLP1 2.07 0.01 1.99 0.01 
BACE2 1.89 0.00 2.26 0.00 
BCHE 1.92 0.00 2.11 0.00 
CTSD 1.77 0.01 1.67 0.05 
GNB4 1.93 0.01 1.87 0.02 
GNG5 1.61 0.02 1.99 0.01 
CHAT 1.76 0.02 1.82 0.02 
BCL2 2.14 0.03 3.30 0.01 
BCL2A1 3.51 0.02 3.97 0.03 
NPY 0.07 0.00 0.10 0.04 
PRKCB1 0.26 0.00 0.34 0.01 
PSEN1 0.65 0.01 0.63 0.01 
SNCA 0.55 0.04 0.46 0.01 
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SPINT2 0.62 0.03 0.56 0.02 
SST 0.36 0.00 0.33 0.01 
UQCRC2 0.51 0.01 0.49 0.01 
Table 6.10. Genes identified as having significantly regulated gene expression in vCJD vs NND 
and OND (i.e. vCJD specific). 
 
 
Potential vCJD-specific changes 









ABCA1 5.64 0.04 CDKL1 2.06 0.01 
APBA1 1.67 0.03 ECE2 1.67 0.00 
APBA3 2.57 0.04 EGR3 1.89 0.00 
APOA1 1.84 0.05 BRCA1 1.83 0.01 
APOE 2.95 0.03    
BDNF 1.71 0.05    
BPTF 1.80 0.01    
LPL 2.83 0.04    
LRP10 1.88 0.01    
CDK2 1.57 0.03    
CDKN1A 3.05 0.00    
CEBPB 1.82 0.00    
EGFR 1.55 0.04    
HSP90AA2 2.12 0.01    
ICAM1 1.55 0.02    
IL2 1.64 0.01    
IL4R 3.05 0.00    
CDK5 0.63 0.02 NCSTN 0.40 0.03 
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PRKCZ 0.51 0.05 PKP4 0.60 0.03 
PRKCB1 0.27 0.00 PLG 0.38 0.02 
CDKN2D 0.42 0.01 PRKCA 0.34 0.03 
EGR1 0.56 0.01 PRKCQ 0.49 0.03 
RBP1 0.59 0.02    
TMEPAI 0.47 0.00    
TNF 0.50 0.03    
TRIM25 0.54 0.00    
WNT2 0.42 0.00    
Table 6.11. Genes identified has having significantly regulated expression in vCJD vs NND or 
OND and may be potential vCJD specific gene expression changes. 
 
 
The etiology and pathogenesis of a number of neurodegenerative disorders appears to 
be related to the formation and accumulation of an aberrant isoform of an 
endogenous protein. Common pathologies have been reported between 
amyloidogenic diseases such as AD, PD, Lewy body and prion diseases, but how 
aggregation of mutant protein leads to neurodegeneration remains unclear. Gene 
expression studies have been carried out to identify possible pathways involved in or 
activated by mutant prion protein aggregation. 
 
A number of gene expression studies of TSE infected brains have been published.  
There is only one comprehensive study of sCJD in humans (Xiang et al., 2005).  
There are no previous studies of gene expression in vCJD brain.  There are several 
comprehensive studies of TSE infected mouse brain at terminal disease (Xiang et al., 
2004; Riemer et al., 2004) and at earlier time points including preclinical disease 
(Xiang et al., 2004; Brown et al., 2005a; Skinner et al., 2006; Booth et al., 2004; 
Sorensen et al., 2008; Xiang et al., 2007).  In addition there are many smaller 
preliminary gene expression studies, studies on specific groups of transcripts or 
studies on transcripts in TSE infected or PrP treated isolated cell types (Gotz et al., 
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1994; Quaglio et al., 2001; Jobling et al., 2001; Kovacs et al., 2007; Brown et al., 
2004; Brown et al., 2003; Baker et al., 2002; Baker & Manuelidis, 2003; Campbell et 
al., 1994; Duguid et al., 1989; Riemer et al., 2000; Dandoy-Dron et al., 1998; 
Dandoy-Dron et al., 2000; Park et al., 2000).  Together these have highlighted the 
following as possible mechanisms for neuronal death and neurodegeneration: 
oxidative stress, copper, iron and calcium metabolism, endoplasmic reticulum (ER) 
and mitochondrial dysfunction, endosomal-lysosomal pathways, endocytosis-
ubiquitin- proteasomal pathways, apoptosis, cell adhesion, transmembrane signaling, 
synaptic function or maintenance and cholesterol biosynthesis its the number of 
genes investigated.  
 
This discussion will concentrate on those genes on the AD and ST arrays which 
showed a statistically significant change in vCJD vs both OND and NND (B1 & B3) 
but will mention other genes of potential relevance that fit with putative mechanisms 
of TSE pathogenesis.  It is worth noting that there many genes that showed no 
significant and specific changes, for example genes associated with cell cycle, the 
retinoic acid, wnt and hedgehog pathways and cytoskeletal organisation amongst 
many others. 
 
PROTEIN SYNTHESIS, MODIFICATION AND TRAFFICKING 
 
Protein synthesis occurs on ribosomes either free in the cytosol or attached to the ER.  
Transmembrane proteins and proteins to be secreted are synthesized on the ER and 
traffic through the Golgi, where glycosylation occurs before transportation to their 
final destination.  Within the ER proteins fold into their native conformations.  
Quality-control processes ensure that only correctly folded proteins are exported to 
the Golgi complex; incorrectly folded proteins are retained within the ER. If retained, 
one of two mechanisms occur; either the protein completes its folding process, or it is 
targeted for degradation. ER dysfunction places the ER under stress. In response, 
signal transduction cascades are initiated to reduce protein synthesis and increase 
protein folding capacity; this is collectively known as the unfolded protein response 
(UPR). Generally, two adaptive mechanisms have been recognized, both aimed at 
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returning the ER to its normal physiological state. 1) Up-regulation of the folding 
capacity of the ER, by transcriptional activation of genes coding for ER-resident 
molecular chaperones and foldases and an increase in total ER size. 2) down-
regulation of the biosynthetic load of the ER through shut-off of protein synthesis at 
a transcriptional (Harding et al., 2002) and a translational level and increased 
clearance of unfolded proteins from the ER through up-regulation of ER associated 
degradation (Harding et al., 1999; Harding et al., 2001). If physiologically normal 
function is not recovered after prolonged stress, apoptosis is activated. It is no 
surprise that the UPR mechanisms have long been linked to diseases such as AD, PD 
and CJD, which have in common aggregated misfolded proteins.  Published 
comprehensive gene expression studies of TSE infected brains have identified a 
number of changes relating to ER stress, protein modification and trafficking.  ER 
stress protein genes which are up-regulated include ER chaperones such as FK506 
binding protein-2, Erp-29, calnexin and heat shock proteins (Hsp).  Genes involved 
in protein trafficking include Golgi-localised short coiled-coil protein, VAMP4 and 
AP1s. 
 
Hsps:  Only two Hsps were present.  (Hsp) 90 kDa alpha, class A member 2 
(HSP90AA2) was significantly upregulated in vCJD vs NND and OND vs NND 
(AD:B1 & B2) (1.6-, 1.8-fold change respectively).  This is a molecular chaperone 
involved in the folding, activation and assembly of a range of proteins, termed Hsp90 
client proteins (Pratt & Toft, 2003).  Its up-regulation may be due to increased 
requirement of stress proteins to facilitate correct or re-folding of abnormally folded 
prion proteins.  Hsp27 was not significantly changed in its expression between vCJD 
and controls.  In sCJD brain (Xiang et al., 2005) Hsp (105 kDa/110 kDa) 1 gene 
expression was down regulated.  In mice, gene expression changes have been 
observed for Hsp1, Hsp90AB1, HSPB3 and HSPA9B (Sorensen et al., 2008; Skinner 
et al., 2006; Xiang et al., 2004). 
 
ERN/IRE1:  In this study, ER to nucleus signaling 2 (ERN2) also known as inositol-
requiring enzyme (IRE)-1β was up-regulated (AD: B1 & B2).  In the vCJD vs NND 
comparison, a 2.5-fold increase was seen, however a 1.8-fold increase was also 
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observed in the OND vs NND comparison (p<0.05) and the vCJD vs OND 
comparison flagged an insignificant change of 1.3-fold.  This change cannot 
therefore be considered to be vCJD-specific.  ERN1 was only upregulated in OND vs 
NND (AD:A2).  ERN1 (IRE1α) and ERN2 are transmembrane protein kinase 
receptors normally suppressed by the binding of the ER chaperone glucose regulated 
protein 78 (GRP78).  During times of ER dysfunction, GRP78 dissociates and binds 
to unfolded proteins triggering ERN oligomerization, autophosphorylation and 
activation.  IRE1α catalyses the spliceosome-independent processing of the 
transcription factor XBP1 pre-mRNA and causes a frame shift resulting in a more 
stable protein (XBP1proc).  This functions as a transcription factor that specifically 
activates genes coding for proteins required for ER protein folding and processing 
(Yoshida et al., 2001).  IRE1β cleaves 28S rRNA resulting in a partial attenuation of 
translation (Imagawa et al., 2008; Iwawaki et al., 2001).  The recent discovery of 
IRE1 mediated degradation of specific ER-localised mRNAs in Drosophila presents 
an additional and novel mechanism by which IRE1 may further decrease the burden 
of ER stress (Hollien & Weissman, 2006).  Up-regulation of proteins that help 
decrease the burden of proteins imported to the ER would be expected in 
amyloidogenic diseases. It has been suggested that increases in IRE1 may extend 
brain cell survival (Lin et al., 2007). 
 
The Superarrays contained a number of genes indicative of other pathways of cell 
stress.  ATF2 activated by a number of stimuli including, ionizing and UV radiation, 
genotoxic agents and glucose or leucine starvation was not statistically upregulated.  




Both (AD and ST) arrays contain genes associated with cell survival and death 
responses.  These include caspases 3 and 4 (CASP3 & CASP4), BCL2, BCL2A1, 
BCL2L1 (Bcl-XL) and BAX.  Caspases are the executioner enzymes of cell death.  
Bcl-2 family members are important regulators of apoptosis; Bcl-2 and Bcl-xL are 
anti-apoptotic, BAX is pro-apoptotic.  Bcl-2 over-expression delays the activation of 
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caspase activated cell death pathways, by forming complexes with pro-apoptotic Bcl-
2 family proteins such as Bax (Oltvai et al., 1993). The intracellular ratio of Bcl-2 or 
Bcl-xL to proteins such as Bax and Bad probably determines cell survival or death 
(Sato et al., 1994). 
 
Caspases: CASP4 showed strong elevation in vCJD (AD:A1 & A3) in two 
comparison groups, >9-fold and >7-fold up-regulation in vCJD vs OND and in vCJD 
vs NND, respectively but there was no statistically significant change in expression 
when all three comparison groups were considered.  CASP4 is generally considered 
to be an inflammatory caspase (Martinon & Tschopp, 2007)  CASP4 up-regulation 
has not been reported in other TSE gene expression studies.  Caspases are generally 
pre-formed in cells and are activated from their pro-caspase in a proteolytic cascade.  
Cell death responses generally do not involve regulation of caspase gene expression.  
CASP3 was upregulated (~2-fold) in all inter-status comparisons (AD: A1, A2 & 
A3) suggesting this was not specific to vCJD pathology. 
 
Bcl2 family genes: BAX (1.5 and 1.8-fold), BCL-2 (2.2 and 3.3-fold) and BCL-2AI 
(3.5 and 4.0-fold) were all significantly up-regulated (ST:B1, B3) in vCJD brains.  In 
murine scrapie models BCL-2 and BAX were reported to be up-regulated (Riemer et 
al., 2004; Xiang et al., 2004; Park et al., 2000) but this was not corroborated by 
another study (Brown et al., 2004) and no change was observed in human sCJD 
(Xiang et al., 2005).  Bcl-2 gene expression has also been reported to be up-regulated 
in PD (Mogi et al., 1996a).  Several studies have discussed the importance of Bcl-2 
and Bax in TSE neurodegeneration (Chiesa et al., 2005; Li et al., 2007; Nicolas et 
al., 2007). Over-expression of Bcl-2 is known to protect neuronal cells against 
apoptotic cell death (Lawrence et al., 1996). An immunohistochemical study showed 
Bcl-2 levels to be increased in cells of the cerebellum of CJD patients (Puig & 
Ferrer, 2001).  Misfolded PrP can bind to and aggregate with Bcl-2 thus promoting 
cell death (Rambold et al., 2006).  It has also been suggested that neuronal death in 
prion disease results from apoptosis via the Bax-pathway and that PrPc is an anti-
apoptotic protein that protects against this independently of Bcl-2 or Bcl-xL (Sakudo 
et al., 2003b).  In prion disease, the observed induction of Bcl-2 may be an attempt to 
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attenuate cell death caused by PrPc deficiency.  However, mice null for Bax or over-
expressing Bcl-2 challenged with scrapie show no overt difference in disease or 
survival (Steele et al., 2007; Coulpier et al., 2006).  Therefore cell death cannot be 
solely controlled by Bcl-2/Bax mediated pathways. 
 
TNF (TNFα), (ST: B1, A1, 2, 3) was down-regulated, although it is unclear whether 
this is biologically relevant since only a 0.5-fold down-regulation was detected.  
There were no significant changes in levels of TNFβ (LTA).  Scrapie and CJD 
studies have reported TNF family members to be up-regulated (Xiang et al., 2005; 
Lu et al., 2004; Brown et al., 2003; Xiang et al., 2007).  Serum-deprivation can 
induce death of Prnp-/- neurons; identity of the serum factor(s) essential for cell 
survival is unclear (Kuwahara et al., 1999). TNFα induces apoptosis in some mitotic 
cells (Polunovsky et al., 1994) but can be protective for neuronal cells (Cheng et al., 
1994), perhaps by induction of anti-apoptotic proteins such as Bcl-2 (Tamatani et al., 
1999).  TNFα is increased in glial cells following scrapie infection (Kim et al., 
1999).  Serum-deprivation of Prnp-/- neuronal cells results in a rapid decrease of Bcl-
2 and Bcl-xL eventually leading to cell death, addition of TNFα to serum deprived 





The ST arrays include interleukins (IL) -1A, -2, -4 and -8, and the interleukin 
receptors IL-4R and IL-2RA.  Transcripts for IL-1α, -2, -4 and -8 and IL-4R and -
2RA were elevated in diseased (VCJD & OND) brains.  A large number of cytokine 
profiling studies have previously been carried out.  Studies on mouse TSE models 
generally identify IL-1 as being upregulated (Baker & Manuelidis, 2003; Campbell 
et al., 1994; Brown et al., 2003; Kim et al., 1999).  In contrast, no interleukin genes 
showed gene expression changes in the only comprehensive sCJD gene profiling 
study (Xiang et al., 2005).  However, both pro-inflammatory (IL-1β and TNFα) and 
anti-inflammatory  (IL-4 and IL-10) cytokines have been detected in the CSF of 
patients with sCJD and vCJD (Sharief et al., 1999; Stoerck et al., 2005).  The best 
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known source of interleukins (hence the name) are leukocytes but these molecules 
can also be produced by other cell types.  In CJD, histopatholgical examination 
reveals an absence of inflammatory infiltrates but activated microglia play a 
prominent role in the atypical inflammatory response releasing both pro- and anti-
inflammatory cytokines (Rock et al., 2004).  Whether it is the accumulation of toxic 
prion protein conformers or the augmented release of tissue-toxic cytokines which 
leads to damage and subsequent neurodegeneration remains unclear. 
 
IL-1α was present on both the AD and ST arrays and was consistently and 
significantly up-regulated (>1.7-fold) in diseased (vCJD, OND) brains relative to 
control (NND) brains (ST:B1 & B2, AD:B1 & B2).  IL-1 is the prototypic 
inflammatory cytokine and is known to play a detrimental role in acute 
neurodegeneration after brain injury (Basu et al., 2005). Certain polymorphisms in 
the genes encoding IL-1α and IL-1β are considered to increase the risk of early 
disease onset in AD (Griffin & Mrak, 2002) and the IL-1α allele 2 has an increased 
frequency in AD (Nicoll et al., 2000). IL-1 is produced by microglial cells on 
exposure to PrP[106-126] and β-amyloid in vitro (Peyrin et al., 1999; Meda et al., 
1999) but a link between glial cells, released cytokines and neuronal death has not 
been established. Increased expression of IL-1 has been reported in numerous murine 
scrapie models (Kim et al., 1999; Campbell et al., 1994; Brown et al., 2003). IL-1β 
is the predominant response, an exception being the Chandler/SWRj scrapie model, 
with IL-1α expression being predominant. IL-1α is generally only observed at 
terminal disease (Campbell et al., 1994; Kordek et al., 1996; Brown et al., 2003). 
 
IL-2 and IL-2RA (ST:B1) were both up-regulated by 1.6-fold only in the vCJD vs 
NND ie specifically in vCJD brains.  There have been few studies on IL-2 in TSE 
infected brains.  IL-2 activates the PI 3-kinase/Akt signaling pathway which may be 
activated during prion disease (Mironov et al., 2003).  IL-2 was not detected 
(ELISA) in  a study on CSF from both sCJD and vCJD cases (Sharief et al., 1999).  
Elevated IL-2 levels in certain neuronal regions of PD patients only occur during late 
disease and are therefore more likely to be a consequence, as opposed to a cause, of 
neurodegeneration (Mogi et al., 1996b).  IL-2 is generally known as a T-cell growth 
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factor.  In the brain, IL-2 is produced in astrocytes and microglial cells and it induces 
oligodendrocyte proliferation and differentiation and enhances sympathetic neurite 
outgrowth (Benveniste & Merill, 1986).  IL-2 is significantly reduced in copper-
deficient animals and could therefore be affected by alterations in copper metabolism 
associated with loss of PrPc function in TSE diseases (Brown et al., 1997a; 
Lukasewycz & Prohaska, 1990). 
 
IL-4 and IL-4R (ST: B1 & B2) showed significantly increased levels of gene 
expression in diseased (vCJD & OND) compared to non-diseased brains (IL-4, B1 
2.0-fold and B2 1.9-fold; IL-4R, B1 3-fold and B2 2.6-fold).  IL-4 can be detected in 
CSF in sCJD (Stoerck et al., 2005).  IL-4 is also produced in other neurodegenerative 
diseases (AD, juvenile PD and PD) and during brain ischemia (Mogi et al., 1996c; 
Szczepanik et al., 2001).  This is in agreement with the finding in the present study 
that IL-4 transcripts are elevated in both vCJD and OND.  It is unlikely to be a CJD 
specific change.  IL-40/0 mice have comparative survival rates to wild-type controls 
when challenged with RML scrapie and no other overt differences (Thackray et al., 
2004).  It is therefore unlikely that IL-4 has a major role in prion disease 
pathogenesis. 
 
IL-8 (ST:B1 & B2) was significantly up-regulated in diseased cases, by 1.9- and 4.3-
fold respectively.  IL-8 is classified as a pro-inflammatory cytokine and is a 
chemokine which attracts neutrophils.  TSE neuropathology does not include 
neutrophil infiltration and the possible relevance of this upregulated gene expression 




Lipid rafts are membrane microdomains enriched in cholesterol and sphingolipids. 
They form platforms in the outer leaflet of membranes; these are connected to 
phospholipids and cholesterol in the inner leaflet.  Caveolae are the best 
characterized lipid rafts and can be differentiated from other lipid rafts by the 
presence of caveolin protein. The physiological role of lipid rafts is still debated; 
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signal transduction, molecular transportation and molecular processing have all been 
suggested as roles (Simons & Toomre, 2000; Parton & Richards, 2003; Salaun et al., 
2004). Membrane proteins which are constitutive raft residents include 
glycophosphatidylinositol-anchored proteins (GPI-anchored) such as PrPc, 
cholesterol-linked and palmitate-anchored proteins such as Hedgehog (Jeong & 
McMahon, 2002) and transmembrane proteins such as β-secretase (BACE) (Simons 
& Toomre, 2000). 
 
Lipids are transported from the gut to the liver and from the liver to other tissues as 
high, low or very low density lipoprotein particles known as HDL, LDL and VLDL, 
respectively.  These can be further subdivided and contain various lipids and 
apolipoproteins (Apo).  For example, LDL particles contain ~3,000 lipid molecules 
and one molecule of ApoB (Segrest et al., 2001).  ApoA-1 is the major component of 
HDL particles and activates cAMP signaling, via protein kinase Cα (PKC) to 
phosphorylate proteins such as ATP-binding cassette A1 (ABCA1) and other key 
proteins in signal transduction pathways for lipid transportation (Haidar et al., 2004; 
Yamauchi et al., 2003).  Many apolipoprotein family members have been linked to 
increased risk for diseases such as hypercholesterolemia and atherosclerosis.  ApoE 
is essential for the normal catabolism of triglyceride-rich lipoprotein constituents.  
APOE mRNAs are highly concentrated within the CNS (Mahley, 1988). The APOE 
gene is polymorphic with three major alleles, ApoE2, ApoE3 and ApoE4.  Genetic 
analysis has found a correlation between increased risk of AD and APOE-ε4 (Corder 
et al., 1993), whereas APOE-ε2 seems to have a protective effect (Corder et al., 
1994). APOE-ε4 has been suggested also to be a risk factor for CJD (Amouyel et al., 
1994).   
 
Apolipoproteins are taken into cells by a variety of receptors.  LDL receptor-related 
protein (LRP), also known as ApoE receptor 2 (APOER2) is an abundant surface 
receptor of neurones which recognizes at least 30 different ligands.  These include 
proteinases, molecules associated with regulating proteolytic activity, including 
members of the Serpin superfamily of serine proteinase inhibitors (eg SERPINA3), 
the pan-proteinase inhibitor alpha-2 macroglobulin (α2M, A2M) and 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 6  Microarray Gene Expression Analysis 
 242
metalloproteinases (MMP) (Herz & Strickland, 2001).  Lipoprotein lipase (LPL) 
binds both ApoE and LRP.  It is found at lower levels in the brain than in other 
tissues but interestingly has increased mRNA, protein and functional activity levels 
in the CA3 pyrimidal neurons of the hippocampus, the region most affected during 
AD (Ben-Zeev et al., 1990; Lorent et al., 1995).  In the brain, one major function of 
LPL may be transport of membrane components such as lipids, cholesterol and 
vitamin E into neurons (Rebeck et al., 1995). This is particularly important because 
neuronal membranes require a constant supply of components in order to maintain 
cellular shape and remodel and/or regenerate neuronal processes.  ApoE can bind to 
amyloid β (Aβ) aggregates, and since LPL may promote the binding of ApoE to 
LRP, it has been suggested that LPL assists in internalisation of ApoE lipoprotein 
particle components into cells (Rebeck et al., 1995; Strickland et al., 1995). It is 
thought that through these interactions, LPL protects neurons by clearing Aβ.  
Mutations in LPL may play a role in AD plaque formation since LPL directly binds 
amyloid precursor protein (APP) (Lorent et al., 1995), is up-regulated in AD and 
collects in plaques (Rebeck et al., 1995). 
 
Cholesterol is required for the processing of APP to the amyloidogenic Aβ peptide 
(De Strooper & Annaert, 2000). Cholesterol plays an essential role in raft assembly 
(Simons & Ikonen, 1997) and cholesterol depletion abolished the association of 
proteins with rafts (Cerneus et al., 1993; Keller & Simons, 1998). Taken together, it 
is therefore reasonable to posit that PrPSc conversion may be dependent on 
cholesterol; reduced levels of lipid rafts may affect intracellular transport, reducing 
intracellular protein targeting efficiency and diminishing PrP aggregation rates. 
Moreover, it has been shown that PrPc-PrPSc conversion is likely to occur on lipid 
rafts (Kaneko et al., 1997; Kazlauskaite & Pinheiro, 2005; Taylor & Hooper, 2006).  
Changes in cholesterol levels affect PrPSc formation and prion incubation time in 
culture (Bate et al., 2004; Borchelt et al., 1992; Baron et al., 2002; Kaneko et al., 
1997; Mok et al., 2006; Taraboulos et al., 1995a). 
 
A number of genes involved in cholesterol and lipid metabolism are included on the 
AD arrays eg ABCA1, APOA1, APOE, LRP8, SYP, LPL and CLU.  The 
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involvement of genes involved in cholesterol and lipid metabolism in TSE diseases 
has previously been described in scrapie gene expression studies (Brown et al., 
2005a; Riemer et al., 2004; Xiang et al., 2007). 
 
Apolipoproteins.  There was significant vCJD specific upregulation of APOE and 
APOA1 (AD:B1 & B3).  Although APOE alleles have been linked to the risk of 
developing AD and CJD, conspicuously expression is not reported as modulated in 
the sCJD profiling study (Xiang et al., 2005) or in scrapie models.  A small study of 
ApoE proteins in human CSF suggested that detection of ApoE was characteristic of 
vCJD but not of sCJD (Chloe et al., 2002) however, other studies suggest that APOE 
may not be suitable as a distinguishing biomarker (Zerr et al., 1996). High levels of 
ApoE proteins in the CSF have been observed in BSE infected cattle (Hochstrasser et 
al., 1997).  In other TSE gene expression studies, APOD is more commonly reported 
as up-regulated (Brown et al., 2004; Riemer et al., 2004). APOE and APOD are both 
expressed by astrocytes and have similar roles in cholesterol transport (Patel et al., 
1995; Pitas et al., 1987; Diedrich et al., 1991b).  In the diseased brain, astrocytes 
may assume the role of macrophages and attempt to repair or limit damage within the 
CNS (Diedrich et al., 1987).  APOE is known to be up-regulated in response to 
generalized neuronal damage (Horsburgh et al., 1997).  It could be argued therefore 
that increased APOE should also have been observed in OND cases.  Clusterin 
(CLU), also known as ApoJ, was upregulated in vCJD and OND (AD:A1 & A2; ~3-
fold).  Expression was also altered in murine scrapie (Xiang et al., 2007; Booth et al., 
2004; Skinner et al., 2006; Brown et al., 2004).  Clusterin expression is induced by 
and prevents the aggregation of PrP[106-126] (McHattie & Edington, 1999; Chiesa 
et al., 1996). 
 
LRP: LRP10 (AD:B1) was significantly up-regulated only in vCJD vs NND (1.9-
fold). LRP5 (AD:B1 & B3) was specifically and significantly down-regulated in 
vCJD.  It has been suggested that LRP on neurons mediates uptake of astrocyte-
derived cholesterol and other lipids (Simons et al., 1998).  PrPc is constitutively 
internalized in cell cultures and recycled back to the cell surface (Sunyach et al., 
2003).  LRP1 facilitates clathrin-coated endocytosis of PrPc (Taylor & Hooper, 
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2007).  Inhibition of LRP1 causes accumulation of PrPc in biosynthetic 
compartments and concomitant lowering of levels of surface PrPc, indicating that 
LRP1 facilitates trafficking of PrPc to the neuronal surface (Parkyn et al., 2008). 
Currently it is unclear whether LRP also binds to PrPsc, although infectious prion 
fibrils bind with picomolar affinity to VLDLs and any therefore be cleared from 
extracellular spaces by LDL receptors (Safar et al., 2006).  In scrapie (ME7) infected 
mouse brain LDL and VLDL receptors were increased in the hippocampus at early 
time points (Brown et al., 2005a) but decreased in an analysis of whole brain at later 
stages of disease (Xiang et al., 2007).  Interestingly, LRP polymorphisms have been 
linked to increased risk of late-onset AD (Kang et al., 1997).  It would be worthwhile 
investigating whether LRP polymorphisms are associated with CJD subtypes.  LRP 
 
LPL is reported as up-regulated in gene expression studies of 139A-scrapie, ME7-
scrapie, RML-scrapie and Fukuoka-CJD infected mouse brains (Riemer et al., 2004; 
Xiang et al., 2004; Xiang et al., 2007; Baker & Manuelidis, 2003).  In the present 
study, significant LPL up-regulation was observed in vCJD vs OND and vCJD vs 
NND (both >2.7-fold), a vCJD specific change (AD:B1 & B3). 
 
ABCA1 was vCJD specially and significantly upregulated (AD:B1 & B3; 1.8- and 
1.6-fold, respectively.  This is in agreement with published data (Xiang et al., 2005; 
Xiang et al., 2004; Riemer et al., 2004; Xiang et al., 2007).  ABCA1 is a membrane-
associated protein expressed by neurons, astrocytes and glial cells (Fukumoto et al., 
2002). Its main function is to remove cellular cholesterol and phospholipids onto 
lipid-poor apolipoprotein particles. This process plays a crucial role in the biogenesis 
of HDL particles and the efflux of cholesterol. Studies have shown increased 
ABCA1 mRNA levels in the brains of prion infected mice (Riemer et al., 2004; 
Xiang et al., 2004; Xiang et al., 2007). Although ABCA1 is only one of several 
genes involved in cholesterol homeostasis differentially expressed in prion infection 
models, altering its concentration is sufficient to modulate levels of PrP in cultured 
cells (Kumar et al., 2008). The cause of increased ABCA1 expression in prion 
disease has not been determined, but it may increase membrane cholesterol 
concentration, resulting in increased condensation of cholesterol-rich lipid raft 
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structures, thereby increasing the number or size of lipid rafts. This may augment 
PrPc bioavailablilty, stability and localization and diminish PrPSc conversion rates. 
The observation that over-expression of ABCA1 reduces amyloid deposition in 
murine models of AD can also be explained within this theory. ABCA1 mediates 
lipidation of a number of Apolipoproteins.  ApoE is one example, and under normal 
physiological conditions, binds to amyloid proteins and facilitate its clearance and 
conformation. But if cellular conditions are such that there is more lipid-poor or 
lipid-free apolipoptoteins, this may in fact promote amyloidogenesis. By mediating 
lipidation of ApoE, increased ABCA1 increases the ration of correctly lipidated 
APOE, initiating more clearance than amyloidogenesis (Wahrle et al., 2005; Wahrle 
et al., 2008). 
 
OTHER GENES OF INTEREST 
 
Protein kinase C (PKC) has many family members.  Alpha, beta-1, delta, epsilon, 
gamma, iota, theta and zeta are on the arrays.  Of these, only beta-1 showed a vCJD 
specific and significant change, it was down-regulated on both (AD and ST: B1 & 
B3) arrays.  PKC-β1 was also down regulated in sCJD brains (Xiang et al., 2005).  
No PKC changes were reported in gene expression studies of scrapie infected brains 
(Brown et al., 2005a; Riemer et al., 2004; Booth et al., 2004; Sorensen et al., 2008; 
Xiang et al., 2007; Xiang et al., 2004; Skinner et al., 2006).  PKC-β1 could be 
involved in CJD pathogenesis in a number of ways.  PKCs can phosphorylate ABC 
transporters affecting cellular lipid metabolism (Mendez et al., 1991). PKC is also a 
buffer of calcium in the brain.  Neuronal cell damage triggers release of calcium ions 
from intracellular stores such as mitochondria and ER.  Reduced levels of PKC could 
therefore predispose to apoptosis. 
 
Proteinases: 
Cathepsin D (CTSD) was up-regulated significantly and specifically in vCJD cases 
(AD:B1 & B3; 1.8- and 1.7-fold, respectively).  CTSD upregulation was only 
involved in one other comprehensive TSE brain gene profiling study (Riemer et al., 
2004).  CTSD is a ubiquitously expressed lysosomal protease (Kagedal et al., 2001).  
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During apoptosis or mild oxidative stress, CTSD is translocated to the cytosol; this is 
a very early response which happens even before cytochrome c release from the 
mitochondria (Roberg & Ollinger, 1998; Roberg et al., 1999). CTSD mediates 
programmed cell death induced by TNFα, interferon-γ and Fas (Deiss et al., 1996).  
In AD, CTSD has been shown to exhibit a beta-secretase-like role and could cleave 
APP in much the same way resulting in deposition of Aβ and formation of plaques 
(Chevallier et al., 1997). An alternative role of CTSD could be to cleave Aβ peptides 
and assist in clearance of aggregated deposits (Hamazaki, 1996).  An 
immunohistochemical study showed CTSD mRNA and protein to be associated with 
activated astrocytes in both human AD and mouse scrapie infected brains (Diedrich 
et al., 1991b).  In contrast in CJD, CTSD was found to colocalise with the disease 
associated form of the prion protein in and around neurons with enlarged lysosomes 
(Kovacs et al., 2007).  How CTSD may be involved in CJD pathogenesis is unclear.  
Enhanced proteolytic cleavage of endocytosed PrPc en route to the ER or Golgi could 
initiate PrPc-PrPSc conversion. Alternatively, it has been suggested that increased 
CTSD activates Bax leading to cell death (Bidere et al., 2003). A recent publication 
suggests CTSD polymorphisms are a risk factor for vCJD (Bishop et al., 2008).  
CTSB is also known as APP secretase, it is also involved in the proteolytic 
processing of amyloid precursor protein (APP). Up-regulation of CTSB (AD:B2) 
was only observed in OND vs NND and it is not therefore a vCJD associated change, 
although it was found to be upregulated in one study of mouse scrapie(Sorensen et 
al., 2008).  CTSC and CTSG were significantly and specifically up-regulated in 
vCJD (AD:B1 & B3) with > 2-fold change in each case.  CTSC upregulation was 
also observed in the comprehensive gene expression studies of sCJD (Xiang et al., 
2005) and one study of scrapie infected mouse brain (Xiang et al., 2004). 
 
The AD array includes probes for a number of genes involved in the processing of 
APP.  APP can be cleaved at three different sites by α- β- and γ-secretases, with 
cleavage by –β and –γ secretases resulting in the formation of Aβ (Wilquet & De 
Strooper, 2004).  β- and γ-secretases are found in lipid rafts.  The α-secretases on the 
array include ADAMs -9, -10 and -17.  These showed no significant change in vCJD.  
The β−secretases,  β-site APP cleaving enzyme (BACE) 1 and 2 are both on the AD 
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array.  Only BACE2 was significantly and specifically upregulated in vCJD (AD:B1 
& B3; ~2-fold).  Prpc in lipid rafts has been reported to bind to β-secretases and its 
conversion to PrPSc has been postulated to result in increased Aβ formation (Parkin 
et al., 2007).  γ-secretase is a complex of presenilins 1 and 2 (PSEN1 and PSEN2), 
nicastrin (NCSTN), Aph-1 (APH1A) and presenilin enhancer (PEN-2).  Of these, 
PSEN1 and APH1A were significantly and specifically regulated (down and up, 
respectively) in vCJD and NCSTN was significantly down regulated (AD:B3) in 
vCJD vs OND.  β-amyloid precursor-like protein-1 (APLP1) is an APP family 
member and is also processed by γ-secretase (Wasco et al., 1993; Scheinfeld et al., 
2002).  APLP1 was significantly and specifically upregulated in vCJD (AD:B1& 
B3). 
 
Proteinase inhibitors:  Alpha-2 macroglobulin (α2M), a general proteinase 
inhibitor, was upregulated in vCJD (AD:A1 & A3; 3.7- and 3.0-fold, respectively).  
This was also observed in two studies of mouse scrapie (Xiang et al., 2004; Riemer 
et al., 2004).  Recently, α2M has been suggested to act as an extracellular chaperone 
binding to unfolded / incorrect folded extracellular proteins (French et al., 2008).  
Activated α2M binds to Aβ and facilitates its degradation by binding to LRP (LDL-
receptor) (Narita et al., 1997).  Exogenous addition of α2M to neuronal cultures from 
APP transgenic mice reduces Aβ as a result of clearance by LRP (Qiu et al., 1999).  
Genetic polymorphisms of α2M are associated with amyloid diseases including AD 
(Tanskanen et al., 2008).  The serine proteinase inhibitor (SERPIN), Kunitz type 2 
(SPINT2) was significantly and specifically down-regulated in vCJD (AD: B1 & B3; 
-0.6- and -0.8-fold, respectively).  In other studies, serine peptidase inhibitors are 
reported to be up-regulated (Riemer et al., 2004; Xiang et al., 2004). 
 
Neuronal proteins:  The arrays contain a number of synapse associated proteins; 
five of these were significantly and specifically changed in vCJD.  Choline 
acetyltransferase (CHAT) was upregulated (AD:B1 & B3).  This enzyme 
synthesises acetylcholine.  Butyrylcholinesterase (BCHE) which degrades esters of 
choline, including acetylcholine, was up-regulated (AD:B1 & B3; 1.9- and 2.1-fold, 
respectively).  BCHE is expressed in neurons and glial cells in the brain and may 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
Chapter 6  Microarray Gene Expression Analysis 
 248
participate in neurogenesis and neurite growth (Darvesh & Hopkins, 2003).  BCHE 
expression is significantly increased in AD brains (Perry et al., 1978; Saez-Valero et 
al., 2003) where it has been associated with neurofibrillar tangles and amyloid 
plaques (Gomez-Ramos et al., 1994; Carson et al., 1991).  Synuclein alpha (SNCA) 
(AD:B1 & B3; -0.6-, -0.5-fold, respectively) was down regulated.  SNCA is also 
down-regulated in sCJD (Xiang et al., 2005).  Neuropeptide Y (NPY) (AD:B1 & 
B3; -0.1-, -0.1-fold, respectively) was down-regulated.  Somatostatin (SST) (AD:B1 
& B3) was down regulated.  That both increases and decreases in the expression of 
genes coding for synapse and neurotransmitter associated proteins were observed is 
not surprising given neuronal loss in CJD.  At the protein level, decreased levels of 
synaptic vesicle-associated proteins and neurotransmitters have been observed in 
CJD and increased levels in AD (Ferrer et al., 1999). 
 
Insulin-like growth factor binding protein (IGFBP3/4) (ST:B1 & B3 / ST:B1, B2 
& B3; IGFBP3 = 2.3-,2.1-fold / IGFBP4 = 3.4-,1.9-,1.8-fold change, respectively) is 
similar to insulin-like growth factor-1 receptor which has been linked to degeneration 
of scrapie-infected neurons (Ostlund et al., 2001). 
 
Urokinase plasminogen activator (PLAU) (AD:B1 & B2; 1.6-, 2.2-fold change, 
respectively) has been recently found to bind to the pathological isoform of PrP 
(Fischer et al., 2000).  Plasminogen is a pro-protease that is converted to its active 
form, plasmin by urokinase-type plasminogen activator systems. Plasmin has been 
suggested to have a neuroprotective role in AD because it is capable of degrading Aβ 
fibrils (Tucker et al., 2000). Urokinase-type plasminogen activator receptor (uPAR) 
bound PLAU elicits intracellular signaling. Up-regulation of PLAU suggests 
activation of downstream signaling cascades involved in neuronal degeneration. 
 
Three other genes, guanine nucleotide binding protein (G protein)-β4 (GNB4) and 
guanine nucleotide binding protein (G protein)-γ5 (GNG5) and ubiquinol-
cytochrome c reductase core protein-2 (UQCRC2) were also significantly and 
specifically changed in their expression in vCJD brains but are not discussed further 
as there is little data available about these genes. 
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The gene expression changes observed in this study are consistent with much of the 
recent literature on the neuropathogenesis of TSEs in that they highlight changes in 
genes associated with the folding, processing and degradation of proteins and in 
particular PrP and the biochemical and membrane events associated with the 
formation and turnover of lipid rafts.  As is the case for many differentially expressed 
genes, the significance of modulation in prion disease is not clear. Molecular 
heterogeneity in which defects in many separate and complicated pathways may 
account for overlapping diseases has been a challenge in understanding the 
pathogenic mechanisms in neurodegenerative disorders. Nonetheless, it is 
encouraging that even on small sample sizes using focused microarray methods, it 
has been possible to identify a list of 48 up-regulated and 33 down-regulated 
differentially expressed genes, some of which have previously been published as 
having links with prion disease or other amyloidogenic diseases. Promisingly, when 
compared to a recent large-scale Affymetrix genechip study of unmatched 
(age/gender) sCJD patients, 14 genes were implicated in both studies. 
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7 CONCLUDING REMARKS 
 
A risk assessment was carried out to develop evidence-based guidelines for an RNA 
extraction protocol from TSE infected human brain material. Techniques for 
isolating RNA and retaining RNA quality whilst removing and/or inactivating the 
TSE agent have not been previously described and are detailed in this project. The 
use of ~4 M GTC and ~2 M phenol in acidic solution (~pH 5.0) was considered 
suitable as previous inactivation studies using similar concentrations have observed 
reduced CJD infectivity titres of ~99.7% (Manuelidis, 1997). For safety and to 
ensure removal of residual PrP, a further phenol-chloroform extraction was carried 
out. Assessment of the RNA preparations using western immunoblotting for PrPres 
detection revealed that the RNA isolation method described in this project reduced 
the level of PrPres by at least 104 fold, and that there was no detectable PrPres in > 
0.5µg vCJD brain equivalent. However, to conclusively prove complete inactivation, 
the protocol must be verified by bioassay for infectivity. Due to time and financial 
constraints, this was not carried out but based on the results of the risk assessment; it 
was considered that the RNA extracts did not contain detectable amounts of 
infectious PrPSc, although samples were still treated as low risk. 
 
Assessment of relevant inclusion and exclusion criteria for case selection was 
undertaken. The decision was made to test vCJD vs control and also vCJD vs OND 
comparisons to verify vCJD-specific modulated genes and differentiate them from 
generalized neurological alterations. Although a number of relevant criteria were 
suggested to be matched for, over-zealous matching would have limited the sample 
strength of the study. Therefore it was necessary to determine which criteria are most 
have the greatest affect on RNA integrity and whether non-specific alterations 
correlate with any of the pre- or post-mortem factors investigated and if so, is it 
possible to match or measure them and account for them by multivariate analysis.  
 
RNA preparations from 78 human cases were tested for quality and quantity as 
measured by the Agilent Bioanalyzer (giving a 28S:18S rRNA ratio, RIN and 
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concentration) and Nanodrop spectrophotometer (giving an A260:280, A260:230 ratio and 
concentration). RNA metrics were evaluated for their suitability for measuring brain 
RNA preparations. As observed in previously published studies, the 28S:18S rRNA 
ratio was not an accurate measure of RNA quality. Quantification was more accurate 
and reproducible using the Nanodrop spectrophotometer. RIN values and A260:280, 
A260:230 gave a good indication of the RNA preparations integrity and purity. Overall, 
human RNA preparations had lower quality and yield when compared to mouse 
brain preparations, in agreement with previous findings, an effect which has been 
suggested to be an intrinsic difference between human and mouse brain tissue. The 
intra- and inter-case variability of RNA preparations was tested. Although there was 
some intra-case variation (~10%) of quality and quantity, this effect was greater 
inter-case, as expected. Variation of RNA quality and quantity occurs mainly across 
patients rather than within a single case. This finding is promising if further work 
was to be carried out using the RNA preparations. If RNA sample variablility was so 
great as to preclude valid transcriptome comparisons, subsequent gene expression 
analysis would be confounded. Additionally, it suggests that differences between 
RNA samples were not introduced due to processing and the samples retained the 
representative in vivo transcriptome situation prior to processing. 
 
Investigation into whether any pre- or post-mortem factors correlated with the quality 
and/or quantity of isolated RNA from human brain material was also carried out. 
RIN values of tissues stored in RNAlater was slightly higher when compared to 
liquid nitrogen or -80ºC storage methods, although this effect was only observed in 
human and not mouse tissues. No effect on RNA quality or quantity was observed to 
correlate with FI or storage temperature. Age at death and PMI did not correlate with 
either RIN or A260:280 irrespective of gender, however there was a significant negative 
correlation between RIN and RNA yields from female cases. Tissue pH and RIN 
values showed a significant positive correlation in the male data set and a large but 
insignificant correlation within the female dataset. Tissue pH did not correlate with 
yield or A260:280 in the male data set, but showed a significant negative correlation 
with yield and a significant positive correlation with A260:280 within the female data 
set. These results were calculated from smaller sample sizes and the p-values are 
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approaching significance level and therefore cannot be conclusive. FTC did not 
correlate with yield or A260:280, but there was a significant negative correlation with 
RIN. Repeated freeze-thawing of tissues is known to severely affect cellular 
molecule integrity. The agonal state of a patient was assessed by reviewing clinical 
and histopathological notes and scoring the presence and degree of a number of 
factors. These factors were selected based on a similar system described by Tomita et 
al and from a literature search for agonal factors have the greatest impact on brain 
tissue (Tomita et al., 2004). IAS scores were calculated, with and without disease 
duration, as preliminary results indicated that disease duration may have a prominent 
effect on RNA quality and quantity. On further assessment, this effect was not 
significant. The data testify to the high postmortem stability of RNA in general, 
although the overall low quality of extracted RNA may have occurred during the 
disease period (pre-mortem) and not as a post-mortem artifact. Overall, age at death, 
PMI, tissue pH and FI including storage method or storage time does not affect RNA 
quality, although there may be a potential connection between age at death and RNA 
quantity.  The amount of variation of RNA quality (RIN) is intrinsic to the particular 
sample and does not correlate with age at death, PMI or tissue pH. This finding is 
consistent with the finding that variability between RNA samples is greater inter-case 
than intra-case. Having established that RIN variation is intrinsic, it was decided that 
sample of high RIN quality would be selected for gene expression analysis. 
 
Ultimately, the aim was to carry out transcriptome analysis and identify potential 
vCJD-specifically modulated genes. Focused microarrays containing Alzheimer 
disease related and signal transduction pathway genes were used. Variability due to 
technical and/or intrinsic case variation was ~13% each and suggests it was 
reasonable to assume that the remaining gene changes were potential disease 
associated changes. With the exception of one anomalous result, the overall SAM 
analysis identified FDR ~9%. While this is slightly higher than the generally 
accepted 5% FDR threshold, it was still within acceptable limits. 
 
Taking all this into account, 46 genes were identified as potential vCJD-specific 
changes. 22 have not been previously described in the context of prion diseases. A 
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comparison of our results with the findings of other groups using similar mouse 
models and a study of sCJD patients identified 25 genes previously described in 
experimental models and 12 genes reported as differentially expressed in a sCJD 
human study (Puig & Ferrer, 2001; Booth et al., 2004; Campbell et al., 1994; 
Skinner et al., 2006; Riemer et al., 2004; Sorensen et al., 2008; Brown et al., 2005a; 
Brown et al., 2005b; Xiang et al., 2004; Xiang et al., 2005). 
 
In conclusion, although the use of focused arrays with limited and targeted gene 
features precludes drawing definitive conclusion regarding gene expression in vCJD 
human brains, it has been shown that even using robust stastistical comparisons, gene 
expression measurements can be carried out on relatively degraded RNA samples 
and preliminary results suggest that differentially expressed gene expression profiles 
would be identified using microarray techniques. Careful selection of cases is 
paramount to the experimental design of gene expression studies, especially when 
using human tissues. However, this study has provided evidence that factors such as 
PMI, FI and agonal state (as determined by IAS) may not have as large an impact as 
previously suspected. Based on the findings from this study, improved method of 
tissue storage, the introduction of RIN assessment of RNA and the introduction of 
agonal state assessments (IAS) have been proposed to the NCJDSU and MRC brain 
banks to increase the importance and value of storaging tissues in tissue banks for 
molecular research. 
 
Overall, this project has shown; that RNA can be safely extracted from CJD brain 
tissues, that RNA quality and quantity does not correlate with tissue pH, PMI or age 
at death, it is of sufficient quality for profiling studies and careful comparison of 
variant CJD and controls can accurately identify disease-specific changes. This 
provides proof of principle for further, more extensive studies providing a more 
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8 FUTURE WORK 
 
8.1 OBJECTIVES 
• Design primers for selected genes of interested. 
• Optimise primers for real-time polymerase chain reaction (PCR).  
 
8.2 INTRODUCTION  
 
Confirming the veracity of microarray data, while currently not a pre-requiste for 
acceptance, is quickly becoming expected for publication (Editor in chief and 
associate editors, 2001; Firestein & Pisetsky, 2002). This has been met with a mixed 
response from the scientific community, one argument being that rigourous 
normalization and large sample size are sufficient to preclude corroborative studies 
(Rockett & Hellmann, 2004). Nonetheless, the inclusion of corroborative data is 
useful for validating microarray data. For this project, proof of concept for the use of 
quantitative real-time polymerase chain reaction (qRT-PCR) was carried out to 
evaluate the technique’s appropriateness for validating the microarray data. Time did 
not permit analysis of samples to verify the array results. 
 
Independent verification of microarray data is generally done by one of four 
methods; northern blot, in situ hybridization, RNase protection assays (RPA) or 
polymerase chain reaction (PCR). Northern blot and RNase protection assays require 
a minimum of 5 μg of total RNA and although conventional RT-PCR requires much 
less total RNA, it is an end-point process which is insufficiently precise for 
quantitative determination. Quantification by real-time RT-PCR (qRT-PCR) has 
become the gold standard of nucleic acid quantification. 
 
Polymerase chain reaction is a technique that allows exponential amplification of 
short, specific DNA sequences (usually 100 to 600 bases) within a longer double 
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stranded DNA molecule. Since its invention in 1985 by Kary B. Mullis, the 
technique has been repeatedly refined to be capable of increasingly more accurate 
and sensitive results (Mullis, 1990; Mullis et al., 1986). RT-PCR is particularly 
suited to studying the transcriptome, as it is sensitive enough to detect even low-level 
mRNA levels in different samples. The addition of fluorescene-based kinetics to 
PCR techniques and real-time quantitation monitoring has meant that qRT-PCR has 
become the method of choice for quantifying mRNA, due to its simple handling, 
high reproducibility, large dynamic range, and low total RNA requirement (~1000-
fold less than conventional methods) (Bustin, 2000). Figure 8.1 represents the 
processes involved in generating qRT-PCR results. 
 
 
Figure 8.1.  Processes required to generate real-time RT-PCR results. Black arrows indicate 
points of the sample preparation protocol which are suitable for normalization. The three most 
commonly used strategies for normalization are stated in the boxes on the right and were also used for 
this project. Modified from (Huggett et al., 2005). 
 
 
PCR uses a pair of primers, each about 20 nucleotides in length, which are 
complementary to a defined sequence on each of the two strands of the DNA. These 
primers are extended by a heat-stable DNA polymerase (i.e. Taq polymerase) to 
enzymatically assemble a copy of the designated DNA sequence. DNA 
oligonucleotides are used to initiate the DNA synthesis. Thermal cycling, i.e. 
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alternately heating and cooling the sample to a defined series of temperature and time 
steps, physically separates the strands of the DNA double helix (higher temp), to uses 
as a template during DNA synthesis (lower temp). Amplification happens 
logarithmically. Real-time modification includes the addition of either florescent 
dyes that intercalate with double-stranded DNA or modified DNA oligonucleotide 
probes that fluoresce when hybridized with a complementary DNA. Quantification 
and amplification are monitored simultaneously. In order to measure messenger 
RNA (mRNA), the method was extended by introducing the use of reverse 
transcriptase to convert mRNA into complementary DNA (cDNA) which was then 
amplified by PCR.  
 
When the sequence of the gene is known, qRT-PCR is well suited for validation of 
differential expression especially when dealing with low-abundance RNA tissues or 
when tissue samples are limited and valuable. A quantitative measure of gene 
expression between different samples requires some form of normalization to a 
reference that provides a common basis for the comparison. There are a number of 
alternative strategies; standardizing tissue sample sizes, normalize to an artificial 
molecule i.e. spiking sample with artificial RNA molecule of known concentration, 
ensure RT reactions contain equivalent amounts of total RNA, use of internal 
reference gene/s and use of genomic DNA. There are inherent problems with each of 
these strategies and in general qRT-PCR data is normalized to an internal control 
gene. Appropriate genes are typically reference genes whose expression usually does 
not change under the conditions of the experiment. Traditionally used transcripts 
included GAPDH, actins, tubulins, cyclophilins and 28S and 18S RNA. These 
transcripts are historical carryovers and were used for many years as references in 
northern blots, Rnase protection assays and conventional RT-PCR. While the 
expression of these historical reference genes in certain cell types or under certain 
conditions may remain stable, this does not hold true for all cell types or all 
conditions and can vary considerably (Suzuki et al., 2000; Bustin, 2000; Thellin et 
al., 1999). qRT-PCR is far more sensitive and as quantitative data becomes an 
increasingly fundamental part of molecular biology, a re-evaluation of these classic 
reference genes is required. It was important for this study to choose specifically 
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relevant reference genes and validate the stability of expression. In addition, a 
number of recent papers have indicated the inappropriateness of any single reference 
gene for normalization and highlighted the need for validating the status of reference 
genes for each type of specimen analyzed (Vandesompele et al., 2002; Huggett et al., 
2005). 
 
While qRT-PCR has become more mainstream, there has been increased focus 
towards pathway analysis and pathway identification. Significance analysis at the 
single gene level can be affected by limited sample number and experimental noise. 
To overcome this, analysis may be undertaken at a higher level where genes are 
categorised into functional groups.Bioinfomatic applications such as, Gene Ontology 
(GO), Database for Annotation, Visualization and Integrated Discovery (DAVID) 
and Pathway Studio have streamlined researcher’s ability to annotate large gene 
expression databases and help to understand how lists of individually altered genes 
are coordinated and interdependently related. Pathway identification based on 
functional classification of gene sets has been shown to be more robust and 
reproducible than using single gene results (Manoli et al., 2006). Key changes in 
gene expression in the vCJD diseased vs control brain could be ranked into 
categories; biological processes, molecular function and cellular components, to 
identify whether there is a relationship between differentially expressed sets of genes 
and to put them into a biologically meaningful context. 
 
 
8.3 CHOICE OF HOUSE-KEEPING GENES 
 
Different control genes are suitable for different cell types under different conditions. 
Attention should be paid to the choice of an appropriate control gene or genes used 
for qRT-PCR for the conditions and tissue/cell type under investigation (Spanakis, 
1993). In recent years, a number of large scale studies into appropriate reference 
genes in a range of tissue types have been published. Barber tested the expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in 72 human pathologically 
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normal tissue types. Significantly different expression levels were observed between 
tissue types and between donors for the same tissue, although there was no specific 
effect of either age or gender on expression levels. GAPDH was selected as a 
candidate house-keeping gene for this study as its expression is highly stable in 
neurological tissues (Barber et al., 2005). More recently, Coulson tested a panel of 
reference genes specifically for use in human post-mortem neuropathological studies 
and for AD vs control cerebellum, GAPDH, β-2-microglobulin (β2M) and ubiquitin 
C (UBC) were ranked top for stability (Coulson et al., 2008). β-actin (ACTB) has 
generally been used as a reference gene for many tissue types, although it has been 
shown that the human genome contains processed β-actin pseudogenes, which can 
result in the amplification of fragments from genomic DNA displaying the same size 
as those generated from the cDNA template (Leavitt et al., 1984). Rigorous testing of 
10 neuronal areas of AD and control human brains with PMI’s between 6 -96 hrs, 
showed invariant expression of the cyclophilin gene (Yasojima et al., 2001). For this 
study, a panel of 9 reference genes were selected from the literature and each was 
evaluated for its suitability as an internal reference for post-mortem human autopsy 
brain material (GAPDH, ACTB, B2M, TrkB, PPIA, UBC, HPRT, 18S rRNA and 
SYP). Details of these genes are given in Table 8.1. 
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& Reddy, 2004) 
 
Table 8.1 Reference gene selected from literature which may be suitable for studying gene 
expression changes in CJD vs control human brains.  
 
 
8.4 RESULTS  
 
Primer sequences for the 9 candidate reference genes (Table 8.1) were designed 
using Primer3 and verified using NetPrimer web-based software applications. The 
primers were then tested on RNA pooled from 12 human RNA preparations with 
RIN >6.0, A260:280 nm absorbance ≥ 2.0 and A260:230 nm absorbance ≥ 1.7.  
 
Only six transcipts were amplified sufficiently to warrant further assessment. Of 
these, five were successfully cloned in the pGEM®-T Easy vector. For quantification 
purposes a reference standard is required. PCR amplicons from these 5 genes (refer 
to Chapter 2, section 2.5.2) were each inserted into pGEM-T Easy vectors 
(Invitrogen, UK) and ligated using T4 ligase (Figure 8.2). Ligation reactions were 
then transformed into high-efficiency competent DH5α cells for transformations. 
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Transformants were screened for inserts by blue/white colony color on IPTG/X-Gal 
indicator plates. Recombinant plasmid DNA was purified using the Qiaprep Spin 
Miniprep DNA purification systems and analysed on 1.5% agarose gels. Purified 
plasmid DNA was restriction digested using ECOR1, and digested and undigested 
plasmid DNA was analysed on an agarose gel to identify fragment sizes. If the 




Figure 8.2. pGEM-T Easy vector map. Amplicon were inserted within the multiple cloning region 
(red arrow). Recombinant clones with the insert within the coding region of β-galactosidase can be 
identified by white colonies obtained following transformation of competent cells. Restriction 
enzyme, ECOR1 was used to release the insert in single-enzyme digestion reactions (see Figure 8.3). 
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Figure 8.3. Electrophoretic analysis of the amplicons of the 5 selected reference genes. A. PCR-
amplified products were analysed on 1.5% agarose gels and visualized with ethidium bromide staining 
and UV illumination. Specific band of appropriate molecular weight are indicated by the black 
triangles. Product sizes are; 18SrRNA. 468bp, GAPDH. 241 bp. ACTB. 241bp. UBC. 245 bp. PPIA. 
179 bp. L. DNA marker ladder (kb). B. Restriction digest reactions of recombinant plasmids using 
EcoR 1. Specific bands of the correct molecular weight for PCR product were released from each of 
the pGEM-T Easy vectors and used for sequencing (red arrows). The extra band seen at the top of 
each lane corresponds to un-cut plasmid.  
 
 
These preliminary results have identified a panel of reference genes and primers 
(Table 8.2) and generated a series of control plasmids to allow their quantification by 
qRT-PCR. Unfortunately, due to the time constraints of this project, it was not 
possible to continue this work to validate the use of these reference genes for the 
comparative analysis of human brain RNA preparations generated in this project. It is 
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ACTB NM_001101.2 ATTCCTATGTGGGCGACGAG 
GCTGGGGTGTTGAAGGTCTC 
241 
Cyclophilin A PPIA NM_021130.3 GGCAAGACCAGCAAGAAGA 
GGGAGGGAACAAGGAAAAC 
179 
Ubiquitin C UBC NM_021009.4 TGGGTCGCAGTTCTTGTTTG 
GGGTGGACTCTTTCTGGATGTT 
245 
18s rRNA 18RNA X03205 TCAAGAACGAAAGTCGGAGG 
GGACATCTAAGGGCATCACA 
468 
Table 8.2. Primer sequences. 
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9 APPENDIX  
9.1 COMMON REAGENT RECIPES 
Water purified with Barnstead NANOpure system (Basingstoke, UK) was used to 
make up all solutions. 
 
EXTRACTION BUFFER; 
0.5% sodium deoxycholate (DOC) 
0.5% NP-40 
TBS pH 7.4 
All reagents obtained from Sigma-Aldrich, UK. 
 
2x SAMPLE BUFFER; 
Made up with deionised water or extraction buffer from NuPAGE LDS sample 
Buffer (4x) (Invitrogen, UK) 
Final concentration for use at 2x 
212 mM Tris HCL 
282 mM Tris base 
4% Lithium salt of dodecyl sulphate (LDS) 
20% Glycerol 
1.02 nM EDTA 
0.44 mM SERVA Blue G250 




NuPAGE MES SDS RUNNING BUFFER 20x STOCK (Invitrogen, UK) 
Final concentration of constituents: 
50 mM MES 
50 mM Tris Base 
0.1% SDS 
1 mM EDTA 
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NuPAGE TRANSFER BUFFER 20x (Invitrogen, UK) 
25 mM Bicine 
25 mM Bis-Tris (free base) 
1 mM EDTA 
pH 7.2 
 
For use; 1x NuPAGE Transfer buffer (Invitrogen, UK) with 10% methanol (VWR 
International, UK) was prepared. 
 




175.3g sodium chloride 
88.2g sodium citrate dehydrate 
Dilute to 1L with ddH2O 
pH 7.0 
All reagents obtained from Sigma-Aldrich, UK. 
 
20% SDS 
200g sodium dodecyl sulfate 
Dilute to 1L with ddH2O 
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9.2 NATIONAL CREUTZFELDT-JAKOB DISEASE 
SURVEILLANCE UNIT DIAGNOSTIC CRITERIA 
(EDINBURGH) 
 
1. SPORADIC CJD 
1.1 DEFINITE: neuropahologically/ 
immunocytochemically confirmed 
1.2.1 I + 2 of II + 
III 
1.2 PROBABLE:  
1.2.2.Possible + 
positive 14-3-3 
1.3 POSSIBLE: I + 2 of II + duration < 2 
years 
 
I        Rapidly progressive dementia. 
 
II      A Myoclonus 
        B Visual or cerebellar problems 
        C Pyramidal or extrapyramidal 
features 
        D Akinetic mutism 
 
 
III      Typical EEG 
 
 
2. ACCIDENTALLY TRANSMITTED 
TSE 
2.1 DEFINITE: definite CJD with a 




syndrome in human 
pituitary hormone 
recipients 
2.2 PROBABLE:  
2.2.2 probable CJD 
with recognized 
risk factors 
RELEVANT EXPOSURE RISKS FOR 
THE CLASSIFICATION AS 
IATROGENIC CJD 
The relevance of any exposure to disease 
causation must take into account the 
timing of the exposure in relation to 
disease onset. 
Treatment with human pituitary growth 
hormone, human pituitary gonadotrophin 
or human dura mater graft. 
Corneal graft in which the corneal donor 
has been classified as definite or 
probable human prion disease. 
Exposure to neurosurgical instruments 
previously used in a case of definite or 
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probable human prion disease.  
This list is provisional as previously 
unrecognized mechanisms of human 
prion disease may occur. 
 
 
3. GENETIC TSE 
3.1.1 definite TSE 
+ definite or 
probable TSE in 1st 
degree relative 
3.1 DEFINITE:  
3.1.2 definite TSE 




disorder + definite 
or probable TSE in 
1st degree relative 






PRNP MUTATIONS ASSOCIATED 
WITH GSS NEUROPATHOLOGICAL 
PHENOTYPE: 
P102L, P105L, A117V, G131V, F198S, 
D202N, Q212P, Q217R, M232T, 192 
bpi 
PRNP MUTATIONS ASSOCIATED 
WITH CJD NEUROPATHOLOGICAL 
PHENOTYPE 
D178N-129V, V180I, V180I+M232R, 
T183A, T188A, E196K, E200K, V203I, 
R208H, V210I, E211Q, M232R, 96 bpi, 
120 bpi, 144 bpi, 168 bpi, 48 bpdel 
PRNP MUTATIONS ASSOCIATED 
WITH FFI NEUROPATHOLOGICAL 
PHENOTYPE 
D178N-129M 
PRNP MUTATIONS ASSOCIATED 
WITH VASCULAR PRP AMYLOID 
Y145s 
PRNP MUTATIONS ASSOCIATED 
WITH PROVEN BUT UNCLASSIFIED 
PRION DISEASE 
H187R, 216 bpi 
MUTATIONS ASSOCIATED WITH 
NEURO-PSYCHIATRIC DISORDER 
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BUT NOT PROVEN PRION DISEASE 
I138M, G142S, Q160S, T188K, M232R, 
24 bpi, 48 bpi, 48 bpi + nucleotide 




4.1 DEFINITE: 1A and 
neuropathological confirmation of vCJD 
4.2.1 I and 4/5 of 
II and IIIA and 
IIIB 
4.2 PROBABLE:  
4.2.2 I and IV Ad 
4.3 POSSIBLE: I and 4/5 of II and IIIA 
I   A Progressive neuropsychiatries 
disorder 
B Duration of illness > 6 months 
C Routine investigations do not suggest 
an alternative diagnosis 
D No history of potential iatrogenic 
exposure 
E No evidence of a familial form of TSE 
 
II   A Early psychiatric symptomsa 
B Persistent painful sensory symptomsb  
C Ataxia 
D Myoclonus or chorea or dystonia 
E Demenitia 
 
III   A EEG does not show the typical 
appearance of sporadic CJDc ( or no EEG 
performed) 




IV   A Positive tonsil biopsyd 
 
a Depression, anxiety, apathy, 
withdrawal, delusions. 
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b This includes both frank pain and/or 
dysaesthesia. 
c Generalised triphasic periodic 
complexes at approximately one per 
second. 
d Tonsil biopsy is NOT recommended 
routinely, nor in cases with EEG 
appearances typical of sCJD, but may be 
useful in suspect cases in which the 
clinical features are compatible with 
vCJD and MRI does not show bilateral 
pulvinar high signal. 
e Spongiform change and extensive PrP 
deposition with florid plaques, 
throughout the cerebrum and cerebellum. 




9.3 CREUTZFELDT-JAKOB DISEASE SURVEILLANCE UNIT, 
PROTOCOL FOR FULL AUTOPSY (EDINBURGH) 
 
SPECIMENS TO BE RETAINED FROM FULL AUTOPSY (EDINBURGH) 
 
SNAP FREEZING 
29 bijou bottles with a small piece of white card in each bottle.  “Risk of Infection” 
sign attached and labelled with patient’s name, RU number, date and following 
specimens: 
 
Adrenal   Kidney  Salivary Gland 
Appendix   Liver   Spleen 
Bone Marrow   Lung   Spinal cord 
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Cerebellum   Muscle  Temporal 
Cervical lymph node  Occipital  Tendon 
Distal Ileum   Ovary/Testes  Thymus 
Dorsal root ganglion  Pancreas  Thyroid 
Frontal    Parietal (NO)  Tonsil 
Heart    Peripheral nerve Trigeminal Ganglia 
Heart Valve   Pituitary 
 
Put bottles in a “Risk of Infection” specimen bag marked on the outside with 
patient’s name, RU number and “SNAP FREEZE”  
 
PLP FIXED 
9 small specimen bottles (PLP to be added just before use).  “Risk of Infection” sign, 
patient’s name,  RU number, date, PLP and following specimens: 
 
Frontal Cerebellum Peripheral nerve 
Temporal Spinal cord Muscle 
Occipital Spleen Tonsil 
Keep together in “Risk of Infection” bag marked with RU number, patient’s name, 
and PLP 
 
3 Universals - one for CSF, one for spleen and one for blood labelled with “Risk of 
Infection” sign, patient’s name, RU number and specimens.  Strip of parafilm for 
sealing. 
 
1 specimen jar for frozen cerebellar hemisphere - labelled as above and 
2 polythene bags (1 labelled) for holding frozen half brain (right hemisphere) 
 
2 specimen bottles (250ml) for microscopic analysis. 
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9.4 POST MORTEM REQUEST FOR ADDITIONAL AUTOPSY 
SPECIMENS TO BE TAKEN FROM SUSPECTED CASES 
OF CJD FOR RNA PROFILING STUDY 
 
AIM 
To assess the variation in gene expression profiles within and between brain regions.  
This will allow us to predict the level of variation that may occur between brain 
samples from patients with different forms of CJD and with other neurodegenerative 
diseases.  For this study, it is important that the neuroanatomical sites of sampling 
are recorded as accurately as is possible and that these sites are reproducibly sampled 
between patients. We are interested in identifying whether there are any disease-
specific changes in the expression of selected genes and to relate these to 
neuropathological features and PrPsc isoform, which would require the samples to be 
taken adjacent to the samples taken for histopathological analysis. We also wish to 
test the effects on RNA yield of storing the tissue freshly frozen or frozen in 
RNALater solution.  We understand that the timing, number and final diagnosis of 
suspected CJD cases is not predictable but if we were able to obtain specimens from 
three cases (one of which was a case of CJD) over the next six months, this would be 
sufficient for this part of our study. 
 
SAMPLES 
Brain region Storage Replicates Code 
Sample #1 F R 1 
Sample #2 F R 2 
Freshly 
frozen 
Sample #3 F R 3 
Sample #1 RNA 1 






Sample #3 RNA 3 
Sample #1 F R 1 
Sample #2 F R 2 
Freshly 
frozen 




cortex RNALater Sample #1 RNA 1 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
  Appendix 
312 
 
Sample #2 RNA 2 
Sample #3 RNA 3 
 
If agreed to then we will provide additional containers for the autopsy set as follows: 
 
12 universals:- 6 containing clear, colourless liquid (RNAlater) and 6 empty. All 
labelled with “Risk of Infection” sign, patient’s RU number and specimen code 
(above), and containing in 2 individual plastic bags. If possible, sample sizes would 





9.5  EMERGENCY RESPONSE INFORMATION 
 
These specimens are packed in compliance with IATA packing instructions 650. 
There is no immediate hazard to health unless the goods are ingested or injected into 
the body. 
There is no risk of fire or explosion. 
In the event of an accident, disposable gloves to be worn for handling the material. 
Surfaces that have been in contact with dangerous goods to be wiped with 2M NaOH 
and left for 1 hour- then wash. 
In the event of fire- the infectious agent is destroyed. 
Spillage in the absence of fire- wipe areas with 2M NaOH and leave for 1 hour- then 
wash. 
First Aid measures- any skin that has had contact with dangerous goods may be 





Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
  Appendix 
313 
 
9.6 Points for basic precautions required for disinfection and 
decontamination. 
 
 Basic precautions for disinfection and decontamination 
1 Clean instruments thoroughly at least twice to remove body fluids prior to 
disinfection. 
2 Use automated decontamination processes where possible, and avoid mixing 
routine instruments with those used in TSE-related work in the same cycle. 
3 Recycle durable items for re-use only after appropriate decontamination- use 
only stringent autoclaving procedures or recommended chemical disinfection 
methods. 
4 Where possible, cover surfaces with disposable material, which can be removed 
and incinerated; otherwise clean and decontaminate surfaces thoroughly- use 
only recommended decontamination procedures. 
5 Use absorbent material to soak up spillages, which can then be contained and 
incinerated. 
6 Use leak-proof containers, e.g. double-bagging, for the safe handling of clinical 
waste. 
7 Avoid external contamination of the waste container. 
8 Wear protective clothing at all times. 
Table 9.2. NCJDSU basic health and safety precautions for work in CL3* (with derogations) 
laboratory. 
 
9.7 Annex 3 of the WHO infection control guidelines: 
Decontamination methods for Transmissible Spongiform 
Encephalopathies 
 
The safest and most unambiguous method for ensuring that there is no risk of 
residual infectivity on contaminated instruments and other materials is to discard and 
destroy them by incineration. In some healthcare situations, as described in the 
guidance, one of the following less effective methods may be preferred. Wherever 
possible, instruments and other materials subject to re-use should be kept moist 
between the time of exposure to infectious materials and subsequent decontamination 
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and cleaning. If it can be done safely, removal of adherent particles through 
mechanical cleaning will enhance the decontamination process. 
The following recommendations are based on the best available evidence at this time 
and are listed in order of more to less severe treatments. These recommendations 
may require revision if new data become available. 
1. Incineration 
2. Use for all disposable instruments, materials, and wastes. 
3. Preferred method for all instruments exposed to high infectivity tissues. 
4. Autoclave/chemical methods for heat-resistant instruments 
 
WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies 
1. Immerse in sodium hydroxide (NaOH)20 and heat in a gravity displacement 
autoclave at 121°C for 30 min; clean; rinse in water and subject to routine 
sterilization. 
2. Immerse in NaOH or sodium hypochlorite21 for 1 hr; transfer instruments to water; 
heat in a gravity displacement autoclave at 121°C for 1 hr; clean and subject to 
routine sterilization. 
3. Immerse in NaOH or sodium hypochlorite for 1 hr.; remove and rinse in water, 
then transfer to open pan and heat in a gravity displacement (121°C) or porous load 
(134°C) autoclave for 1 hr.; clean and subject to routine sterilization. 
4. Immerse in NaOH and boil for 10 min at atmospheric pressure; clean, rinse in 
water and subject to routine sterilization. 
5. Immerse in sodium hypochlorite (preferred) or NaOH (alternative) at ambient 
temperature for 1 hr; clean; rinse in water and subject to routine sterilization. 
6. Autoclave at 134°C for 18 minutes.22 
20 Unless otherwise noted, the recommended concentration is 1N NaOH. 
21 Unless otherwise noted, the recommended concentration is 20 000 ppm available 
chlorine. 
22 In worse-case scenarios (brain tissue bake-dried on to surfaces) infectivity will be 
largely but not completely removed. 
 
WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies 
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4. Chemical methods for surfaces and heat sensitive instruments 
1. Flood with 2N NaOH or undiluted sodium hypochlorite; let stand for 1 hr.; mop up 
and rinse with water. 
2. Where surfaces cannot tolerate NaOH or hypochlorite, thorough cleaning will 
remove most infectivity by dilution and some additional benefit may be derived from 
the use of one or another of the partially effective methods listed in Section 5.1 
(Table 8). 
3. Autoclave/chemical methods for dry goods 
4. Small dry goods that can withstand either NaOH or sodium hypochlorite should 
first be immersed in one or the other solution (as described above) and then heated in 
a porous load autoclave at ≥ 121°C for 1 hr. 
5. Bulky dry goods or dry goods of any size that cannot withstand exposure to NaOH 
or sodium hypochlorite should be heated in a porous load autoclave at 134°C for 1 
hr. 
 
WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. 
5. Notes about autoclaving and chemicals 
Gravity displacement autoclaves: Air is displaced by steam through a port in the 
bottom of the chamber. Gravity displacement autoclaves are designed for general 
decontamination and sterilization of solutions and instruments. Porous load 
autoclaves: Air is exhausted by vacuum and replaced by steam. Porous load 
autoclaves are optimized for sterilization of clean instruments, gowns, drapes, 
towelling, and other dry materials required for surgery. They are not suitable for 
liquid sterilization. 
Sodium Hydroxide (NaOH, or soda lye): Be familiar with and observe safety 
guidelines for working with NaOH. 1N NaOH is a solution of 40 g NaOH in 1 litre 
of water. 1 N NaOH readily reacts with CO2 in air to form carbonates that neutralize 
NaOH and diminish its disinfective properties. 10 N NaOH solutions do not absorb 
CO2, therefore, 1N NaOH working solutions should be prepared fresh for each use 
either from solid NaOH pellets, or by dilution of 10 N NaOH stock solutions. 
Sodium hypochlorite (NaOCl solution, or bleach): Be familiar with and observe 
safety guidelines for working with sodium hypochlorite. Household or industrial 
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
  Appendix 
316 
 
strength bleach is sold at different concentrations in different countries, so that a 
standard dilution cannot be specified. Efficacy depends upon the concentration of 
available chlorine and should be 20 000 ppm available chlorine. One common 
commercial formulation is 5.25% bleach, which contains 25 000 ppm chlorine. 
Therefore, undiluted commercial bleach can be safely used. If solid precursors of 
hypochloric acid is available, then stock solution and working solutions can be 
prepared fresh for each use. 
 
WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. 
6. Cautions regarding hazardous materials 
In all cases, hazardous materials guidelines must be consulted. 
1. Personnel 
NaOH is caustic but relatively slow acting at room temperature, and can be removed 
from skin or clothing by thorough rinsing with water. Hot NaOH is aggressively 
caustic, and should not be handled until cool. The hazard posed by hot NaOH 
explains the need to limit boiling to 10 minutes, the shortest time known to be 
effective. 
Hypochlorite solutions continuously evolve chlorine and so must be kept tightly 
sealed and away from light. The amount of chlorine released during inactivation may 
be sufficient to create a potential respiratory hazard unless the process is carried out 
in a well-ventilated or isolated location. 
2. Material 
In principle, NaOH does not corrode stainless steel, but in practice some 
formulations of stainless steel can be damaged (including some used for surgical 
instruments). It is advisable to test a sample or consult with the manufacturer before 
dedicating a large number of instruments to decontamination procedures. NaOH is 
known to be corrosive to glass and aluminum. Hypochlorite does not corrode glass or 
aluminum and has also been shown to be an effective sterilizing agent; it is, however, 
corrosive both to stainless steel and to autoclaves and (unlike NaOH) cannot be used 
as an instrument bath in the autoclave. If hypochlorite is used to clean or soak an 
instrument, it must be completely rinsed from the surfaces before autoclaving. Other 
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decontamination methods may need testing, or consultation with the manufacturer to 
verify their effect on the instrument. 
 
9.8 FUMIGATION OF MICROBIOLOGICAL SAFETY 
CABINET(S) 
The equipment is supplied with a Formalin vaporisor unit (fixed to cabinet). 
Switch off cabinet fans. 
Switch off cabinet lights. 
Fit the night door and ensure properly fitted so there are no leaks into the open 
laboratory. 
Measure approximately 35-40 mls formalin BP, remove screw cap on unit and pour 
in contents. 
Replace the cap and tighten securely. 
Press the vaporisor switch on control panel. A lamp on the switch illuminates to 
show the power on. A second lamp on the vaporisor unit also illuminates indicating 
that the heating elements are working. 
After approximately 10 minutes, the formalin BP will have vaporized. 
Leave the cabinet in this condition, preferably overnight, but for a minimum of 3 
hours. 
Purge the cabinet by simply running the exhaust fan and removing the night door 
high velocity inlet bung. After a few minutes the night door may be removed and 
purging allowed to continue for at least 30 minutes.  
NOTE: From time to time, the boiling pot should be cleaned of residual 
Formaldehyde polymers, by heating the pot with water containing a small amount of 
mild detergent. 
 
9.9 INDEX OF AGONAL STATE SCORES 
 
Table 9.3 details the IAS scored for all 21 vCJD and 26 OND patients for which the 
NCJDSU had clinical and/or histological reports. 
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01/69 1309 28 F 15/06/01 15/09/00 1 4 0 0 0 0 0 0 0 0 0 
01/76 1318 26 M 10/07/01 15/09/00 2 4 0 0 0 0 1 0 0 0 0 
01/88 1368 30 F 30/08/01 15/10/00 2 4 0 0 0 0 0 0 0 0 0 
00/101 1184 27 M 15/10/00 15/12/99 2 4 0 0 1 0 1 1 0 0 0 
00/25 1015 17 F 21/03/00 Sep-98 2 4 0 0 1 0 0 0 0 0 0 
00/29 1070 27 M 13/02/00 01/04/99 2 4 0 1 0 0 0 0 0 0 0 
00/57 949 17 M 26/02000 Jun-01 3 4 0 0 0 0 0 1 0 0 0 
02/103 1553 53 F 25/11/02 Oct-01 2 4 0 0 0/1 0 0 0 0 0 0 









96/45 497 31 M 17/02/96 19/09/94 2 4 0 1 0 0 0 0 0 0 0 
97/221 623 25 M 06/02/97 Dec-95 2 4 0 0 0 0 1 1 0 0 0 
97/282 707 36 M 20/10/97 Dec-96 2 4 0 0 0 1 0 0 0 0 0 
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98/148 834 20 M 10/10/98 Nov-97 2 4 1 0 0 0 1 1 0 0 0 
98/154 845 36 M 22/10/98 15/07/97 2 4 0  0  1 1 0   
98/155 869 39 M 13/10/98 01/11/97 2 4 1 0 0 0 1 1 0 0 0 
99/100 730 17 F 02/09/99 Aug-96 4 4 0  1  1 0    
99/129 1016 33 M 28/11/99 01/04/19 1 4   0  1 1 0 0  
99/15 927 51 F 26/01/99 Feb-98 2 4 0 1 1 1 1 1 0 0 0 
99/82 907 39 M 20/07/99 01/05/98 2 4 0 0 1 0 0 0 0 1 0 
99/90 1030 29 M 07/08/99 Jan-99 1 4 1 0 2 0 0 0 0 0 0 
01/84 \ 71 M    4          
07/2006 \ 68 M    4   1       
02/14 \ 25 F    4 1 0 0 0 0 0 0 0 0 
00/49 1135 67 M 02/05/00 Nov-99 1 4 1 0 1 0 1 1 0 1  
03/132 \ 40 M    3 0 1 1 0 1 1 0 0 0 
24/2005 \ 86 M    4    1      
31/2005 \ 70 F    4 1 0 1       
33/2005 \ 85 F    4 1 0 1 1 0 0 1 0  
67/2004 2270 66 F 18/10/04 01/05/04 1 4  0 1    0 1  
Preparation, characterisation and transcriptome analysis of RNA frm human vCJD brains. 
Karen Sherwood (2008) 
University of Edinburgh PhD thesis 
       Appendix 
320 
 
89/2005 \ 76 M    1          
93/17 \ 43 M    4   2    0 1  




 4   2  0 0 0   
94/135 \ ? M    4          
94/140 \ 69 M    4   1  0 0 0   
94/154 344 54 M 25/12/94 Jun-94 1 4 0 0 2  1 1 0   
94/75 \ 44 F    2   0       
97/03 \ 68 F    4 0 0 2 1 2 2 0   
97/14 \ 47 F    4   2       
97/265 719 72 M 01/10/97 Jun-97 1 4 1 0 2 0 1 1 0 0 0 
98/144 891 77 F 27/09/98   4 0 0 1 1 0 0 0 1 0 
98/145 \ 67 M    4   1  1     
98/70 828 79 M 15/05/98 01/02/98 1 1 0 0 2 1 0 0 0 1 0 
99/118 \ 78 M    4   \  \ \    
99/20 \ 78 M    4   1  1 1 0   
99/54 995 79 M    4   0  0 0    
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Table 9.3. Index of Agonal State scores for vCJD and OND cases. Yellow shading: vCJD. White/grey shading: OND. Grey shading indicates cases with clinical or 
histological notes missing. Green shading: factors which were scored 0-absence, 1-evidence, 2-severe. The duration of illness was calculated from the dates of death 
and onset from the patient notes, and scored 1 for every 9months duration. Mode of death scores are detailed in Chapter 4. All other factors are scored 0-absence, 1-
presence. 
99/61 1010 55 M 29/05/99 20/04/99 1 4   0  0 0    
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9.10 GENE EXPRESSION DATA 
 
 
Table 9.4. Gene table Oligo GEArray® Human Alzheimer's Disease Microarray. Numbers 
represent gene spot position (p.338). 
 
 
Table 9.5. Gene table for Oligo GEArray® Human Signal Transduction PathwayFinder 
Microarray. Numbers represent gene spot position (p.339). 
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9.10.1 GEAnalysis Expression Suite Formulae for Data 
Analysis 
CLUSTERGRAM 
Clicking the Clustergram menu item generates a simple cluster diagram that 
calculates the correlation of the genes in a project. The correlation coefficient is used 
to express similarity. The formula for the correlation coefficient between two-





5. Background correction methods 
a. Terms 
xk – brightness of k-th pixel in X area (measured but not included to readout). 
Nx – number of pixels belonging to X area (measured when building readout). 
Ix – sum of brightness of pixels belonging to X area (measured when building 
readout). 
 
V – spot brightness (total) q – average value of q 
Areas on image: S – spot, C – clover area excluding spots (if applicable), L – local 
background. 
 
Total Density:          
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Average density:     
 
b. No correction 
1. No clover: 
 
 
2. Clover included: 
 
 
c. Background correction 
1. No clover:  
 
 
2. Clover included:  
 
Where B is average brightness of background area calculated in the following way: 
1. Local background  
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2. Empty cells 
 (no clover), summation by empty cells 
 
3. Global background  
, summation by all cells 
4. “Brightest” spot  
 is the minimum average value for all spots, calculated with 





V – raw spot brightness 
N – normalized spot brightness 
 
b. Calculation 
1. Selected genes:  
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2. Median:  
, where M is median of all spots brightness 
3. Interquartile:  
, where T is number of spots in the interquartile range of all 
spots brightness’s. Summation by all spots in the interquartile range. 
 
c. Dataset Adjustment 
1. Adjust to common mean: , where M is mean value of all genes 
brightness’s for current sample and D is desired mean value. 
2. Adjust minimal positive value: ,where 
, D is desired minimal value in percents from M, and M is mean 
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1 Ribosomal protein S27a 
2 Alpha-2-macroglobulin 
3 ATP-binding cassette, sub-family A (ABC1), member 1 
4 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
5 ADAM metallopeptidase domain 17 (tumor necrosis factor, 
alpha, converting enzyme) 
6 Amyloid beta (A4) precursor protein-binding, family A, member 
3 (X11-like 2) 
7 Amyloid beta (A4) precursor protein-binding, family B, member 
1 (Fe65) 
8 Anterior pharynx defective 1 homolog A (C. elegans) 
9 Amyloid beta (A4) precursor-like protein 1 
10 Apolipoprotein A-I 
11 Apolipoprotein E 
12 Amyloid beta (A4) precursor protein (peptidase nexin-II, 
Alzheimer disease) 
13 Beta-site APP-cleaving enzyme 2 
14 Butyrylcholinesterase 
15 Caspase 3, apoptosis-related cysteine peptidase 
16 Caspase 4, apoptosis-related cysteine peptidase 
17 Cell division cycle 2, G1 to S and G2 to M 
18 Cyclin-dependent kinase 5 
19 Cyclin-dependent kinase-like 1 (CDC2-related kinase) 
20 Clusterin 
21 Cathepsin C 
22 Cathepsin D 
23 Cathepsin G 
24 Cathepsin L1 
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25 Endoplasmic reticulum to nucleus signalling 2 
26 Bromodomain PHD finger transcription factor 
27 Guanine nucleotide binding protein (G protein), alpha z 
polypeptide 
28 Guanine nucleotide binding protein (G protein), beta polypeptide 
4 
29 Guanine nucleotide binding protein (G protein), gamma 7 
30 Guanine nucleotide binding protein (G protein), gamma 8 
31 Glycogen synthase kinase 3 beta 
32 Insulin-degrading enzyme 
33 Interleukin 1, alpha 
34 Insulin 
35 Lipoprotein lipase 
36 Low density lipoprotein receptor-related protein 10 
37 Microtubule-associated protein 2 
38 Nicastrin 
39 Neuropeptide Y 
40 Phosphodiesterase 7B 
41 Plakophilin 4 
42 Plasminogen activator, urokinase 
43 Plasminogen 
44 Protein kinase C, alpha 
45 Protein kinase C, beta 1 
46 Protein kinase C, iota 
47 Protein kinase C, theta 
48 Protein kinase C, zeta 
49 Synuclein, alpha (non A4 component of amyloid precursor) 
50 Synuclein, beta 
51 Somatostatin 
52 Ubiquinol-cytochrome c reductase core protein II 
53 Visinin-like 1 
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54 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
55 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
56 Actin, beta 
57 Actin, beta 
Table 9.6. Gene names for graph 6.14. Comparison group 1, AD arrays. 
 
 




1 ATP-binding cassette, sub-family A (ABC1), member 1 
2 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
3 ADAM metallopeptidase domain 10 
4 ADAM metallopeptidase domain 17 (tumor necrosis factor, 
alpha, converting enzyme) 
5 ADAM metallopeptidase domain 9 (meltrin gamma) 
6 Alkylglycerone phosphate synthase 
7 Amyloid beta (A4) precursor protein-binding, family A, member 
1 (X11) 
8 Amyloid beta (A4) precursor protein-binding, family A, member 
3 (X11-like 2) 
9 Amyloid beta (A4) precursor protein-binding, family B, member 
1 (Fe65) 
10 Amyloid beta (A4) precursor-like protein 1 
11 Apolipoprotein A-I 
12 Apolipoprotein E 
13 Amyloid beta (A4) precursor protein (peptidase nexin-II, 
Alzheimer disease) 
14 Brain-derived neurotrophic factor 
15 Caspase 3, apoptosis-related cysteine peptidase 
16 Caspase 4, apoptosis-related cysteine peptidase 
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17 Cell division cycle 2, G1 to S and G2 to M 
18 Cathepsin C 
19 Cathepsin D 
20 Cathepsin G 
21 Endoplasmic reticulum to nucleus signalling 2 
22 Bromodomain PHD finger transcription factor 
23 Guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 1 
24 Interleukin 1, alpha 
25 Insulin 
26 Insulin receptor 
27 Low density lipoprotein receptor-related protein 10 
28 Low density lipoprotein receptor-related protein 4 
29 Low density lipoprotein receptor-related protein 5 
30 Low density lipoprotein receptor-related protein 6 
31 Microtubule-associated protein 2 
32 Microtubule-associated protein tau 
33 Myeloperoxidase 
34 Nicastrin 
35 Neuropeptide Y 
36 Phosphodiesterase 7B 
37 PHD finger protein 1 
38 Plasminogen activator, tissue 
39 Plasminogen 
40 Protein kinase C, alpha 
41 Protein kinase C, beta 1 
42 Protein kinase C, delta 
43 Protein kinase C, epsilon 
44 Protein kinase C, iota 
45 Protein kinase C, zeta 
46 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
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antitrypsin), member 3 
47 Somatostatin 
48 Ubiquinol-cytochrome c reductase core protein II 








1 Ribosomal protein S27a 
2 ATP-binding cassette, sub-family A (ABC1), member 1 
3 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
4 ADAM metallopeptidase domain 10 
5 ADAM metallopeptidase domain 17 (tumor necrosis factor, 
alpha, converting enzyme) 
6 ADAM metallopeptidase domain 9 (meltrin gamma) 
7 Amyloid beta (A4) precursor protein-binding, family A, member 
3 (X11-like 2) 
8 Amyloid beta (A4) precursor protein (peptidase nexin-II, 
Alzheimer disease) 
9 Caspase 3, apoptosis-related cysteine peptidase 
10 Choline acetyltransferase 
11 Clusterin 
12 Endoplasmic reticulum to nucleus signalling 2 
13 Guanine nucleotide binding protein (G protein), alpha activating 
activity polypeptide O 
14 Guanine nucleotide binding protein (G protein), beta polypeptide 
1 
15 Guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 1 
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16 Guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 2 
17 Glycogen synthase kinase 3 alpha 
18 Insulin 
19 Insulin receptor 
20 Lipoprotein lipase 
21 Low density lipoprotein-related protein 1 (alpha-2-macroglobulin 
receptor) 
22 Microtubule-associated protein 2 
23 Microtubule-associated protein tau 
24 Neuropeptide Y 
25 PHD finger protein 1 
26 Plasminogen activator, tissue 
27 Protein kinase C, beta 1 
28 Protein kinase C, epsilon 
29 Protein kinase C, iota 
30 Synuclein, beta 
31 Somatostatin 
32 Visinin-like 1 
33 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
34 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
35 Actin, beta 
36 Actin, beta 
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9.10.5 Tabulated gene names for significantly modulated 




1 Ribosomal protein S27a 
2 ATP-binding cassette, sub-family A (ABC1), member 1 
3 Amyloid beta (A4) precursor protein-binding, family A, member 
1 (X11) 
4 Amyloid beta (A4) precursor protein-binding, family A, member 
3 (X11-like 2) 
5 Anterior pharynx defective 1 homolog A (C. elegans) 
6 Amyloid beta (A4) precursor-like protein 1 
7 Apolipoprotein A-I 
8 Apolipoprotein E 
9 Amyloid beta (A4) precursor protein (peptidase nexin-II, 
Alzheimer disease) 
10 Beta-site APP-cleaving enzyme 2 
11 Butyrylcholinesterase 
12 Brain-derived neurotrophic factor 
13 Cyclin-dependent kinase 5 
14 Choline acetyltransferase 
15 Clusterin 
16 Cathepsin B 
17 Cathepsin D 
18 Endoplasmic reticulum to nucleus signalling 2 
19 Bromodomain PHD finger transcription factor 
20 Guanine nucleotide binding protein (G protein), beta polypeptide 
1 
21 Guanine nucleotide binding protein (G protein), beta polypeptide 
2 
22 Guanine nucleotide binding protein (G protein), beta polypeptide 
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23 Guanine nucleotide binding protein (G protein), gamma 5 
24 Glycogen synthase kinase 3 alpha 
25 Interleukin 1, alpha 
26 Lipoprotein lipase 
27 Low density lipoprotein receptor-related protein 10 
28 Neuropeptide Y 
29 Plasminogen activator, tissue 
30 Plasminogen activator, urokinase 
31 Protein kinase C, beta 1 
32 Protein kinase C, iota 
33 Protein kinase C, zeta 
34 Presenilin 1 (Alzheimer disease 3) 
35 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 13 (pseudogene) 
36 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
37 Synuclein, alpha (non A4 component of amyloid precursor) 
38 Synuclein, beta 
39 Serine peptidase inhibitor, Kunitz type, 2 
40 Somatostatin 
41 Ubiquinol-cytochrome c reductase core protein I 
42 Ubiquinol-cytochrome c reductase core protein II 
43 Visinin-like 1 
44 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
45 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
46 Actin, beta 
47 Actin, beta 
Table 9.9 .Gene names for graph 6.18 from all significantly modulated genes identified on the 
AD arrays. 
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1 B-cell CLL/lymphoma 2 
2 BCL2-related protein A1 
3 BCL2-like 1 
4 NLR family, apoptosis inhibitory protein 
5 Chemokine (C-C motif) ligand 2 
6 Chemokine (C-C motif) ligand 20 
7 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
8 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
9 Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 
10 Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
11 Cathepsin D 
12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 
1) 
13 Chemokine (C-X-C motif) ligand 9 
14 Early growth response 1 
15 Engrailed homeobox 1 
16 Fatty acid synthase 
17 Stimulated by retinoic acid gene 6 homolog (mouse) 
18 Fibronectin 1 
19 V-fos FBJ murine osteosarcoma viral oncogene homolog 
20 Forkhead box A2 
21 Hexokinase 2 
22 Homeobox A1 
23 Homeobox B1 
24 Heat shock protein 90kDa alpha (cytosolic), class A member 2 
25 Inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta 
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26 Interleukin 1, alpha 
27 Interleukin 4 receptor 
28 Interleukin 8 
29 Nitric oxide synthase 2A (inducible, hepatocytes) 
30 Interferon regulatory factor 1 
31 Lymphotoxin alpha (TNF superfamily, member 1) 
32 Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha 
33 Nuclear receptor interacting protein 1 
34 Ornithine decarboxylase 1 
35 Platelet/endothelial cell adhesion molecule (CD31 antigen) 
36 Protein kinase C, beta 1 
37 Protein kinase C, epsilon 
38 Patched homolog 1 (Drosophila) 
39 Patched homolog 2 (Drosophila) 
40 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
41 Retinoblastoma binding protein 8 
42 Retinol binding protein 2, cellular 
43 Selectin E (endothelial adhesion molecule 1) 
44 Selectin P ligand 
45 TRAF family member-associated NFKB activator 
46 Transcription factor 7 (T-cell specific, HMG-box) 
47 Telomerase reverse transcriptase 
48 Transmembrane, prostate androgen induced RNA 
49 Tumor necrosis factor (TNF superfamily, member 2) 
50 Fas (TNF receptor superfamily, member 6) 
51 Fas ligand (TNF superfamily, member 6) 
52 Tripartite motif-containing 25 
53 Vascular endothelial growth factor A 
54 WNT1 inducible signaling pathway protein 1 
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55 WNT1 inducible signaling pathway protein 2 
56 WNT1 inducible signaling pathway protein 3 
57 Wingless-type MMTV integration site family member 2 
58 WD repeat and SOCS box-containing 1 
Table 9.10. Gene names for graph 6.32. Comparison group 1, ST arrays. 
 
 





1 B-cell CLL/lymphoma 2 
2 BCL2-related protein A1 
3 Bone morphogenetic protein 4 
4 Chemokine (C-C motif) ligand 2 
5 Cyclin D1 
6 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
7 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
8 Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
9 Early growth response 1 
10 Fatty acid synthase 
11 V-fos FBJ murine osteosarcoma viral oncogene homolog 
12 GREB1 protein 
13 Hedgehog interacting protein 
14 Hexokinase 2 
15 Homeobox A1 
16 Heat shock protein 90kDa alpha (cytosolic), class A member 2 
17 Insulin-like growth factor binding protein 3 
18 Insulin-like growth factor binding protein 4 
19 Interleukin 4 
20 Interleukin 4 receptor 
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21 Interleukin 8 
22 Nitric oxide synthase 2A (inducible, hepatocytes) 
23 Interferon regulatory factor 1 
24 Leptin (obesity homolog, mouse) 
25 Lymphotoxin alpha (TNF superfamily, member 1) 
26 Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) 
27 Ornithine decarboxylase 1 
28 Platelet/endothelial cell adhesion molecule (CD31 antigen) 
29 Protein kinase C, beta 1 
30 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
31 Transcription factor 7 (T-cell specific, HMG-box) 
32 Transmembrane, prostate androgen induced RNA 
33 Wingless-type MMTV integration site family member 2 
Table 9.11. Gene names for graph 6.32. Comparison group 2, ST arrays. 
 
 





1 Ribosomal protein S27a 
2 BCL2-related protein A1 
3 NLR family, apoptosis inhibitory protein 
4 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
5 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
6 CCAAT/enhancer binding protein (C/EBP), beta 
7 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 
1) 
8 Forkhead box A2 
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9 Growth arrest and DNA-damage-inducible, alpha 
10 GREB1 protein 
11 Hedgehog interacting protein 
12 Hexokinase 2 
13 Homeobox A1 
14 Homeobox B1 
15 Heat shock transcription factor 1 
16 Heat shock 27kDa protein 1 
17 Heat shock protein 90kDa alpha (cytosolic), class A member 2 
18 Insulin-like growth factor binding protein 4 
19 Inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta 
20 Interleukin 2 
21 Interleukin 2 receptor, alpha 
22 Interleukin 4 
23 Interleukin 4 receptor 
24 Interferon regulatory factor 1 
25 Leptin (obesity homolog, mouse) 
26 Lymphotoxin alpha (TNF superfamily, member 1) 
27 Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) 
28 NGFI-A binding protein 2 (EGR1 binding protein 2) 
29 Nuclear receptor interacting protein 1 
30 Ornithine decarboxylase 1 
31 Platelet/endothelial cell adhesion molecule (CD31 antigen) 
32 Progesterone receptor 
33 Protein kinase C, alpha 
34 Protein kinase C, beta 1 
35 Protein kinase C, epsilon 
36 Patched homolog 1 (Drosophila) 
37 Patched homolog 2 (Drosophila) 
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38 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
39 Retinol binding protein 1, cellular 
40 Retinol binding protein 2, cellular 
41 Selectin E (endothelial adhesion molecule 1) 
42 Selectin P ligand 
43 TRAF family member-associated NFKB activator 
44 Transcription factor 7 (T-cell specific, HMG-box) 
45 Telomerase reverse transcriptase 
46 Tumor necrosis factor (TNF superfamily, member 2) 
47 Fas (TNF receptor superfamily, member 6) 
48 Fas ligand (TNF superfamily, member 6) 
49 Tumor protein p53 (Li-Fraumeni syndrome) 
50 Glyceraldehyde-3-phosphate dehydrogenase 
51 Beta-2-microglobulin 
52 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
53 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
54 Actin, beta 
55 Actin, beta 
Table 9.12. Gene names for graph 6.32. Comparison group 5, ST arrays. 
 
 
9.10.9 Tabulated gene names for significantly modulated 




1 B-cell CLL/lymphoma 2 
2 BCL2-related protein A1 
3 Cyclin-dependent kinase 2 
4 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
5 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
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6 Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
7 CCAAT/enhancer binding protein (C/EBP), beta 
8 Epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avian) 
9 Early growth response 1 
10 Forkhead box A2 
11 GREB1 protein 
12 Homeobox B1 
13 Heat shock protein 90kDa alpha (cytosolic), class A member 2 
14 Intercellular adhesion molecule 1 (CD54), human rhinovirus 
receptor 
15 Insulin-like growth factor binding protein 4 
16 Interleukin 1, alpha 
17 Interleukin 2 
18 Interleukin 4 
19 Interleukin 4 receptor 
20 Protein kinase C, beta 1 
21 Retinol binding protein 1, cellular 
22 Transmembrane, prostate androgen induced RNA 
23 Tumor necrosis factor (TNF superfamily, member 2) 
24 Tripartite motif-containing 25 
25 Wingless-type MMTV integration site family member 2 




9.11  MANUSCRIPTS IN PREPARATION 
• RNA quality assessment from post-mortem human brain material. 
• Effects of agonal and post-mortem factors on the RNA profile in extracts 
of post-mortem human brain tissue. 
• Validating house-keeping genes for normalizing RNA expression in RT-
PCR in extracts of post-mortem human brain tissue. 
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